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ABSTRACT 
 
Functional Analyses of the Molecular Mechanisms Underlying 
Two Equine Respiratory Diseases: Recurrent Airway 
Obstruction and Rhodococcus equi  Pneumonia. (May 2012) 
Priyanka Kachroo, B.E., PES Institute of Technology 
Chair of Advisory Committee: Dr. Bhanu P. Chowdhary 
 
Recurrent airway obstruction (RAO) and Rhodococcus equi (R. equi) pneumonia are two 
equine respiratory diseases. RAO is an allergic asthma like disease of the middle-aged 
horses while the R. equi pneumonia affects only young foals. Respiratory disease is 
considered among the major causes of economic loss to the equine industry and tops the 
priority list for research that will focus on preventative and diagnostic facets of such 
disease. The objective of this research was to investigate the effect of antigen exposure 
and remission (via allergen avoidance and/or drug) on chronically affected RAO horses. 
Additionally, we also wanted to understand the changes in equine neonatal immune 
system due to R. equi exposure and identify molecular biomarkers for early disease 
screening. Various biological samples (lung tissue for the RAO study and blood 
leukocytes and nasal epithelial cells for the R. equi study) were used to extract 
ribonucleic acid (RNA). Complimentary deoxyribonucleic acid (cDNA) obtained from 
RNA was used to perform microarray hybridization experiments.  
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Our findings suggest that compared to control horses allergen exposure leads to an 
elevated protein synthesis and inflammation that contributes to aggravation of symptoms 
and airway changes. We found that allergen avoidance controls inflammation and causes 
an improvement in lung function and other chronic features of RAO. The drug 
administration led to an accelerated remission in the chronic RAO features; a complete 
remission could however not be achieved. Hence it appears that although not a complete 
resolution, but allergen avoidance and drugs will help in a better management of chronic 
RAO symptoms. 
 
Our results suggest that the neonatal immune system is capable of initiating a protective 
immune response through birth up to 8 weeks of age. However there are also processes 
present that may be counter-productive to the host. Induction of such suppressive 
mechanisms may be a result of bacterial modulation of the host immune response or a 
result of immature host immune system. We also identified molecular biomarkers that 
will have the potential to screen foals for R. equi pneumonia soon after birth and before 
the onset of clinical symptoms. The research findings of this study will improve the 
current understanding of the two equine diseases. 
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CHAPTER I 
 
INTRODUCTION AND LITERATURE REVIEW 
 
INTRODUCTION TO RESPIRATORY DISEASES IN THE HORSE 
The respiratory system of a horse begins at the nostrils and continues via the airway 
passages to the nasopharynx then through the larynx to the trachea. The trachea then 
leads to the bronchi and bronchioles, and finally culminates at the alveoli of the lungs. 
The alveolus is the place where the exchange of oxygen and carbon dioxide occurs 
between inspired air and circulating blood. The interplay between the respiratory and 
other body systems confers the horse with a considerable proportion of its athletic 
ability. Dysfunction in the respiratory system is one of the factors that is known to 
seriously limit the athletic potential of horses Clarke (1987). Early detection of 
respiratory ailments is hence a priority to minimize the treatment and management cost 
associated with the disease and improve the horses’ fitness and performance potential.  
In the United States, the equine industry has an annual impact of $112 billion on the 
national economy (Chowdhary and Bailey, 2003). Respiratory disease is considered 
among the major causes of economic loss to the equine industry and therefore 
necessitates immediate research attention.  
 
 
 
 
____________ 
This dissertation follows the style of Veterinary Immunology and Immunopathology. 
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Diseases of the respiratory system can be broadly categorized according to the specific 
anatomical locations in the respiratory tract: i) diseases affecting the upper respiratory 
tract and ii) diseases affecting the lower respiratory tract. Disease in both categories can 
then be further classified as infectious or non-infectious. Pleuropneumonia and 
Rhodococcus equi pneumonia are examples of infectious diseases of the lower 
respiratory tract. Summer pasture associated obstructive pulmonary disorder (SPAOPD), 
inflammatory airway disease (IAD) and recurrent airway obstruction (RAO) are 
examples of the non-infection diseases of the lower respiratory tract. Equine influenza 
and strangles are examples of the infectious, and recurrent sinus empyema and laryngeal 
hemiplegia are examples of non-infectious upper respiratory tract diseases. This doctoral 
research will focuses on recurrent airway obstruction (RAO or Heaves) and 
Rhodococcus equi (R. equi) pneumonia: diseases of the lower respiratory tract. While 
RAO is a non-infectious disease affecting adult horses, R. equi pneumonia is an 
infectious disease of the foals.  
 
RECURRENT AIRWAY OBSTRUCTION (RAO) 
Equine RAO, also known as heaves, is a performance limiting allergic respiratory 
disease caused by exposure to organic dust. This disease becomes clinically evident in 
middle-aged horses and commonly develops in horses stabled during winter months. It is 
a multifactorial condition caused individually by environmental, infectious and genetic 
factors or a combination of these factors (Robinson et al., 1993b; Couetil and Ward, 
2003). The pathological features of RAO include reversible airway obstruction, 
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inflammation of lower airways, and bronchial hyperresponsiveness. Similar to RAO, a 
syndrome named summer pasture-associated obstructive pulmonary disease (SPAOPD) 
occurs in horses that are kept on pasture during warm weather (Robinson et al., 1993a). 
RAO shares many pathological features with human asthma; therefore, research in 
equine RAO will increase the understanding in this field and contribute to the existing 
knowledge of various features of causes, pathogenesis and treatment of asthma in 
humans as one of the large animal models for the disease.  
 
Clinical signs  
RAO horses show early signs of respiratory distress including cough, wheezing and 
difficulty in breathing (Robinson, 2001). If left unmanaged, mild clinical symptoms will 
progress and become severe. Clinical signs can be assessed during a physical exam; in 
severe cases, these signs include nasal discharge, exercise intolerance, flared nostrils and 
heaves line (caused by severe respiratory distress) (Robinson, 2001). The hypertrophy 
and forceful contraction of smooth muscles to assist in breathing leads to the 
development of heaves line, which is visible as a groove in the external abdominal 
oblique muscles (Lowell, 1964). Depending on the severity of the disease, wheezing and 
varying levels of lung sounds (crackles) can also be heard due to obstructed airways 
(Gerber, 1973; Robinson, 2001). Clinical symptoms are pronounced when horses are 
stabled whereby they get exposed to allergens. Environmental management of RAO 
susceptible horses (e.g. moving them to pasture) help in resolving the severity of clinical 
symptoms.  
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Diagnosis 
Diagnosis of RAO is mainly based on history and physical exams. The likelihood of 
other lung diseases can be ruled out by radiography. If the horses with seven years of age 
and older have been stabled and fed hay for most of their life, they begin to cough while 
stabled and begin to display exercise intolerance. Knowing these important facts while 
assessing the history of such horses is important in diagnosis. Further diagnosis can be 
evaluated by bronchoalveolar lavage fluid (BALF) and tracheal aspirates, lung function 
tests, thoracic radiography and ultrasound (Leguillette, 2003). While tracheal mucus or 
tracheal lavage is not as reliable for evaluating lung inflammation, BALF can be used for 
a more accurate assessment (Hoffman, 1999). Cytology of BALF in affected horses 
displays elevated levels of neutrophils (Gerber, 1973; Robinson, 2001). Lung function 
tests provide an assessment of the degree of airway obstruction, but the variability in 
results make them less reliable (Robinson, 2001). Techniques like forced oscillation (van 
Erck et al., 2003), forced expiration, volume capnography (Herholz et al., 2003) and 
respiratory induced plethysmography (Hoffman et al., 2001) are considered more 
sensitive and less invasive (Lavoie, 2007) for the measurement of airway function in 
order to assess airway obstruction. Following bronchodilator administration, the 
measurement of the degree of reversibility in airway obstruction can assist the evaluation 
of obstructive pulmonary diseases (Richter et al., 2008).  
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Pathology and Pathophysiology 
Pathological changes of the disease constitute inflammation of lower airways that are 
infiltrated mainly with lymphocytes and monocytes along with neutrophils and mucus in 
lumen (Leguillette, 2003). Persistent airway inflammation due to the presence of 
immune cells and the inflammatory mediators in the lower airways, combined with poor 
management of RAO horses (maintaining horses in dusty stables and feeding hay) lead 
to structural changes of the airways termed as “remodeling”. The latter is an aberrant 
repair processes to airway injuries following constant inflammation (Elias et al., 1999; 
Sumi and Hamid, 2007; Halwani et al., 2010). Features of airway remodeling include 
epithelial damage, subepithelial fibrosis, thickening of the airway wall, increase in 
smooth muscle mass, goblet cell hyperplasia and hypertrophy and also vascular changes 
(Elias et al., 1999; Vignola et al., 2000; Vignola et al., 2001; Sumi and Hamid, 2007; 
Halwani et al., 2010).  
 
Similar to observations in human asthma, elevated airway smooth muscle mass is an 
important component of airway remodeling in RAO too. A study by (Herszberg et al., 
2006) was the first to show that horses with heaves also display an increased airway 
smooth muscle mass (ASM) like asthmatic patients and that the ASM increase is 
associated with elevated myocyte proliferation (Herszberg et al., 2006). Similarly, 
Leclere et al. (2011a) reported smooth muscle hyperplasia due to in-situ proliferation of 
myocytes (2 fold increase compared to control) without reduced apoptosis. Airway 
remodeling contributes to airway hyperresponsiveness and eventual loss of lung 
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function. Hence it is important to understand the molecular mechanism underlying 
remodeling and develop treatment to reverse it (Herszberg et al., 2006). 
 
Pathogenesis  
Environmental factors  
RAO is caused by inhalation of organic dust containing allergens, endotoxins, mold and 
particulate matter in the stabling environment of horses. Bacterial products like 
endotoxins and peptidoglycans, plant debris, dust and noxious gases like ammonia or 
methane can initiate the inflammatory response (Lavoie, 2007). Environmental 
management and drugs have been known to alleviate disease severity; hence any 
management strategy for RAO should encompass reduction in aero-allergens. Since 
main sources of allergens are feed hay and straw bedding, maintaining an allergen free 
environment would be one such step in the management of horses, for example, keeping 
the horses on green pasture (Woods et al., 1993; Vandenput et al., 1997; Robinson, 
2001). Instead of dry hay that generates air-borne dust and allergens, moistened hay, 
silage or pelleted diet are considered more beneficial and shown to improve lung 
function (Robinson, 2001; Art et al., 2002). 
 
Immunity and Immunologic factors 
Immunological basis of RAO is still not completely understood and the underlying 
immune mechanism is believed to be a hypersensitivity reaction to inhaled allergens. 
Mediated by immunoglobulin E (IgE), type I hypersensitivity/ immediate type 
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hypersensitivity eventually leads to production of inflammatory mediators initiating the 
early phase reaction (within 0.5-1hr of exposure), which is followed by late phase 
reactions (Kunzle et al., 2007). Type III hypersensitivity (3-10 hrs. post exposure) also 
known as late type reaction is initiated due to deposition of immune complex causing 
activation of complement system (Lavoie et al., 2001). While type IV hypersensitivity 
(within 24-48 hrs. post exposure) is also known as delayed type reaction where CD8+ 
and CD4+ cell types recognize antigen presented by type 1 or 2 major histocompatibility 
complex (MHC) and initiate cell mediate immune response (Averbeck et al., 2007).  
 
It was believed that RAO develops in two phases: first phase is an IgE mediated type I 
hypersensitivity reaction, while the second phase is a type III or type IV reaction (Lavoie 
et al., 2001; Robinson, 2001; Pietra et al., 2007; Tahon et al., 2009). However, the role 
of Type I hypersensitivity in RAO pathogenesis is controversial (Tahon et al., 2009). It 
is due to the contradictory results supporting an IgE-mediated type-I hypersensitivity 
reaction, that its role in RAO pathogenesis is considered debatable.  
 
Type I hypersensitivity has been supported by researchers due to findings like: release of 
histamine following allergen exposure (Gerber et al., 1982; Dirscherl et al., 1993; 
McGorum et al., 1993), elevated degranulation of mast cells after allergen exposure in 
RAO affected horses (Hare et al., 1999) and presence of elevated allergen specific IgE in 
serum (Eder et al., 2000; Kunzle et al., 2007). However, some studies did not find any 
difference in the serum levels of IgE against molds (Halliwell et al., 1993). Also a poor 
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correlation between intradermal testing and clinical diagnosis was observed in RAO 
horses (McGorum et al., 1993; Lorch et al., 2001). Again, some of the recent research 
findings do not support the role of IgE mediated reactions in RAO (Tahon et al., 2009; 
Wagner, 2009). Tahon et al. (2009) used an in-vitro allergy test and intradermal tests to 
find if type-I hypersensitivity reaction is associated with RAO. Although they found 
slightly elevated IgE levels in RAO animals compared to controls, these values were 
below the acceptable test threshold and hence their results do not support a type-I 
reaction (Tahon et al., 2009). A more recent study in 2010 hypothesized involvement of 
type-I hypersensitivity in RAO with a role of IgE and some IgG subclass of antibodies. 
Using an in-vitro assay for such antibodies but they found that only 30% of horses tested 
positive (Moran et al., 2010).  
 
Further disfavor for early phase reaction in RAO comes from the observation that 
immediate onset of airway obstruction which is typical of type I reaction and presence of 
eosinophil in BALF after allergen exposure is rarely observed in RAO and also because 
hours or days of stabling eventually leads to obstruction (Lavoie, 2007). Hence, until 
consistent results do not confirm the role of type-I hypersensitivity in RAO pathogenesis 
its association with the disease will not be certain.  
 
Some of the recent studies suggest a role of late or delayed type reaction contributing to 
the pathogenesis of RAO (Tahon et al., 2009; Wagner, 2009; Moran et al., 2010). There 
are studies that support type III hypersensitivity reaction associated with RAO (Halliwell 
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et al., 1979; Robinson, 2001). Lavoie et al. (2001) reported neutrophil release after 3-5 
hours of allergen exposure that is a feature of type III reactions. There is also growing 
support for involvement of type IV reaction in RAO (Halliwell et al., 1979; McGorum et 
al., 1993; Tahon et al., 2009). For example, occurring of reactivity to allergic response 
24 hours after exposure supports a delayed type response (Jose-Cunilleras et al., 2001; 
Wong et al., 2005). Hence, due to inconclusive proof to support any single type of 
hypersensitivity reaction underlying this disease, further research will be needed to 
conclusively associate type-I, type III or/and Type IV reactions with RAO pathogenesis. 
 
In addition to the immunologic reactions that mediate the host immune factors in 
response to allergenic stimuli, it is also important to discuss the role of innate and 
adaptive immunity in RAO pathogenesis.  
 
Innate immunity is the first line of defense against various antigens via recognition 
molecules like toll like receptors and immune cells like neutrophils and macrophages 
(Moran and Folch, 2011). Toll like receptors (TLR) are important for recognition of 
fungal and bacterial allergens (Shizuo, 2003). However, it has been shown that stabling 
does not increase the expression of TLR2 because it is the cellular localization of this 
protein that influences its function and not the transcript abundance (Berndt et al., 2009). 
TLR4 are important for recognition of lipopolysaccharide and expressed in various cell 
types within lungs and elevated mRNA levels of TLR4 were observed after allergen 
challenge in bronchial epithelium of RAO-affected horses (Berndt et al., 2007). 
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Neutrophils are key contributors to innate immunity and their influx into airways occurs 
within 3-5 hours post exposure (Fairbairn et al., 1993). Neutrophils exert their effect by 
producing pro-inflammatory mediators and cytokines (Franchini et al., 2000; Giguere et 
al., 2002). Elevated expression of various cytokines produced by equine neutrophils 
from RAO affected horses: interleukins 8, 13, 17 (IL-8, IL-13, IL-17) and tumor necrosis 
factor-alpha (TNF-α) further enhance inflammation (Franchini et al., 2000; Giguere et 
al., 2002; Debrue et al., 2005; Ainsworth et al., 2006). Cytokines and chemokines 
involved in migration and recruitment of neutrophils have also been elevated in RAO 
affected horses highlighting the important of neutrophils in pulmonary inflammation 
(Lavoie, 2007).  In addition to neutrophils, macrophages also contribute to the airway 
inflammation, tissue damage and repair.  Upon allergen challenge alveolar macrophages 
up regulate the expression of TNF-α, IL-1β and IL-8 (Laan et al., 2006). These cytokines 
contribute to the inflammatory reaction and initiate adaptive immunity.  
 
Modulation of immune response via T-lymphocytes is a component of adaptive 
immunity and critical for RAO pathogenesis. It is believed that T-helper cells (both Th1 
and Th2) play an important role in the T-cell mediated immune response in RAO 
(Leclere et al., 2011b; Moran and Folch, 2011). A common immunological basis has 
been suggested for RAO and asthma due to shared similarities between the two diseases. 
In asthma T-helper 2 (Th2) cells and cytokines IL-4, IL-5 and IL-13 have been linked to 
allergen inhalation response (Bowles et al., 2002). Hence a similar immune response was 
implicated in equine RAO and suggested that Th2 cells and associated cytokines may 
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contribute to the pathogenesis (Lavoie et al., 2001). Initial evidence pointing towards a 
Th-2 immune response was provided by various studies that reported production of IgE 
to inhaled allergens (Dirscherl et al., 1993; Eder et al., 2000), degranulation of basophils 
and mast caused due to allergenic stimulus (Dirscherl et al., 1993; Hare et al., 1998), 
infiltration of T cells into the lungs of RAO horses (Watson et al., 1997) and elevated 
levels of IL-4 and IL-5 positive BALF cells (Lavoie et al., 2001). 
 
In contrast, other data suggests role of Th1 or a mixed Th1/Th2 cellular response in 
RAO (Beadle et al., 2002; Giguere et al., 2002; Ainsworth et al., 2003). Involvement of 
Th-1 type cytokines has been reported by many studies, which may suggest role of this 
type of immune response in RAO pathogenesis (Giguere et al., 2002; Ainsworth et al., 
2003; Debrue et al., 2005). Another important study in 2003 documented elevation 
expression of IFN-γ in chronically affected horses (5 weeks exposure), indicating that 
disease is not a polarized Th2 response. Furthermore, at no stage (pre-exposure, acute or 
chronic), IL-4 and IL-13 expression was increased in RAO affected horses (Ainsworth et 
al., 2003). Study by Giguere et al. (2002) support these results since they did not detect 
significant increases in IL-4 expression in BALF cells While a study by Ainsworth et al. 
(2003) observed an increase in mRNA expression of only IFN-γ in RAO affected horses 
while the Th2 type cytokines remained unaltered suggesting a polarized Th1 response in 
affected horses. And finally, apart from evidence that supports a polarized Th1 or Th2 
response, increase in mRNA levels of both IL-4 and IFN-γ by some studies suggest a 
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mixed Th1/Th2 response (Beadle et al., 2002; Giguere et al., 2002; Ainsworth et al., 
2003). 
 
Hence based on the literature, it can be hypothesized that RAO affected horses produce 
both Type 1 and 2 cytokines based on the stage of their disease. Hence, no consensus has 
been reached towards whether RAO condition is mediated by a polarized T-cell response 
or a mixed response. This may be due to complexity of the factors that determine heaves 
phenotype, and suggest that multiple pathways and mechanism may lead to this disease.  
 
Mucus production 
It has been long established that goblet cell hyperplasia and mucus hyper-secretion are 
associated with RAO affected horses (Gerber, 1973; Robinson et al., 1996). Excessive 
mucus production and accumulation (compared to healthy animals) is one of the factors 
leading to airway obstruction and is hence considered a key feature of RAO (Gerber et 
al., 2004b). Exposure to allergen and dust increases mucus accumulation in RAO horses 
compared to control (Gerber et al., 2004b). It has been reported that RAO phenotype is 
associated with qualitative and/or quantitative alterations of mucin side chains leading to 
persistent increased secretion of mucin in airways of affected individuals (Jefcoat et al., 
2001). In a similar study increased viscoelasticity of mucus was observed as a 
consequence of disease exacerbation, and hence it was suggested that change in mucus 
rheology might also contribute to its accumulation in the airways (Gerber et al., 2004a). 
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Since accumulation of mucus in RAO can only partly be explained by decrease in mucus 
clearability (Gerber et al., 2003), it was suggested that the hypersecretion (and 
accumulation) of mucus might be explained by overexpression of mucin genes. It was 
found that MUC5AC gene was up regulated in RAO affected horses (Gerber et al., 
2003), and later by Rousseau et al. (2007) suggested that mucus in equine airways is a 
mixture of MUC5B and MUC5AC. Calcium-activated chloride channel (CLCA) 
proteins are considered important targets in respiratory disorders like asthma and COPD 
and an elevated expression of human and murine CLCA gene has been reported to cause 
overproduction of mucus and disease exacerbation (Nakanishi et al., 2001; Hoshino et 
al., 2002).  An up-regulation of chloride channel accessory 1 (CLCA1) protein was 
observed in RAO affected horses by Anton et al. (2005). A strong correlation between 
CLCA1 and MUC5AC mRNA levels further supported the role of CLCA1 signaling in 
mucus regulation in RAO affected horses (Gerber et al., 2009b). However during 
chronic stages of RAO, CLCA1 was not differentially expressed between RAO affected 
and healthy controls (Ryhner et al., 2008). Hence different genes and signaling pathways 
seem to be involved in mucus production in acute and chronic phases of RAO. A 
thorough understanding of genes involved with mucus production at various stages of 
the disease might help resolve mucus hypersecretion. Since mucus hypersecretion is 
associated with airway inflammation, it is suggested that a therapy or drug targeted 
towards airway inflammation should in theory resolve mucus hypersecretion too (Lugo 
et al., 2006). 
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Host genes and genetic factors  
Some studies have proposed RAO to have a genetic basis and an inheritance mode that is 
considered to be complex (Marti et al., 1991; Ramseyer et al., 2007; Swinburne et al., 
2009).  A familial predisposition for RAO was first reported by (Schaeper, 1939) and 
later supported by the findings of (Koch, 1957), (Gerber, 1989) and Jost et al. (2007). 
Study by Gerber et al. (2008) reported a genetic basis for the disease with high 
heritability. They suggest that offsprings with one parent affected with RAO are at a 3-
fold increased risk of developing the disease while a higher risk (5-fold) is observed 
when both parents are affected with RAO Research findings by Gerber et al. (2009a) and 
Swinburne et al. (2009) once again proposed genetic basis for RAO and suggested a role 
of locus heterogeneity. In a sample of swiss warmblood horses (obtained from two 
RAO-affected stallions), autosomal dominant mode of inheritance was observed in one 
family while an autosomal recessive mode was evident in the second family suggesting a 
mixed mode of inheritance in RAO affected horses (Gerber et al., 2009a). 
 
There have been three studies that have hinted at association of genomic regions with 
RAO (Jost et al., 2007; Gerber et al., 2009a; Swinburne et al., 2009). Jost et al. (2007) 
employed linkage analysis and observed significant association of a region on 
chromosome 13 in only one of the two families considered in their study, implying locus 
heterogeneity associated with RAO. They studied the association of microsatellite 
markers in two warmblood families and obtained a region on equine chromosome 13 
that showed signs of statistical association, and also reported gene IL4RA (within the 
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candidate region) as a candidate gene for further research. Gerber et al. 2009 also 
suggested association of miscrosatellite markers with equine chromosome 13 and found 
mixed mode of inheritance in RAO-affected animals Gerber et al. (2009a). A more 
recent study in 2009 implicated regions on chromosome 13 and 15 having a strong 
statistical association with RAO, while region on chromosome 11 showing modest 
association (Swinburne et al., 2009). Swinburne et al. 2009 used 250 microsatellite 
markers for genotyping 239 warmblood horses belonging to two half-sib families and 
report significant and modest association of few genetic loci with RAO.  They found 
regions significantly associated with QTL’s from their study: 6-28MB on chromosomes 
13, 40-62MB on chromosome 15 and 6-44MB on chromosome 21. Within these regions 
they found many biologically relevant genes liked IL21R, CCL24, IL27, IL4R and 
SOCS5. Variants of IL4R gene have been associated with asthma risk and in RAO 
studies, a SNP in this gene due to locus heterogeneity was only associated with one of 
the two families studies by Jost et al. 2007. IL4R and other genes reported by Swinburne 
et al. 2009, due to their positional significance (presence within regions statistically 
associated with RAO) are good candidates for future research.  
 
In addition to the studies focused on identifying the genetic association with the disease, 
research during recent years has been focused on evaluating the role of various candidate 
genes in RAO pathogenesis while very few attempts have been made in understanding 
the transcriptional profile associated with the lung tissue in RAO affected horses.  
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 To date, there has been only a single attempt at using microarrays to understand the 
transcriptome profile of blood and BALF in RAO affected animals (Ramery et al., 
2008a). However, the limitation of this study was the use of a cross-species microarray, 
which has limited sensitivity due to sequence divergence between species and is prone to 
reduced hybridizations and cross hybridization, reducing the reliability of results. 
Recently another study reported transcriptional changes associated with SPAOPD-RAO 
horse and found 18 differentially expressed genes via differential display PCR (DD-
PCR) mainly involved in defense, inflammation and oxidative stress (Venugopal et al., 
2010a). There are very few studies that have focused on genome wide transcriptome 
analysis and hence the tools of expression analysis like microarrays to understand the 
pathogenesis of RAO are largely unexplored and offer great research potential.  
 
In addition to the whole genome approaches that have only recently been utilized, 
researchers have mainly been using candidate gene approach to understand the role of 
biologically relevant gene/genes in RAO pathogenesis. Selection of these candidate 
genes have been done on the premise of their potential role in RAO disease pathology 
due to their biological functional relevance, while many candidates have also been 
chosen due to their relevance with other respiratory diseases like asthma or COPD etc. 
For example, Pentraxin 3 (PTX3) gene plays a role in host defense and its elevated 
expression is observed in airway injury. Overexpression of PTX3 in cells like bronchial 
epithelium, macrophages and neutrophils derived from BALF has been observed in 
RAO affected horses (Ramery et al., 2010).  
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Neurokinins are neuropeptides that function via their receptors and mediate various 
airway functions, neurogenic inflammation and lung function (Bochner et al., 1994; 
Cohen et al., 2005a; Ramalho et al., 2011). Venugopal et al. 2009, evaluated the 
expression of neurokinins: NK-A, NK-B and neurokinin receptor NK-2 in RAO affected 
horses and reported that NK-A to be a more potent contractile agent than NK-B 
(Venugopal et al., 2009). According to their study, bronchial samples from RAO-
affected horses showed increased hyperresponsiveness towards NK-A than control 
horses, and this was attributed to overexpression of NK-2 receptors in smooth muscle 
cells and epithelium of bronchi. NK-A activates NK-2 receptor and causes contraction of 
the airway smooth muscle leading to airway constriction.  Their study proposes that 
antagonists to this receptor may be of therapeutic efficacy in RAO affected horses as 
some studies in asthma have already reported (Gao and Peet, 1999; Joos et al., 2004; 
Schelfhout et al., 2009) 
 
Clara cell secretory protein (CCSP) possesses anti-inflammatory activity and it has been 
suggested based on studies in human asthma patients that this protein may have a vital 
role in airway inflammation. A reduced level of this protein is suggested to increase the 
inflammatory response in asthma (Van Vyve et al., 1995; Luo et al., 2003). Based on the 
hypothesis that CCSP has anti-inflammatory properties and important for airway 
response against allergens, Katavolos et al. 2009 reported a decrease in number of clara 
cells (non-ciliated CCSP producing epithelial cells of distal airways) containing fewer 
secretory granules (storing CCSP) and also a reduced CCSP content in BALF of RAO-
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affected horses (Katavolos et al., 2009). In a more recent study by the same group, it was 
suggested that CCSP directly interacts with neutrophils and reduces the oxidative burst 
capacity and increases phagocytosis (Katavolos et al., 2011). During the lung 
inflammation in RAO with neutrophils as predominant inflammatory cells, CCSP enters 
and alters the functions of blood neutrophils. Hence based on their findings, authors 
propose that a reduced CCSP (observed in RAO-affected animals) will allow 
uncontrolled respiratory burst and release of inflammatory mediators by neutrophils that 
may lead to structural changes in airways.  
 
Endothelin-1 is a potent bronchoconstrictive peptide that mediates its response through 
type A and B receptors. These receptors have been implicated to have a role in asthma 
and RAO pathogenesis (Benamou et al., 1998; Granstrom et al., 2004; Venugopal et al., 
2006; Kassuya et al., 2008). Endothelin-1 is involved in airway smooth muscle 
contraction, obstruction of bronchi, airway remodeling and up regulation of cytokines 
like IL-1, IL-4, TNF-α and IL-8 causing a pro-inflammatory environment in the airways 
(Polikepahad et al., 2006; Kassuya et al., 2008). 
 
 An elevated ET-1 concentration was first reported in blood and BALF of RAO-affected 
horses compared to control horses by Benamou et al. (1998). Later the same group tried 
to evaluate the effect of ET-1 on airways and blood vessels, and found that ET-1 causes 
contraction of third generation bronchus via both ET-A and ET-B receptor while 
modulation of vasoconstriction was mediated via ET-A receptor only (Benamou et al., 
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2003). Later, Venugopal et al. 2006 found that ET-1 causes potent contraction in equine 
airways and in SPAOPD affected horses, they proposed that ET-1 is involved in 
hyperresponsiveness due to alteration of ET-B receptors(Venugopal et al., 2006). The 
latest study in this area reported that ET-1 exerts its role via enhanced expression of both 
ET-A and ET-B receptors in bronchial smooth muscle of SPAOPD-affected horses 
compared to healthy horses (Polikepahad et al., 2006). Hence, it appears that ET-1 may 
have a role in RAO pathophysiology due to its role in bronchoconstriction and airway 
hyperresponsiveness, and therefore developing antagonists for ET-1 receptors maybe of 
therapeutic value.  
 
Parallels with human Asthma  
Equine RAO is very similar to human asthma and hence it is easy to draw parallels 
between the two diseases. In both cases the severity of the disease increases by 
inhalation of aero-allergens, while reducing or eliminating the inciting factors lead to 
clinical remission. Pathological features like reversible airway obstruction, 
bronchospasm, airway hyperreactivity and airway remodeling are similar in both the 
diseases. However there are few differences between the equine and human forms of the 
disease: primary influx of the airways in human asthma is eosinophils; contrary to this, 
the cell population released in the equine airway in RAO is predominantly neutrophils 
(Art et al., 2008).  Although there have been few studies that have reported neutrophils 
in airways of non-atopic and atopic human asthmatics (Leclere et al., 2011b), majority of 
the literature still supports that predominant inflammatory cell type in asthma is 
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eosinophil. Compared to this, allergenic reaction in asthma is proposed to be two phased, 
with an early type I hypersensitivity reaction (modulated by mast cells and IgE) followed 
by a type IV hypersensitivity reaction. Early phase response has not been found to be 
associated with RAO (Deaton et al., 2007; Lavoie, 2007; Tahon et al., 2009). It is 
believed that type I hypersensitivity reactions are not important for RAO pathogenesis 
(Marti et al., 2008; Wagner, 2009) while late (Type-III) and delayed reactions (Type-IV) 
may be important (Halliwell et al., 1979; Tahon et al., 2009).  
 
However, recent publications show a closer correlation between asthma and RAO, due 
to similarities in various pathological features like bronchoconstriction, 
hyperresponsiveness, chronic inflammation and features of airway remodeling, hence 
supporting that horse can a good large animal model (Herszberg et al., 2006; Leclere et 
al., 2011a; Leclere et al., 2011b). Horse as an animal model has various advantages; to 
start with, RAO is a naturally occurring disease unlike rodents where asthma needs to be 
induced. Features of ASM remodeling are same in asthma and RAO (Herszberg et al., 
2006; Leclere et al., 2011a) and hence it would be easier to study chronic asthma with 
remodeling in horses and extend those findings in humans. It is easier to design 
controlled experiments in horses (e.g. repeated allergen exposure or time course 
experiments) compared to humans where stringent ethical concerns prevent conducting 
similar work. Also large size of airways in the horse makes it easier to repeatedly sample 
biopsies (Leclere et al., 2011b) that can be very useful in understanding temporal 
changes leading to progression of the disease. However, genetic heterogeneity of the 
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RAO affected horses and cost prohibitiveness (animal related cost and other facilities) 
have been suggested as some of the limitations of using RAO horses as a model for 
human asthma, because genetic heterogeneity will make it difficult to obtain statistical 
significance for small effects measured in genetic studies with a small sample size 
(Leclere et al., 2011b). 
 
Summary 
RAO is an allergic, obstructive, pulmonary equine disease. This disease causes exercise 
intolerance and severely affects the athletic potential of horses. Equine industry suffers 
economic loss due to expensive management practices, decreased athletic potential of 
horses and treatment costs associated with RAO and hence this equine disease 
necessitates research attention.  
 
Presently RAO research suffers from various limitations that need to be addressed in the 
near future in order to gain a more comprehensive understanding of this disease. One of 
the limitations is our inadequate understanding of the genes and genetic mechanisms 
orchestrating RAO pathogenesis. Very little is known about the molecular interactions 
and signaling that triggers the early reaction in the epithelial layer of the lower airway 
which is the primary site of allergen-host interactions. There is also limited knowledge 
about mechanisms contributing to airway inflammation, neutrophilic influx, mucus 
hyper-secretion and airway remodeling. Moreover, interplay of innate and adaptive 
immune responses in causing RAO are not yet fully elucidated. It is still not clear if 
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RAO is a polarized Th1/Th2 or a mixed immune response and hence targeted therapies 
cannot be tailored if a clear understanding of immune response underlying this disease is 
not achieved.  
 
Complex diseases with an immunologic basis need to be studied using high throughput 
techniques to capture interplay between various immune components. Only one study 
has used a high throughput method to study RAO thus far (Ramery et al., 2008b).  
Therefore genome wide identification of signature gene profile associated with various 
stages of the disease will add tremendously to the present knowledge base by providing 
extensive information at transcriptional level. Additionally, there are many potential 
susceptibility genes implicated in human asthma and only a handful of those genes have 
been characterized in RAO thus far. Hence, utilizing an equine specific microarray will 
expedite the process of identifying genes involved in RAO. 
 
My study on recurrent airway obstruction strives to address two key issues. Firstly, to 
understand the change in gene expression profile of RAO affected horses compared to 
their control counterparts before and after a short-term allergen exposure. The RAO 
susceptible horses are asymptomatic when in remission (without any allergen exposure) 
and become became symptomatic after being exposed to allergens. Secondly, to identify 
gene expression profile of RAO affected animals after a long-term (3 months) allergen 
challenge and also obtain the transcriptional profile when allergen are eliminated from 
their environment. This study also attempts to identify the effect of fluticasone 
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propionate (a corticosteroid) on the airway remodeling by observing the changes in the 
pattern of gene expression profile at the two time points (6 and 12 months).   
 
The objectives of the first study (Chapter II)  
1. Obtain the gene expression profile for peripheral lung biopsies from 
asymptomatic and symptomatic RAO affected horses and similarly for control 
horses before and after the allergen exposure using the whole genome 70-mer 
equine oligoarray. 
2. Obtain DE genes for asymptomatic RAO horses compared to control horses 
before allergen exposure and similarly identify DE genes between symptomatic 
horses compared to control horses.  
3. Perform pathway and network analysis of the obtained differentially expressed 
genes (p-value <0.05) to identify key molecular and cellular processes and 
networks involved in RAO pathogenesis.  
 
The objectives of the second study (Chapter III)  
1. Perform a time course study (baseline, 6 months and 12 months as time points) to 
understand gene expression changes associated with prolonged allergen cessation 
and fluticasone propionate treatment of horses with chronic allergen exposure (3 
months).  
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2. Perform pathway and network analysis of the obtained differentially expressed 
genes (p-value <0.05) to identify key molecular and cellular processes and 
networks associated with chronic RAO due to allergen exposure.  
3. Identify pathways and processes associated with the transcription profile after 
allergen cessation and corticosteroid treatment in the horses with chronic RAO.  
 
RHODOCOCCUS EQUI PNEUMONIA 
Rhodococcus equi (R. equi) is recognized globally as a leading causes pneumonia in 
foals up to 6 months of age, while adult horses do not develop the disease unless they are 
immune deficient (Prescott, 1991; Takai et al., 2001; von Bargen et al., 2009). There are 
also non-equine species susceptible to R. equi pneumonia, like pigs (Karlson et al., 
1940), cattle (Woolcock and Rudduck, 1973), cats (Elliott et al., 1986), goats (Addo and 
Dennis, 1977), dogs (Takai et al., 2003), and even humans, in which it affects only HIV-
infected or immune-comprised individuals (Linder, 1997; Kedlaya et al., 2001). The 
course of R. equi infection in foals is insidious, and disease is often progressed by the 
time diagnosis is made (Cohen et al., 2005b). The mortality rate due to foal pneumonia 
is estimated to be around 2-13% (Mousel et al., 2003). Hence, this disease has serious 
implications on the equine industry and requires research attention. A comprehensive 
understanding of the genetic factors, pathogenesis, and host immunity will help in 
developing early and accurate screening and diagnostic tools and improved treatment. In 
the sections that follow, the ecology, epidemiology, pathogenesis, and immunity to R. 
equi are discussed.  
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Ecology  
R. equi is a gram-positive intracellular bacterium belonging to the Actinomycetales order 
(Barton and Hughes, 1984). It is a soil-dwelling organism also present in the fecal matter 
of herbivores (Barton and Hughes, 1984; Takai, 1997). Once ingested, the pathogen 
survives and proliferates in the gastrointestinal tract and enters the environment via feces 
(Takai et al., 1986; Takai et al., 1991). Proliferation of R. equi in soil depends on 
temperature, concentration of horse feces, and soil pH (Takai et al., 1996; Muscatello et 
al., 2006). Acidic conditions and high temperatures are believed to assist in the 
expression of virulence genes (Muscatello et al., 2006), and the optimal growth of 
bacteria is observed at 38°C and at pH 6.5 (Takai et al., 1996). R. equi has simple 
nutritional requirements and hence can survive in the manure of herbivores and in 
summer temperatures (Chaffin et al., 2003b). It is a ubiquitous organism and is 
detectable in most equine farms (Muscatello et al., 2007). 
 
Epidemiology 
In addition to gaining knowledge about the pathogenesis and virulence, understanding 
the epidemiology of R. equi will help in the prevention and control of foal pneumonia 
(Narren, 2007). The natural route of entry of the pathogen is via inhalation or ingestion 
(Takai et al., 1991; Giguere and Prescott, 1997), and the clinical signs appear in infected 
foals around 30-90 days after birth (Giguere and Prescott, 1997). Though foals are 
exposed early in life, the actual onset of infection is not well established. Some 
researchers believe infection may coincide with waning of maternal antibodies (Wichtel 
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et al., 1991; Hines et al., 1997; Heidmann et al., 2006; Jacks et al., 2007). However, an 
increasing body of evidence now points toward a greater likelihood of early infection in 
foals (Horowitz et al., 2001; Cohen et al., 2002; Chaffin et al., 2008; Kuskie et al., 
2011). Thus, future research should provide further evidence for determining the precise 
time after birth when foals are exposed to the pathogen and whether this exposure is 
variable from foal to foal.  
 
Rhodococcus equi pneumonia of foals is prevalent around the world. A study by 
Muscatello et al. in 2006 found that up to 10% of foals in Australia were infected with R. 
equi (Muscatello et al., 2006), while in the United States, a study of 138 farms found a 
disease incidence rate of 13% and mortality rate of 8% (Cohen et al., 2005c). A study by 
Chaffin et al. (2003) conducted at two Texas equine breeding farms using 220 foals 
found that 15% were affected by pneumonia and the mortality rate was 13% (Chaffin et 
al., 2003b). The same study reported that factors like large farms and high foal and/or 
mare-foal pair density increased the risk of pneumonia (Chaffin et al., 2003a). Recently, 
Kuskie et al. 2011 performed a study on a single R. equi endemic farm in Kentucky. The 
study results support the hypothesis that foals get infected early in life by reporting that 
airborne virulent R. equi may increase the risk of foals developing the disease if they are 
exposed during their first week of life. This study also found a significantly increased 
association of virulent R. equi concentrations in the presence of mares and foals during 
sampling (Kuskie et al., 2011).  
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On farms where the R. equi infection is endemic, foals are exposed to increased levels of 
virulent R. equi (von Bargen and Haas, 2009). Since only virulent strains of R. equi 
cause the disease (Takai et al., 1991; Takai et al., 1993), characterizing virulent R. equi 
is important in epidemiological studies. The proportion of foals with R. equi pneumonia 
at endemic farms has been reported to be around 10-20%, or at times more (Cohen et al., 
2008). Hence, evaluating the factors that contribute to the environmental burden of R. 
equi and understanding their association with the disease is important. It is believed by 
some that the feces of mares potentially contributes to the environmental burden of R. 
equi (Debey and Bailie, 1987; Takai et al., 1987); however, a study by Grimm et al. 
(2007) reported that although increased fecal shedding by mares is a contributing source 
of R. equi into the environment, it is not related to disease incidence in foals (Grimm et 
al., 2007). Some research studies have suggested a correlation between soil 
contaminated with virulent R. equi and disease incidence in foals (Takai et al., 1991; 
Takai, 1997), but recent research does not support this finding and has instead found a 
strong association between the prevalence of foal pneumonia and aerosolized virulent 
strains (Takai et al., 2001; Muscatello et al., 2006; Kuskie et al., 2011).  
 
Pathogenesis 
R. equi is an intracellular bacterium that infects only cells of the monocyte/macrophage 
lineage (Giguere and Prescott, 2000). An organism’s pathogenicity depends on its ability 
to proliferate and eventually kill macrophages (Giguere and Prescott, 2000). Virulent 
strains of R. equi can survive and replicate in alveolar macrophages, and this capacity is 
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conferred by the presence of virulence plasmid (Hines, 2006). Hence, defining the 
mechanism by which R. equi survives and proliferates within macrophages, the role of 
virulence plasmid, and the host factors will increase understanding of the pathogenesis 
of the disease.  
 
A pathogen’s ability to thrive in the macrophage relies on the lack of phagosomal-
lysosomal fusion (Hietala and Ardans, 1987). R. equi interferes with endosomal 
maturation and prevents vacuole acidification (Fernandez-Mora et al., 2005). The intra-
macrophage proliferation kills the host cell and also causes damage to the lung tissue 
(formation of granuloma) (Meijer and Prescott, 2004). It has been proposed that the 
means by which R. equi enters into macrophages dictates the fate of the pathogen 
(Giguere and Prescott, 2000). Entry of the microorganism via binding of the complement 
receptor into macrophages can avoid microbial killing caused by oxidative burst, while 
opsonization of R. equi with antibodies enhances phagosome-lysosome fusion and hence 
killing of the microbe (Hietala and Ardans, 1987).  
 
R. equi is widespread in the environment, and foal pneumonia is caused by virulent 
strains containing an 85-90 Kb plasmid (Takai et al., 1991; Takai et al., 1993). It has 
been shown that plasmid is important for virulence because plasmid-cured strains do not 
survive and replicate in macrophages and fail to induce pneumonia (Giguere and 
Prescott, 1997; Wada et al., 1997). Therefore, it appears that the pathogenesis of virulent 
R. equi depends on extrachromosomal DNA: an 85-90 Kb plasmid. Plasmid harbors a 
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27.5 Kb region called pathogencity island (PI) that contains genes critical for virulence 
(Takai et al., 2000). It has been reported that the PI contains nine virulence-associated 
(Vap) genes (Muscatello et al., 2007), and these virulence genes are overexpressed 
during growth of R. equi inside macrophages (Ren and Prescott, 2003). Other factors 
contributing to the pathogenesis of pneumonia are the polysaccharide capsule of the 
pathogen, iron acquisition, and glycolipids of the bacterial cell wall (Hondalus, 1997; 
Hines, 2006)). The polysaccharide capsule may affect virulence because it hinders the 
process of leukocytes binding and phagocytosing the bacterium (Prescott, 1991). Also, 
the length of the mycolic acid chains of glycoplipids constituting the cell wall influence 
virulence since longer chains have more capacity to induce granulomas than shorter 
chains (Gotoh et al., 1991). Finally, R. equi’s mechanisms of sequestering iron may also 
represent virulence factors since iron is important for its growth and survival (Jordan et 
al., 2003).  
 
Immunity 
While adult horses do not develop R. equi pneumonia, all newborn foals get exposed to 
it as some point early in life. Though most do not develop pneumonia, subsets of foals 
do get sick (Heidmann et al., 2006). The role of immunity seems critical in 
understanding the disease pathogenesis of foal pneumonia because unlike susceptible 
foals, most foals can mount a protective immune response. It appears that both innate 
immunity and adaptive immunity are important factors in fighting R. equi pneumonia 
infection (Takai et al., 1995b; Hines et al., 1997; Giguere and Prescott, 2000). 
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Innate immunity 
Cells like neutrophils and macrophages are important components of an innate immune 
system, and a deficiency in radical generating mechanisms or reduced toll-like receptor 
(TLR) response of these cells may contribute to disease susceptibility (Hines, 2006). 
Neutrophils are key components of host immunity against bacterial pathogens and have 
been found to play a protective role against microbial infections in neonates (McTaggart 
et al., 2001; Martens et al., 2005). Although the phagocytic capability of foal neutrophils 
is comparable to that of adults (Takai et al., 1985; Hietala and Ardans, 1987; Martens et 
al., 1988), foal serum has limited opsonic capability (McTaggart et al., 2001). Demmers 
et al. (2001) suggested that the low killing capacity of neutrophils in foals up to 3 
months of age could be a contributing factor toward foal susceptibility. Also, a 
significantly reduced concentration of neutrophils in the blood of foals for 2 to 4 weeks 
after birth has been observed in foals that developed pneumonia (Chaffin et al., 2004). 
Even in mice, a deficiency of neutrophils was found in R. equi-infected subjects; hence, 
it appears that neutrophils exert a protective immune response in the R. equi infected 
mice (Martens et al., 2005). Cytokines like IFN-γ and TNF-α are important for 
neutrophil and macrophage activation to start microbial killing (Meijer and Prescott, 
2004); however, reduced expression of IFN-γ has been reported in young foals 
(Breathnach et al., 2006; Ryan et al., 2010). Additionally, in mice, it has been observed 
that IFN-γ and TNF-α are produced in response to virulent R. equi and play a role in 
restricting the proliferation of the pathogen. Also, IFN-γ is important for clearing the 
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infection since it a component of the T-helper 1 (Th1) immune response (Kasuga-Aoki 
et al., 1999).  
 
TLRs are important components of innate immunity for pathogen recognition and also 
initiate adaptive immunity (Schnare et al., 2001; Pasare and Medzhitov, 2004). The R. 
equi surface antigen Vap-A activates TLRs on macrophages; however, a reduced TLR 
signaling in neonates has been observed that further contributes to the deficiency in 
innate immunity. TLR2, but not TLR4, has been associated with the macrophage 
response to R. equi where it was shown that a macrophage devoid of TLR2 was not able 
to generate a strong cytokine response to the pathogen (Darrah et al., 2004). In addition 
to factors discussed so far, dendritic cells (DCs) form a critical constituent of innate 
immunity. DCs, also known as professional antigen-presenting cells, are critical for 
innate immune response to infection. Dendritic cell function is reportedly reduced in 
foals (Chen et al., 2006), and although foal and adult DCs appear similar in many 
aspects (Flaminio et al., 2009), foal DCs do not have a robust MHC-II expression, which 
may compromise efficient priming of the effector cells (Prescott et al., 2010). Thus, 
reduced expression of class-II MHC by antigen-presenting cells may also contribute to 
the enhanced susceptibility of foals (Pargass et al., 2009; Dawson et al., 2010). 
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Adaptive immunity 
Humoral immunity 
Immunoglobulins like IgA, IgM, IgG, and IgE are expressed in horses (Wagner et al., 
2004), and IgGa, IgA, and IgG(T) are the constituents of the early immunoglobulins in 
neonatal foals (Sheoran et al., 2000). Opsonization via IgG has been reported to enhance 
phagocytosis of R. equi and microbial killing via phagosomal-lysosomal fusion 
(Cauchard et al., 2004; Dawson et al., 2010). After the waning of maternal antibodies, 
synthesis of immunoglobulins persists for up to 5-8 weeks of life (Holznagel et al., 
2003); however, a delayed synthesis of IgGb and lower level of this immunoglobulin is 
observed in foals (Sheoran et al., 2000; Holznagel et al., 2003). Given the role of IgGb in 
bacterial resistance, this immunoglobulin may contribute to foal susceptibility 
(Holznagel et al., 2003). Sheoran et al. (2000) reported that nasal secretions are devoid 
of IgA during the first month of life, which may also contribute to susceptibility 
(Sheoran et al., 2000). 
 
Cell-mediated immunity 
Due to the intracellular nature of survival and replication of R. equi, an efficient cell-
mediated immune response is a critical form of immunity against infection (Hines et al., 
1997; Meijer and Prescott, 2004). It is known that CD4+ and CD8+ lymphocytes 
contribute to immunity toward R. equi infection (Nordmann et al., 1992; Kanaly et al., 
1993; Ross et al., 1996). CD4+ lymphocytes have subtypes like T helper 1 (Th1) and T 
helper 2 (Th2) cells. Th1 cells produce IFN-γ and hence contribute to the killing of R. 
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equi via macrophage activation, while Th2 cells initiate the humoral response 
(Weinstock and Brown, 2002). Th1 immune responses contribute to protective immunity 
against R. equi, while Th2 immune responses are believed to be detrimental (Dawson et 
al., 2010). The protective role of Th1 immune responses has been elucidated by various 
studies in mice. One such study showed that the transfer of R. equi-specific CD4+ Th1 
cells in nude mice cleared the bacteria, while nude mice receiving Th2 cell lines 
developed pulmonary lesions (Giguere et al., 1999). The role of CD4+ and CD8+ in 
producing IFN-γ and clearing R. equi infection has been studied in mice and adult horses 
(Kanaly et al., 1993; Hines et al., 2001; Hines et al., 2003). It was shown in mice that 
CD4+ and CD8+ lymphocytes are involved in the clearance of virulent strains of R. equi 
by producing IFN-γ (Hines et al., 2003). IFN-γ in turn activates macrophages to cause 
phagolysosomal fusion killing the bacteria (Hines et al., 1997; Darrah et al., 2000).  
 
Infection with R. equi can have immunomodulatory effects. Giguere et al. (1999) found 
that foals that received in-vitro stimulation of CD4+ lymphocytes with a virulent R. equi 
strain showed a significant decline in the production of IFN-γ compared to foals that 
were infected with strains made devoid of the plasmid (Giguere et al., 1999). This 
immunomodulatory effect initiates a Th2-like response instead of the protective Th1 
response. Hines et al. (2003) showed that adult horses’ infection cleared with enhanced 
production of IFN-γ via CD4+ and CD8+ lymphocytes, highlighting the differences 
between the adult and neonatal immune responses. Modulation of immune response 
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could also be due to the PI on virulence plasmid or the dose of bacteria (Hines et al., 
2003).  
 
The immature immune system of young foals makes them more susceptible to microbial 
infections than adults. Furthermore, additional deficiencies of some foals may 
predispose them to R. equi infection. Young foals are deficient in IFN-γ production 
(Boyd et al., 2003; Breathnach et al., 2006) and cytotoxic T-cell activity (Patton et al., 
2005). Liu et al. 2009 demonstrated selective impairment of specific cytokines in 
neonatal foals, like IL-6 and IFN-γ in peripheral blood mononuclear cells (PBMCs), in 
response to R. equi stimulation (Liu et al., 2009). Pargass et al. (2009) also found that R. 
equi-infected, monocyte-derived macrophage cells expressed less of the Cd1b molecule 
compared to uninfected cells (Pargass et al., 2009). Cd1b is important for the 
presentation of lipid antigens, and reduced expression can be just another predisposing 
factor (Dawson et al., 2010).  
 
In addition, there are age-related deficiencies in antigen-presenting molecules and 
cytokines important for effective cell-mediated immunity that, in response to pathogen 
exposure, further result in an ineffective immune response (Prescott et al., 2010). 
 
Clinical Manifestations 
The lung infection in R. equi pneumonia progresses slowly; thus, diagnosing the disease 
early is challenging. Early clinical signs include a mild fever and slightly elevated 
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respiratory rate that if missed will often progress in severity (Prescott, 1991; Giguere and 
Prescott, 1997). Disease progression causes clinical symptoms like reduced appetite, 
fever, lethargy, and increased breathing effort (Giguere and Prescott, 1997; Wada et al., 
1997). There are three types of R. equi pneumonia. The first is the pneumonia type with 
suppurative bronchopneumonia (i.e., lung infection with abcessation); the second is the 
enteritis type with ulcerative enteritis (ulcers and inflammation of the mucosal lining of 
intestines due to bacterial infection) and abdominal abscesses; and the third is the mixed 
type with features from both types one and two (Takai et al., 1995b). Foals most 
commonly have chronic suppurative bronchopneumonia (Zink et al., 1986). A small 
percentage of foals develop intestinal manifestations or abdominal forms of the disease 
with symptoms like fever, colic, and diarrhea (Giguere and Prescott, 1997).  
 
Diagnosis 
The course of infection in foal pneumonia is insidious because the early signs of the 
disease are difficult to diagnose (Horowitz et al., 2001). Initial signs are often mild and 
could be detected by physical exams, but some foals succumb to infection without any 
previous signs of sickness (Heidmann et al., 2006). Recommended screening of foals for 
possible R. equi pneumonia involves monitoring the respiratory rate and, if it increases, 
taking the rectal temperature. If the rectal temperature is more than 39.2°C opting for a 
complete blood count is advised. If the blood count (>13,000/ul) and fibrinogen 
(>600mg/dL) levels are elevated, then advanced diagnostic tools should be employed 
(Heidmann et al., 2006).  
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Currently, there is no vaccination for R. equi pneumonia, and administration of 
hyperimmune plasma is commonly used; however, it is expensive and labor intensive 
(Martens et al., 2002; Chaffin et al., 2011). Hence, reliable, cost-effective, and accurate 
diagnostic tools to detect early infection are needed.  
 
A variety of serological assays have been developed, e.g., ELISA, agar-gel 
immunodiffusion (AGID), and synergistic hemolysis inhibitor (SHI) assays. A study by 
Martens et al. (2002) evaluated five assays (three ELISA types, AGID, and SHI) and 
found them to be unreliable because of occurrences of high false positives and false 
negatives (Martens et al., 2002). Another study evaluated the concentration of white 
blood cells (WBCs) and fibrinogen and an AGID test for the purpose of early diagnosis 
and found that monitoring WBC count can be an effective diagnostic tool (Giguere et al., 
2003). Monitoring hemotologic and immunophenotypic features of peripheral blood, like 
concentration of WBC, fibrinogen, neutrophils, CD4+ and CD8+ T-lymphocytes, and B 
lymphocytes, has also been found to be an unreliable screening tool (Chaffin et al., 
2004). Recently, Sonmez et al. (2011) evaluated the efficacy of the 
immunocytochemical procedure on tracheal wash fluid. Their results do not show 
significant improvement in sensitivity (87.7%) and suffered from poor specificity 
(59.5%). It was believed that concentration of Serum Amyloid A (SAA) could be a 
helpful marker for foal pneumonia infection (Hulten and Demmers, 2002); however, the 
study evaluating the efficacy of this marker as a diagnostic or screening tool found that 
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concentration of SAA was variable among the diseased foals and hence not a useful tool 
(Cohen et al., 2005b). 
 
PCR-based diagnostic methods have been regarded as superior to bacteriologic cultures 
(Heidmann et al., 2006). Bacterial culture methods yield false negative results and do not 
differentiate between virulent and avirulent strains of the pathogen (Pusterla et al., 
2007). To circumvent this limitation, PCR-based methods can be employed (Takai et al., 
1995a; Sellon et al., 2001; Ladron et al., 2003; Halbert et al., 2005; Harrington et al., 
2005; Rodriguez-Lazaro et al., 2006). Using multiplex PCR assays for simultaneous 
confirmation of the pathogen (R. equi) and strains (virulent vs. avirulent) has been found 
to be an effective diagnostic tool and superior to traditional morphologic and 
biochemical tests that have limited specificity for pathogen discrimination (Halbert et al., 
2005). Recently, repetitive sequence-based PCR (rep-PCR) was used by Bolton et al. 
(2010) to discriminate the genotypic variants of R. equi since genotyping variations were 
observed among individual R. equi-infected foals. Hence, there is evidence suggesting 
the superiority of PCR-based diagnostic assays over bacteriological or serological 
assays; however, PCR-based tests rely solely on detection of pathogenic factors to 
determine disease status and can lead to false positives. 
 
Based upon the limitations of the present screening and diagnostic tools, using molecular 
biomarkers will be a superior method for early identification of infected foals. This 
information will reveal genetic signatures and statistically significant gene biomarkers of 
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the susceptible foal’s immune response, which can then lead to the development of 
better therapies, more effective vaccines, and improved screening and diagnostic tests.  
 
Host genes and genetic factors 
Susceptibility to infection is a complex mechanism initiated by multiple genes, 
pathways, and proteins (Heller et al., 2010). Therefore, genetic studies that identify 
causative loci associated with the disease or genomic studies encompassing expression 
analysis are an important component as well. While genetic studies identify genetic loci 
associated with the affected foals and help to ascertain foals at greater risk, expression 
studies provide information about gene signatures that may contribute to foal 
susceptibility and influence the immune responses. 
 
There have been few studies that have examined the association of certain genes and loci 
with R. equi pneumonia. In one such study, Horin et al. (2004) tested immune-related 
gene markers and microsatellite loci for association with Rhodococcus equi infection and 
found genes on equine chromosomes 5, 10, and 15 to be associated with clearance of the 
infection. Another study by the same group reported a single nucleotide polymorphism 
(SNP) within the caspase 1 (Casp1) gene was found to be associated with high bacterial 
burden (Horin et al., 2008) in foals. In a more recent study, the same group tested 
various functional and positional candidate genes, but none of them had a statistical 
relevance with the infection, with the exception of IL17R, for which a statistically 
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significant association was found between an SNP in IL17R and the R. equi burden 
(Horin et al., 2010).  
 
In addition to the genetic studies, there have also been reports based on the candidate 
gene approach to test the role of a gene/gene product contributing to R. equi 
susceptibility. Cohen et al. (2004) suggested that the deletion of solute carrier 11 
member 1 (SLC11A1/NRAMP1) does not contribute to susceptibility to R. equi in mice, 
while Halbert et al. (2006) reported an association between SLC11A1 and susceptibility 
to R. equi (Cohen et al., 2004; Halbert et al., 2006). The NRAMP1 gene promotes 
resistance against various intracellular bacteria because it is likely involved in restricting 
pathogen survival and proliferation by inhibiting pahgosome-lysosome fusion or by 
affecting iron availability, thereby creating an iron-restricted environment that is hostile 
and hinders bacterial survival (Halbert et al., 2006). Another study based on the 
knowledge that iron is critical for intracellular persistence and replication of R. equi 
evaluated the role of transferrin in R. equi infection by typing the transferrin from 
paraffin-embedded tissues from 34 thoroughbred foals (Jordan et al., 2003). Transferrin 
is a bacteriostatic iron-binding protein, and its biochemical polymorphism has been seen 
in many species including horses. A study by Mousel et al. (2003) found an association 
between foal death due to R. equi and transferrin type (Mousel et al., 2003).  
 
In a separate study, association of a functionally relevant candidate gene, Galectin 3, 
with foal pneumonia was tested; this gene is considered to have a key role in innate and 
 40 
adaptive immunities, which assist in clearance on microorganisms by macrophages via 
phagocytosis (Sano et al., 2003). The study reported that the knockout of this gene 
increased resistance to R. equi in mice because this gene regulated immune response by 
reducing the production of IL-1β by macrophages (Ferraz et al., 2008). The role of IL-1 
was shown to regulate immune response by suppressing Th2 response, in turn affecting 
the susceptibility because the mice were resistant to bacterial infection.  
 
Heller et al. (2010) studied the role of indoeamine 2,3-dioxygenase (IDO), which is 
involved in breakdown of tryptophan and whose role in immune response is to induce 
tolerance. Neonatal foals are IFN-γ deficient, and this deficiency may decrease IDO 
expression. In Heller et al.’s study, the IDO enzyme in mice was found to have an 
immunoregulatory role in the pathogenesis of R. equi infection  (Heller et al., 2010). In 
another study, the same group used the suppression subtractive hybridization (SSH) 
technique to obtain differentially expressed genes from R. equi-infected, monocyte-
derived dendritic cells from foals. The differentially expressed genes were mainly 
involved in biological functions including T-cell regulation, immune and inflammatory 
response, cellular migration, and vesicular transport and were suggested as topics for 
further research to understand host immunity and susceptibility to infection (Heller et al., 
2010).  
 
The aforementioned studies have provided valuable information on genes and proteins 
that may be involved in R. equi infection in foals. However, none of the studies so far 
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have focused on understanding the role of the R. equi molecular mechanism at a 
genome-wide level. A study at the transcriptome level will reveal expression signatures 
that may validate previously reported findings and yield novel foci for future research. It 
will also enable researchers to understand the molecular mechanism underlying R. equi 
infection in a more comprehensive manner.  
 
Summary 
Rhodococcus equi is the leading cause of pneumonia in foals. Expenses related to the 
foal management, treatment costs, and loss due to death negatively impact the equine 
industry. R. equi pneumonia is caused by interaction of the bacterial pathogen, host, and 
environment. Hence, all these critical factors need to be extensively understood to design 
effective and early courses of treatment.  
 
Present research on R. equi pneumonia has made great attempts to understand the 
mechanism of bacterial pathogenesis. However, there is still a great need to understand 
the role of various genes and genetic factors that contribute to the susceptibility of foals. 
It is known that critical deficiencies like reduced IFN-γ production, reduced recognition 
of the pathogen, reduced function of antigen-presenting cells, and delayed synthesis of 
certain key immunoglobulins contribute to susceptibility of the foals. However, since 
these factors individually or in concert do not completely account for the susceptibility, 
there are additional undiscovered components that need to be identified in order to 
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explain what causes some foals to succumb to the infection while others clear it and 
remain resistant throughout their lives.  
 
R. equi pneumonia research to date has focused on selected genes or proteins and limited 
cell types. Disease processes involve coordinated interaction of several pathways, 
processes, and proteins, which in turn are reflected in expression and interactions of 
several genes. Also, candidate gene approach is biased and has a limited scope because a 
single gene or few genes are evaluated in the context of the condition.  
 
Therefore, detailed knowledge of the key genes modulating the disease pathogenesis is 
limited, and the interactions of genes or gene environments are sparsely known. 
Transcriptional profiling can be a useful tool in identifying signature genes associated 
with the disease. Microarrays explore genes in an unbiased manner and assess thousands 
of genes in parallel for a time point, disease state, or treatment type; hence, not only are 
genes with known functions obtained but also the ones with a novel function are 
revealed. The differential expression of genes obtained from microarrays may be due to 
host, pathogen, and environmental interactions. However, they still provide preliminary 
information about the genes associated with a condition, and the role of these genes can 
be dissected subsequently. Microarrays have some inherent limitations that will be 
discussed in detail in the final chapter, and alternate techniques that can be employed in 
the future for related studies will be examined.  
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This study on foal pneumonia strives to address two key issues: (1) develop an 
understanding of the changes in equine neonatal immune response upon foal in-vitro R. 
equi exposure of blood leukocytes during the first 3 months of life; (2) identify the 
candidate molecular markers for predicting R. equi pneumonia development from 
leukocytes and nasal epithelial cells at birth, week 2, and week 4 in foals. 
 
The objectives of the first study (Chapter IV) are 
1. Establish the temporal changes in gene expression profiles for equine peripheral 
blood leukocytes in response to in-vitro virulent R. equi exposure during the first 
3 months of life (day 1, week 2, week 4, and week 8). 
2. Compare the gene expression profile between R. equi stimulated and un-
stimulated peripheral blood leukocytes at day 1, week 2, week 4, and week 8.  
3. Perform functional analysis to identify key pathways and networks involved in 
foal immune responsiveness. 
 
The objectives of the second study (Chapter V) are 
1. Compare the gene expression profiles of R. equi pneumonia affected and 
unaffected foals from leukocytes and nasal epithelial cells at birth, week 2, and 
week 4. 
2. Perform classification of differentially expressed genes using linear discriminant 
analysis (LDA) to discover strong and robust classifiers for the affected and 
unaffected foals. 
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CHAPTER II 
 
TRANSCRIPTOME PROFILING OF EQUINE PERIPHERAL LUNG TISSUE 
TO UNDERSTAND THE EFFECTS OF ANTIGEN EXPOSURE IN 
RECURRENT AIRWAY OBSTRUCTION 
 
SYNOPSIS 
Recent studies in RAO have focused on airway remodeling and effect of antigen 
exposure on the structural changes. However, the molecular mechanisms associated with 
allergen exposure on already established remodeling in RAO-susceptible horses is still 
not fully understood. The purpose of this study is to determine the expression profile 
associated with asymptomatic (without allergen exposure) and symptomatic (after 30-
day allergen exposure) RAO-susceptible horses and to compare it with control horses. 
Six RAO-susceptible horses and five control horses were maintained in low antigen 
environment (pasture) after which they were exposed to allergen for 30 days and 
peripheral lung biopsies were collected before (baseline) and after exposure. RNA was 
extracted and generated cDNA was labeled with fluorescent dyes for microarray 
hybridizations using equine whole genome oligoarray. Our results suggest that the 30-
day allergen exposure causes minimal perturbation of the expression profile of the RAO-
susceptible horses and the genes were mainly involved in cellular turnover.  We found 
biologically relevant processes including cellular proliferation, cytoskeleton organization  
and apoptosis involved at both time points when RAO horses were compared to control.  
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Certain processes were also significantly enriched at either baseline (regulation of blood 
vessel size, immune system development etc.) or after 30-day allergen exposure 
(translation and translation elongation process). 30-day allergen exposure in RAO-
susceptible horses does not cause a significant perturbation of the expression profile. We 
report novel biomarkers of RAO at remission and exacerbation and molecular processes 
governing disease pathogenesis with and without the allergenic stimulus.   
 
INTRODUCTION 
Recurrent airway obstruction (RAO) also known as heaves, is an equine lower airway 
respiratory disease that is caused by exposure to dust from moldy hay and straw. Horses 
affected by RAO are generally 7 years of age or older and display increased repiratory 
effort, exercise intolerance, neutrophilic influx into the airways and mucus accumulation 
(Robinson, 2001). Presently there are very few epidemiological studies regarding the 
prevalence of RAO in different parts of the world including careful evaluation based on 
breed, age, sex environment and other factors. The current limited data estimated 
prevalence of RAO to be around 14% in a selected horse population in Great Britain 
(Hotchkiss et al., 2007). Similar to RAO, a syndrome named summer pasture-associated 
obstructive pulmonary disease (SPAOPD) also occurs in horses that are kept on pasture 
in warm humid weather (Robinson, 2001). The clinical signs of RAO begin soon after 
exposure to aeroallergens, which cause airway inflammation, bronchoconstriction, and 
hypersecretion of mucus. Persistent airway inflammation and poor management of RAO 
lead to structural changes of the airways termed as “remodeling”, which includes a 
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distinct increase in airway smooth muscle (ASM) mass among other observed changes 
(Herszberg et al., 2006). The molecular mechanisms underlying pathogenesis of chronic 
RAO, and the associated inflammatory and remodeling processes, are not completely 
understood; therefore identification of genes and biological processes involved in RAO 
will help in improved understanding of this disease.  
 
Some studies have proposed RAO to have a genetic basis and an inheritance mode that is 
considered to be complex (Marti et al., 1991; Ramseyer et al., 2007; Swinburne et al., 
2009).  A familial predisposition for RAO was first reported by (Schaeper, 1939) and 
later supported by the findings of (Koch, 1957), (Gerber, 1989) and Jost et al. (2007). 
Based on these initial studies it appears that RAO is a polygenic disease.  
 
However, irrespective of whether or not RAO is an inherited disease, one of the key 
limitations of present research is our inadequate understanding of the genes and genetic 
mechanisms orchestrating RAO pathogenesis. The primary focus in developing this 
understanding has been restricted to either specific cell types or few candidate genes 
chosen for analysis based on their likely involvement in modulating pathogenesis 
(Franchini et al., 2000; Laan et al., 2005; Polikepahad et al., 2008; Ainsworth et al., 
2009; Reyner et al., 2009; Venugopal et al., 2009; Ramery et al., 2010; Katavolos et al., 
2011). Complex diseases involve coordinated interaction of several genes and genetic 
pathways that are associated with disease progression. Therefore, there is an acute need 
for expanding the investigations to several or possibly all genes, eventually facilitating 
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an improved understanding of this important disease. The comparison of the global 
transcriptional profile of lung tissues at the disease state compared to the profile of 
corresponding tissue in the control animals will reveal differences in expression pattern 
of genes that can play an important role in the modulation of RAO and may contribute to 
the susceptibility of horses to a range of allergens.  
 
Microarrays have been extensively used as a high-throughput tool to identify 
differentially expressed genes in human asthma (Brutsche et al., 2001; Laprise et al., 
2004; Syed et al., 2005; Hansel and Diette, 2007) and other animal models of asthma 
(Zou et al., 2002; Zimmermann et al., 2003; Heidenfelder et al., 2009). To date, there has 
been only a single attempt at using microarrays to understand the transcriptome profile 
of RAO-susceptible animals (Ramery et al., 2009). However, the limitation of this study 
was the use of a cross-species microarray, which has restricted sensitivity due to 
sequence divergence between species that leads to reduced hybridizations and/or cross 
hybridization, thus reducing the accuracy of results. 
 
Hence, the aim of this study was to utilize for the first time a whole genome equine 70-
mer oligoarray to investigate the transcriptome profile associated with chronic RAO 
including airway remodeling.  The findings will provide global insight into the genes 
and biological processes associated with this disease, and will be of value in adding to 
current quest for understanding the basis of asthma in humans.  
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MATERIALS AND METHODS 
Study Animals and Experimental Design 
Animals, procedures and experimental design used for this study have been descripted 
previously (Relave et al., 2008; Leclere et al., 2010). In brief, six horses affected with 
RAO and 5 age-matched controls were used in this study. For RAO-susceptible horses 
the median age was 16 years while the range was 15–20 years; for control horses the 
median age was 14 years and the range was 11–17 years. RAO horses had a well-
documented 3 to 10-year history of reversible inflammation and airway obstruction upon 
hay exposure. Control horses had never previously developed RAO. Both groups were 
otherwise healthy based on physical examination and blood count. All Animal 
procedures outlined below were performed in accordance with the Canadian Council for 
Animal Care guidelines as described by Leclere et al. (2010). RAO-susceptible and 
Control horses were maintained on a pasture for three months (baseline) to precondition 
all the horses in a low-allergen environment. Both groups (RAO and Control) were then 
stabled and continuously exposed to a 30-day allergen challenge to poorly cured moldy 
hay (allergen exposure).  
 
Lung Biopsies and RNA extraction 
The peripheral lung biopsies were obtained via thoracoscopy wherein peripheral lung 
tissue was harvested from the caudo-dorsal region of the lung in sedated horses (Relave 
et al., 2008). Tissue samples were frozen in liquid nitrogen and stored at -80C for a 
maximum of 5 months. The RNA was isolated using the cesium chloride technique as 
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describe previously (Bedard et al., 2003). The extracted RNA quality was evaluated 
using bioanalyzer (Agilent, CA) and only samples with RNA integrity number (RIN) >7 
were considered suitable for the microarray analysis. 
 
Experimental Design 
We co-hybridized cDNA obtained from peripheral lung biopsies at baseline with cDNA 
obtained from biopsies after allergen exposure for the six RAO animals. Similarly, 
cDNA from 30-day allergen exposure samples were co-hybridized to baseline for the 
five control horses. We used a balanced block design for cDNA hybridization in which 
dye-swaps are embedded within the biological replicates (Dobbin et al., 2003; Simon 
and Dobbin, 2003).  
 
Labeling and Microarray Hybridization  
For each sample, cDNA was generated from total RNA using Superscript II Reverse 
Transcription kit (Invitrogen) and labeled with Cy3 or Cy5 dye via an indirect labeling 
method utilizing dendrimer technology (Stears et al., 2000).  Labeling was carried out 
with the 3DNA Array 900 MPX Expression Array Detection kit (Genisphere, PA). 
Hybridizations were performed in a SureHyb hybridization chamber (Agilent, CA) at 
55°C.  Following post-hybridization washes, arrays were scanned with a GenePix 4000B 
scanner at 5-micron resolution (Molecular Devices, CA).  GenePix Pro 6.1 software was 
utilized for raw data acquisition, spot-finding, and quantification of array images.   
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Equine 21K oligonucleotide microarray 
We used an whole genome equine oligonucleotide expression array with 21,351 
elements designed at Texas A&M University (Bright et al., 2009). This 70-mer 
oligoarray is the most comprehensive expression array available for expressed equine 
sequences. Probes were synthesized (Invitrogen, Carlsbad, CA) and printed onto amino-
silane coated slides (Corning Incorporated, Corning, NY). 
 
Expression Analysis 
Differential expression analysis of microarray data was conducted using Bioconductor’s 
LIMMA package running in the R statistical software environment (Smyth, 2004).  
Background correction of raw intensities was performed using the normexp correction 
method (Ritchie et al., 2007). Subsequently, the background corrected intensities were 
normalized using printip-loess normalization (within array normalization), and aquantile 
method was used to perform across array normalization (Smyth and Speed, 2003a). 
Linear modeling using moderated t-tests was performed to identify differentially 
expressed genes (Smyth, 2004).  To account for the multiple comparisons, the false 
discovery rate correction method of Benjamini and Hochberg was used (Benjamini and 
Hochberg, 1995). Linear models were used to assess the differentially expressed (DE) 
genes in RAO-susceptible animals after 30-day allergen challenge compared to baseline 
(RAO T30/T0); similarly, linear models were fit to obtain DE genes in the control group 
of animals after 30-day allergen challenge compared to the baseline (CON T30/T0). 
Genes were considered significantly differentially expressed if they had a p value < 0.05 
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and fold change > 1.5. In order to compare the expression profile of RAO animals with 
the control group at baseline and after 30-day allergen challenge, we conducted 
individual channel analysis of the two-channel microarray data (Smyth, 2005), since no 
direct co-hybridizations of RAO and control group were performed due to limited 
availability of RNA. For this analysis the array information is converted to separate 
single channel data and two additional contrasts were set up: expression profile for 
symptomatic RAO horses compared to healthy after 30-day allergen exposure 
(RAO/CON T30) and also expression profile for asymptomatic RAO horses compared to 
healthy horses at baseline (RAO/CON T0) to obtain the list of differentially expressed 
genes.  
 
Functional Gene Ontology analysis 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 and 
GO Term Mapper online free software were used for the purpose of functional 
annotation. For any given gene list, DAVID functional annotation tools provide gene–
term enrichment analysis to identify the most relevant statistically significant (p<0.05) 
biological GO terms associated with a given gene list (Huang et al., 2009b, a). For a 
more comprehensive functional analysis to understand the overall biological meaning of 
the differentially expressed genes we used GO Term Mapper 
(http://go.princeton.edu/cgi-bin/GOTermMapper). GO Term Mapper maps Gene 
Ontology (GO) annotations of genes to GO slim terms to provide a higher-level view of 
functions (http://www.geneontology.org/GO.slims.shtml). GO slims terms are especially 
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valuable for summarizing the GO annotation results of microarray data for a broad 
classification of gene product function (Onsongo et al., 2008). 
 
Linear Discriminant Analysis  
Linear Discriminant Analysis (LDA) is a statistical classification technique to find a 
linear combination of features to classify and discriminate two or more classes and 
perform dimensionality reduction (Ye and Ji, 2009). In our analysis, the features were 
differentially expressed genes and the two classes were RAO and control groups. We 
employed LDA to identify molecular classifiers based on 1, 2 and 3 DE genes that 
discriminate RAO-susceptible horses from controls. These classifiers, when ranked 
using their misclassification error, provide potential biomarkers for differentiating the 
asymptomatic and symptomatic horses from healthy horses. Thus, LDA can be used to 
obtain gene sets that can classify/distinguish two or more groups of experimental 
conditions or phenotypes. While performing classification it is vital to estimate the 
classification error when potential feature sets are large in number, particularly in cases 
where several hundred/thousand genes are simultaneously analyzed. When the sample 
size in terms of the number of animals tested is limited, the estimator of the 
classification error may have a large variance. This can produce many feature sets 
composed of several DE genes and classifiers based on those feature sets with low error 
estimates (Zhao et al., 2009). This problem was mitigated by applying bolstered error 
estimation (Zhao et al., 2009), which produces more conservative error estimates by 
injecting Gaussian noise in the real data. In our study DE genes (p<0.05) from the two 
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comparisons RAO/CON T0 and RAO/CON T30 were used as features for the 
subsequent LDA. The number of genes for each classifier was tested for three or less, 
which permitted to circumvent problems associated with the small-sample sized 
experimental designs. Thus, the classifiers based on feature/gene sets of sizes 1, 2, and 3 
were used to discriminate between the RAO and Control groups at the two time points. 
In order to estimate the improvements in the classification, quantities like  εbolstered and 
Δεbolstered have been used for each gene-set. εbolstered represents bolstered resubstitution 
error of the discriminant classifier, and Δεbolstered represents the reduction in error 
relative to the highest ranked of its subsets of genes (Braga-Neto and Dougherty, 2004). 
The gene sets were ranked based on the value of εbolstered.  
 
Quantitative Real-Time PCR 
Quantitative real-time PCR was performed on genes significantly differentially 
expressed (Log fold change >0.58 or < -0.58 and p-value<0.05) and also biologically 
relevant to RAO (as determined from the function of the DE gene in relation to the 
disease). This technique was used to validate results obtained from the statistical analysis 
of the microarray data.  Each gene was tested in duplicate along with 18s rRNA as the 
housekeeping gene. The fold change was calculated using the Pfaffl method (Pfaffl, 
2001). The total RNA was directly reverse transcribed to cDNA using the TaqMan® 
Reverse Transcriptase reagents (Applied Biosystems, CA) and subsequently amplified 
using gene specific primers and master mix by qPCR in a single step reaction as 
described.   
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When possible, primers were designed to span intron-exon boundaries to represent a 
region of the mRNA corresponding to the location of the cDNA sequence present on the 
arrays. Serial dilutions of RNA from the reference sample were used to generate relative 
standard curves and test the amplification efficiency of each primer set. For each qPCR 
assay, ~100 ng of total RNA was used in a 25 µl reaction with 1x Universal SYBR® 
Green Master Mix (Applied Biosytems, CA) and 300 nM primers, and amplified on a 
LightCycler 480 (Roche Diagnostics, IN).   
 
RESULTS 
Differentially expressed Genes  
Comparison of the lung tissue of the control animals at time points T0 and T30 showed 
that 25 genes were differentially expressed between them, of which 14 were up-
regulated and 11 down-regulated (Table 2-1). These genes are mainly involved in active 
cell recruitment and inflammation. A similar comparison between RAO-susceptible 
animals at the two time points led to the identification of only 7 DE genes that are 
mainly involved in translation. In contrast to these observations, when comparisons were 
made between RAO-susceptible and control animals at time point T0, we found 154 DE 
genes (61 up-regulated and 93 down-regulated) suggesting that there are intrinsic 
differences between the two groups of animals at this time point. Next, following a 30-
day allergen exposure (T30), 104 DE genes were found across the two groups, of which 
70 were up-regulated and 34 were down-regulated. A closer examination of the genes 
that were differentially expressed between the RAO-susceptible and control animals 
 55 
irrespective of their exposure to allergens or not (i.e. at T0 as well as T30) showed only 
30 of the total DE genes (154+104=258) were common to both time point comparisons, 
indicating that the majority of the DE genes at the two time-points were different. 
Predominant functions of the 30 common genes are signal transduction, response to 
stress, cell differentiation and death. A summary of these genes is presented in figure 2-
1. Of these 30 genes, 19 remained up-regulated and 11 remained down-regulated. 
Detection of only a small proportion of common DE genes between the two groups 
suggests that the impact of allergen exposure on the expression profile at the two time 
points, as assessed by the different set of DE genes at T0 and T30, is clearly different in 
the RAO-susceptible versus control comparisons. 
 
 
 
Table 2-1: Differentially expressed genes. List of differentially expressed genes for 
each comparison is shown in the table. Genes were considered differentially expressed 
with pvalue<0.05 and fold change >1.5. [T30 represents 30-day allergen exposure time 
point and T0 represents baseline].  
Comparison Differentially expressed genes 
RAO T30 versus Control T30 Up: 70 Down: 34 
RAO T0 versus Control T0 Up: 61 Down: 93 
RAO T30 versus RAO T0 Up: 3 Down: 4 
Control T30 versus Control T0  Up: 14 Down: 11 
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Figure 2-1: Overlap analysis. The venn diagram represents overlap of the DE genes at 
baseline and 30 days after allergen exposure in RAO versus Control comparison. 30 
genes were found to be common between RAO-control comparison at 30 days (104 DE 
genes) and RAO-control comparison at baseline (154 DE genes).  
 
 
 
Quantitative real-time PCR validation 
Real-time PCR (qPCR) was used to validate findings of select genes that were 
significantly differentially expressed from the four comparisons in this study. Because 
limited amount of RNA was available from each peripheral lung tissue sample, we could 
choose only 6 genes for the validation purposes. Of the 6 genes selected for validation, 
we could confirm the differential expression for 5 genes in relation to the microarray 
data: NLRP1 (CON T30/T0), HCK (RAO/CON T30), ELAVL1 (RAO/CON T0), 
PIK3R1 (RAO/CON T0) and KIF2A (RAO T30/T0). Based on microarray results, genes 
ELAVL1 and NLRP1 were up-regulated and HCK, KIF2A and PIK3R1 were down-
regulated (figure 2-2).  
 
Although qPCR results were not as pronounced as the microarray results, the trend (up- 
and down-regulation) essentially matched. Variation in correlation between microarray 
RAO T30 vs. 
Control T30 
RAO T0 vs. 
Control T0 
74 124  30 
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based fold change values and lack of repeatability of the results in qPCR could be 
attributed to various factors. Small sample size increases the probability of obtaining 
false positives that pose challenge in qPCR validation. Additionally, various factors like 
data normalization, fold change and p-value stringency also effect confirmation of 
correlation between microarray and qPCR results (Dallas et al., 2005; Morey et al., 
2006). Greater correlation is observed between the two results when genes exhibit at 
least 1.4 fold change, and stringent p-value limits of 0.0001 or less are imposed in 
microarray data analysis (Morey et al., 2006).  
 
 
 
 
Figure 2-2: Real-time PCR validation. Fold changes (log base 2) of five genes were 
validated using qPCR. The genes were differentially expressed (p<0.05 and fold 
change>1.5) EVAVL1 (RAO/CON T0), NLRP1 (CON T30/T0), HCK (RAO/CON 
T30), KIF2A (RAO T30/T0), PIK3R1 (RAO/CON T0). 
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Gene Ontology Analysis 
 
Gene ontology analysis was performed using the list of DE genes (both up- and down-
regulated). Biological processes, cellular components and molecular functions associated 
with the DE genes were obtained in each of the four comparisons. 
 
RAO-susceptible horses at 30-day exposure versus baseline (RAO T30/T0) 
Comparison of gene expression in the lung tissue among RAO-susceptible animals at 
time points T0 and T30 revealed the involvement of biological process of translation 
elongation, with a central role of ribosomal protein S3A (RPS3A) and ribosomal protein 
S15a (RPS15A) genes (table A-1). The table shows that both genes are predominantly 
present at all the levels of gene ontology highlighting their importance. 
Control horses at 30-day exposure versus baseline (CON T30/T0)  
The GO analysis for DE genes in this comparison is detailed in table A-2. Some of the 
relevant GO biological processes that emerged from this comparison include a) 
regulation of cell adhesion involving genes like protein phosphatase 2, catalytic subunit, 
alpha isoform (PPP2CA), adenosine deaminase (ADA), and phosphoinositide-3-kinase, 
regulatory subunit 1 alpha (PIK3R1) b) purine base metabolic process involving genes 
like ADA and adenosine monophosphate deaminase 1 (AMPD1) and, c) B-cell 
differentiation, with genes like ADA and PIK3R1. Genes ADA and AMPD1 appear to 
be predominantly associated with majority of biological processes in this comparison 
listed in the table (table A-2.).  
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RAO-susceptible versus control horses at baseline (RAO/CON T0)  
The GO analysis of the DE gene for this comparison is presented in table A-3. Key 
biological processes associated with these genes include a) regulation of blood pressure 
and blood vessel size b) regulation of protein kinase cascade, and c) immune system 
development (figure 2-3). Regulation of blood pressure includes genes like actin alpha 
2, smooth muscle, aorta (ACTA2), angiotensinogen (AGT) and hemoglobin beta (HBB). 
Regulation of protein kinase cascade includes genes like ubiquitin-conjugating enzyme 
E2N (UBE2N), cardiotrophin-like cytokine factor 1 (CLCF1), erythroblastic leukemia 
viral oncogene homolog 2 (ERBB2), angiotensinogen (AGT) and cystathionine-beta-
synthase (CBS). Key genes involved in the immune system development process 
included tumor necrosis factor receptor superfamily, member 11a, NFKB activator 
(TNFRSF11A), cardiotrophin-like cytokine factor 1 (CLCF1), sialomucin (CD164) and 
phosphoinositide-3-kinase, regulatory subunit 1 alpha (PIK3R1). 
 
RAO-susceptible versus control horses after 30-day allergen exposure (RAO/CON 
T30) 
After 30-day allergen exposure of horses in the two groups, GO analysis yielded 
enriched biological process, molecular function and cellular component terms associated 
with the DE genes (table A-4). The most significant GO biological processes were 
translation and translation elongation (figure 2-3). The translation process was 
associated with genes like eukaryotic elongation factor 1A1 (EEF1A1), MRPL21, 
ribosomal protein S3A (RPS3A), ribosomal protein L13a (RPL13A) and ribosomal 
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protein, large, P1 (RPLP1).  In the translation elongation category we found genes such 
as EEF1A1, RPS3A, RPL13A and RPLP1 as significant players. The overall results of 
the GO analysis suggest that at baseline (T0), difference between RAO and control 
animals were mainly related to vasculature and immune response. However, at the 30-
day time point (post allergen exposure), difference between the RAO-susceptible and 
control horses is largely related to triggering of the protein synthetic machinery. 
 
 
 
Figure 2-3: Enriched biological process terms in RAO animals compared to 
control. The enriched biological process terms were obtained via DAVID. Count 
represents the number of genes belonging to each process.  
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GO slim analysis of differentially expressed genes 
DAVID analysis of DE genes yields only statistically significant GO terms. Hence, in 
order to get a broader overview of biological processes associated with expression 
profile comparisons carried out in this study between animals at different time points, we 
conducted additional analysis of the DE genes using GO Term Mapper that conducts 
GO-slim analysis and provides the GO-slim terms.  GO-slim terms thus obtained give an 
overview of the ontology content, and hence are useful in summarizing results of GO 
annotation of microarray results. The analysis led to the identification of additional 
(compared to DAVID analysis only) biologically meaningful processes associated with 
the DE genes including cellular component organization, response to stress, signal 
transduction, death, cell differentiation, cell communication and cell proliferation 
(figure 2-4). Although broadly these GO categories were common to both RAO/CON at 
T0 and RAO/CON at T30 comparisons, the DE genes present in each of the categories 
were largely different (the degree of differentiation i.e. the difference between the genes 
in the two categories, ranged between 90-100%). For example, in the GO term “death”, 
only 1 gene was common for the comparison at time point T0 (total 10 genes) and T30 
(total 6 genes), due to which the difference in the genes involved between the groups is 
around 93.75%.   
 
GO Term Mapper results also provide differences in GO term usage in the DE gene list 
versus their usage across the genome. All the over-represented GO terms associated with 
DE genes in RAO-susceptible versus control horses at T0 and after T30 time points are 
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listed in table A5. For both the comparisons at T0 and T30, we observed that certain GO 
terms were highly enriched in the list of DE genes compared to 18410 annotated genes 
present in human gene database.  Comparisons indicate that the genome levels most of 
the above mentioned biological process i.e. percentage of genes belonging to each 
process from the list of DE genes were higher than percentage of genes involved in that 
process at the genomic level.  For example, we observed that 22 out of 90 (24.44%) DE 
genes at T0 were involved in cellular component organization (GO term), while only 
3370 of 18410 (18.31%) of annotated genes in human database were associated with that 
GO term (table A-5). Hence, over-representation of certain GO terms with the list of DE 
genes suggests that these processes may potentially explain the molecular mechanisms 
underlying the transcriptional changes occurring at two time points (T0 and T30).  
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Figure 2-4: GO Term Mapper result. Bar graph represents certain biologically 
relevant processes associated with RAO versus Control comparison. Plum bars represent 
number of genes associated with each process at baseline. Blue bars represent number of 
genes associated with each process after 30-day allergen exposure. Yellow line denotes 
percentage of differentiation (in terms of number of genes different for each process) 
between the baseline and exposure group.  
 
 
 
Linear Discriminant Analysis 
In order to explain the effect of allergen exposure in RAO-susceptible horses compared 
to control horses, we utilized the LDA classification technique to identify the best 
single-gene and combinations of two- to three- genes classifiers that are key 
discriminators between the transcription profiles of RAO-susceptible and control 
animals. The classifiers were ranked based on their misclassification error (εbolstered), 
with the understanding that the best classifiers have lower misclassification error. We 
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identified the top ten 1-, 2- and 3-gene classifiers with the lowest misclassification error 
(εbolstered) that distinguish RAO-susceptible and control animals at time points T0 (table 
2-2) and T30 (table 2-3). The classification results demonstrate that there are noteworthy 
instances where a single gene can adequately distinguish the RAO-susceptible animals 
from the control with a low error estimate. Furthermore, when these single-gene features 
were considered as part of the 2 or 3-gene classifiers, a significant decrease in the 
classification error was observed as evident from the percent decrease in the error 
depicted by Δεbolstered shown in table 2-2 and 2-3. The specific results for discriminating 
the expression profiles of RAO from control horses at T0 and T30 are detailed below.  
 
Classification of expression profile of RAO-susceptible from control horses at baseline 
At time-point T0, the top single-gene classifier discriminating RAO-susceptible animals 
from the controls was found to be CT02034A1G04 (top in the list of single-gene 
classifiers; table 2-2), with an estimated classification error of 0.0877. Among the 2-
gene classifiers, a combination of MYLIP and PTGS2 ranked high in the ability to 
distinguish between the two groups of animals (εbolstered= 0.0368). Moreover, together the 
two genes were better discriminators (lower error estimate) compared to either of them 
individually, as evidenced by around 7% (Δεbolstered =0.0749) reduction in 
misclassification error. While, programmed cell death 5 (PDCD5), CX602251, and 
C17orf63 formed the top 3-gene classifier set distinguishing the two groups of animals 
with an error estimate of 0.0107, it was also interesting to note that none of these genes 
were among the top ten single gene classifiers. There was an improvement of around 3% 
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(Δεbolstered =0.0365) in the classification when PDCD5 was used in combination with 
CX602251 and C12orf63 over the 2-gene classifier with the two genes. Among the top 
1-, 2- and 3-gene classifiers, the latter not only had the lowest classification error but 
also showed sizable decrease in the error when compared to the single- and two-gene 
classifiers. Thus, the top three-gene classifiers appear to be better discriminators between 
the RAO-susceptible and control group of horses at time point T0 (table 2-2). A clear 
separation of RAO-susceptible and control animals at time point T0 by the three 
dimensional LDA hyperplane based on the top triplet classifier is presented on figure 2-
5. The figure illustrates how the separating plane (LDA hyperplane) defined by the 
classifiers based on genes PDCD5, CX602251, and C17orf63 (representing the three 
axes) clearly separates the RAO (represented by circles in the figure) and control 
(represented by triangles in the figure) horses on the two sides of the plane without any 
overlap. 
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Table 2-2: Linear discriminant analysis of RAO versus control animals at baseline. 
The top ten one-, two-, and three-gene LDA classifiers are shown in the table below.  ε 
bolstered represents the bolstered resubstitution error for the respective gene classifier and  
Δ ε bolstered represents the decrease in error for each feature set relative to its highest 
ranked subset of genes.  
1 feature 2 feature 3 feature ε bolstered 
Δ ε 
bolstered 
CT02034A1G04.f1.ab1     0.0877   
MYLIP     0.1117   
CT020018B20G01.ab1     0.1272   
TLOC1     0.1469   
PTGS2     0.1475   
SERPINB7     0.149   
RPS15A     0.1539   
PLT23-F13-M13R.ab1     0.1595   
CT020024A20C11.ab1     0.1615   
TMPO     0.165   
MYLIP PTGS2   0.0368 0.0749 
RPL13A gnl|UG|Eca#S36639312   0.0401 0.1396 
MYLIP CT02034A1G04.f1.ab1   0.043 0.0447 
PTGS2 OR6C2   0.0431 0.1044 
CT020018B20G01.ab1 gnl|UG|Eca#S36639312   0.0457 0.0815 
TLOC1 RPL13A   0.0463 0.1006 
CT020024A20C11.ab1 C17orf63   0.0466 0.1149 
gnl|UG|Eca#S3664480
1 C17orf63   0.0472 0.178 
RPL13A WDR36   0.0505 0.1292 
CT02034A1G04.f1.ab1 gnl|UG|Eca#S36644799   0.0515 0.0362 
PDCD5 CX602251 C17orf63 0.0107 0.0365 
RPL13A WDR36 OR6C2 0.0131 0.0374 
RPL13A ACCN5 gnl|UG|Eca#S36639312 0.0151 0.025 
RPL13A WDR36 gnl|UG|Eca#S36639312 0.0169 0.0232 
MYLIP gnl|UG|Eca#S36644801 C17orf63 0.0207 0.0265 
 
MYLIP PIGW PTGS2 0.0222 0.0146 
PIGW gnl|UG|Eca#S36644801 C17orf63 0.0236 0.0236 
TLOC1 RPL13A PIGW 0.0238 0.0225 
CT02034A1G04.f1.ab1 TP53BP2 CLCF1 0.0241 0.0292 
TP53BP2 CT020018B20G01.ab1 gnl|UG|Eca#S36639312 0.0251 0.0206 
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Figure 2-5: Linear discriminant analysis using three-gene classification model for 
RAO versus control at baseline. C17orf, CX602251 and PDCD5 provided the best-
performing three-gene feature set. The three dimensional LDA hyperplane discriminates 
between control (circles) and RAO-susceptible (triangles). Normalized intensity values 
of the corresponding genes are represented on the axes.  
 
 
 
Classification of expression profile of RAO-susceptible from control horses after 30-
day allergen exposure 
At time-pint T30, the top 1-gene classifier discriminating RAO-susceptible animals from 
the controls was found to be GRHL2 (top in the list of single-gene classifiers), with an 
estimated classification error of 0.0788 (table 2-3). Among the 2-gene classifiers, a 
combination of GRHL2 and CT020008B20C03.ab1 ranked high in the ability to 
distinguish between the two groups of animals (εbolstered= 0.035). Jointly, the two genes 
were better discriminators (lower error estimate) compared to either of them 
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individually, as evidenced by around 4% (Δεbolstered =0.0463) reduction in 
misclassification error. Next, gnl|UG|Eca#S36625350, GRHL2 and 
CT020008B20C03.ab1 formed the top 3-gene classifier distinguishing the two groups of 
animals with an error estimate of 0.0141. This classifier showed an improvement of 
1.8% (Δεbolstered =0.0184) in the classification over the 2-gene classifier based on 
GRHL2 and CT020008B20C03.ab1 only. A clear separation of RAO and control group 
at time point T30 by the respective LDA plane is presented on figure 2-6. The figure 
illustrates the separation plane (LDA hyperplane) obtained by classifiers based on genes 
gnl|UG|Eca#S36625350, GRHL2 and CT020008B20C03.ab1 (representing the three 
axes) clearly separates the RAO (represented by circles in the figure) and control 
(represented by triangles in the figure) horses on the two sides of the plane without any 
overlap.  
 
Overall, it is noteworthy that GRHL2, in addition to being the best 1-feature classifier 
was a part of combinations of genes for the best 2- and 3-feature classifiers. Another 
notable feature was that GRHL2 appears frequently with other lower ranked 2- and 3-
feature classifiers highlighting the potential significance of this gene as a discriminating 
feature between the RAO and control groups. 
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Table 2-3: Linear discriminant analysis of RAO from control animals after allergen 
exposure. The top ten one-, two-, and three-gene LDA classifiers are shown in the table 
below.  ε bolstered represents the bolstered resubstitution error for the respective gene 
classifier and  Δ ε bolstered represents the decrease in error for each feature set relative to 
its highest ranked subset of genes.  
 
1 feature 2 feature 3 feature ε bolstered 
Δ ε 
bolstered 
GRHL2     0.0788   
GENE:17761     0.0999   
COPS3     0.1186   
C9orf23     0.1303   
CT020013B10D12.ab1     0.1355   
gnl|UG|Eca#S36626276     0.1421   
C17orf49     0.1432   
ACTR2     0.1434   
CT020003A10_PLT_B0
8_58_064.ab1     0.1445   
TYRP1     0.1517   
GRHL2 CT020008B20C03.ab1   0.0325 0.0463 
C9orf23 GENE:17761   0.0358 0.0641 
GRHL2 CT020003A10_PLT_B08_58_064.ab1   0.0396 0.0392 
GRHL2 gnl|UG|Eca#S38809095-5   0.0401 0.0387 
GRHL2 CT02040B1E07.f1.ab1   0.047 0.0318 
gnl|UG|Eca#S36625350 GRHL2   0.0474 0.0314 
SH2D1A GRHL2   0.0483 0.0305 
CT020013B10D12.ab1 GRHL2   0.0507 0.0281 
CT020013B10D12.ab1 HCK   0.0532 0.0823 
NENF GRHL2   0.055 0.0238 
gnl|UG|Eca#S36625350 GRHL2 CT020008B20C03.ab1 0.0141 0.0184 
SH2D1A GRHL2 CT020008B20C03.ab1 0.0183 0.0142 
GRHL2 CT020022B10E09.ab1 CT020003A10_PLT_B08_58_064.ab1 0.0184 0.0212 
GRHL2 CT020008B20C03.ab1 CT020003A10_PLT_B08_58_064.ab1 0.0189 0.0136 
CT010001000_PLT_G0
9_71_068.ab1 GRHL2 CT020008B20C03.ab1 0.0205 0.012 
GRHL2 CT020008B20C03.ab1 TYRP1 0.0207 0.0118 
CT010001000_PLT_G0
9_71_068.ab1 GRHL2 
gnl|UG|Eca#S38809095
-5 0.021 0.0191 
HCK GRHL2 gnl|UG|Eca#S38809095-5 0.0211 0.019 
TMEM165 GRHL2 CT020008B20C03.ab1 0.0215 0.011 
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Table 2-3 Continued 
 
1 feature 2 feature 3 feature ε bolstered Δ ε bolstered 
GRHL2 GENE:17761 gnl|UG|Eca#S38809095-5 0.0215 0.0186 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-6: Linear discriminant analysis using three-gene classification model for 
RAO versus control after allergen exposure. CT_PLT_B08_58_064.ab1, GRHL2, 
CT020008B20C03.ab1 provided the best-performing three-gene feature set. The three 
dimensional LDA hyperplane discriminates between RAO (circles) and Control 
(triangles). Axes represent normalized intensity values of the corresponding genes.  
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DISCUSSION 
Expression profiles associated with peripheral lung tissue in asymptomatic (without 
allergen exposure: T0) and symptomatic (after 30-day allergen exposure: T30) RAO-
susceptible horses were compared with the expression profiles of control horses at the 
two time points. Our findings suggest that allergen exposure in RAO-susceptible horses 
(compared to baseline) modulates processes related to protein synthesis, immune 
response and inflammation. While RAO-susceptible horses show a lingering impact of 
airway remodeling from prior exposure (and subsequent remission) compared to the 
controls before being exposed to allergens for 30 days, it is apparent that allergen 
exposure led to elevated protein synthesis and inflammation that contributes to 
aggravation of symptoms and airway changes. 
 
Differentially expressed genes  
We observed dozens of differentially expressed genes while comparing expression 
profiles of RAO-susceptible and control animals both at time-points T0 and T30. In 
contrast, only a few genes (7) were differentially expressed between asymptomatic (T0) 
and symptomatic (T30) RAO-susceptible animals. A similar trend was observed for 
comparison involving the control group before and after allergen exposure, where only a 
limited number of DE genes (25) were identified. In essence, changes in gene expression 
profile are greater in the RAO-susceptible horses vs. the controls following allergen 
exposure, while the changes were limited within the susceptible/diseased group for the 
before and after allergen exposure comparison. Further, detection of largely different 
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sets DE genes between the RAO vs. CON at T0 and RAO vs. CON at T30 comparisons 
point to marked differences in the transcription profile between the two groups that 
could be attributed to allergen exposure.  
 
Functional analysis  
RAO-susceptible horses at 30-day exposure versus baseline (RAO T30/T0) 
In the asymptomatic RAO-susceptible animals, 30-day allergen exposure resulted in 
differential expression of genes involved in translation elongation, among which 
ribosomal protein S3A (RPS3A) and S15a (RPS15A) are prominent.  Collectively, 
ribosomal proteins are involved in protein synthesis, however, various components of 
protein machinery like ribosomal proteins, translation initiation and elongation factors 
have been reported to be involved in the regulation of cell growth, regulation of 
apoptosis, DNA repair and RNA splicing (Naora et al., 1998; Lai and Xu, 2007). 
RPS3A, which was found to be down-regulated in symptomatic RAO horses, is reported 
to play a key role in translation initiation and regulation of cellular apoptosis (Naora, 
1999). Suppression of RPS3A expression has been proposed to induce apoptosis, hence 
reduced expression of this gene after allergen exposure may contribute to an increase in 
the apoptosis of smooth muscle cells (Naora et al., 1998). Study by Leclere et al. (2010)., 
suggested that increase in airway smooth muscle mass in chronically affected RAO 
horses is maintained by an elevated cellular proliferation and apoptosis (cellular 
turnover). They suggested that the allergen exposure in such horses does not lead to 
further increase in muscle mass. RPS3A could be contributing to myocyte apoptosis and 
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thus maintenance of an increased muscle mass in the RAO-susceptible horses compared 
to control horses.  
 
Since, limited number of DE genes were obtained for the RAO T30/T0 comparison, we 
expanded the list of the DE genes by relaxing the threshold to p-value <0.05 with no fold 
change restriction to obtain a broader overview of genes impacted at/during this time 
point. The DE genes thus obtained were associated with biologically processes like 
induction and regulation of apoptosis (RPS3A, UBC, TP53, MAL, TRAF6, UNC13B, 
RPS27A), immune response (HLA-DRB1, PLUNC, ANXA11, CD1A, TRAF6, 
S100A9, TP53) and antigen processing and presentation (HLA-DRB1, CD1A, TRAF6). 
Genes like TP53, RPS3A and RPS27A are known to be associated with induction and 
regulation of apoptosis. Further, S100A9, one of the central genes in the immune 
response process in our results, has a role in neutrophil migration to the sites of 
inflammation (Ryckman et al., 2003; Vandal et al., 2003; Gebhardt et al., 2006). 
Interestingly a heteromeric complex of S100A8 and S100A9 has been reported to play a 
role in human asthma pathogenesis and is also proposed to be involved in airway 
remodeling (Halayko and Ghavami, 2009). Likewise PLUNC (down-regulated in our 
findings), another immune response gene, is involved in an inflammatory response to 
irritants in upper airways (Bingle and Craven, 2002) and has been found to be down-
regulated in murine model of allergic asthma (Follettie et al., 2006). Further, human 
leukocyte antigen (HLA) class II genes that are part of both immune response and 
antigen presentation processes, are present on antigen presenting cells (APC’s) like DC, 
 74 
macrophages, B-lymphocytes(Brown et al., 1993). DRB1 alleles have been implicated in 
atopic asthma (Lara-Marquez et al., 1999; Cho et al., 2000; Spinetti et al., 2003) and are 
proposed to modulate total serum IgE concentration and IgE response to allergens 
(Moffatt et al., 2001).  
 
Next, gene TRAF6 was associated with all the three biological processes: apoptosis, 
immune response and antigen presentation in our results. TRAF6 has been reported to 
play a role in innate immunity, maintaining immune homeostasis and critical for 
maturation and function of dendritic cells (DC’s) (Kobayashi et al., 2003a). Since DC’s 
cells are known to play an important role in Th2 immune response and allergic 
inflammation (Lambrecht, 2005; Lambrecht and Hammad, 2010) involvement of this 
gene in maturation and functioning of DC’s can be of significance as a biomarker of 
inflammation during RAO.  
 
Hence, it is plausible that the allergenic stimulus to the RAO-susceptible horses initiates 
inflammatory reaction (with migration of neutrophils for example due to genes like 
S100A9), activates innate immunity, and by presentation of antigens via APC’s (HLA-
DRB1 and TRAF6 gene), recruits components of adaptive immunity. Thus, the 30-day 
allergen exposure in RAO-susceptible animals potentially causes increased protein 
synthesis (possibly to account for slightly increased smooth muscle cellular turnover due 
to increased apoptosis), increased apoptosis, antigen recognition and inflammation.  
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Control horses at 30-day exposure versus baseline (CON T30/T0) 
In the control horses, allergen exposure for 30 days (compared to T0) caused differential 
expression of genes involved in processes like cell adhesion (PPP2CA, ADA, PIK3R1), 
B-cell differentiation (ADA, PIK3R1) and purine base metabolic process (ADA, 
AMPD1).  
 
Adenosine deaminase (ADA) metabolizes adenosine and its deficiency in mice causes 
respiratory distress and lung inflammation due to accumulation of adenosine (Blackburn 
and Kellems, 2005). Adenosine levels increase during acute and chronic inflammation 
(asthma) and its exogenous administration is known to cause bronchoconstriction in 
asthmatics and not in healthy subjects (Mann et al., 1985). Down-regulation of ADA in 
the control horses could thus primarily be contributing to inflammation in response to 
the allergen exposure without any concomitant development of airway obstruction.  A 
similar observation was also reported by, Leclere et al. 2010 who found that 30-day 
allergen exposure in healthy horses (controls) resulted in a transiently increased 
inflammation as evidenced by an elevated neutrophil count in bronchoalveolar lavage 
but no evidence of bronchoconstriction in the control horses (Leclere et al., 2010).  
 
Phosphoinositide-3-kinase, regulatory subunit 1 (PIK3R1) is associated with biological 
processes including cell activation, regulation of cell-matrix adhesion, immune system 
development and leukocyte differentiation. Since PIK3R1 gene is involved in signaling 
 76 
events that mediate various biological processes, it will be difficult to comment on its 
exact functional role in control horses.  
 
To summarize, we found a small number of DE genes (25) associated with the control 
horses. In line with this observation, we found very few distinct biological processes 
associated with the DE genes. Genes ADA and AMPD associated with purine nucleoside 
synthesis and metabolism related processes were predominantly present in the list of 
statistically significant processes.    
 
In essence, indications are that although the control horses are inherently not susceptible 
to allergen exposure, underlying molecular mechanisms do get underway in this group of 
horses as evidenced by the DE genes. However, it appears that the impact of these genes 
either does not reach a threshold necessary for manifestation of clinical signs, or it is 
contained by other genes that potentially render resistance to visible reaction to allergen 
exposure.  
 
RAO-susceptible versus control horses at baseline (RAO/CON T0) 
The DE genes between RAO-susceptible and control animals before allergen exposure 
(at T0 time-point) were related to biological processes including regulation of blood 
pressure (PTGS2, ACTA2, AGT, HBB), regulation of blood vessel size (ACTA2, AGT, 
HBB), protein kinase signaling (UBE2N, CLCF1, ERBB2, AGT, CBS), and immune 
system development (POLL, TNFRSF11A, CLCF1, CD164, PIK3R1) as deduced from 
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GO biological terms using DAVID, and response to stress (AGT, AP1G1, ATG3, 
ERBB2, HFE, HSPE1, LAT, MARK2, PIK3R1, POLL, PSMA1, PTGS2, SLC7A7, 
TNFRS11A, UBE2N) , cellular proliferation (AGT, CD164, ERBB2, PTGS2, RPS15A, 
TNFRS11A) and apoptosis (AGT, ATG3, CLCF1, ERBB2, HSPE1, PDCD5, PEO1, 
PSMA1, PTGS2, TP53BP2) as indicated by GO-slim terms.  
 
Airway remodeling is associated with features like angiogenesis and elevated smooth 
muscle mass (Chu et al., 2001; Herszberg et al., 2006; Ribatti et al., 2009; Leclere et al., 
2010). It is known that blood pressure regulation and size of blood vessels are features of 
angiogenesis (Charan et al., 1997; Chu et al., 2001; Nissim Ben Efraim and Levi-
Schaffer, 2008; Simcock et al., 2008), and increased cellular proliferation and apoptosis 
are considered as factors that contribute to increased smooth muscle mass (Herszberg et 
al., 2006; Leclere et al., 2010). For example, angiotensinogen (AGT) gene associated 
with blood pressure and blood vessel size in our study is a member of renin-angiotensin 
system, and is known to regulate angiogenesis (formation of blood vessels) that 
underlies pathogenesis of variety of disorders including asthma (Corvol et al., 2003; 
Clapp et al., 2009). Angiotensinogen has anti-angiogenic properties (Clapp et al., 2009) 
and reduced mRNA levels are known to promote angiogenesis (Chang and Perlman, 
1988). Hence we speculate that down-regulated of AGT in RAO-susceptible horses at 
T0 possibly contributes to the vascular remodeling component of lower airways. 
Response to stress was another process associated with the DE genes at T0, and among 
those genes was heat shock protein 1 (HSPE1) that was found to be up-regulated in 
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RAO-affected horses. HSPE1 acts as a chaperonin by enhancing protein folding and also 
protects cell against stress induced by inflammation (Johnson et al., 2005; Jia et al., 
2011). Gene CD164 (sialomucin; up-regulated in asymptomatic RAO animals compared 
to controls) is a component of both immune system development and cellular 
proliferation process. The up-regulation of CD164 is known to cause cell growth 
dysregulation (Kurosawa et al., 1999; Chan et al., 2001), And the gene has been reported 
to be up-regulated in patients with seasonal allergic rhinitis caused by grass pollens 
(Wolanczyk-Medrala et al., 2010), in response to pollen exposure. Up-regulation of this 
gene in asymptomatic RAO-susceptible horses at T0 (in absence of any allergen 
stimulus) suggests remnant effects of the gene in response to previous allergen exposure, 
and it is plausible that the gene mediates hyperplasia/hypertrophy of smooth muscle cells 
of lower airways in these animals.  
 
It is noteworthy that comparing asymptomatic RAO-susceptible horses and their healthy 
counterparts at time-point T0 (no allergen exposure) yielded a number of DE genes even 
though both group of horses are expected to be almost in the same ‘stage of health and 
no-exposure. A possible explanation for this difference could partly be attributed to 
inherent differences between the RAO susceptible and control animals, but partly also 
because of past allergen exposures of RAO-susceptible horses that established 
remodeling and thus have a lingering impact of genes and processes associated with it in 
the observed DE genes even at time-point T0 when animals have not been exposed to 
allergens. Since majority of the identified processes contribute to airway remodeling, 
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further investigation of the significance of the genes involved in these processes can 
potentially shed light on molecular mechanisms associated with airway smooth muscle 
remodeling.  
 
RAO-susceptible versus control after 30-day allergen exposure (RAO/CON T30) 
The 30-day allergen exposure in RAO-susceptible horses compared to control at time-
point T30 mainly highlighted genes that were associated with biological processes like 
translation (EEF1A1, MRPL21, RPS3A, RPL13A, RPLP1) and translation elongation 
(EEF1A1, RPS3A, RPL13A, RPLP1). GO-slim terms associated with the DE genes 
revealed processes like response to stress (ALDOB, CCL5, EYA4, HCK, HSPE1, 
SH2D1A, SPHK1, TFPI2, UBE2N), proliferation (IGFBP6, SPHK1), and apoptosis 
(DNASE1L3, HSPE1, RPS3A, SH2D1A, SPHK1). Elongation factor 1 alpha (EEF1A) 
gene from our results is a part of both translation and translation elongation processes. 
The EEF1A1 transcript was up-regulated in symptomatic RAO horses compared to the 
controls. Recently, Venugopal et al. 2010 also found this gene to be up-regulated in 
RAO animals compared to the controls (Venugopal et al., 2010b). Although no direct 
role of EEF1A1 has been reported so far in RAO or human asthma studies, its 
overexpression may contribute to cellular proliferation and apoptosis, that are 
histological features of asthma and RAO (Johnson et al., 2001; Huang et al., 2005; 
Herszberg et al., 2006; Leclere et al., 2010). High mRNA levels of this gene are 
observed in rapidly proliferating cultured cells, embryos, and various human tumors 
(Condeelis, 1995); however its overexpression has also been reported to play a role in 
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increased apoptosis by increasing protein synthesis of pro-apoptotic factors (Duttaroy et 
al., 1998). 
 
 Some of the DE genes in our results were not a part of any of the identified statistically 
significant biological processes in the symptomatic RAO/CON comparison at the time-
point T30. However, we found few such genes up-regulated in symptomatic RAO-
susceptible horses (compared to controls). We found some immune response and 
inflammation related genes in this comparison that are worthy of discussion. These 
genes include signaling lymphocytic activation molecule-associated protein (SH2D1A), 
hemopoietic cell kinase (HCK), chemokine ligand 5 (CCL5)/RANTES, CCL8 and 
CCL11.  
 
HCK gene is essential in the signaling pathway resulting in polymorphonuclear 
leukocyte (PMN) degranulation. PMNs synthesize pro-inflammatory cytokines and 
chemokines that cause inflammation. Elevated mRNA levels of HCK gene has been 
shown to cause increased PMN degranulation leading to severe inflammation in COPD 
patients (Zhang et al., 2007). HCK gene is known to influence neutrophilic 
degranulation that can contribute in inflammation and tissue injury (Mocsai et al., 1999; 
Lacy, 2006). Allergen induced inflammation in RAO-affected animals is known to be 
predominantly neutrophilic (Lavoie et al., 2001). Up-regulation of HCK gene in RAO-
affected horses at T30 maybe contributing to inflammation compared to control horses. 
Expression of SH2D1A (up-regulated in RAO-affected horses at T30) is reported to be 
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increased post allergen exposure and its role is considered to be involved in Th2 
activation (Mobini et al., 2009).  
 
Chemokines like CCL5, CCL11 and CCL8 release pro-inflammatory mediators and 
activate Th2 cells (Romagnani, 2002). In mouse model of asthma it was shown that 
neutralizing CCL5 reduces the features of allergic asthma (Schuh et al., 2001). Th2 cells 
promote allergic airway inflammation (Lloyd and Hessel, 2010) and underlie 
pathogenesis of asthma and RAO. Targeting chemokine ligands (due to their role in Th2 
immune response) or their receptors are considered promising therapeutic strategies for 
asthma (Caramori et al., 2008). These chemokines and genes HCK and SH2D1A should 
hence be targeted for their therapeutic potential in RAO research.  
 
To summarize, our results suggest that allergen exposure increases protein synthesis, 
possibly to meet needs due to elevated cellular proliferation and apoptosis in RAO 
horses compared to control horses. Since allergen exposure is causing a modulation in 
the components of the protein synthesis machinery, it will be interesting to investigate 
whether targeting these components affects cellular turnover of smooth muscle cells that 
could indirectly affect ASM and hence remodeling.  There is also evidence of increased 
inflammation caused by allergens in the RAO-affected horses compared to controls since 
we identified genes that release pro-inflammatory mediators and activate Th2 cells. Our 
study identifies genes that influence cellular turnover (feature of airway remodeling) and 
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inflammation and can hence be promising targets for therapeutic strategies that reduce 
remodeling and inflammation component of the disease pathology.  
 
GO slim analysis of differentially expressed genes 
An interesting observation with respect to GO-slim analysis was that many shared GO 
biological categories for RAO/CON T0 and RAO/CON T30 comparison had a high level 
of differentiation in terms of genes associated with each category. The allergenic 
stimulus could be the factor that induces the same molecular pathways via induction of 
different genes (very different genes associated with biological GO slim terms). 
Biological processes like cellular proliferation and apoptosis were found common in 
both comparisons, but they were associated with different genes at the two time points. 
Both these processes have been shown to be important for airway remodeling in 
horses(Leclere et al., 2011a). Because of their presence at both time points, it appears 
that both proliferative and apoptotic pathways are important for maintenance of RAO 
phenotype, however different genes are contributing to the asymptomatic and 
symptomatic phase of the disease.  
 
Positional relevance of DE genes 
A study by Swinburne et al. 2009 identified two positional candidate regions on equine 
chromosome 13 and 15 as significantly associated with RAO via a genome-wide scan 
using microsatellite markers to genotype two half-sib families 
(Swinburne et al., 2009). Some of the DE genes obtained by us (RAO T30/T0, 
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RAO/CON T0, RAO/CON T30 comparison) are interesting candidates for future 
investigation because of their chromosomal location. Ribosomal protein S15 (RPS15A) 
gene is located on chromosome 13 adjoining the positional candidates region (6-28 Mb) 
identified by Swinburne et al. 2009 while zinc finger, HIT type 1 (ZNHIT1) is within the 
candidate region of chromosome 13. ARP2 actin-related protein 2 (ACTR2) gene was 
adjoining the positional candidate region (40-62 Mb) on chromosome 15. Genes, kinesin 
heavy chain member 2A (KIF2A) and v-erb-b2 erythroblastic leukemia viral oncogene 
homolog 2 (ERBB2) were also found to be within 6-44 Mb region on chromosome 21. 
Due to the proximity of these genes to the candidate regions defined in the family based 
genetic association study, we hypothesize that such genes could possibly be associated 
with RAO phenotype. At the mRNA level, we observed a differential expression of the 
transcript abundance of these genes; it will be interesting to probe if a polymorphism at 
DNA level is causing this alteration. These genes could hence be contributing to the 
susceptibility of the RAO-affected horses and hence can be good targets for further 
investigation into the role they play in RAO pathogenesis.   
 
Linear discriminant analysis 
LDA classification found the best one, two or three-feature classifiers for discriminating 
the asymptomatic RAO animals from control. Since the classifiers can discriminate the 
two groups of horses, such classifiers will have the potential to be used as the markers of 
the disease state (remission or clinical exacerbation) from the normal healthy state. Such 
discrimination will hence enable diagnosis of animals even when no clinical symptoms 
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are present. At remission, the differences between RAO-affected and control horses 
should primarily be governed by genetic factors. Our findings can thus be extended to 
screen animals for RAO susceptibility from the animals that will not develop the disease 
under similar environmental conditions. We observed that classifiers including 
programmed cell death 5 (PDCD5), CX602251, and C17orf63 (three-feature classifier 
with the lowest error estimate) were the best triplet set to classify the two groups of 
horses. No functional annotation is currently available for CX602251 and C17orf63 and 
therefore although they are a part of the best three-gene classifier, it is difficult to 
comment on their functional relevance. PDCD5 (third member of the three-gene 
classifier set) is a positive regulator in classic apoptotic and paraptotic programmed cell 
death. PDCD5 mRNA and protein levels are up-regulated in response to various 
apoptotic signals (Li et al., 2000; Liu et al., 2003). The expression of this protein has 
been shown to be elevated in cells undergoing apoptosis and is considered an early 
apoptotic marker (Chen et al., 2001).  Increased apoptosis is a hallmark of asthma and 
along with increased cell proliferation it is known to contribute in airway remodeling as 
well. Hence, this classifier maybe acting as a discriminatory biomarker since RAO-
affected horses have an elevated rate of apoptosis of smooth muscle cells compared to 
the control animals.  
 
Grainyhead-like 2 (GRHL2), CT020008B20C03 and CT020003A10_PLT_B08_58_064 
were the best triplet classifiers with the ability to discriminate the symptomatic RAO 
animals from the control animals. These classifiers will help in discriminating horses 
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that develop airway obstruction and other clinical symptoms of RAO after an allergen 
exposure from the animals that do not.  Additionally, these classifiers can be potential 
targets for developing therapeutics to resolve severity of disease in RAO-affected horses. 
Currently, there is no functional annotation available for CT020008B20C03 and 
CT020003A10_PLT_B08_58_064 and hence it is beyond the scope of this study to 
rationalize their functional relevance to the disease. It has been proposed that grhl2 (pat 
of the three-gene classifier set) transcription factor has a role in morphogenesis of 
alveolar epithelial cells and are involved in maintaining cuboidal shape of the distal 
alveolar epithelial cells and help in epithelial differentiation (S. Varma, 2009; Werth et 
al., 2010). This gene appears to have role in formation, structural integrity and 
differentiation of alveolar epithelial cells. Allergenic reactions cause injury to airway 
epithelium; one of the ways to repair this damage involves migration of progenitor cells 
that proliferate and differentiate in order to assist in functioning and integrity of 
epithelium (Crosby and Waters, 2010). Epithelium injury and mechanistic changes of 
epithelium are observed during RAO/asthma and gene GRHL2 may contribute to this 
impairment.  
 
LDA results suggest that the three-gene classifiers can provide a good separation of 
asymptomatic and symptomatic RAO animals from control. LDA has been used to 
obtain discriminatory molecular signature for various studies (Kim et al., 2002; 
Kobayashi et al., 2003b; Morikawa et al., 2003). However, to our knowledge this 
technique is relatively novel in the field of large animal disease genetics. We therefore 
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provide a preliminary evidence for the potential of this technique in high-throughput 
genomic studies utilizing microarrays or next-generation sequencing.  Our study 
provides the first line of evidence for their potential role as a disease biomarker and 
these genes should be further investigated for their role in disease pathogenesis and as 
possible therapeutic targets. For our future studies, we will extend our present research 
findings to understand the role of some of the molecular biomarkers and processes for 
their direct relevance to the disease.  
 
Summary 
This study reports many biologically relevant differentially expressed genes that may 
have a role in disease pathogenesis and contribute to airway remodeling. We also present 
significant GO categories and enriched GO terms associated with the list of DE genes. 
These data contributes to information about important processes associated with RAO. 
Based on our results it also appears that airway remodeling is maintained in RAO horses 
via processes of cell proliferation, apoptosis and cellular component organization. 
 
The classifiers obtained from this study are potential biomarkers of the disease and may 
play important role in disease pathogenesis. The findings from our study contributes to 
the field of equine RAO, however more research investigation is needed to validate these 
findings. Given the parallels between human asthma and equine RAO, our study reports 
several novel genes that can be of importance to asthma research. Hence, this study 
supports that equine RAO is an appropriate animal model for the study of asthma. We 
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propose potential new targets that are discriminatory molecular biomarkers obtained 
from LDA classification: programmed cell death 5 (PDCD5) and grainyhead-like 2 
(GRHL2).  
 
CONCLUSION 
The results obtained from this study will contribute to the advancement of understanding 
of molecular mechanisms involved in RAO and asthma. There were some limitations in 
our study that should be taken into consideration while interpreting the results, which 
include small sample size and inadequate amount of RNA from biopsies. These 
shortcomings prevented us from doing direct hybridizations between RAO and control 
horses at the two time points and validating more genes via qPCR.  Small sample size 
did not allow us to perform false discovery rate correction of the microarray results. For 
our future studies, we will be using larger sample size to understand the process of 
airway remodeling in horses affected with RAO.  Also with next generation tools 
becoming more affordable, application of RNA-Seq will provide more accurate and 
extensive data and also reveal different isoforms, single nucleotide polymorphisms 
(SNP’s) and structural variations (Hurd and Nelson, 2009; Wang et al., 2009). These 
tools have greater sensitivity and accuracy and overcome many limitations inherent to 
microarray platforms. Hence application of such tools in RAO research will expedite the 
process of understanding molecular causes underlying the disease or identify associated 
susceptibility loci.  
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CHAPTER III 
 
EFFECT OF ALLERGEN CESSATION AND FLUTICASONE PROPIONATE 
ON AIRWAY REMODELING IN RECURRENT AIRWAY OBSTRUCTION 
AFFECTED HORSES  
 
SYNOPSIS 
Recurrent airway obstruction (RAO) is an obstructive, pulmonary, equine respiratory 
disease characterized by airway inflammation and morphological changes (termed as 
remodeling) in the airways of affected horses. Airway remodeling leads to increased 
airway obstruction, hyper-responsiveness and a decline in lung function. Understanding 
the molecular mechanisms underlying airway remodeling and its reversal is essential for 
developing therapeutic treatments. The aim of this study was to understand the effect of 
prolonged allergen avoidance and the corticosteroid treatment (fluticasone propionate) of 
established airway remodeling. Eleven horses affected with RAO were exposed to 
allergens for 3 months. During this time, they developed airway obstruction and 
inflammation (considered baseline). Out of eleven, five horses were placed in the 
allergen-avoidance group and the remaining six horses were placed in the treatment 
group. The allergen avoidance group was maintained in a low-antigen environment 
(pasture) for 12 months. The treatment group received the drug for 12 months; for the 
first six months, the horses were maintained in a stable, and for the next 6 months, they 
were moved to the pasture. Peripheral lung biopsies were obtained for both the groups at 
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baseline, 6 months and 12 months.  RNA was extracted and converted to cDNA that was 
labeled with fluorescent dyes for microarray hybridizations using equine whole genome 
oligoarray. Allergen avoidance for 6 months did not resolve inflammation and features 
of airway remodeling. After 12 months of prolonged allergen avoidance, the 
environmental management led to less pronounced features of remodeling. The 
fluticasone propionate treatment concurrently with the allergen challenge (first six 
months) predominantly did not diminish the inflammatory response. Administration of 
the drug during allergen avoidance (last six months) appeared to reduce inflammation 
and features of remodeling.  Environmental management (like allergen avoidance) is a 
critical component in the reversal of chronic features of RAO. However allergen 
avoidance alone is not sufficient to result in an early reversal of the airway remodeling. 
Since the concurrent administration of fluticasone propionate and allergen avoidance 
helped in achieving a relatively early recovery, an early introduction of the drug together 
with environmental management will be a beneficial strategy to reduce airway 
remodeling in RAO affected horses.  
 
INTRODUCTION  
Recurrent airway obstruction (RAO) is an asthma-like is a naturally lower airway 
respiratory disease in horses that is caused by exposure to dust from moldy hay and 
straw. Horses affected by RAO are generally 7 years of age or older and display an 
increased breathing effort and exercise intolerance when stabled during cold weather 
(Robinson, 2001). 10-20% of horses are estimated to be affected by RAO (Leclere et al., 
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2011b) and an epidemiological study has reported the disease prevalence to be around 
14% in a selected horse population in Great Britain (Hotchkiss et al., 2007). The clinical 
signs of RAO begin soon after exposure to aeroallergens, which cause airway 
inflammation, bronchoconstriction, and hypersecretion of mucus. Persistent airway 
inflammation and poor management of RAO leads to structural changes of the airways 
termed as “remodeling,” which includes an increase in airway smooth muscle (ASM) 
mass (Herszberg et al., 2006). The molecular mechanisms underlying pathogenesis of 
chronic RAO, and the associated inflammatory and remodeling processes, are not 
completely understood; therefore, identification of genes and biological processes 
involved in RAO will help to improve the understanding of this disease.  
 
The remodeling response in the airways consists of structural alterations that are 
considered manifestations of chronic allergic inflammation or a consequence of an 
aberrant process of wound repair (Elias, 2000; Jeffery, 2001; Homer and Elias, 2005; 
Zuyderduyn et al., 2008). Features of airway remodeling include the thickening of 
airways due to abnormal epithelium, an increased sub-basement membrane size, an 
increased vascularization and an enhanced mucus production (Chakir et al., 2003; 
Vignola et al., 2003; Postma and Timens, 2006; Doherty and Broide, 2007). An increase 
of airway smooth muscle mass and alterations in extracellular matrix also contribute to 
airway remodeling (Jeffery, 2001; Vignola et al., 2003; Lazaar and Panettieri, 2005). 
Airway remodeling can lead to an increased airway hyperresponsiveness and obstruction 
and can eventually lead to a decline in lung function (Pascual and Peters, 2005). 
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Prevention or reversing of airway remodeling is hence considered an important 
therapeutic target. However, exact pathophysiological and molecular mechanisms 
underlying remodeling are not fully understood.  
 
Studies in RAO and asthma have highlighted the significance of environmental 
management, for example reducing allergens in the environment (Custovic et al., 1998; 
Vandenput et al., 1998; Platts-Mills, 2003; Simpson and Custovic, 2004) and drugs for 
the treatment of the disease (Jackson et al., 2000; Nelson et al., 2000; Robinson et al., 
2002; Picandet et al., 2003; Harrison et al., 2004; Couetil et al., 2006; Woodcock et al., 
2011). Currently, the focus of the treatment revolves around beta-agonists and 
corticosteroids to reduce inflammation and allergic reactions (Barnes, 2006).  
 
There have been several studies conducted in the field of RAO and asthma that focus on 
the evaluation of the effect of allergen avoidance and corticosteroid therapy on affected 
individuals. A study in 2005 by Couetil at al. highlighted the importance of combining 
environmental management and early corticosteroid therapy (Couetil et al., 2005). 
Another study by Giguere et al. 2002 reported that inhaled fluticasone propionate (a 
potent corticosteroid) during severe disease exacerbation causes resolution of clinical 
signs and pulmonary function tests (Giguere et al., 2002).  
 
The aim of our study was to perform transcriptome profiling using equine whole genome 
expression array to understand the effect of allergen avoidance and fluticosone 
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propionate on structural alterations of the airways in RAO-affected horses. Allergen 
avoidance and a corticosteroid drug like fluticasone propionate can aid in treatment of 
allergic respiratory diseases like asthma and RAO. Transcriptome profiling will enable 
the understanding of the genes/processes/pathways that are being modulated by each 
disease management strategy (allergen avoidance and/or fluticasone propionate). These 
genes/pathways can then be targeted to achieve improved resolution of chronic RAO 
symptoms. Even though a complete resolution of symptoms may not be achieved by 
either treatment strategy alone or in combination, knowledge of the molecular 
mechanisms underlying their therapeutic action will enhance the understanding of each 
strategy’s effect on RAO.  
 
MATERIALS AND METHODS 
Study Animals and Experimental Design 
Eleven horses affected with RAO were exposed to allergen (poorly cured moldy hay) for 
3 months during which they developed airway obstruction and inflammation (considered 
baseline time period). During this time, they developed airway obstruction and 
inflammation (considered baseline). Out of eleven, five horses were placed in the 
allergen-avoidance group and the remaining six horses were placed in the treatment 
group. The allergen avoidance group was maintained in a low-antigen environment 
(pasture) for 12 months. Peripheral lung biopsies were obtained from these five horses at 
the end of the 3-month allergen challenge (baseline) and the end of 6 and 12 months.  
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The treatment group received the drug for 12 months; for the first six months, the horses 
were maintained in a stable (with naturally occurring antigens present in the 
environment).  For the next 6 months, the six horses were moved to the pasture. Out of 
these, five horses were then maintained in a low-antigen environment (Pasture) for 
12 months. Peripheral lung biopsies were obtained for the treatment group of horses at 
baseline, 6 months and 12 months.  
Treatments 
Antigen avoidance consisted in keeping horses on pasture and supplementing them with 
a pelleted diet. In the ICS group, fluticasone propionate (Flovent HFA, 
GlaxoSmithKline, Montreal, Canada) was administered at a dosage of 2000 μg q12h for 
a month, then dosages were adjusted to control clinical signs (2000 to 3000 μg q12 to 
24h). Two horses received 2000 μg q24h from month 1, the other ones requiring higher 
or more frequent administration during the first 6 months.  
 
Lung Biopsies and RNA extraction 
The peripheral lung biopsies were obtained via thoracoscopy wherein peripheral lung 
tissue was harvested from the caudo-dorsal region of the lung in sedated horses (Relave 
et al., 2008). Tissue samples were frozen in liquid nitrogen and stored at -80C. The RNA 
was isolated using the cesium chloride technique as describe previously (Bedard et al., 
2003). The extracted RNA quality was evaluated using bioanalyzer (Agilent, CA) and 
only samples with RNA integrity number (RIN) >7 were considered suitable for the 
microarray analysis. 
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Experimental Design 
We co-hybridized cDNA obtained from the 5 horses at baseline with cDNA obtained 
from biopsies after 6 and 12 months of allergen avoidance. Similarly for the treatment 
group, cDNA from the 6 horses at baseline were hybridized with cDNA obtained from 
biopsies extracted at the 6 and 12-month time point. We used a balanced block design 
(BBD) for microarray hybridizations because for class comparison studies, BBD is 
considered optimal (Dobbin and Simon, 2002). The dye swap was embedded within the 
biological replicates to overcome any bias associated with the fluorescent dyes (Dobbin 
et al., 2003; Simon and Dobbin, 2003) 
 
Labeling and Microarray Hybridization 
For each sample, cDNA was generated from total RNA using Superscript II Reverse 
Transcription kit (Invitrogen) and labeled with Cy3 or Cy5 dye via an indirect labeling 
method utilizing dendrimer technology (Stears et al., 2000).  Labeling was carried out 
with the 3DNA Array 900 MPX Expression Array Detection kit (Genisphere, PA). 
Hybridizations were performed in a SureHyb hybridization chamber (Agilent, CA) at 
55°C.  Following post-hybridization washes, arrays were scanned with a GenePix 4000B 
scanner at 5-micron resolution (Molecular Devices, CA).  GenePix Pro 6.1 software was 
utilized for raw data acquisition, spot-finding, and quantification of array images.   
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Equine 21K oligonucleotide microarray 
We used an whole genome equine oligonucleotide expression array with 21,351 
elements designed at Texas A&M University (Bright et al., 2009). This 70-mer 
oligoarray is the most comprehensive expression array available for expressed equine 
sequences. Probes were synthesized (Invitrogen, Carlsbad, CA) and printed onto amino-
silane coated slides (Corning Incorporated, Corning, NY). 
 
Expression Analysis 
Differential expression analysis of microarray data was conducted using Bioconductor’s 
LIMMA package running in the R statistical software environment (Smyth, 2004).  
Background correction of raw intensities was performed using the normexp correction 
method (Ritchie et al., 2007). Subsequently, the background corrected intensities were 
normalized using printip-loess normalization (within array normalization), and aquantile 
method was used to perform across array normalization (Smyth and Speed, 2003a). 
Linear modeling using moderated t-tests was performed to identify differentially 
expressed genes (Smyth, 2004).  To account for the multiple comparisons, the false 
discovery rate correction method of Benjamini and Hochberg was used (Benjamini and 
Hochberg, 1995). Linear models were used to assess the differentially expressed (DE) 
genes in RAO-affected animals after 6-month (R-t6/t0) and 12-month (R-t12/t0) of 
allergen avoidance compared to baseline (t0). Linear models were fit to obtain DE genes 
in the treatment group of animals for the first 6-months of treatment concomitant with 
allergen exposure compared to baseline (T-t6/t0). Similarly, DE genes were obtained for 
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the treatment group of animals for the next six months of continued treatment and 
allergen avoidance (T-t12/t0).  Genes were considered significantly differentially 
expressed if they had a p value < 0.05 and fold change > 1.2.  
 
Quantitative Real-Time PCR 
Quantitative real-time PCR was performed on a subset of genes that were significantly 
differentially expressed (Fold change > 1.5 and p-value<0.05). Each gene was tested in 
duplicate along with a housekeeping gene control peptidylprolyl isomerase A (PPIA).  
This technique was used to validate results obtained from the statistical analysis of the 
microarray data.  The total RNA was directly reverse transcribed to cDNA using the 
SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen, Carlsbad, CA) and 
subsequently amplified using gene specific primers and master mix by qPCR in a single 
step reaction. When possible, primers were designed to span intron-exon boundaries to 
represent a region of the mRNA corresponding to the location of the cDNA sequence 
located on the arrays. Serial dilutions of RNA from the reference sample were used to 
generate relative standard curves and test the amplification efficiency of each primer set. 
For each qPCR assay, ~100 ng of total RNA was used in a 25 µl reaction with 1x 
Universal SYBR® Green Master Mix (Applied Biosytems, CA) and 300 nM primers 
and amplified on a LightCycler 480 (Roche Diagnostics, IN).  
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RESULTS 
Differentially expressed genes  
The genes were considered DE with the pvalue <0.05 fold change restriction of 1.2 
(table 3-1). Comparing the lung tissue from the RAO-affected animals (allergen 
avoidance group) at the 6-month time point (R-t6/t0) to baseline yielded 86 DE genes, of 
which 23 genes were up-regulated and 63 down-regulated. We found 157 DE genes (43 
up-regulated and 114 down-regulated) by comparing the RAO-affected animals (allergen 
avoidance group) at the 12-month time point to baseline. In contrast to these 
observations, for the treatment group of animals, RAO-affected horses at the 6-month 
time point (T-t6/t0) compared to baseline yielded 31 DE genes (6 up-regulated and 25 
down-regulated). 65 genes were DE (49 up-regulated and 26 down-regulated) at the 12-
month time point (T-t12/t0) when RAO-affected horses in the treatment group were 
compared to the baseline. The list of DE genes for all four comparisons is presented in 
table B-1 (R-t6/t0), table B-2 (R-t12/t0), table B-3 (T-t6/t0) and table B-4 (T-t12/t0).  
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Table 3-1: List of differentially expressed genes. The genes are listed in the table 
according to fold regulation and total number in each comparison: Allergen avoidance 
group at 6-month time point (R-t6/t0), allergen avoidance group at 12-month time point 
(R-t12/t0), treatment group at 6-month time point (T-t6/t0), treatment group at 12-month 
time point (T-t12/t0). DE genes for each comparison were calculated by comparing the 
expression values at each time point with respect to baseline (t0). Genes were considered 
DE if the pvalue<0.05 with fold change cut off of 1.2. 
 
Comparisons Up-regulated genes 
Down-regulated 
genes 
Total DEG  
R-t6/t0 63 23 86 
R-t12/t0 43 114 157 
 
T-t6/t0 6 25 31 
T-t12/t0 49 26 65 
 
 
 
In the allergen avoidance group, out of the 374 DE genes at the 6-month time point and 
553 DE genes at the 12-month time point, only 25 genes (common fraction) remained 
differentially expressed between the two time points (figure 3-1). In the treatment group, 
out of the 269 DE genes at the 6-month time point and 572 DE genes at the 12-month 
time point, 18 genes (common fraction) remained differentially expressed between the 
two time points (figure 3-1). Obtaining only a few DE genes common across the two-
time points in the allergen avoidance and the treatment group suggests that the 
interventions (allergen cessation or/and corticosteroid treatment) indeed had an impact 
on the expression profile at the two time points.  
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Figure 3-1: Overlap analysis. a) Overlap of gene expression profile of the allergen 
avoidance group at the 6-month and 12-month time point.  
In total 374 (349+25) genes were differentially expressed for R-t6/t0 (6-month time 
point) and 553 (528+25) genes were differentially expressed for R-t12/t0 (12-month time 
point). Out of these, 25 genes were found to be common across the two time points.  
b. Overlap of gene expression profile of the treatment group at the 6-month and 12-
month time point.  
In total 269 (251+18) genes were differentially expressed for T-t6/t0 (6-month time 
point) and 572 (554+18) genes for T-t12/t0 (12-month time point). Out of these, 18 
genes were found to be common across the two points.  
 
 
 
Real-time PCR  
Real-time PCR was used to validate the regulation of expression of 11 DE genes from 
the four comparisons in this study. The fold regulation for these genes was calculated 
using the Pfaffl method (Pfaffl, 2001). The following 11 genes were considered for the 
real-time analysis: RASGEF1, CX603642, B4GALT3, NAGK, ITGA9, LOC651, 
RHOG, PES, ACSM5, WHSC2 and UQCRB (figure 3-2). We validated the direction of 
regulation of all 12 genes, however, ITGA9, RHOG and PES fold change did not 
correlate well with the microarray results.  
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Real-time PCR was used to validate findings of select genes that were significantly 
differentially expressed from the four comparisons in this study. Because limited amount 
of RNA was available from each peripheral lung tissue sample, we chose only 11 genes 
for the validation purposes. We could confirm the differential expression of all 11 genes 
in relation to the microarray data: UQCRB (R-t6/t0), WHSC2 (R-t6/t0), LOC651 (R-
t6/t0), RASGEF1 (R-t12/t0), CX603642 (R-t12/t0), B4GALT3 (R-t12/t0), NAGK (R-
t12/t0), PES (R-t12/t0), ITGA9 (T-t6/t0), ACSM5 (T-t6/t0) and ITGA9 (T-t12/t0). 
 
Based on the microarray results, genes LOC651, RASGEF1, B4GALT3, ITGA9 were 
down-regulated AND UQCRB, WHSC2, CX60364, NAGK, PES, ACSM5 were up-
regulated (figure 3-2). Though the real-time PCR results were not as pronounced as the 
microarray results for some of the genes, the trend (up and down regulation) essentially 
matched. Variation in correlation between the microarray based fold change values and 
lack of repeatability of the results in real-time PCR could be attributed to various factors. 
Small sample size increases the probability of obtaining false positives that pose 
challenge in qPCR validation. Literature also suggests that various factors like data 
normalization, fold change and p-value stringency also effect correlation between 
microarray and qPCR results (Dallas et al., 2005; Morey et al., 2006). Greater 
correlation is observed between the two results when genes exhibit at least 1.4 fold 
change and stringent p-value limits of 0.0001 or less are imposed in microarray data 
analysis (Morey et al., 2006).  
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Figure 3-2: Real-time PCR validation of the microarray results. The y-axis 
represents fold change value of the genes selected for real-time validation. The Y-axis 
depicts the genes from each of the experimental comparisons.  
 
 
 
DISCUSSION 
Allergen avoidance for 6 months led to a reduction in the inflammation and 
improvement in lung function. At the end of 12 months, allergen avoidance caused a 
further reduction in the bronchial inflammation and a marked improvement in ASM 
reduction. Compared to the allergen avoidance group, in the treatment group during the 
first six months a marked reduction in ASM mass was observed and was comparable to 
results achieved after 12-months of allergen avoidance. During the next six months, 
when the treatment groups of horse were maintained on a pasture, a better resolution of 
inflammation was achieved. 
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Allergen avoidance group at the end of 6-months on pasture 
We observed decreased expression of genes related to inflammatory processes at this 
time point. This supports the clinical findings of reduced perivascular inflammation and 
decreased numbers of neutrophils in brochoalveolar lavage fluid (Leclere 2012 
unpublished data). Specifically, down-regulation of genes MHC class I polypeptide-
related sequence B (MICB) and Interferon alpha 5 (IFNA5) suggest that the signals 
required to activate cytolytic response of NK and CD8 cells maybe diminished. NK cells 
have been reported to have a role in the development of allergenic inflammation, but the 
exact mechanism of its role is not established. However high number of NK, CD4+ and 
CD8+ cells have been observed after allergen challenge in broncho-alveolar lavage fluid 
(BAL) and lung parenchyma (Korsgren, 2002).  
 
Cytochrome P450, family 26, subfamily A, polypeptide 1 (CYP26A1) metabolizes 
retinoic acid (RA), where overexpression of CYP26A1 reduced RA levels (Chang et al., 
2008). Retinoic acid directly influences T-cells to suppress the production of IFN-g 
production and augments IL-4, IL-5 synthesis, thus promoting Th2 response (Iwata et 
al., 2004). It is well established that Th2 immune response underlies the pathophysiology 
of allergic disease like asthma (Barnes, 2001a). Since RA is known to exacerbate the 
allergic immune response, up-regulation of CYP26A1 could be contributing to the 
reduction in pulmonary inflammation by suppressing T-cell recruitment. Hence 
modulation of these genes could underlie the observed reduction in pulmonary 
inflammation and clinical indices of disease severity. There is no direct association 
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between the anti-inflammatory role of CYP26A1 in allergic diseases, and further studies 
will be needed to evaluate this observation.  
 
However, the up-regulation of CCR8, which is a receptor for the T-cell chemokine 
CCL1 (Spinetti et al., 2003), indicates that lymphocytes are still trafficking to the lung at 
this time point. Our data suggest that, during the initial months of allergen avoidance, 
therapies aimed at prevention of T-cell migration to the lung might be of some use, 
although treatments targeting the innate branch of the immune system would probably 
not provide any further benefit. 
 
We also observed reduced expression levels of collagen (COL1A1, COL5A1) and other 
extracellular matrix (CH13L1) related genes that could contribute to the process of 
reducing airway remodeling. Clinically, allergen avoidance alone resulted in a decrease 
in pulmonary elastance and resistance at 6-months. Our results suggest that allergen 
avoidance for a duration of 6 months may improve pulmonary function and reduce 
airway remodeling by down-regulating genes encoding collagen types I and V. Collagen 
I and V are the predominant sub-types of collagen genes that, in addition to other 
extracellular components, contribute to structural alteration of the airways in pulmonary 
diseases like asthma and RAO (Takizawa, 2007). Since structural alterations of the 
airway lead to functional changes, alteration in ECM composition and excessive 
collagen deposition will increase airway elastance and resistance (Xisto et al., 2005; 
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Lancas et al., 2006). Since allergen avoidance led to a decrease in collagen genes, it 
might contribute to the reduced elastance and resistance observed in the clinical data.  
 
CH13L1 may also contribute to reduction in fibrosis since it can interact with type I 
collagen to regulate collagen fibril formation (Bigg et al., 2006). It is still not clear if the 
role of this gene in tissue remodeling and angiogenesis is limited to its capacity to 
interact with collagen (Coffman, 2008). However, preliminary studies in asthma have 
shown increased expression of CH13L1 to correlate positively with thickening of the 
sub-epithelial basement membrane and disease severity and negatively with pulmonary 
function (Ober et al., 2008). Hence the down-regulation of CH13L1 and the above 
mentioned collagen genes could be a response to the environmental intervention and 
lead to the structural reversibility in chronic RAO. 
 
Allergen avoidance group at the end of 12-months on pasture 
At the end of 12-months we observed down-regulation of genes involved in 
inflammatory process (CD99, ULBP3/NKG2DL3 and C5AR1). This observation lends 
support to the clinical observation of further reduction in BALF inflammation and 
biopsy inflammation as measured by neutrophil count (Leclere 2012, in press). Our data 
suggest that prolonged allergen avoidance (12 months) led to a decline in inflammation 
via modulation of genes involved in activation and migration of immune cells. We 
observed down-regulation of genes that would lead to a decline in neutrophilic influx 
into the site of inflammation (CD99 gene), activation of NK cells (ULBP3) and 
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migration of leukocytes (C5AR1) (Eleme et al., 2004; Lou et al., 2007; Gonzalez et al., 
2008). Since RAO is characterized by neutrophilic inflammation, reduced activity of 
CD99 and C5AR1 (a potent neutrophil chemoattractant) could be a factor in reduction of 
the pulmonary inflammation.  
 
A complete resolution of inflammation was not achieved due to mechanisms that sustain 
residual inflammation, for example, via up-regulation of TNFSF4 gene.  The expressed 
protein of TNFSF4 is present on airway smooth muscle cells (ASMC) and antigen 
presenting cells (APC). Also known as OX40L, it is highly expressed on ASMC and 
their engagement with OX40 on CD4+ T-cells leads to a Th2 biased cytokine production 
(Lane, 2000).  The OX40L-OX40 interaction causes proliferation and long-term survival 
of CD4+ cells and generates memory T-cells (Krimmer et al., 2009). Hence elevated 
OX40L would suggest its role in inflammation by promoting Th2 environment that 
underlie pathology of chronic allergic disease like asthma. Also OX40L activation could 
have a role in sustained inflammation because of its role in proliferation of antigen-
specific CD4+ T cells and memory T cells.  
 
We also observed down-regulation of various genes involved in the regulation of cell 
cycle and proliferation (TMEM97, RPL29, PAPPA2, PES1, FOXJ3, HES7, PPM1A) 
which could be involved in reducing airway smooth muscle (ASM) cell number and 
thereby reducing ASM mass. At this time point, clinical data showed a reduction in 
ASM mass but no significant difference in the myocyte proliferation or apoptosis (as 
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measured by PCNA and TUNEL assays). Reduction in ASM could be initiated as a 
consequence of decrease in ECM matrix as observed during first 6 months of allergen 
avoidance. Although during the next 6-months of allergen avoidance, we did not observe 
modulation of genes influencing ECM matrix but we did notice down-regulation of 
certain genes that regulate cell cycle that could lead to modest reduction in myocyte 
proliferation (since a significant different was not found clinically). Since there was not 
a significant reduction in myocyte proliferation at this time point, anti-inflammatory 
factors active at 12-months could also drive a reduction in myocyte size.   
 
However we speculate that reduction in ASM could also be a consequence of reduced 
ECM deposition observed during the first six months. ECM proteins can also influence 
various features like survival, proliferation and contraction of ASM cells (Schwartz and 
Assoian, 2001). In addition to the ability of ECM components to affect the proliferative 
potential of myocytes, it can influence its phenotype. For example in a study it was 
shown that fibronectin and collagen type I enhanced the proliferation of myocytes and 
promotes a less contractile phenotype (Hirst et al., 2000).  
 
Treatment group at the end of 6-months in stable 
At this time point, clinical data suggested that the inhaled corticosteroid (ICS) caused an 
accelerated reduction in ASM mass when compared to the allergen avoidance group 
(Lecelre 2012, in press). However, the ICS was not able to reduce inflammation in the 
face of continuous allergen exposure. In our study we did not observe differential 
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expression of any gene involved in inflammation at this time point compared to baseline. 
This possibly suggests that the induction of pro-inflammatory genes due to the three-
month allergen challenge at baseline was not altered by the ICS administration due to 
continued allergen exposure during the 6-month time period.  
 
In line with the clinical observation that ICS administration led to a decrease in ASM 
mass, we observed modulation of genes that could contribute to this reduction. We 
observed the down-regulation of genes involved in the ECM receptor pathway (ITGA9, 
RHOG) and cellular proliferation (ITGA9, RHOG, ATAD2, ZNF423). ITGA9 is 
involved in collagen, laminin binding and fibronectin assembly (Bazigou et al., 2009). 
Integrins are signaling molecules involved in cell-cell and cell-matrix interactions 
(Dekkers et al., 2009). During remodeling altered ECM deposition occurs not only under 
the basement membrane but also surrounding bundles of smooth muscle. ECM proteins 
can also influence various features like survival, proliferation and contraction of ASM 
cells (Schwartz and Assoian, 2001). Since integrins have a key role in ECM-cell 
signaling blocking them offers a target to reduce alterations in ECM as well as ASM 
proliferation. In an animal model of allergic asthma, blocking integrin with a peptide 
having motif specificity for fibronectin, collagen and laminin decreased the ASM 
proliferation (Dekkers et al., 2009). Direct involvement of ITGA9 in ECM signaling and 
its role in ASM proliferation has not been explored and it therefore provides an exciting 
target for further research in remission of airway remodeling by blocking this integrin 
activity.  
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The clinical data suggested a significant decrease in myocyte proliferation due to ICS 
administration at this time point. Down-regulation of genes like ITGA9 and RHOG that 
are involved in cytoskeleton rearrangement could decrease the muscle thickness caused 
by ECM deposition. RHOG is involved in cytoskeleton rearrangement and contributes to 
negative regulation of immune response (Vigorito et al., 2003; Vigorito et al., 2004).  
RHOG is hypothesized to regulate cellular growth of vascular smooth muscle cells, 
specifically G1-S transition in the cell cycle (Vincent et al., 1992). Down-regulation of 
genes like ATAD2 that is involved in progression of cell cycle could influence the 
proliferative potential of myocytes (Muller et al., 2011).  
 
Treatment group at the end of 6-months on pasture 
After 6-months of concurrent administration of the drug while the horses were 
maintained on a pasture, clinical data suggested that the inflammation had resolved at 
this time point. Twelve months of treatment with fluticasone resulted in a similar 
reduction in ASM as did the 12-month allergen avoidance protocol. However, compared 
to the 12-month allergen avoidance group, in the treatment group we observed down-
regulation of genes TNFSF4 and ITGA9. Down-regulation of ITGA9 compared to 
baseline is seen only in the treatment group at both time points. The ICS could be 
modulating the reduction in its expression thereby causing a decrease in extracellular 
matrix although there is no published evidence of this observation so far. Down-
regulation of TNFSF4 probably represents one of the anti-inflammatory mechanisms of 
ICS on chronic RAO pathology, which could lead to a reduction in sustained Th2 
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inflammation via reducing CD4+ T-cells and memory cell expansion (Hoshino et al., 
2003; Wang and Liu, 2007).  
 
The sustained low-grade inflammation and generation of antigen specific memory cells 
will generate stronger effector response every time there is an antigenic re-exposure 
(Wang and Liu, 2007). Down-regulation of TNFSF4 due to ICS could therefore be 
contributing to reduced Th2 immune response and memory T-cell expansion thereby 
alleviating inflammation and reducing a future allergic response. Clinical data showed a 
residual low-grade airway obstruction even after the ICS treatment (12-month time 
point), inadequate anti-inflammatory actions of ICS could be one of the factors 
responsible for it. Incomplete reduction in ASM mass (only 30%) could be another 
factor contributing to bronchoconstriction. Abnormal cholinergic signaling (neural 
transmission) of airways may be another contributor of the residual airway obstruction 
(Barnes, 2001b). ICS are able to control airway inflammation and hyperresponsiveness, 
adding long-acting β2-agonist (LABA) to the treatment should yield better control of 
chronic RAO symptoms because LABA assist in bronchodilation by inhibiting release of 
mast cell mediators and reducing nervous stimulation of airways (Barnes, 2002). 
However, ICS and LABA therapy combined with allergen avoidance should be tested 
early for safety and efficacy prior to use in horses suffering from chronic RAO.  
 
One such mechanism could be via importin 13 (IPO13), where this gene regulates the 
nuclear import of glucocorticoid receptor (GR) thus affecting the anti-inflammatory 
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effect of glucocorticoid (GC) (Tao et al., 2006). Most of the effects of GC’s are exerted 
by its interaction with glucocorticoid receptor, where the receptor after GC binding 
enters nucleus where it regulated transcription of the steroid-responsive DNA elements 
(Tao et al., 2006). Function of GC depends in the translocation of GR from cytoplasm to 
nucleus and IPO13 mediates this transport.  Inhibiting IPO13 prevents the entry of GR 
and abolishes the anti-inflammatory effects of GC (Raby et al., 2009) for e.g. inhibit the 
synthesis of pro-inflammatory cytokines. We found IPO13 to be down-regulated at this 
time point, which could reduce the anti-inflammatory potential of the drug, preventing it 
from achieving a complete resolution of inflammation.  
 
Clinical data showed that all of the reversibility in airway remodeling occurred only 
within the first 6-months of study with ICS administration with no addition improvement 
during the next 6-months. The lack of complete reversibility of the airway remodeling 
could be due to certain additional unresponsive molecular mechanisms that prevent the 
complete remission of chronic features. For example, EGF-like repeats and discoidin I-
like domains 3 (EDIL3) that encodes an angiogenic ECM protein was found to be up-
regulated. This protein initiates angiogenesis and promotes vessel wall remodeling (Sun 
et al., 2010). Up-regulation of this gene could therefore be inhibiting resolution of 
vascular remodeling component of the structural alterations of the airways. We did not 
measure changes in vascular remodeling during the clinical study. Hence we can only 
speculate that certain factors promoting angiogenesis might reduce the efficacy of the 
drug in reversal of airway structural alterations.  
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CONCLUSION 
This study assessed the effects of allergen avoidance and ICS drug (fluticasone 
propionate) administration on the transcriptome profile RAO affected horses. Our goal 
was to identify the mechanisms in which both allergen avoidance and drug treatment 
achieved reduced airway remodeling and inflammation. Allergen avoidance for 6 
months led to a reduction in the inflammation and an improvement in the lung function. 
At the molecular level, the decrease in the inflammatory response could be due to 
reduced activation of cytotoxic cells. In addition, diminished synthesis of metabolic 
intermediate that promotes a Th2 environment could also contribute to reduction in 
inflammation. Regulation of genes that affect extracellular matrix deposition were also 
observed at this time point. However this modulation did not lead to a significant 
reduction in ASM mass at this time point.  At the end of 12 months, allergen avoidance 
caused a further reduction in the bronchial inflammation and a marked improvement in 
ASM reduction. A decrease in neutrophil chemotaxis could be have contributed to the 
improvement in inflammation at this time point, since neutrophils are the predominant 
immune cells involved in pathology of RAO.  
 
Compared to the allergen avoidance group, in the treatment group during the first six 
months a marked reduction in ASM mass was observed and was comparable to results 
achieved after 12-months of allergen avoidance. The reduction in muscle mass are due to 
mechanisms that reduce cellular proliferation and ECM deposition and signaling. During 
the next six months, when the treatment groups of horse were maintained on a pasture, a 
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better resolution of inflammation was achieved. A better control of inflammation at this 
time point compared to allergen avoidance alone is due to various anti-inflammatory 
actions of the drug including its ability to reduce expansion of primed CD4+ T-cells and 
memory cells. However, the presence of factors that limit the effects of the drug and the 
inherent shortcoming of ICS as standalone treatment strategy were evident at this time 
point. First, it did not cause an additional decrease in ASM mass compared to what was 
observed during that first six months. Second, it did not to completely resolve 
bronchoconstriction. We propose that adding LABA to ICS may achieve better results 
for remission of chronic RAO symptoms.  
 
Despite the insights obtained from this study, the results need to be interpreted with 
caution. For example, this study has a small sample size and, the treatment group lacked 
internal controls. When the treatment group of horses were maintained on pasture, there 
were no horses that were administered a placebo to better resolve the drug versus 
environment effects. Finally, the same set of horses was used in the treatment group. 
After they were exposed to allergen for first six months they were maintained on pasture 
for the next six; hence the two time-points in the treatment group were not entirely 
independent.  
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CHAPTER IV 
 
GENE EXPRESSION PROFILING TO ESTABLISH TEMPORAL CHANGES IN 
PERIPHERAL BLOOD LEUKOCYTES OF HEALTHY FOALS AND FOALS 
AFFECTED WITH RHODOCOCCUS EQUI PNEUMONIA 
 
SYNOPSIS 
Rhodococcus equi (R. equi) is an intracellular bacterium that is primarily known as an 
equine pathogen that infects young foals causing a pyogranulomatuous pneumonia. The 
molecular mechanism mediating the foal immunity in response to R. equi is not fully 
elucidated. Hence global genomic high throughput tools like expression microarray 
analysis will elucidate genetic signatures and molecular pathways that modulate the 
immune system of young foals in response to R. equi infection. Identifying such genes 
will therefore help in disease control and design of drugs and vaccines. The objectives of 
this study were two-fold a) to determine the age-dependent changes in the expression 
profile associated with blood leukocytes stimulated with virulent R. equi compared to the 
un-stimulated ones.  b) to obtain the temporal changes in the gene expression profile 
associated with blood leukocytes in response to the virulent R. equi stimulation. 
Peripheral blood leukocytes from six foals a day after birth and two, four and eight 
weeks after birth were obtained. The blood was grouped in two, where the first half was 
stimulated with the pathogen and second half served as un-stimulated control. RNA was 
extracted and generated cDNA was labeled with fluorescent dyes for microarray 
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hybridizations using equine whole genome oligoarray. Our findings suggest that the 
stimulated leukocytes appear capable of initiating a protective immune response through 
birth and up to 8 weeks of age. Concurrently, we also observed modulation of processes 
that may be detrimental to the host. Temporally it appeared that the across all the time 
points, the bacterial stimulation led to induction of pathogen recognition and mounting 
of immune response.  
 
INTRODUCTION 
Rhodococcus equi (R. equi) is recognized globally as a leading source of pneumonia in 
young foals up to six months of age while adult horses do not develop the disease unless 
they are immune-deficient (Heller et al., 2010). There are also non-equine species 
susceptible to R. equi pneumonia like pigs, cattle, cats, goats, dogs and humans 
(Muscatello et al., 2007). In humans, it affects only HIV-infected or immune-comprised 
individuals (Linder, 1997; Kedlaya et al., 2001). Mortality rate due to foal pneumonia is 
estimated to be 2-13% (Mousel et al., 2003) and hence this disease has serious 
implications on the equine industry. The course of R. equi infection in foals is insidious 
and disease is often progressed by the time diagnosis is made (Horowitz et al., 2001).  
 
In addition to being one of the major equine pathogens, R. equi is evolving as a human 
pathogen (Weinstock and Brown, 2002). Till date the knowledge about the foal immune 
response against the R. equi infection has mainly been garnered by studying differences 
between foal and adult horse response to the pathogen. The ability of the foal to fight R. 
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equi infection heavily depends on its immunity. Young foals have immature immune 
system and leukocytes are critical in defense of the host against a plethora of infectious/ 
foreign agents. There is limited knowledge about the development of immune system in 
equine neonates. Additionally, knowledge about the changes in the gene expression of 
leukocytes during the first few months of foal life will help in understanding the 
development of its immune responses.  
 
Hence the objective of this study is to identify the age-related expression profile of 
peripheral blood leukocytes after an in-vitro stimulation with virulent R. equi and 
compare it with the un-stimulated leukocytes. We also aimed to identify genes that are 
being modulated temporally in the stimulated blood leukocytes. We propose that this 
study will help in identifying genes and processes that modulate the immune system of 
the young foals in response to virulent R. equi. Additionally, we will also determine the 
age-related differences in the transcriptome of the stimulated peripheral blood 
leukocytes from healthy foals.  
 
MATERIALS AND METHODS 
Sample collection 
Approximately 60 mL of blood was collected in 10 mL EDTA vacutainers via jugular 
venipuncture from each foal at day 1 (within first 24 hours) and weeks 2, 4, and 8. All 
blood was immediately processed in the laboratory following collection.  The blood was 
divided into two aliquots (30 ml each) that was further divided into six portions and 
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added to a 6 well cell culture plate. For one plate the blood was subjected to the 
stimulation of live, virulent R.equi at an approximate multiplicity of infection (MOI) of 
10, and another 6 well culture plate with the other 30 mL of blood served as the un-
stimulated control.  The plates were incubated for 3 hours (37°C, 5% CO2) with slow 
rotation.  After incubation, the blood of each treatment type was combined, and the 
leukocytes were isolated and stabilized using the LeukoLOCK Total RNA Isolation 
System (Ambion, CA).     
 
RNA extraction 
Total RNA was extracted from whole blood (both un-stimulated and stimulated with 
R.equi) using the LeukoLOCK Total RNA Isolation System (Ambion, CA) per the 
manufacturer’s instructions. A DNase I treatment was also performed as a part of the 
RNA extraction protocol to remove any contaminating genomic DNA. Extracted RNA 
was quantified with a spectrophotometer (NanoDrop) while the RNA quality was then 
evaluated with the Agilent 2100 Bioanalyzer.  
 
Experimental design 
In order to obtain the temporal expression changes in the in-vitro R. equi stimulated 
leukocytes, we utilized the common reference design for microarray hybridizations 
(reference). Hybridizations were performed with 6 biological replicates at each 
experimental time-point: day-1 (D-1) and weeks 2 (W-2), 4 (W-4) and 8 (W-8).  The D-
1 sample served as the reference for each foal and all other experimental samples from  3 
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that foal were co-hybridized to it.  Additionally, in order to compare the stimulated 
blood leukocytes with the un-stimulated ones, we performed perform direct co-
hybridization of un-stimulated and the stimulated samples at each experimental time-
point.   
 
RNA amplification 
Due to low quantity of RNA obtained from some of the samples, we had to amplify the 
RNA samples. Not all the samples needed amplification but to ensure uniformity across 
all the samples RNA was amplified for every sample (for both nasal epithelial cells and 
blood leukocytes). 500ng of RNA was used for each amplification reaction using the 
sensation kit (Genisphere) as per the manufacturer’s protocol.  
 
Labeling and Microarray Hybridization 
For each sample, cDNA was generated from total RNA using Superscript II Reverse 
Transcription kit (Invitrogen, Carlsbad, CA) and labeled with Cy3 or Cy5 dye via an 
indirect labeling method utilizing dendrimer technology (Stears et al., 2000).  Labeling 
was carried out with the 3DNA Array 900 MPX Expression Array Detection kit 
(Genisphere, PA). Hybridizations were performed in a SureHyb hybridization chamber 
(Agilent, CA) at 55°C.  Following post-hybridization washes, arrays were scanned with 
a GenePix 4000B scanner at 5-micron resolution (Molecular Devices, CA).  GenePix 
Pro 6.1 software was utilized for raw data acquisition, spot-finding, and quantification of 
array images.   
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Equine 21K oligonucleotide microarray 
We used an equine whole genome oligonucleotide array with 21,351 elements developed 
at Texas A&M University (Bright et al., 2009). This 70-mer equine oligoarray is one of 
the most exhaustive gene arrays currently present for expression analyses. Probes were 
synthesized (Invitrogen, Carlsbad, CA) and printed onto amino-silane coated slides 
(Corning Incorporated, Corning, NY). 
 
Expression Analysis 
Differential expression analysis of microarray data was conducted using Bioconductor’s 
LIMMA package running in the R statistical software environment (Smyth, 2004).  
Background correction of raw intensities was performed using the normexp correction 
method with offset 50 (ref). Subsequently, the background corrected intensities were 
normalized using printip-loess normalization (within array normalization) but no across 
array normalization was performed (Smyth and Speed, 2003b). Linear modeling using 
moderated t-tests was performed to identify differentially expressed genes (Smyth, 
2004).  To account for the multiple comparisons, the false discovery rate correction 
method of Benjamini and Hochberg was used (Benjamini and Hochberg, 1995). Linear 
models were used to assess the age-related differentially expressed (DE) genes in the 
stimulated leukocytes (temporal expression) for the three comparisons: a) day1 versus 
week2 (C1) b) day1 versus week4 (C2) and c) day1 versus week8 (C3). Similarly, linear 
models were fit to obtain DE genes between the stimulated and the un-stimulated 
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leukocytes at each time point (D-1, W-2, W-4, W-8). Genes were considered 
significantly differentially expressed if they had a p value < 0.05 and fold change > 1.5.  
 
Functional analysis 
Functional gene ontology analysis was performed using a web-based tool WebGestalt : 
WEB-based GEne SeT AnaLysis Toolkit (Zhang et al., 2005; Duncan et al., 2010). 
Gene ontology analysis was performed using the list of differentially expressed genes to 
obtain statistically significant biological processes. In order to calculate the statistical 
significance, DE genes for each comparison were compared to all the genes present on 
our equine microarray. Benjamini Hochberg method was used for multiple test 
adjustment with significance level < 0.1.  
 
RESULTS 
Differentially expressed genes (table 4-1) 
Comparison of the stimulated versus un-stimulated peripheral blood leukocytes at day-1 
showed that 125 genes were differentially expressed between them, of which 89 were 
up-regulated and 36 down-regulated (D-1). A similar comparison at week-2 time point 
led to the identification of 127 DE with 92 up-regulated and 35 down-regulated genes 
(W-2). At week-4 time point, 73 genes were differentially expressed with 35 up-
regulated and 38 down-regulated genes (W-4). Finally at week-8 time point, there were 
135 genes that were differentially expressed, of which 92 were up-regulated and 43 
down-regulated (W-8).  
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Likewise, when the first time point was compared to the remaining three time points 
(week-2, week-4 and week-8) for the stimulated peripheral blood leukocytes, 
differentially expressed genes were obtained for each comparison due to temporal 
changes in gene expression profile. There were 102 DE genes for the comparison C1, 
with the highest number of DE genes was comparison C2 (192 genes) and finally C3 
with 148 genes.   
 
 
 
Table 4-1: Differentially expressed (DE) genes. List of differentially expressed genes 
for each comparison is shown in the table. Genes were considered differentially 
expressed with pvalue<0.05 and fold change >1.5. C1: comparison 1, C2: comparison 2, 
C3: comparison 3.  
 
Comparison type  Time point  DE genes Total DE genes  
Stimulated versus unstimulated 
leukocytes 
Day1 (D1) Up: 89 Down: 36 125 
Week-2 (W2) Up: 92 Down: 35 127 
Week-4 (W4) Up: 35 Down: 38 73 
Week-8 (W8) Up: 92 Down: 43 135 
Temporal changes in stimulated 
leukocytes 
Day1 vs. week-2 (C1) Up: 30 Down: 72 102 
Day1 vs. week-4 (C2) Up: 83 Down: 109 192 
Day1 vs. week8 (C3) Up: 75 Down: 73 148 
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Functional analysis  
Stimulated versus un-stimulated blood leukocytes 
We performed functional analysis of the DE genes associated with each time point for 
each comparison type. The top ten biological processes (figure 4-1) associated with the 
up-regulated genes at the earliest time point (day1), appeared to be involved in variety of 
roles ranging from adiponectin secretion, defense response to endocrine process. 
Strikingly different, the biological processes associated with the down-regulated genes 
were mainly involved in wound healing and blood coagulation. Interestingly among the 
down-regulated genes, mainly PLSCR1, SELP and SCUBE1 were involved with all the 
statistically significant biological process.  
 
For the W-2 time point, we did not find association of any statistically significant 
biological process with the down-regulated genes. For the up-regulated genes, the top 
ten biological processes (figure 4-1c) were associated with regulation of temperature 
(fever) and immune response (leukocyte migration, neutrophil chemotaxis, immune 
system process). Similarly for the W-4 time point, we did not find any statistically 
significant biological process associated with the down-regulated genes. For the up-
regulated genes, the top ten biological processes (figure 4-1d) very closely resembled 
the ones obtained for W-2 time point (e.g. fever, immune response).  
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Uniqueness of the expression profile 
In order to identify the genes that were unique for each experimental time point, we 
compared the list of DE genes across all four time-points and obtained the intersection 
and union of the gene sets (figure 4-2). The expression profile at each time point 
appeared to be largely distinct with very few common genes as depicted in the figure 3. 
Out of the 88 (D-1), 88 (W-2), 51 (W-4) and 87 (W-8) DE genes for each time point, 
only 11 genes were present in all the four. IL1A, IL1B and IL1RA were among the 
genes differentially expressed (up-regulated) across all four time-points.  
 
 
 
 
Figure 4-1: Biological processes associated with DE genes in leukocytes stimulated 
with R. equi compared to the un-stimulated leukocytes. Graphical representation of 
top fifteen statistically significant processes associated with the DE genes a) up-
regulated (colored red bars) at day 1(D-1) and b) down-regulated genes (colored green 
bars) at day 1(D-1), c) up-regulated genes after two weeks (W-2) d) up-regulated genes 
after four weeks (W-4). The Y-axis represents the biological processes and the X-axis 
represents the pvalue displayed as -log2(pvalue). 
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Figure 4-1 Continued 
 
 
 
 
 
 
 
 
 
 
 124 
Figure 4-1 Continued 
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Figure 4-2: Venn diagram for pairwise comparison of the gene expression profile of 
stimulated versus un-stimulated leukocytes. The four time points are designated in the 
diagram as 1: day1, 2: week-2, 3: week-4, 4: week-8. In the figure below the letters 
represent: a-genes found in 1 only, b-genes found in 2 only, c-genes found in 3 only, d-
genes found in 4 only, e-genes in 1&2 only, f-genes in 1&3 only, g-genes in 2&3 only, 
h-genes in 1&4 only, i-genes in 2&4 only, j-genes in 3&4 only, k-genes in 1,2,3 only, l-
genes in 1,2,4 only, m-genes in 1,3,4 only, n-genes in 2,3,4 only, o-genes in 1,2,3,4.  
 
 
 
 
Day 1 (88) 
Week-4 (51) 
Week-8 (87) 
Week-2 (88) 
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Temporal changes in stimulated blood leukocytes 
We also performed functional analysis for the DE genes obtained for the three 
comparisons (C1, C2, C3) when the expression profile obtained at day1 was compared to 
the remaining three time points individually. For comparison C1 (day1 vs. week-2) the 
top ten biological processes associated with the up-regulated genes were primarily 
involved in immune response (antigen processing and presentation and immune related 
process like antigen processing and presentation, immune response and hypoxia (figure 
4-3). The top ten processes associated with the up-regulated genes appeared to be 
involved in synthesis and catabolism of various organic compounds (sulfur amino acid 
biosynthetic process, cellular nitrogen compound biosynthetic process). Similar to our 
observations for W-2 and W-4 functional analysis (stimulated versus unstimulated 
comparison), for the C2 (day1 vs. week2) and C3 (day1 vs. week4) comparisons there 
were no statistically significant processes associated with the down-regulated genes. The 
down-regulated genes for the C2 comparison were associated with few processes (five), 
which were involved lipid transport and macrophage chemotaxis (figure 4-3c). The top 
ten processes associated with the up-regulated genes for the C3 comparison were 
involved in protein translation (e.g. translation, translation elongation), protein folding 
(e.g. Chaperone mediated protein folding requiring cofactor, de -novo protein folding) 
are depicted in figure 4-3d.  
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Figure 4-3: Biological processes associated with temporal expression of genes in 
leukocytes stimulated with R. equi. Graphical representation of top fifteen statistically 
significant processes associated with the DE genes a) down-regulated (colored green 
bars) for comparison C-1 (day1 vs. week2) b) up-regulated genes (colored red bars) at 
for comparison C-1 (day1 vs. week2), c) down-regulated genes for comparison C-2 
(day1 vs. week4) and d) up-regulated genes for comparison C-3 (day1 vs. week8).The 
Y-axis represents the biological processes and the X-axis represents the pvalue displayed 
as -log2(pvalue). 
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Figure 4-3 Continued 
 
 
 
 
 
 
 
Uniqueness of the expression profile 
We compared the list of DE genes obtained for each temporal comparison and obtained 
the intersection (figure 4-4). The expression profiles of the three comparisons (C1, C2, 
C3) were largely distinct, with the largest overlap between C1 and C2 (30 genes). None 
of the genes were present in all three comparisons once again highlighting the 
uniqueness of the expression profile. 
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Figure 4-4: Venn diagram for temporal gene expression changes. This venn diagram 
depcts DE genes unique to each comparison: day1-week2 (C1), day1-week4 (C2) and 
day1-week8 (C3).  
 
 
 
DISCUSSION 
 
The gene expression profile of the stimulated leukocytes compared to the un-stimulated 
ones appears to be largely unique for each time point. However, after the functional 
analysis some patterns emerged that stayed common across the four time points. Our 
results suggest that the bacterial stimulation up-regulated many genes involved in 
fighting and clearance of the infection. However, there was also modulation of genes 
that could be detrimental for the host and lead to bacterial survival and proliferation.  
 
Day1-Week2 (75) Day1-Week4 (137) 
Day1-Week8 (43) 
106 36 
33 
30 
9 1 
0 
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Stimulated versus un-stimulated blood leukocytes 
When the expression profiles of the stimulated leukocytes were compared to the un-
stimulated ones, a pattern emerged between that was consistent across all the four time-
points. For example, across all four time-points, we observed induction of processes 
involved in host protection/bacterial clearance as well as processes contributing to 
immune suppression. The pathogen seems to be stimulating a tug of war between the 
protective immune response and the suppressive factors that promote susceptibility to 
infection.  
 
Soon after birth (D-1), the stimulated cells appear to modulate genes towards a 
protective immune response against the bacterium e.g. processes like defense response, 
fever, immune system process and immune response. However modulation of various 
other genes/processes could attenuate such protective response, preventing effective 
pathogen clearance by the host. It appears that across all the time points the genes (IL1A, 
IL1B) involved in fever were induced. Fever is a natural response to elevate the body 
temperature to create hostile environment for the pathogen. IL1A is a pyrogen (Hartung 
et al., 1998) that may be induced to assist host response against R. equi. We also 
observed induction of various pro-inflammatory mediators like CCL20, IL1A, IL1B, 
IFNA5 at this time point that recruit immune related cells to fight off the infectious 
agent.   
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CCL20, IL1A, IL1B and IFNA5 are pro-inflammatory cytokines whose induction by 
leukocytes (from a day old foal) due to bacterial stimulation leads to protective response 
by recruiting immune cells in order to contain the bacteria and fight the infection. Over 
expression of CCL20 is thought to be involved in development and maintenance of 
pulmonary granulomas (foci of infection) by causing migration of meutrophils, 
macrophages and lymphocytes to these sites (Lee et al., 2008). Such an elevated 
expression of this cytokine has been observed in human peripheral blood mononuclear 
cells (PBMC) and macrophages in response to mycobacterium tuberculosis (Lee et al., 
2008). IL1A and IL1B involved in recruitment of early inflammatory cells to the sites of 
infection (Burger et al., 2006). Early during the course of infection, host needs 
inflammatory agents to curtail pathogen spread to stop the infection, and such pro-
ifnalmmatory factors will have a protective role against R. equi.  
 
In addition to the protective immune response discussed so far, various other processes 
may diminish migration of immune cells (anti-inflammatory) and promote spread of 
infection (coagulation). For example at day-1, we observed down-regulation of genes 
involved in blood coagulation and platelet activation (SCUBE1, SELP, PLSCR1) in the 
stimulated cells. In mycobacterial infection of lungs, platelets have a protective role 
where the aggregation of platelets obstructs blood vessels around the foci of infection 
preventing the spread of the bacteria (Buyukasik et al., 1998). Elevated platelet count is 
seen as one of the clinical symptoms of the foal pneumonia. If the platelets are 
performing a similar action in foals then an elevated platelet count should have a 
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protective role in the pathology of the infection. However just a day after birth, reduced 
expression of genes associated with platelet activation possibly points towards a weak 
immune system unable to activate platelets soon after bacterial infection. As the disease 
progresses in severity the platelet count increases and can be detected as one of the 
clinical symptoms during the first three months of life.  Elevated expression of genes 
involved in blood coagulation and platelet activation are observed at the later time 
points: W-2 (PLEK, PTAFR) and W-4 (PLEK, PLAU).   
 
Adiponectic secretion could be another unfavorable factor that could be antagonizing the 
effect of protective immune response at D-1. Adiponectin is an anti-inflammatory 
adipokine. It suppresses the activity of NF-kB and pro-inflammatory cytokine like TNF-
α in macrophages. Adiponectin also induces expression of various anti-inflammatory 
cytokines like IL-10 and IL1RN (Wolf et al., 2004). From our results at D-1, various 
anti-inflammatory factors seem to be induced by pathogenic stimulation like: IL1RN, 
NFKBIA, adiponectin (via GPR109A). Their anti-inflammatory action can dampen the 
protective immune response at this time point.  
 
 As the foals aged and their immunity matured, we observed up-regulation of a variety of 
chemokines: CCL20 (D-1); CXCL10, CXCL3 (W-2); CXCL2 (W-4), CXCL2, CCL20, 
CXCL10 (W-8). Activation of variety of chemokines and their increased expression only 
in the stimulated leukocytes may be helping in fighting R. equi infection. Neutrophils are 
the first responders to the site of infection and critical for mounting innate immunity. 
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Neutrophils in mice with R. equi infection can reduce the bacterial burden (Martens et 
al., 2005) and are important in controlling early infection. Induction of CCL20 after one 
day of birth, CXCL3 after two weeks and CXCL2 after four weeks of birth cause 
neutrophil chemotaxis and leukocyte migration to the site of infection (Kobayashi, 2008; 
Ha et al., 2010). Hence these chemokines at the various time points are invoking 
neutrophil response to control the early infection due to R. equi and also limit their 
spread. Eight weeks after birth chemokines involved in neutrophil recruitment are 
present. Induction of CXCL10 is involved in activation and recruitment of CD4+ and 
CD8+ T-cells (Lande et al., 2003). CD4+ T-cells are critical in effective clearance of R. 
equi (Kanaly et al., 1993), making induction of CXCL10 a key factor in host immune 
response. It is interesting to observe that at the earlier time points, chemokine profile is 
mainly supportive of the neutrophil recruitment to tackle the pathogen, however at week-
8 the host appears capable of invoking CD4+ and CD8+ T-cells in addition to 
neutrophils.  
 
Due to bacterial stimulation, the host is able to induce protective immune response, but 
the pathogen via modulation of host immune system is able to induce processes favoring 
its survival and proliferation. It appears that the immune related deficiencies of the foal 
allow the pathogen to regulate host immune response. Similar to D-1, at later time points 
we observed processes that maybe favorable to pathogen. For example, we observed up-
regulation of superoxide dismutase 2 (SOD2) at W-2, W-4 and W-8. Up-regulation of 
SOD2 (superoxide dismutase) enables pathogen survival due to its ability to catalyze the 
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superoxide radicals and evade the damage from the reactive oxygen radicals within 
phagocytes (Roberts and Hirst, 1996).  
 
Temporal changes 
Compared to baseline, two weeks after birth, the expression profile from stimulated 
leukocytes showed elevated protein synthesis (ribosomal proteins) and antigen 
processing and presentation. High protein turnover could be a host response against 
bacteria (anti-microbial), or a consequence of pathogen modulating host machinery for 
its survival and replication. Genes involved in protein synthesis (translation and 
processing) was also reported to be elevated in the human macrophages stimulated by 
virulent Mycobacterium tuberculosis (Wang et al., 2003). It appears from our results that 
two weeks after birth, there is an improvement in the host immune response evident by 
up-regulation of genes expressing MHC class II antigens. A reduced expression of MHC 
class II by APC’s like macrophages or dendritic cells is seen in young foals (Dawson et 
al., 2010). Reduced antigen presentation of such molecules can lead to diminished 
activation of class II restricted CD4+ T-cells. Since CD4+ cells are critical in pathogen 
clearance, effective antigen presentation is critical part of host immunity. For C-1, the 
down-regulated genes predominantly performed lipid transport and metabolism. Lipid 
metabolism is a major source of energy for mycobacterium and if a similar mechanism 
exists in R. equi then down-regulation of lipid transport and metabolism genes are 
probably modulated a reduction in pathogen survival. For the other two comparisons (C-
2 and C-3), similar functional profile was revealed were processes contributing to 
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immune response and antigen processing and presentation were up-regulated and lipid 
metabolism was down-regulated.  
 
CONCLUSION  
We obtained the age-related gene expression profile associated with the stimulated 
leukocytes compared to the un-stimulated ones. We also identified genes that are 
modulated temporally when the blood leukocytes were stimulated with virulent R. equi. 
Our findings suggest that the stimulated cells seem capable of initiating a protective 
immune response through birth and up to 8 weeks of age, however there also were 
present genes/processes that may be counter-productive to the host. It is not clear from 
this study if such suppressive responses favoring the pathogen are indeed caused due to 
the immune-modulation by the pathogen or a host response due to immature immune 
system. Temporally it appeared that the across all the time points, the bacterial 
stimulation led to induction of pathogen recognition and mounting of immune response. 
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CHAPTER V 
 
POTENTIAL MOLECULAR BIOMARKERS OF DISEASE SUSCEPTIBILITY 
FOR RHODOCOCCUS EQUI PNEUMONIA IN FOALS BY TRANSCRIPTOME 
PROFILING 
 
SYNOPSIS 
Rhodococcus equi (R. equi) is a gram-positive intracellular bacterium. It is an equine 
pathogen, which infects young foals causing pyogranulomatuous pneumonia. The host 
molecular mechanisms contributing to disease susceptibility are not fully understood. 
Current research to understand the host immunity has only targeted selected cytokines, 
candidate genes, and certain cell types. Global genomic high throughput tools such as 
expression microarrays may provide host genetic signatures and identify molecular 
pathways that contribute to disease susceptibility. Identifying the genes involved in 
disease susceptibility/resistance will help in disease control. The purpose of this study is 
to obtain molecular biomarkers discriminating infection-susceptible foals from healthy 
ones by examining expression profiles in blood leukocytes and nasal epithelial cells in R. 
equi affected and healthy foals. Peripheral blood leukocytes and nasal epithelial cells 
were obtained from six affected and six unaffected foals at birth, and at two and four 
weeks of age. RNA was extracted and the generated fluorescent-tagged cDNA was used 
for microarray hybridization, using an equine whole genome oligoarray. Profiles from 
infected blood leukocytes and nasal epithelial cells collected at birth indicate up-
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regulation of genes involved in reduced immunity and increased susceptibility to 
infection. Samples collected at four weeks of age showed microarray profiles, which 
indicate up-regulation of cellular defense and immune-related genes. Results suggest that 
the most susceptible time point is at birth. Differences in expression profiles between 
infected and uninfected foals at birth suggest that disease susceptibility could be due to 
early exposure to R. equi, which could result in the different gene expression patterns 
observed between the two groups. These results may lead to the identification of specific 
cellular processes that contribute to foal susceptibility and disease progression. 
Identification of specific biomarkers will help to determine early foal susceptibility, and 
could provide for better drug design to treat infections. 
 
INTRODUCTION 
Rhodococcus equi (R. equi) is recognized globally as a primary cause of pneumonia in 
young foals (up to six months after birth). Adult horses do not develop the disease unless 
they are immune-deficient (Heller et al., 2010). R. equi can also cause pneumonia in 
pigs, cattle, cats, goats, dogs, and humans (Muscatello et al., 2007). However, in 
humans, only HIV infected or immune comprised individuals are infected (Linder, 1997; 
Kedlaya et al., 2001).  
 
Mortality rates due to foal pneumonia are estimated to be 2-13% (Mousel et al., 2003) 
making this disease a serious economic problem for the equine industry. It is difficult to 
make an early diagnosis of foal pneumonia since clinical signs do not appear till the 
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disease has progressed in severity (Horowitz et al., 2001). Thus a lack of early and 
definitive diagnosis makes prevention and control of the disease difficult. There is a 
need to screen foals at a very early age to identify early infections and to determine 
which animals are more likely to have the disease. Early and accurate screening methods 
for foals, before the onset of clinical symptoms, are not available. Currently available 
screening methods are expensive, have low sensitivity, and are unreliable (Cohen et al., 
2002). Gene microarrays from infected foals could identify target biomarkers for this 
disease. Compared to existing screening methods, identifying biomarkers at the 
molecular level will provide an early and more reliable screening of the disease status of 
the foals.  
 
Although all foals on endemic farms are exposed to R. equi, some foals develop 
pneumonia while others do not (Chaffin et al., 2004). Clearly, the cause of resistance to 
R. equi-related pneumonia is a key to detection and treatment. The pathogen multiplies 
in alveolar macrophages, inside membrane-enclosed vacuoles. Survival of the bacteria 
may be due to impaired phagosomal maturation or lack of fusion with the lysosome 
(Fernandez-Mora et al., 2005; Rahman et al., 2005; Flaminio et al., 2009). In addition to 
the pathogen’s subversion of the immune system host factors also contribute to 
susceptibility for R. equi related pneumonia. The mechanism by which this occurs 
remains unknown. Biomarkers identified by use of microarrays could help determine the 
mechanism by which the R. equi provides susceptibility to pneumonia. 
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Components of both innate and adaptive immunity are critical in prevention and 
clearance of the infection (Muscatello et al., 2007). In foals less than three months of 
age, reduced dendritic cell (DC) function and low killing capacity of neutrophils is 
observed (Demmers et al., 2001; Chen et al., 2006). Mounting a Th1 driven immune 
response against the R. equi infection is beneficial since it favors recruitment of IFN-γ, 
producing CD4+ and cytotoxic CD8+ cells (Dawson et al., 2010). It is the activation of 
macrophages by IFN-γ that assists in pathogen killing through stimulating the fusion of 
phagolysosomes, and increasing the synthesis of reactive oxygen species (von Bargen 
and Haas, 2009). Young foals have a reduced capacity to produce IFN-γ (Giguere et al., 
1999). Thus, they may be more susceptible to pneumonia. 
 
Information about the foal immune response against R. equi infection comes from 
studies of differences between foal and adult horse responses to the pathogen. Studying 
the differences in the transcriptome, using microarray analyses of infected and 
uninfected foals prior to onset of the clinical symptoms, will reveal the molecular 
mechanisms underlying susceptibility of some foals, while others remain unaffected.  
 
We hypothesized that there are differences between foals susceptible to R. equi infection 
and the ones that remain healthy even after the pathogen exposure and that such 
differences can be captured at the transcriptome level. Additionally, the expression 
profile will provide us with biomarkers that could potentially be used to screen foals for 
early detection of infection/disease prior to the onset of clinical symptoms 
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MATERIALS AND METHODS 
Study design 
Peripheral blood leukocytes and nasal epithelial cells were collected from 100 foals at 
three time points: at birth, two weeks, and four weeks of age. Samples were taken from 
foals on a farm with a previously established high incidence of R. equi related 
pneumonia. We anticipated that about 20% of the foals would develop the disease. Soon 
after birth, every foal was closely monitored for cough, runny nose, lethargia, and 
diarrhea. Once any of these early symptoms were observed in a foal, they were evaluated 
for elevated body temperature, complete blood cell count (CBC), and fibrinogen levels. 
Ultrasound examination of foals was performed to evaluate lung abscesses. Based on the 
diagnosis, diseased foals were started on an antibiotic treatment regimen. During the 
treatment, CBC’s and lung ultrasounds were performed every two weeks, while 
temperature was monitored 2-3 times per day.  
 
Once the clinical diagnosis of pneumonia was made, the samples retrieved from all the 
foals (nasal epithelial cells and blood leukocytes) were assigned to either the R. equi 
pneumonia affected group or unaffected group. All foals on the farm could have been 
exposed to R. equi, however only foals that displayed the clinical symptoms were 
considered affected and the rest grouped as unaffected. No serological test was 
performed on the foals to definitively know the infection status of unaffected foals, since 
they did not display signs of pneumonia they were considered to be unaffected.  
 
 141 
Of the samples collected from 100 foals, 45 foals were diagnosed with R. equi infection, 
and the remaining 55 healthy foals were uninfected. Out of the two groups of foals 
(infected and healthy), 10 foals were used in each group. Samples were typed (blood 
leukocyte and nasal epithelial) and saved for future experiments. In this study, we 
encountered various limitations that restricted the sample size to six. In addition, we 
could not extract enough RNA from nasal epithelial samples for further analyses. In 
specific cases, samples were of low quantity or quality of RNA, rendering that sample 
unusable.  
 
Sample types and sampling time points  
For the present study two sample types: peripheral blood leukocytes and nasal 
epithelium were considered. Since leukocytes defend the body against foreign/infectious 
agents and are mediators of innate and adaptive immunity, knowledge about the age-
related response of leukocytes will provide a snapshot of the foal’s immunity. We chose 
peripheral blood leukocytes under the premise that the systemic immunity will 
efficiently correlate with the host pulmonary immunity. Also leukocytes are easily 
accessible. Nasal epithelial cells were chosen to represent a component of the pulmonary 
system and also because nasal epithelium is the first to encounter the pathogen. 
Moreover, if the signatures from nasal epithelium can efficiently reflect the disease 
status before the clinical onset, than this could be developed as a non-invasive way to 
screen the foals.  
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R. equi pneumonia is rare in adult horses therefore the disease appears to be age-
dependent. Young foals have immature immune system compared to adult horses, and 
are most susceptible to infection up to 3-months of age. The time points were therefore 
chosen starting from birth (T-0) and weeks 2 (T-2) and 4 (T-4). The foals in were 
diagnosed as clinically sick in the 5-6th week, after which we grouped the samples into 
affected and unaffected group. The three time-points in the affected group therefore 
reflect stages of susceptibility before foals show any clinical symptoms. Therefore if 
from any of the above time points (before clinical onset of disease), we can obtain 
discriminative biomarkers they will help in early screening of the foals that will most 
likely become sick in the near future.  
 
Sample collection 
Ten mL peripheral blood was collected via jugular venipuncture from each foal and 
stored in an EDTA-containing Vacutainer (Becton Dickinson Co., Franklin Lakes, NJ, 
USA). The leukocytes were isolated and stabilized using LeukoLOCK Total RNA 
Isolation System (Ambion, Grand Island, NY, USA). Nasal epithelial cells were 
retrieved from inferior turbinate using an interdental brush. Samples were collected from 
foals at birth, two weeks, and four weeks of age (Ramalho et al., 2004). The epithelial 
cells were collected by gently rubbing the brush head inside the nostrils of the foals. The 
brush head was then placed in a 1.5 mL tube containing RNAlater (Qiagen, Valencia, 
CA, USA). The interdental brush assembly had an ultrafine cylindrical brush head to 
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minimize any discomfort (Proxabrush, model #422, with a Proxabrush snap-on handle, 
model #625, Sunstar/GUM, Chicago, IL, USA). 
 
RNA extraction 
Total RNA was extracted from whole blood using the LeukoLOCK Total RNA Isolation 
System (Ambion, Grand Island, NY, USA) and from nasal epithelial cells using the 
RNeasy mini kit (Qiagen, Valencia, CA, USA) per the manufacturer’s instructions. A 
DNase I treatment was also performed as part of the RNA extraction protocol to remove 
any contaminating genomic DNA as per the instructions in RNeasy mini kit. Extracted 
RNA was quantified with a spectrophotometer (NanoDrop, Thermo Scientific, 
Wilmington, DE, USA) and the RNA quality was evaluated with the Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). RNA extraction for nasal 
epithelial cells was performed by a modified protocol as described by Beck et al. (1999) 
and Ramalho et al. (2002) (Section D-3). 
 
RNA amplification 
Due to low quantity of some RNA samples, all RNA samples were amplified to ensure 
uniformity of procedure, both for nasal epithelial cells and blood leukocytes. Five 
hundred nanograms of RNA was used for each amplification reaction, using the 
Sensation Kit (Genisphere, Hatfield, PA, USA) as per the manufacturer’s protocol.  
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Experimental design 
The cDNA obtained at birth, two, or four weeks of age from nasal epithelium and blood 
leukocytes were co-hybridized between the six affected foals and six unaffected foals. 
We used a balanced block design (BBD) for microarray hybridizations because for class 
comparison studies, BBD is considered optimal (Dobbin and Simon, 2002). The dye 
swap was embedded within the biological replicates to overcome any bias associated 
with the fluorescent dyes. The same animals were used for extracting leukocytes and 
nasal epithelial cells at all three time points.  
 
Labeling and microarray hybridization  
For each sample, cDNA was generated from total RNA using Superscript II Reverse 
Transcription kit (Invitrogen, Carlsbad, CA, USA) and labeled with Cy3 or Cy5 dye via 
an indirect labeling method utilizing dendrimer technology (Stears et al., 2000). 
Labeling was carried out with the 3DNA Array 900 MPX Expression Array Detection 
kit (Genisphere, Hatfield, PA, USA). Hybridizations were performed in a SureHyb 
hybridization chamber (Agilent Technologies, Santa Clara, CA, USA) at 55°C. 
Following post-hybridization washes, arrays were scanned with a GenePix 4000B 
scanner at 5 micron resolution (Molecular Devices, Sunnyvale, CA, USA). GenePix Pro 
6.1 software (Molecular Devices) was utilized for raw data acquisition, spot-finding, and 
quantification of array images.  
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Equine 21K oligonucleotide microarray  
We used an whole genome equine oligonucleotide array with 21,351 elements designed 
at Texas A&M University (Bright et al., 2009). This 70-mer equine oligoarray is one of 
the most exhaustive gene arrays currently present for expression analyses. Probes were 
synthesized (Invitrogen, Carlsbad, CA) and printed onto amino-silane coated slides 
(Corning Incorporated, Corning, NY). 
 
Expression analyses 
Differential expression analyses of microarray data were conducted using the freely 
available Bioconductor Limma package running in the R statistical software 
environment (Smyth, 2004). Background corrections of raw intensities were performed 
using the “normexp” correction method (Ritchie et al., 2007). Subsequently, the 
background corrected intensities were normalized using printip-loess normalization 
(within array normalization), but no across array normalization was performed (Smyth 
and Speed, 2003a). Linear modeling using moderated t-tests was performed to identify 
differentially expressed genes (Smyth, 2004). To account for the multiple comparisons, 
the false discovery rate correction method of Benjamini and Hochberg was used 
(Benjamini and Hochberg, 1995). Linear models were used to assess the differentially 
expressed (DE) genes from blood leukocytes at birth (B-T0), two weeks (B-T2), and 
four weeks of age (B-T4). Similarly, linear models were fit to obtain DE genes from 
nasal epithelium of animals at birth (N-T0), two weeks (N-T2), and four weeks of age 
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(N-T4). Genes were considered significantly differentially expressed if they had a p 
value of p< 0.05 and fold change > 1.5.  
 
Functional analyses 
Functional gene ontological analyses were performed using a web-based tool 
WebGestalt: WEB-based GEne SeT AnaLysis Toolkit (Zhang et al., 2005). Gene 
ontological analyses were performed using the list of differentially expressed genes to 
obtain statistically significant biological processes. In order to calculate the statistical 
significance, DE genes for each comparison were compared to all the genes present on 
our equine microarray. The method of Benjamini and Hochberg [24] was used for 
multiple test adjustments with significance level of p< 0.1.  
 
Quantitative real-time PCR 
Quantitative real-time PCR was performed on a subset of genes that were significantly 
differentially expressed (fold change > 1.5, and p<0.05). Each gene was tested in 
duplicate, with a housekeeping gene control. This technique was used to validate results 
obtained from the statistical analysis of the microarray data. The total RNA was directly 
reverse transcribed to cDNA using the SuperScript® VILO™ cDNA Synthesis Kit 
(Invitrogen) and subsequently amplified using gene-specific primers and master mix by 
qPCR, in a single-step reaction.  
When possible, primers were designed to span intron-exon boundaries, to represent a 
region of the mRNA corresponding to the location of the cDNA sequence located on the 
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arrays. Serial dilutions of RNA from the reference samples were used to generate 
relative standard curves and to test the amplification efficiency of each primer set. For 
each qPCR assay, ~100 ng of total RNA was used in a 25 µl reaction with 1x Universal 
SYBR® Green Master Mix (Applied Biosystems, Carlsbad CA, USA) and 300 nM 
primers, and amplified on a LightCycler 480 (Roche Diagnostics, Indianapolis, IN, 
USA).  
 
RESULTS 
Differentially expressed genes  
We obtained 268 DE genes (119 up-regulated and 149 down-regulated) for blood 
leukocytes samples at birth (B-T0) from infected foals compared to the controls (table 
D-1). There were 180 DE genes (93 up-regulated and 87 down-regulated) for blood 
leukocyte samples when infected foals were compared to control foals at two weeks (B-
T2) and 319 DE genes (191 up-regulated and 128 down-regulated) for blood leukocyte 
samples from infected foals compared to controls at four weeks (B-T4).  
 
Similarly, for nasal epithelial samples at birth (N-T0), we obtained 501 DE genes (360 
up-regulated and 141 down-regulated) when infected foals were compared to control 
foals. There were 348 DE genes (228 up-regulated and 348 down-regulated) for nasal 
epithelial samples at two weeks (N-T2) when infected foals were compared to control 
foals while 267 genes were differentially expressed (108 up-regulated and 159 down-
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regulated) for nasal epithelial samples at four weeks (N-T4), when infected foals were 
compared to control foals.  
 
Functional analysis 
Blood leukocytes 
Functional analyses were performed to obtain statistically significant biological 
processes associated with the DE genes (for both up- and down-regulated genes) at the 
three time points for each biological sample type (leukocytes and nasal epithelium). The 
top 15 statistically significant biological processes associated with the down- and up-
regulated DE genes for B-T0 comparison are presented in figure 5-1a and figure 5-1b, 
respectively. Various immunologically relevant processes that could be modulating the 
development of disease pathology were found to be associated with the down-regulated 
genes (e.g. endosome to lysosome transport, lysosome transport, negative regulation of 
immune functions) compared to those associated with the up-regulated genes (e.g., 
regulation of IL-6 biosynthetic processes). The list of all significant biological processes 
is presented in table D-6a and table D-6b.  
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Figure 5-1: Biological processes associated with differentially expressed genes in 
blood leukocytes at birth. Graphical representation of top fifteen statistically significant 
processes associated with the DE genes in blood leukocytes at birth a) represents 
biological processes at birth (T0) associated with down-regulated (colored green bars) 
and b) up-regulated genes (colored red bars). The Y-axis represents the biological 
processes and the X-axis represents the value displayed as -log2 (p value). 
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The B-T2 comparison (figure D-7a and D-7b) found a majority of down-regulated 
genes associated with cellular growth and division-related processes (e.g., RNA splicing, 
mRNA processing, DNA packaging, nuclear division), while the up-regulated genes 
were predominantly associated with lipid synthesis and metabolism (e.g., steroid 
metabolic process, lipid biosynthesis, lipid metabolism).  
 
The biological processes identified as down-regulated genes in B-T4 comparisons 
(figure D-8a and D-8b) were involved in neurogenesis (e.g., oligodendrocyte 
development, oligodendrocyte differentiation, neural fate commitment). The up-
regulated genes for this comparison were associated with processes involved in 
respiratory system development (e.g., lung development, respiratory tube development) 
and immunologically relevant iron homeostasis.  
 
Nasal epithelial cells  
Similarly for nasal epithelial cells, functional analyses of the DE genes revealed various 
biological processes associated with the expression profiles at the three time points. For 
N-T0 comparisons (figure 5-2), the top 15 processes associated with the down-regulated 
genes were involved in synthesis and metabolism of biomolecules (e.g. alcohol 
biosynthetic processes, amino sugar metabolic processes, and oxoacid metabolic 
processes) and pathogen recognition and responses (e.g. response to polysaccharide, 
response to molecule of bacterial origin, response to cytokine stimulus). The biological 
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processes associated with up-regulated genes were predominantly associated with 
muscle cell growth and development.  
 
 
 
 
Figure 5-2: Biological processes associated with differentially expressed genes in 
nasal epithelium at birth. Graphical representation of top fifteen statistically significant 
processes associated with the DE genes in nasal epithelium at birth a) represents 
biological processes at birth (T0) associated with down-regulated (colored green bars) 
and b) up-regulated genes (colored red bars). The Y-axis represents the biological 
processes and the X-axis represents the p value displayed as -log2 (p value). 
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Figure 5-2 Continued 
 
 
 
 
 
For the N-T2 comparison, the top 15 processes associated with the down-regulated genes 
were involved in early developmental processes (e.g., anterior/posterior pattern 
formation) and regulation of ligase activity. The top 15 processes associated with the up-
regulated genes were involved in neuronal differentiation (e.g., neuron fate commitment, 
neuron fate specification) and biosynthetic processes (e.g., macromolecule biosynthetic 
processes, regulation of nucleobase, nucleoside, nucleotide, and nucleic acid metabolic 
processes). Finally, for the N-T4 comparison, the top 15 biological processes were 
involved in heme biosynthesis and metabolism (e.g. tetrapyrrole biosynthetic processes, 
porphyrin biosynthetic processes, heme metabolic processes). The biological processes 
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associated with the up-regulated genes were involved in carbohydrate biosynthesis and 
metabolism (e.g. glycogen metabolic processes and glucan metabolic processes). 
 
Real-time PCR validation  
Real-time PCR was used to validate findings of selected genes that were significantly 
differentially expressed from the two sample types at three time points (figure 5-3). We 
chose 15 genes for the validation purposes and confirmed their differential expression in 
relation to the microarray data. Two genes were selected from B-T0 (IQCF1, STX11), 
four genes from B-T2 (DNAH2, HRH1, KIAA0460, WDR90) and two genes from B-T4 
(BBS5, CEP55). Similarly, three genes were selected for N-T0 (CNTROB, SLMAP, 
VAMP7), two genes from N-T2 (GNDPA1, SLC6A12) and two genes from N-T4 
(HCCS, SYVN1). We could validate the direction of regulation (up/down) for all fifteen 
genes using real-time PCR
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Figure 5-3: Real-time PCR validation. Differentially expression (pvalue<0.05 and fold change cutoff of 1.5) of fifteen genes 
was validated using real-time PCR
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Linear discriminant analyses (LDA) 
In order to obtain discriminatory molecular biomarkers, we utilized the LDA 
classification technique to identify the best single gene and two to three combinations of 
genes, generating classifiers which discriminate between the transcription profiles of R. 
equi affected vs. unaffected foals. The classifiers were ranked based on their 
misclassification errors (εbolstered), i.e. the higher a classifier was ranked the lower its 
misclassification error. We identified the top ten single, two, and three gene classifiers 
with the lowest εbolstered to distinguish R. equi infected from control foals, using blood 
leukocytes and nasal epithelial cell samples at each time point. The classification results 
demonstrate that there are several cases where single genes can separate the R. equi 
infected foals from control foals with a low error estimate. Furthermore, when 
considering these features as part of two or three gene classifiers, we observed a 
significant decrease in the classification error as evident from the percent decrease in 
error (Δεbolstered).  
 
It has been suggested that multivariate feature sets (i.e. those containing two or more 
genes) are better discriminators when the phenotype is complex (Chapkin, 2010). For 
example, a two-feature classifier would be considered a better discriminator than a one-
feature classifier, if the pair of genes performs better than either of the genes 
individually, as evident from the improvement in classification (Chapkin 2010, Chen 
Zhao 2009). The specific results for discriminating the expression profiles of R. equi 
infected from control foals at T0, T2, and T4 are detailed below.  
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Classification of expression profiles of R. equi infected foals from control foals using 
blood leukocytes  
At birth (T0), the top single-gene classifier discriminating R. equi infected foals from the 
controls was found to be CARD9 (top in the list of single-gene classifiers), with an 
estimated classification error of 0.0719 (table 5-1). Among the 2-gene classifiers, the 
combination of CDKN2AIP and CARD9 ranked high in the ability to distinguish 
between the two groups of animals (εbolstered= 0.0278), and together they were better 
discriminators (lower error estimate) when compared to either of them individually. 
Around 9% (Δεbolstered =0.0926) improvement in classification can be observed when 
CDKNZAIP is combined with CARD9 as a two-feature classifier. From the table it is 
evident that of the top five three-feature classifiers listed, GLRA2, CARD9, and 
PHOX2A constituted the best three-gene classifier set with an error estimate of 0.0142. 
There was an improvement of around 2.8% (Δεbolstered =0.028) in classification when 
CARD9 was used in combination with GLRA2 and SRR over the 2-gene classifier based 
on GLRA2 and PHOX2A. Among the top one, two, and three gene classifiers, triplet 
classifiers not only had the lowest error but also showed sizable decrease in the 
classification error when compared to the single- and two-gene classifiers. Thus, the top 
triplet classifiers are better discriminators between the R. equi infected and control group 
at birth.  
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Table 5-1: Linear discriminant analysis of infected versus control foals at birth 
(blood leukocytes). The top five one-, two-, and three-gene LDA classifiers are shown 
in the table below.  ε bolstered represents the bolstered resubstitution error for the 
respective gene classifier and  Δ ε bolstered represents the decrease in error for each feature 
set relative to its highest ranked subset of genes.  
 
1 feature 2 feature 3 feature εbolstered Δεbolstered 
CARD9     0.0719   
CDKN2AIP 
     0.1204   
PLT3-M24-M13.rgy.ab1     0.1543   
SRR 
     0.1644   
GLRA2 
     0.1656   
CDKN2AIP 
 CARD9   0.0278 0.0926 
CDKN2AIP 
 
ARF3 
   0.0401 0.0803 
GLRA2 
 
SRR 
   0.0422 0.1234 
CT02031B1C07.f1.ab1 SDPR    0.0449  0.1195 
SRR 
 CARD9   0.0453 0.0266 
GLRA2 
 CARD9 
PHOX2A 
 0.0142 0.028 
CDKN2AIP 
 
ARF3 
 CARD9 0.0151 0.0127 
ARF3 
 CARD9 XM_001490209.1 0.0171 0.0377 
CDKN2AIP 
 CARD9 gnl|UG|Eca#S38808416-m70 0.0182 0.0096 
CDKN2AIP 
 
AMZ1 
 
ARF3 
 0.0196 0.0205 
 
 
 
Similar results were obtained at T2, where PLEK2, DDX47, and HSPD1 were the best 
triplet classifiers, with an error estimate of 0.026 (table D-2). The modest improvement 
in error by using these triplet sets was 0.53% relative to the highest ranked subset of 
features (PLEK2 and HSPD1, with error estimate of 0.0313). At T4, best triplet 
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classifiers with lowest error were ZNF420, KRT4, and PROCR, with an error estimate 
of 0.0046 (table D-3). The improvement in error by using these triplet sets was around 
3% relative to the highest ranked subset of features (ZNF420 and KRT4, with error 
estimate of 0.0361). A clear separation of R. equi infected vs control animals was 
observed at the three time points by the three dimensional LDA hyperplane, based on the 
top triplet classifier (figure 5-4). 
 
 
 
 
 
Figure 5-4: Linear discriminant analysis using three-gene classification model for 
infected versus control foals at birth (blood leukocytes). The best performing three-
gene feature sets that classify infected foals from control foals at are; a) birth (T0) b) 
week2 (T2), and c) week4 (T4). The three dimensional LDA hyperplane discriminates 
between R. equi infected (circles) and control (triangles) foals. Axes represent 
normalized intensity values of the corresponding genes.  
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Classification of expression profile of R. equi infected foals from control foals using 
nasal epithelial cells  
At birth (T0), the top single-gene classifier discriminating R. equi infected foals from the 
controls was found to be GNG12 (top in the list of single-gene classifiers), with an 
estimated classification error of 0.0185 (table 5-2). Among the 2-gene classifiers, a 
combination of GNG12 and RGS19 ranked high in the ability to distinguish between the 
two groups of animals (εbolstered= 0.0234), and together they were better discriminators 
(lower error estimate) when compared to either of them individually. While GNG12, 
COL9A2, and RGS19 formed the top three gene classifier set, with an error estimate of 
0.0177, it was also important to note that these genes were also among the top ten single 
and two-gene classifiers. There was a very modest improvement (Δεbolstered =0.0057) in 
classification when COL9A2 was used in combination with GNG12 and RGS19 over the 
2-gene classifier based on GNG12 and RGS19. Among the top one, two, and three gene 
classifiers, triplet classifiers not only have the lowest error but also show sizable 
decreases in the classification error when compared to the single- and two-gene 
classifiers. Thus, the top triplet classifiers are better discriminators between the infected 
and control group at birth.  
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Table 5-2: Linear discriminant analysis of infected versus control foals at birth 
(nasal epithelial cells). The top five one-, two-, and three-gene LDA classifiers are 
shown in the table below.  ε bolstered represents the bolstered resubstitution error for the 
respective gene classifier and  Δ ε bolstered represents the decrease in error for each feature 
set relative to its highest ranked subset of genes.  
 
1 feature 2 feature 3 feature εbolstered Δεbolstered 
GNG12 
     0.0185   
BOC 
     0.118   
GENE 16246     0.1226   
CLDN3 
     0.1309   
LOC124220 
     0.1347   
GNG12 
 
RGS19 
   0.0234 -0.0049 
GNG12 
 
COL9A2 
   0.0339 -0.0154 
C1orf216 
 
MRPS18A 
   0.0343 0.1543 
GNG12 
 
MRPS18A 
   0.0369 -0.0184 
GNG12 
 
FICD 
   0.0414 -0.0229 
GNG12 
 
COL9A2 
 
 RGS19 
 0.0177 0.0057 
LOC100052930 
 
ZNF709 
 
PSCD4 
 0.0224 0.0549 
TFDP1 
 
HDAC8 
 
GJA5 
 0.0232 0.0688 
OR4F16 
 
TFDP1 
 
FANCI 
 0.0235 0.0265 
GENE:16246 GNG12  
COL9A2 
 0.0239 0.01 
 
 
 
Similar results were obtained at T2, when CX604514, AHSA1, and GORASP2 were the 
best triplet classifiers with an error estimate of 0.013 (table D-4). The improvement in 
error by using these triplet sets was 1.87% (Δεbolstered =0.0187) relative to its highest 
ranked subset of features (CX604514 and AHSA1, with error estimate of 0.0317). At T4, 
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the best triplet classifiers with lowest error were OR2L2, COL28A1, and DN508139, 
with an error estimate of 0.0397 (table D-5). The improvement in error by using these 
triplet sets was around 4% (Δεbolstered =0.0397) relative to the highest ranked subset of 
features (OR2L2 and DN50139, with error estimate of 0.0794). A clear separation of R. 
equi infected and control animals at the three time points as shown by the three 
dimensional LDA hyperplane based on the top triplet classifier is shown in figure 5-5. 
 
 
 
 
 
Figure 5-5: Linear discriminant analysis using three-gene classification model for 
infected versus control foals at birth (nasal epithelial cells). The best performing 
three-gene feature sets that classify infected foals from control foals are; at a) birth (T0) 
b) week2 (T2) and c) week4 (T4). The three dimensional LDA hyperplane discriminates 
between R. equi infected (circles) and control (triangles) foals. Axes represent 
normalized intensity values of the corresponding genes.  
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DISCUSSION 
 
We hypothesized that the transcriptome profiling of peripheral blood leukocytes and 
nasal epithelial cells will yield key genes and biological processes that will contribute to 
the foal susceptibility to infection. Using the expression profile we will be able to 
identify biomarkers for early screening of foals that are likely to develop pneumonia.  
Obtaining hundreds of DE genes at each time point shows that there are differences 
between the two groups of foal at the transcriptional level. Using these DE genes we 
obtained sets of genes (triplets) that can classify the two groups with low error rate.  
 
Although all neonatal foals have immature immune systems, our results suggest that 
there are additional molecular pathways that predispose some foals to contract R. equi 
pneumonia. Our findings suggest that the differences in the transcriptome profile 
between the susceptible foals (foals that later develop pneumonia) and the healthy foals 
early in life (soon after birth) contribute to the reduced immunity and increased 
susceptibility to infection. In blood leukocytes at birth, our findings suggest that at birth 
gene expression is supportive of a Th2 immune response. Similar to these observations, 
in the nasal epithelial cells at birth, we observed reduced expression of genes involved in 
mucosal immunity and intracellular pathogen killing. At the later time points (in both 
sample types) protective immune responses against the pathogen were observed. The 
molecular biomarkers identified in this study may allow early detection of at-risk foals. 
We discuss each group below. 
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Expression of genes from blood leukocytes of affected vs. unaffected foals 
At birth, expression profiles from blood leukocytes of susceptible foals suggest that 
modulation of genes involved in phagocytosis, IFN-γ signaling, immune activation via 
dendritic cells, and IL-6 biosynthesis could promote susceptibility to intracellular 
pathogens by influencing their ability to eliminate the pathogen. In order to support our 
hypothesis that deficiencies at the molecular level (in addition to the immature neonatal 
immune system) predispose certain foals to develop R. equi infection and pneumonia, 
we identified the biological processes, which would be associated with the differentially 
expressed genes at birth.  
 
Vesicle-associated membrane protein 7 (VAMP7) and sorting nexin 1 (SNX1) genes 
(associated with endosome to lysosome transport processes) play a role in phagosomal 
fusion, and are down-regulated in susceptible foals at birth. It is known that VAMP7 
assists in completing membrane coalescence to facilitate phagosomal fusion by bringing 
organelles, such as endosomes and lysosomes, into close proximity (Flannagan et al., 
2009). VAMP7 plays a crucial role in the onset of phagocytosis in macrophages while 
syntaxin 1(SNX1) is involved in fusion with endocytic compartments during maturation 
of phagosomes (Braun et al., 2004). Normally, immune responses prevent entry of a 
foreign body through phagocytosis by macrophages, dendritic cells, and neutrophils 
(Braun et al., 2004). However, lack of phagosomal-lysosome fusion or an altered 
phagocyte maturation process would allow R. equi to survive and replicate in 
macrophages (Fernandez-Mora et al., 2005). Reduced expression of genes associated 
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with phagocytosis in susceptible foals, as observed in our study, may predispose them to 
infection with R. equi.  
 
Interleukin 27 receptor, alpha (IL27RA/ WSX1) associated with negative regulation of 
immune response processes are known to be important for normal IFN-γ production by 
CD4+ cells, and is therefore essential for mounting a Th1 response (Takeda et al., 2003). 
In addition, it has been reported that mice deficient in WSX1 display increased 
susceptibility to infection with the intracellular pathogen, Listeria due to reduced IFN-γ 
production (Chen et al., 2000). JAK-STAT signaling was also down-regulated at birth in 
affected foals. The JAK2 gene associated with JAK-STAT signaling is important for 
development and functionality of dendritic cells (DCs) and IFN-γ signaling (Campbell et 
al., 1994). In mice, loss of JAK2 is reported to impair the capacity of DCs to initiate 
innate immune responses due to reduced expression of TNF-α and IL-12 (Zhong et al., 
2010). IFN-γ and TNF-α are involved in clearance of Rhodococcus equi by activating 
macrophages to kill the intracellular pathogen (Darrah et al., 2004). Neonatal foals have 
reduced capacity to produce IFN-γ and mount Th1 responses, and down-regulation of 
IL27RA and JAK2 could contribute towards reduced ability of susceptible foals to 
mount sufficient protective responses when compared to healthy foals.  
 
Among the processes associated with up-regulated genes, regulation of IL-6 biosynthesis 
appeared most relevant. IL-6 produced by antigen presenting cells is known to modulate 
differentiation of CD4+ T-cells into effector Th1 or Th2 cells, and has been found to 
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shift the T-cell helper type one and two balance towards a type two response by 
inhibiting IFN-γ production (Diehl and Rincon, 2002). Elevated expression of IL-6 has 
been reported in R. equi infected foals (Giguere et al., 1999; Ferraz et al., 2008; Nerren 
et al., 2009), and increased expression in neutrophils stimulated by R. equi is greater in 
newborn foals than two, four, and eight week old foals (Nerren et al., 2009). Hence, it 
appears that elevated IL-6 could be responsible for promoting a Th2-driven immune 
response, especially at birth in the infected group of foals, making foals highly 
susceptible to exposure early in life. Although, we did not observe an upregulation of IL-
6 in susceptible foals, we found overexpression of genes that modulate IL-6 production 
(CARD9 and CEBPB).  
 
The CCAAT/enhancer binding protein (C/EBP), beta (CEBPB/ NF-IL6) gene modulates 
IL6 biosynthesis and is a key element in IL-6 signaling as well as in transcriptional 
regulation of IL-6 (Lu et al., 2009). In addition to regulating IL-6, CEBPB is responsible 
for regulation of genes encoding many acute phase proteins and cytokines critical for 
bacterial killing by macrophages (Tanaka et al., 1995). The caspase recruitment domain 
family, member 9 (CARD9) gene (also associated with IL-6 biosynthetic processes) is 
required for cytokine production in response to intracellular bacterial and viral 
infections. Deficiency or aberrant activation of CARD9 is associated with susceptibility 
to infection or immune diseases, respectively (Ruland, 2008). Both CEBPB and CARD9 
could be favoring Th2 immune responses via influencing IL-6 production and increasing 
susceptibility to infection.  
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Two weeks after birth we observed, in blood leukocytes, upregulation of genes involved 
in antimicrobial actions involved in fighting R. equi infection. At week four, up-
regulated genes were associated with biological processes that could help fight against 
infection, including genes involved in development of lymphocytes, defense, and iron 
homeostasis. The details for these time-points are presented in Appendix D (section D-1 
and D-2).  
 
Linear discriminant analysis 
The objective of this study was to identify biomarkers for early screening of foals. Since 
we identified biomarkers that could discriminate the two groups of foal at birth with 
minimum misclassification error rate, the remaineder of the discussion will focus only 
on those.  
 
Using discriminant analyses, triplet classifiers like genes, glycine receptor, alpha 2 
(GLRA2), paired-like homeobox 2a (PHOX2A), and caspase recruitment domain 
family, member 9 (CARD9) were found to discriminate the R. equi infected group of 
foals from the healthy foals at birth with a low misclassification error. Protein encoded 
by PHOX2A gene is involved in the development of autonomous nervous system. In 
neonatal mice expression of this genes is considered critical in development of normal 
respiratory rhythm (neuronal impulse muscle that control inspiration an expiration) 
(Viemari et al., 2004; Wrobel et al., 2007). GLRA2 are ligand-gated chloride channels 
and is proposed to have a role in neuronal development (Young-Pearse et al., 2006). The 
caspase recruitment domain family member-9 (CARD9) gene is proposed to have a role 
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in innate immune responses against certain intracellular bacterium. Alterations in 
CARD9 expressions are thought to influence susceptibility to infections (Ruland, 2008). 
Hence, it appears that the biological role of these genes in concert could influence the 
susceptibility of foals towards R. equi pneumonia and discriminate such foals from the 
unaffected ones. 
 
We propose that these biomarkers can be developed as a qPCR based screening test to 
identify foals at a high risk of infection. Once this screening test is validated 
experimentally, it should be possible to screen foals soon after birth for earlier disease 
detection and lowering the disease incidence by starting the foals on appropriate 
treatment regimen.  
 
Expression of nasal epithelial cell genes in affected vs. unaffected foals  
Nasal epithelium is the first host tissue to encounter the R. equi bacterium and provides 
the first line of defense against this pathogen. Down-regulation of genes involved in 
mucosal immunity and intracellular pathogen killing may lead to the pathogen evading 
immune responses at the epithelium and entering the lower airways. In spite of these 
deficiencies, the mucosal barrier appears to be responding and limiting the R. equi 
growth by recognizing the bacterial lipids and creating a hostile environment by 
reducing iron bioavailability. 
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From our results one significant biological process was response to bacterium associated 
with genes, FOS, CCL20, SNCA, and NOS3. Mucosal surfaces are key portals of 
antigen/ pathogen/ foreign particle entry into the body and gene chemokine (C-C motif) 
ligand 20 (CCL20) is involved in mucosal immunity (Williams, 2006) and is up-
regulated under inflammatory conditions (Schutyser et al., 2003). CCL20 stimulates 
migration of immature DC, B-cells, and a subset of memory T-cells to mucosal 
epithelium, providing antimicrobial properties (Starner et al., 2003). Reduced expression 
of CCL20 and eNOS3 is involved in mucosal immunity and may contribute towards 
immune incompetency of R. equi susceptible foals at birth. 
 
Cell mediated immunity is essential against R. equi infection, and CD4+ and CD8+ T-
lymphocytes are of critical importance in R. equi clearance. Hence down-regulation of 
IL-7 and IL-17F could contribute to lower T cell proliferation in susceptible foals. IL17F 
shares homology with IL-17 and is hence thought to stimulate T cell proliferation and 
regulate inflammatory responses (Chang and Dong, 2007). IL-7 has a role in 
maintenance and growth of T lymphocytes, regulation of naïve and memory T cells, 
stimulation of CD8+ T cell proliferation, and other antimicrobial properties (Vranjkovic 
et al., 2007). Low serum levels of IL-7 cause impaired T cell function (Holm et al., 
2005; O'Connor et al., 2010). In mice, IL-7 enhanced the ability of murine macrophages 
to kill Lishmania major infected cells, and in vivo administration stimulated protective 
immunity against Toxoplasma gondii by increasing IFN-γ production and CD8+ CTL 
responsiveness (Pierrete Appaswamy 1998). Since both Lishmania major and 
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Toxoplasma gondii are intracellular pathogens like R. equi, reduced IL-7 could 
contribute to susceptibility towards R. equi infection as well.  
 
Up-regulated genes at N-T0 are involved in responses to fatty acid metabolism, vesicle 
fusion, leukocyte degranulation, and iron homeostasis. Presence of fatty acids may be a 
response reaction to the R. equi cell envelope. R. equi belongs to Mycolata, and 
members of this bacterial group have a characteristic cell envelope composed of 
branched fatty acids (mycolic acid). It has been recently suggested that recognition of 
lipids in bacterial cell walls is an important part of host defense responses to R. equi 
(Harris et al., 2010).  
 
Genes involved in iron homeostasis (HPX, HMOX1, HAMP) are also up-regulated in 
foals at birth. Availability and acquisition of iron is crucial for survival and growth of 
most bacterial pathogens. Prophylactic and therapeutic strategies designed to interfere 
with acquisition and use of iron have proven to be effective in the management of other 
bacterial diseases and may help in control of pneumonia attributable to R. equi in foals 
(Jordan et al., 2003). The HPX gene encodes a glycoprotein with high heme binding 
affinity, which protects the cell from oxidative stress. Heme oxygenase (HMOX1) 
catalyzes the degradation of heme. Up-regulation of genes involved in heme homeostasis 
could be a response to R. equi infection and may represent host defenses to limit iron 
mediated survival and replication of the pathogen.  
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At two weeks of age, the gene expression profiles of nasal epithelial cells suggest 
upregulation of genes involved in wound healing, negative regulation of T-cell 
proliferation, and regulation of IFN-γ production. Four weeks after birth, expression 
profiles of nasal epithelial cells suggested that genes are being modulated (up or down) 
to initiate protective immune responses to restrict bacterial growth for e.g. by limiting 
iron pathogen’s iron supply.   
 
Linear discriminant analysis 
We found biomarkers from nasal epithelial cells at birth with the potential to screen foals 
for pneumonia before the onset on clinical symptoms. The advantage of using nasal 
epithelium (over blood) for screening purposes is that this method is less invasive and 
can be stored and shipped easily.  
 
Linear discriminant analysis of nasal epithelium produced three-gene classifiers, guanine 
nucleotide binding protein (G protein), gamma 12 (GNG12), regulator of G-protein 
signaling 19 (RGS19), and collagen, type IX, alpha 2 (COL9A2), that could discriminate 
R. equi infected foals from healthy foals at birth with the lowest misclassification error. 
The GNG12 gene is involved in signal transduction and G-protein coupled receptor 
signaling. GNG12 is believed to be involved in inflammatory pathways and is thought to 
be involved in negative regulation of inflammation (Larson et al., 2010). It may also play 
a role in signal transduction on phagosomal membranes (Lee et al., 2010). RGS19 is also 
involved in signal transduction and is found in germinal centers of B cells, suggesting a 
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possible role in germinal center formation and maintenance (H. Chok 2004). These 
classifiers can discriminate the two groups of foals at birth using nasal epithelial cells, 
and could potentially be utilized to screen foals that will develop R. equi from resistant 
foals. 
 
Finally, we observed that all the time points the misclassification error was <2% for 
blood leukocytes and <4% for nasal epithelial cells. Since detecting an early 
susceptibility to infection is ideal, based on our results biomarkers obtained at birth from 
leukocytes and nasal epithelium with 98.58% (due to error rate 0.0142) and 98.23% (due 
to error rate of 0.0177) accuracy, respectively, can be used for discriminating affected 
group from the unaffected. The accuracy and reliability of the discriminatory genes can 
only be assessed after validation on new samples from various farms to avoid any bias. 
However, since the handling of nasal epithelial cells is easier, not temperature sensitive 
and less invasive; this may be the choice of screening tools for some equine farms.  
 
CONCLUSION 
In summary, data from samples of blood leukocytes and nasal epithelial cells taken at 
three time points demonstrate that genes involved in maintaining the balance of Th1/Th2 
immune response, T cell proliferation, and antimicrobial actions are up-regulated. This 
could contribute to susceptibility/resistance to infection in foals. While temporal changes 
improving host defense (antimicrobial action and protective immunity) against the 
pathogen may be developing as the foal ages, there are biological processes or gene 
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functions that lead to impaired/less efficient defense responses compared to healthy 
control counterparts. This study provides novel biomarkers of R. equi susceptibility with 
potential to be developed into qPCR-based screening tests. Future research should focus 
on extending this study at various equine farms across the country to validate the 
reproducibility and usefulness of the molecular biomarkers for screening purposes.  
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CHAPTER VI 
 
CONCLUSION 
 
This research represents one of the first attempts to perform the transcriptome profiling 
to uncover the molecular mechanism underlying the two equine respiratory diseases 
(RAO and R. equi pneumonia).  
 
One of the limitations of present research in recurrent airway obstruction is our 
inadequate understanding of the molecular mechanisms orchestrating RAO 
pathogenesis. Research till date has focused on specific cell types or selected genes only 
(Franchini et al., 2000; Laan et al., 2006; Polikepahad et al., 2006; Ainsworth et al., 
2009; Katavolos et al., 2009; Venugopal et al., 2009). Complex diseases involve 
coordinated interaction of several pathways and hence needs investigation of hundreds 
and thousands of genes simultaneously. Therefore a complete understanding of this 
disease requires a global genomic approach. Such an approach will ensure that all the 
genes are investigated at the same time in the disease state. The transcriptional profiling 
of disease state compared to control animals will reveal informative expression pattern 
of genes that can play important role in RAO and may contribute to the susceptibility.  
 
Microarrays have been extensively used as a high-throughput tool to identify 
differentially expressed genes in human asthma (Brutsche et al., 2001; Laprise et al., 
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2004; Syed et al., 2005; Hansel and Diette, 2007) and other animal models of asthma 
(Zou et al., 2002; Zimmermann et al., 2003; Heidenfelder et al., 2009). To date, there has 
been only a single attempt at using microarrays to understand the transcriptome profile 
of RAO affected animas (Ramery et al., 2009).  
 
We aimed at understanding the effect of allergen exposure on RAO-susceptible horses 
with airway remodeling and obtained the biological processes and pathways associated 
with the gene profiles. We found that allergen exposure in susceptible horses only causes 
an increase in inflammation without any further increase in the airway smooth muscle 
mass. We also identified biomarkers that were able to discriminate/ classify the affected 
group of animals from the control group.  
 
Our findings also suggest that allergen avoidance is a key factor in the resolution of 
inflammation. We found that an inhaled corticosteroid alone is not sufficient and 
together with allergen avoidance it should be introduced early in disease management. It 
appeared from the clinical reports that corticosteroid administration along with allergen 
avoidance could not resolve the airway obstruction completely. Hence we propose 
exploring the efficacy of adding long acting beta-agonists (LABA) to the inhaled 
corticosteroid (ICS) treatment protocol. LABA’s are bronchodilators that together with 
ICS act synergistically in reducing the airway inflammation (Barnes, 2002). Finally, 
from our studies on RAO-susceptible horses, we report association of a variety of genes 
with different aspects of the RAO pathology like inflammation and remodeling. These 
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genes can likely be used as candidates for developing new research hypotheses to 
examine their direct role in disease progression or remission. 
Next, from our research on R. equi pneumonia, we attempted to understand the age-
related immune response of foals exposed to the pathogen. In order to achieve this goal 
we in-vitro stimulated blood leukocytes and examined the changes in gene expression 
profile during the first few weeks of life. The results suggested that immune cells are 
capable of Our findings suggest that the stimulated immune cells are capable of initiating 
a protective immune response through birth and up to 8 weeks of age, however there 
also were present genes/processes that could be counter-productive to the host.  It was 
beyond the scope of this study to identify if such suppressive responses are caused due to 
the pathogen modulation host response, or a consequence of the immature immune 
system of the host. Therefore, future studies can be designed to understand the role of 
these suppressive mechanisms (and associated genes) in the pathogenicity of R. equi. If 
found directly implicated, these genes can be targeted to improve the host immune 
response against the pathogen.  
 
We also report genes and molecular mechanisms associated with the susceptibility to R. 
equi pneumonia using blood leukocytes and nasal epithelial cells. This susceptibility can 
be attributes to modulation of genes involved in phagosome maturation, IFN-γ signaling, 
dendritic cell activation, IL-6 biosynthesis and T-cell proliferation. This study also 
identified biomarkers that can be used for screening foals that have a likelihood of 
developing pneumonia. 
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Early screening using such molecular biomarkers will allow appropriate management of 
foals and starting them timely antibiotic treatments, thus reducing disease incidence and 
foal mortality. For the future studies in R. equi pneumonia, understanding the host-
pathogen interactome will be of utmost importance. The interactome studies will capture 
the host and pathogen gene expression overlay it with protein and metabolome level. It is 
the complex interaction between components of host and pathogen that can determine 
the outcome of an infection. Investigating such interaction networks will elucidate the 
complex interplay of the host and pathogen factors, and hence improve the 
understanding of the disease pathogenesis (Raman et al., 2009). Identifying such 
extensive host-pathogen networks will help in designing novel drugs and developing of 
targeted immunotherapeutics.  
  
To summarize, the knowledge garnered from the RAO research will have a cross species 
impact. RAO shares many pathological features with human asthma and hence research 
in equine RAO will contribute to the existing knowledge of pathogenesis and treatment 
of asthma in humans. R. equi is an opportunistic pathogen that also affects other species 
like cats, dogs, pigs and cattle and immunocompromised human subjects like HIV 
affected patients. The outcomes from my research can hence be extended to other 
species. The classification technique used in this study is a relatively novel tool in 
animal research and can therefore be extended to accelerate biomarker discovery in other 
animal diseases.  
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APPENDIX A 
 
Table A-1: Gene Ontology analysis of differentially expressed (DE) genes from RAO-
affected exposed to allergen compared to baseline.  
 
Category Term Pvalue Genes 
Biological 
process GO:0006414~translational elongation 0.035272 RPS3A, RPS15A 
Cellular 
component 
GO:0022627~cytosolic small ribosomal 
subunit 0.012511 RPS3A, RPS15A 
GO:0015935~small ribosomal subunit 0.019648 RPS3A, RPS15A 
GO:0005737~cytoplasm 0.0206 ELAVL1, FDFT1, KIF2A,PFCP,RPS15A,RPS3A 
GO:0022626~cytosolic ribosome 0.025204 RPS3A, RPS15A 
GO:0033279~ribosomal subunit 0.039594 RPS3A, RPS15A 
GO:0044445~cytosolic part 0.046876 RPS3A, RPS15A 
GO:0005840~ribosome 0.065782 RPS3A, RPS15A 
Molecular 
function 
GO:0003723~RNA binding 0.020402 ELAVL1,RPS3A,RPS15A 
GO:0003735~structural constituent of 
ribosome 0.054261 RPS3A, RPS15A 
 
 
 
Table A-2: Gene Ontology analysis for DE genes from control horses exposed to 
allergen compared to baseline. 
 
Category Term Pvalue Genes 
Biological 
Process 
  
  
  
  
  
  
  
  
  
  
  
GO:0030155~regulation of cell adhesion 0.007883 PPP2CA, ADA, PIK3R1 
GO:0006144~purine base metabolic process 0.013802 ADA, AMPD1 
GO:0009168~purine ribonucleoside monophosphate biosynthetic 
process 0.017713 ADA, AMPD1 
GO:0009127~purine nucleoside monophosphate biosynthetic 
process 0.017713 ADA, AMPD1 
GO:0009126~purine nucleoside monophosphate metabolic 
process 0.019663 ADA, AMPD1 
GO:0009167~purine ribonucleoside monophosphate metabolic 
process 0.019663 ADA, AMPD1 
GO:0009156~ribonucleoside monophosphate biosynthetic process 0.022581 ADA, AMPD1 
GO:0009112~nucleobase metabolic process 0.022581 ADA, AMPD1 
GO:0009161~ribonucleoside monophosphate metabolic process 0.024522 ADA, AMPD1 
GO:0046483~heterocycle metabolic process 0.042108 P4HA2, ADA, AMPD1 
GO:0030183~B cell differentiation 0.046589 ADA, PIK3R1 
GO:0009124~nucleoside monophosphate biosynthetic process 0.048485 ADA, AMPD1 
 
 
 
  
222 
Table A-2 Continued 
 
Category Term Pvalue Genes 
 
GO:0005737~cytoplasm 0.013886 
OPA3, P4HA2, 
RPL7, EXOC8, 
PPP2CA, UBE2G2, 
GLCCI1, DPP7, 
GRHL2, NLRP1, 
ADA, PIK3R1 
GO:0044444~cytoplasmic part 0.036444 
OPA3, P4HA2, 
RPL7, EXOC8, 
PPP2CA, UBE2G2, 
DPP7, ADA, 
PIK3R1 
Molecular 
Function 
 
GO:0019239~deaminase activity 0.022876 ADA, AMPD1 
GO:0016814~hydrolase activity, acting on carbon-nitrogen 
(but not peptide) bonds, in cyclic amidines 0.028294 ADA, AMPD1 
 
 
 
Table A-3: Gene Ontology analysis for DE genes from RAO-affected horses versus 
control at baseline. 
 
Category Term Pvalue Genes 
Biological 
Process 
GO:0008217~regulation of blood pressure 0.012397 PTGS2, ACTA2, AGT, HBB 
GO:0031399~regulation of protein 
modification process 0.013757 
UBE2N, PSMA1, CLCF1, AGT, 
PAX5, CBS 
GO:0032268~regulation of cellular protein 
metabolic process 0.026343 
UBE2N, PSMA1, CLCF1, AGT, 
PAIP1, PAX5, CBS 
GO:0035150~regulation of tube size 0.026908 ACTA2, AGT, HBB 
GO:0050880~regulation of blood vessel size 0.026908 ACTA2, AGT, HBB 
GO:0003018~vascular process in circulatory 
system 0.031787 ACTA2, AGT, HBB 
GO:0010627~regulation of protein kinase 
cascade 0.031969 
UBE2N, CLCF1, ERBB2, AGT, 
CBS 
GO:0014065~phosphoinositide 3-kinase 
cascade 0.033244 ERBB2, PIK3R1 
GO:0002520~immune system development 0.043978 POLL, TNFRSF11A, CLCF1, CD164, PIK3R1 
GO:0010740~positive regulation of protein 
kinase cascade 0.046619 UBE2N, CLCF1, ERBB2, AGT 
GO:0051246~regulation of protein metabolic 
process 0.047347 
UBE2N, PSMA1, CLCF1, AGT, 
PAIP1, PAX5, CBS 
GO:0030384~phosphoinositide metabolic 
process 0.048273 SEMA6D, PIGW, PIK3R1 
GO:0002376~immune system process 0.049142 
POLL, UBE2N, LAT, TNFRSF11A, 
VTCN1, CLCF1, HFE, PAX5, 
CD164, PIK3R1 
Cellular 
Component GO:0044444~cytoplasmic part 1.08E-03 
TYRP1, CYP2F1, PTGS2, CYP2B6, 
AP1G1, EXOC8, ERBB2, 
TIMM17B, MRFAP1, RPS15A, 
HFE, TPM3, EIF3CL, PGRMC1, 
AGT, DAO, HSPE1, HBB, PIK3R1, 
KIF2A, ACTA2, TP53BP2, PIGW, 
BTBD6, CD164, ATG3, MARK2, 
AGTRAP, CCT7, PSMA1, LAMP1, 
MRPL21, RPL13A, USO1, VAMP4, 
CALR3, CBS, RCN2 
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Table A-3 Continued 
 
Category Term Pvalue Genes 
 
GO:0005737~cytoplasm 0.002828 
PTGS2, AP1G1, COPS3, 
TIMM17B, MRFAP1, MYLIP, 
EIF3CL, ACTR2, PGRMC1, DAO, 
KIF2A, ACTA2, PIGW, BTBD6, 
CD164, MARK2, UBE2N, PSMA1, 
SERPINB7, USO1, VAMP4, 
CALR3, TYRP1, CYP2F1, PLEK2, 
CYP2B6, EXOC8, ERBB2, HFE, 
CDC42SE1, RPS15A, TPM3, AGT, 
WIPF2, HSPE1, HBB, PIK3R1, 
TP53BP2, PAIP1, ELAVL1, ATG3, 
AGTRAP, CCT7, LAMP1, 
MRPL21, SEMA6D, RPL13A, CBS, 
RCN2 
GO:0045178~basal part of cell 0.009215 ERBB2, HFE, MARK2 
GO:0048471~perinuclear region of cytoplasm 0.012865 TP53BP2, AP1G1, ERBB2, USO1, HFE, MRFAP1 
GO:0044425~membrane part 0.013064 
TYRP1, CYP2F1, PTGS2, PLEK2, 
CYP2B6, AP1G1, VTCN1, 
TSPAN4, ERBB2, OR2T4, 
TIMM17B, EFNA3, HFE, 
CDC42SE1, MYLIP, LRRC15, 
TMEM61, SLC7A7, OR4D1, 
VN1R4, TNFRSF11A, OR6C2, 
PGRMC1, OR13C8, ABCA13, 
PIGW, SIGLEC10, CD164, 
MARK2, AGTRAP, OR5B3, 
LRRC25, LAT, LAMP1, TMEM66, 
RPAP2, SEMA6D, USO1, VAMP4, 
OR2D3, TMPO, OMG, ACCN5 
GO:0044432~endoplasmic reticulum part 0.026426 CYP2F1, PTGS2, CYP2B6, PIGW, CALR3, RCN2 
GO:0005792~microsome 0.027906 CYP2F1, PTGS2, CYP2B6, PGRMC1, USO1 
GO:0044464~cell part 0.028928 
PTGS2, VTCN1, AP1G1, TSPAN4, 
COPS3, TIMM17B, EFNA3, 
MRFAP1, PAX5, MYLIP, LRRC15, 
TMEM61, SLC7A7, OR4D1, 
ACTR2, VN1R4, EIF3CL, 
TNFRSF11A, WDR36, OR6C2, 
PGRMC1, DAO, KIF2A, POLL, 
ACTA2, PIGW, SIGLEC10, 
BTBD6, CD164, LRRC25, MARK2, 
UBE2N, PSMA1, TMEM66, 
SERPINB7, USO1, VAMP4, 
CALR3, OR2D3, TYRP1, CYP2F1, 
PLEK2, EXOC8, CYP2B6, OR2T4, 
ERBB2, RPS15A, HFE, 
CDC42SE1, TPM3, AGT, WIPF2, 
HSPE1, OR13C8, HBB, PIK3R1, 
ABCA13, C17ORF49, MYO1B, 
TP53BP2, PAIP1, ELAVL1, ATG3, 
OR5B3, AGTRAP, CCT7, LAMP1, 
LAT, MRPL21, RPAP2, SEMA6D, 
RPL13A, TMPO, OMG, ACCN5, 
RCN2, CBS 
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Table A-3 Continued 
 
Category Term Pvalue Genes 
 
GO:0005623~cell 0.029054 
PTGS2, VTCN1, AP1G1, TSPAN4, 
COPS3, TIMM17B, EFNA3, 
MRFAP1, PAX5, MYLIP, LRRC15, 
TMEM61, SLC7A7, OR4D1, 
ACTR2, VN1R4, EIF3CL, 
TNFRSF11A, WDR36, OR6C2, 
PGRMC1, DAO, KIF2A, POLL, 
ACTA2, PIGW, SIGLEC10, 
BTBD6, CD164, LRRC25, MARK2, 
UBE2N, PSMA1, TMEM66, 
SERPINB7, USO1, VAMP4, 
CALR3, OR2D3, TYRP1, CYP2F1, 
PLEK2, EXOC8, CYP2B6, OR2T4, 
ERBB2, RPS15A, HFE, 
CDC42SE1, TPM3, AGT, WIPF2, 
HSPE1, OR13C8, HBB, PIK3R1, 
ABCA13, C17ORF49, MYO1B, 
TP53BP2, PAIP1, ELAVL1, ATG3, 
OR5B3, AGTRAP, CCT7, LAMP1, 
LAT, MRPL21, RPAP2, SEMA6D, 
RPL13A, TMPO, OMG, ACCN5, 
RCN2, CBS 
GO:0042598~vesicular fraction 0.0306 CYP2F1, PTGS2, CYP2B6, PGRMC1, USO1 
GO:0019898~extrinsic to membrane 0.032343 CYP2F1, PTGS2, PLEK2, CYP2B6, USO1, MYLIP, MARK2 
GO:0044445~cytosolic part 0.037448 CCT7, RPS15A, HBB, PIK3R1 
GO:0016020~membrane 0.046637 
TYRP1, CYP2F1, PTGS2, PLEK2, 
CYP2B6, AP1G1, VTCN1, 
TSPAN4, OR2T4, ERBB2, 
TIMM17B, EFNA3, HFE, 
CDC42SE1, MYLIP, LRRC15, 
TMEM61, SLC7A7, OR4D1, 
VN1R4, TNFRSF11A, OR6C2, 
PGRMC1, OR13C8, ABCA13, 
PIK3R1, PIGW, SIGLEC10, 
CD164, MARK2, AGTRAP, 
OR5B3, LRRC25, LAT, LAMP1, 
TMEM66, RPAP2, SEMA6D, 
USO1, VAMP4, OR2D3, TMPO, 
OMG, ACCN5 
GO:0031224~intrinsic to membrane 0.049187 
TYRP1, VTCN1, TSPAN4, ERBB2, 
OR2T4, EFNA3, TIMM17B, HFE, 
CDC42SE1, LRRC15, TMEM61, 
SLC7A7, OR4D1, VN1R4, 
TNFRSF11A, OR6C2, PGRMC1, 
OR13C8, ABCA13, PIGW, 
SIGLEC10, CD164, AGTRAP, 
LRRC25, 
Molecular 
function GO:0020037~heme binding 3.11E-04 
CYP2F1, PTGS2, CYP2B6, 
PGRMC1, HBB, CBS 
GO:0046906~tetrapyrrole binding 4.18E-04 CYP2F1, PTGS2, CYP2B6, PGRMC1, HBB, CBS 
GO:0005506~iron ion binding 0.00392 CYP2F1, PTGS2, CYP2B6, PGRMC1, HFE, HBB, CBS 
GO:0019825~oxygen binding 0.018694 CYP2F1, CYP2B6, HBB 
GO:0043125~ErbB-3 class receptor binding 0.019406 ERBB2, PIK3R1 
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Table A-3 Continued 
 
Category Term Pvalue Genes 
 
GO:0005515~protein binding 0.020697 
PTGS2, AP1G1, COPS3, TSPAN4, 
TIMM17B, MRFAP1, PAX5, 
MYLIP, LRRC15, EIF3CL, 
SH2D4B, ACTR2, TNFRSF11A, 
CLCF1, PGRMC1, ACTA2, 
SIGLEC10, BTBD6, CD164, 
MARK2, UBE2N, PSMA1, USO1, 
CALR3, TYRP1, EXOC8, ERBB2, 
HFE, CDC42SE1, LRRC36, 
RPS15A, TPM3, AGT, WIPF2, 
HSPE1, UNK, HBB, PIK3R1, 
MYO1B, TP53BP2, PAIP1, 
ELAVL1, ATG3, AGTRAP, CCT7, 
LAT, TMPO, OMG, CBS, RCN2 
 GO:0016705~oxidoreductase activity, acting 
on paired donors, with incorporation or 
reduction of molecular oxygen 
0.028383 TYRP1, CYP2F1, PTGS2, CYP2B6 
 
 
 
Table A-4: Gene ontology analysis for DE genes from RAO-affected versus control 
horses after 30-day allergen exposure. 
 
Gene Ontology 
Category Term Pvalue Genes 
Biological 
Process 
GO:0006414~translational 
elongation 0.003806 EEF1A1, RPS3A, RPL13A, RPLP1 
GO:0006412~translation 0.019292 EEF1A1, MRPL21, RPS3A, RPL13A, RPLP1 
Cellular 
Component 
 
 
 
 
 
 
GO:0005737~cytoplasm 0.017422 
TYRP1, COPS3, IGFBP6, ALDOB, 
COX7C, COPS7B, CCL5, ZNRF2, 
SLC25A21, ACTR2, SH2D1A, RPS3A, 
C4ORF35, EMID2, RPLP1, HSPE1, 
SLC25A1, HBB, EEF1A1, HCK, SPHK1, 
DDN, GRHL2, GCC1, UBE2N, EYA4, 
SGSM1, GAPVD1, MRPL21, RPL13A, 
ATF7, PLA2G5, CBS 
GO:0008180~signalosome 0.03222 COPS3, COPS7B 
GO:0005840~ribosome 0.033144 MRPL21, RPS3A, RPL13A, RPLP1 
Molecular 
Function 
 
 
 
GO:0003735~structural constituent 
of ribosome 0.014363 MRPL21, RPS3A, RPL13A, RPLP1 
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Table A-5: GO Term Mapper results for DE genes from RAO-affected versus control 
horses at baseline. 
 
GO Term (GO ID)  GO Term Usage in Gene List  Genome Frequency of Use 
cellular component organization ( GO:0016043 
)  22 of 90 genes, 24.44%  
3370 of 18410 annotated 
genes, 18.31% 
protein metabolic process ( GO:0019538 )  20 of 90 genes, 22.22%  3090 of 18410 annotated genes, 16.78% 
transport ( GO:0006810 )  20 of 90 genes, 22.22%  3061 of 18410 annotated genes, 16.63% 
multicellular organismal development ( 
GO:0007275 )  18 of 90 genes, 20.00%  
3292 of 18410 annotated 
genes, 17.88% 
response to stress ( GO:0006950 )  15 of 90 genes, 16.67%  2248 of 18410 annotated genes, 12.21% 
signal transduction ( GO:0007165 )  13 of 90 genes, 14.44%  2432 of 18410 annotated genes, 13.21% 
protein modification process ( GO:0006464 )  12 of 90 genes, 13.33%  1851 of 18410 annotated genes, 10.05% 
death ( GO:0016265 )  10 of 90 genes, 11.11%  1397 of 18410 annotated genes, 7.59% 
cell differentiation ( GO:0030154 )  10 of 90 genes, 11.11%  2039 of 18410 annotated genes, 11.08% 
cell death ( GO:0008219 )  10 of 90 genes, 11.11%  1394 of 18410 annotated genes, 7.57% 
cell communication ( GO:0007154 )  9 of 90 genes, 10.00%  1624 of 18410 annotated genes, 8.82% 
organelle organization ( GO:0006996 )  9 of 90 genes, 10.00%  1599 of 18410 annotated genes, 8.69% 
catabolic process ( GO:0009056 )  9 of 90 genes, 10.00%  1364 of 18410 annotated genes, 7.41% 
reproduction ( GO:0000003 )  7 of 90 genes, 7.78%  989 of 18410 annotated genes, 5.37% 
response to external stimulus ( GO:0009605 )  7 of 90 genes, 7.78%  983 of 18410 annotated genes, 5.34% 
protein transport ( GO:0015031 )  6 of 90 genes, 6.67%  904 of 18410 annotated genes, 4.91% 
response to biotic stimulus ( GO:0009607 )  6 of 90 genes, 6.67%  501 of 18410 annotated genes, 2.72% 
lipid metabolic process ( GO:0006629 )  6 of 90 genes, 6.67%  999 of 18410 annotated genes, 5.43% 
cell proliferation ( GO:0008283 )  6 of 90 genes, 6.67%  1191 of 18410 annotated genes, 6.47% 
translation ( GO:0006412 )  5 of 90 genes, 5.56%  425 of 18410 annotated genes, 2.31% 
viral reproduction ( GO:0016032 )  4 of 90 genes, 4.44%  420 of 18410 annotated genes, 2.28% 
mitochondrion organization ( GO:0007005 )  3 of 90 genes, 3.33%  143 of 18410 annotated genes, 0.78% 
response to endogenous stimulus ( GO:0009719 
)  3 of 90 genes, 3.33%  
608 of 18410 annotated genes, 
3.30% 
cellular homeostasis ( GO:0019725 )  3 of 90 genes, 3.33%  513 of 18410 annotated genes, 2.79% 
behavior ( GO:0007610 )  2 of 90 genes, 2.22%  360 of 18410 annotated genes, 1.96% 
secondary metabolic process ( GO:0019748 )  1 of 90 genes, 1.11%  63 of 18410 annotated genes, 0.34% 
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Table A-6: GO Term Mapper results for DE genes from RAO-affected versus control 
horses after 30-day allergen exposure. 
 
GO Term (GO ID)  GO Term Usage in Gene List  Genome Frequency of Use 
biosynthetic process ( 
GO:0009058 )  16 of 56 genes, 28.57%  4533 of 18302 annotated genes, 24.77% 
transport ( GO:0006810 )  12 of 56 genes, 21.43%  2917 of 18302 annotated genes, 15.94% 
cellular component 
organization ( GO:0016043 )  11 of 56 genes, 19.64%  2996 of 18302 annotated genes, 16.37% 
response to stress ( 
GO:0006950 )  9 of 56 genes, 16.07%  1936 of 18302 annotated genes, 10.58% 
signal transduction ( 
GO:0007165 )  8 of 56 genes, 14.29%  2350 of 18302 annotated genes, 12.84% 
catabolic process ( 
GO:0009056 )  7 of 56 genes, 12.50%  1255 of 18302 annotated genes, 6.86% 
cell communication ( 
GO:0007154 )  6 of 56 genes, 10.71%  1502 of 18302 annotated genes, 8.21% 
death ( GO:0016265 )  5 of 56 genes, 8.93%  1318 of 18302 annotated genes, 7.20% 
translation ( GO:0006412 )  5 of 56 genes, 8.93%  420 of 18302 annotated genes, 2.29% 
cell death ( GO:0008219 )  5 of 56 genes, 8.93%  1315 of 18302 annotated genes, 7.19% 
ion transport ( GO:0006811 )  5 of 56 genes, 8.93%  843 of 18302 annotated genes, 4.61% 
response to endogenous 
stimulus ( GO:0009719 )  4 of 56 genes, 7.14%  526 of 18302 annotated genes, 2.87% 
lipid metabolic process ( 
GO:0006629 )  4 of 56 genes, 7.14%  926 of 18302 annotated genes, 5.06% 
reproduction ( GO:0000003 )  3 of 56 genes, 5.36%  855 of 18302 annotated genes, 4.67% 
DNA metabolic process ( 
GO:0006259 )  3 of 56 genes, 5.36%  619 of 18302 annotated genes, 3.38% 
response to biotic stimulus ( 
GO:0009607 )  3 of 56 genes, 5.36%  482 of 18302 annotated genes, 2.63% 
response to external stimulus ( 
GO:0009605 )  3 of 56 genes, 5.36%  773 of 18302 annotated genes, 4.22% 
cell-cell signaling ( 
GO:0007267 )  3 of 56 genes, 5.36%  728 of 18302 annotated genes, 3.98% 
generation of precursor 
metabolites and energy ( 
GO:0006091 )  
2 of 56 genes, 3.57%  305 of 18302 annotated genes, 1.67% 
cell growth ( GO:0016049 )  2 of 56 genes, 3.57%  288 of 18302 annotated genes, 1.57% 
growth ( GO:0040007 )  2 of 56 genes, 3.57%  570 of 18302 annotated genes, 3.11% 
viral reproduction ( 
GO:0016032 )  1 of 56 genes, 1.79%  166 of 18302 annotated genes, 0.91% 
secondary metabolic process ( 
GO:0019748 )  1 of 56 genes, 1.79%  63 of 18302 annotated genes, 0.34% 
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Table A-7: Linear discriminant analysis of control animals after allergen exposure 
compared to baseline. The top ten one-, two-, and three-gene LDA classifiers are shown 
in the table below.  ε bolstered represents the bolstered resubstitution error for the 
respective gene classifier and  Δ ε bolstered represents the decrease in error for each feature 
set relative to its highest ranked subset of genes.  
 
1 feature 2 feature 3 feature ε bolstered Δ ε bolstered 
PPP2CA     0.1445   
DPP7     0.1576   
ADA     0.1661   
P4HA2     0.1935   
OPA3     0.2049   
NLRP1     0.2134   
EXOC8     0.221   
CT020013A20H09.ab1     0.2234   
RPL7     0.2359   
HL020010000_PLT_A12
_89_087.ab1     0.2552   
CT020019B20A11.ab1 OPA3   0.1083 0.0966 
DPP7 PPP2CA   0.1216 0.0229 
PPP2CA ADA   0.1346 0.0099 
OPA3 CT020013A20H09.ab1   0.1378 0.0671 
DPP7 CT020012B20E04.ab1   0.1387 0.0189 
PPP2CA EXOC8   0.14 0.0045 
P4HA2 ADA   0.1413 0.0248 
GLCCI1 CT020013A20H09.ab1   0.1456 0.0778 
CT020012B20E04.ab1 CT02035B1A10.f1.ab1   0.1479 0.1097 
GLCCI1 ADA   0.1518 0.0143 
CT020019B20A11.ab1 OPA3 CT020013A20H09.ab1 0.0595 0.0488 
GLCCI1 DPP7 CT020012B20E04.ab1 0.071 0.0677 
GLCCI1 CT020013A20H09.ab1 ADA 0.0731 0.0725 
CT020019B20A11.ab1 OPA3 ADA 0.0749 0.0334 
CT020019B20A11.ab1 GLCCI1 OPA3 0.0846 0.0237 
CT020019B20A11.ab1 OPA3 EXOC8 0.0893 0.019 
GLCCI1 CT020013A20H09.ab1 EXOC8 0.0931 0.0525 
CT020019B20A11.ab1 PPP2CA OPA3 0.0958 0.0125 
CT020019B20A11.ab1 OPA3 P4HA2 0.0993 0.009 
CT020019B20A11.ab1 OPA3 CT020012B20E04.ab1 0.1033 0.005 
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Table A-8: Linear discriminant analysis for allergen exposed RAO-affected horses 
compared to baseline. The top ten one-, two-, and three-gene LDA classifiers are shown 
in the table below.  ε bolstered represents the bolstered resubstitution error for the 
respective gene classifier and  Δ ε bolstered represents the decrease in error for each feature 
set relative to its highest ranked subset of genes.  
 
1 feature 2 feature 3 feature ε bolstered Δ ε bolstered 
KIF2A     0.1377   
FDFT1     0.1853   
ELAVL1     0.2497   
CT020014A10G07.ab1     0.2816   
CT020014A10G07.ab1     0.3085   
RPS3A     0.3601   
RPS15A     0.3785   
KIF2A FDFT1   0.1438 -0.0061 
RPS15A KIF2A   0.1625 -0.0248 
RPS15A FDFT1   0.2089 -0.0236 
RPS3A FDFT1   0.2385 -0.0532 
KIF2A RPS3A   0.2439 -0.1062 
CT020014A10G07.ab1 ELAVL1   0.25 -0.0003 
CT020014A10G07.ab1 CT020014A10G07.ab1   0.2531 0.0285 
RPS15A KIF2A FDFT1 0.1859 -0.0421 
KIF2A RPS3A FDFT1 0.19 -0.0462 
CT020014A10G07.ab1 CT020014A10G07.ab1 ELAVL1 0.2397 0.0103 
RPS15A RPS3A FDFT1 0.2454 -0.0365 
RPS15A KIF2A RPS3A 0.2794 -0.1169 
CT020014A10G07.ab1 CT020014A10G07.ab1 RPS15A 0.3473 -0.0942 
CT020014A10G07.ab1 RPS15A KIF2A 0.3564 -0.1939 
 
 
 
Table A-9: List of differentially expressed genes (pvalue<0.05) for allergen exposed 
RAO-affected horses compared to baseline. ** Represents genes with pvalue<0.05 and 
fold change ≥ 0.58 or ≤ -0.58 selected for qPCR. 
 
Gene symbol NCBI accession RefSeq accession Log fold change Pvalue 
ABCA13 XM_001496546 XP_001496596 -0.56289 0.014525 
ABO XM_001491153 XP_001491203 -0.28231 0.022564 
ANKRA2 XM_001504688 XP_001504738 0.276074 0.035059 
ANKRD38 XM_001500075 XP_001500125 0.245804 0.048664 
ANXA11 XM_001504023 XP_001504073 0.316336 0.036306 
ARF1 XM_001494630 XP_001494680 0.174403 0.039539 
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Gene symbol NCBI accession RefSeq accession Log fold change Pvalue 
ARHGEF10 XR_036140 NULL 0.191463 0.033482 
ARL5A XM_001488594 XP_001488644 -0.12865 0.042757 
C12orf60 XM_001497318 XP_001497368 0.24732 0.036306 
C17orf56 XM_001489994 XP_001490044 0.213744 0.0336 
C20orf177 XM_001490535 XP_001490585 -0.11794 0.04638 
CCBP2 XM_001497290 XP_001497340 -0.1504 0.04585 
CD1A XM_001490547 XP_001490597 0.269643 0.027989 
CD82 XM_001489923 XP_001489973 0.419028 0.020188 
CDK9 CX605189 NULL 0.270423 0.038016 
CERK XM_001488742 XP_001488792 -0.18976 0.010087 
CMTM5 CX594400 XP_001489647 0.443946 0.020844 
COX7C XM_001504630 NULL 0.184777 0.026098 
DAO XM_001500936 XP_001500986 -0.14051 0.041508 
DCXR XM_001489215 NULL 0.247633 0.014717 
DR1 XM_001491648 XP_001491698 0.394033 0.016238 
EIF4B CX604925 NULL -0.19675 0.027704 
ELAVL1 XM_001497883 XP_001497933 -0.63751 0.009965 
ENTPD8 XM_001490804 XP_001490854 -0.16128 0.040257 
EPB41L4A XM_001504580 XP_001504630 -0.15229 0.043272 
EWSR1 XM_001495303 XP_001495353 0.211883 0.045809 
FDFT1 XR_036232 NULL -0.651 0.047877 
FLJ22222 XM_001490418 XP_001490468 -0.29984 0.008046 
FXR1 XM_001495885 XP_001495935 0.147859 0.032671 
GALNTL2 XM_001496032 XP_001496082 -0.154 0.037805 
GBL NULL NULL 0.49018 0.042397 
GEMIN7 XM_001502450 XP_001502500 -0.13277 0.047512 
GJD3 XM_001497718 XP_001497768 0.332869 0.023295 
GLYAT XM_001504695 XP_001504745 -0.27249 0.042987 
HIST1H2AG XM_001494400 XP_001494450 0.235065 0.024662 
HLA-DRB1 XM_001495531 XP_001495581 0.172331 0.038692 
HRH4 XM_001494911 XP_001494961 0.216031 0.035668 
HSPA9 XM_001502530 XP_001502580 0.355392 0.02675 
KIF27 XM_001488810 XP_001488860 -0.22622 0.03835 
KIF2A** XM_001493976 XP_001494026 -0.58275 0.018499 
LAIR1 XM_001488882 XP_001488932 -0.15478 0.035582 
LOC645638 XM_001503882 NULL 0.292343 0.03972 
LOC651536 XM_001493214 XP_001493264 0.23644 0.047877 
LUZP1 XM_001504239 XP_001504289 -0.11806 0.035944 
MAL XM_001494113 XP_001494163 0.367886 0.047754 
MTHFD1L XM_001503676 XP_001503726 0.424522 0.029772 
NUCKS1 XM_001489449 XP_001489499 -0.25888 0.03597 
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Gene symbol NCBI accession RefSeq accession Log fold change Pvalue 
NULL DN511058 NULL -0.15791 0.022052 
NULL XM_001504718 XP_001504768 0.206873 0.03212 
NULL CX594544 NULL 0.55437 0.034214 
NULL DN509646 NULL 0.214341 0.036032 
NULL CX602146 NULL -0.17521 0.036646 
NULL XR_035802 NULL 0.15049 0.037322 
NULL DN509801 NULL 0.154664 0.038794 
OR12D3 XM_001491536 XP_001491586 -0.22555 0.042161 
OR2A14 XM_001504219 XP_001504269 -0.19007 0.044514 
OR2S2 XM_001504440 XP_001504490 -0.19947 0.037691 
OR4A15 XM_001495924 NULL 0.199356 0.027319 
OR6C4 XM_001504715 XP_001504765 -0.21596 0.014641 
P4HA3 XM_001495901 XP_001495951 0.201425 0.029781 
PDPR XM_001501064 XP_001501114 0.315757 0.028449 
PGCP** XM_001490623 XP_001490673 1.317639 0.004671 
PHF12 XM_001504186 XP_001504236 -0.25994 0.038917 
PHF16 XM_001491297 XP_001491347 -0.17259 0.046324 
PHOX2A XM_001499157 XP_001499207 0.240919 0.043696 
PLA2G10 XM_001489049 XP_001489099 -0.43093 0.034256 
PLUNC XM_001498706 XP_001498756 -0.19161 0.029585 
RAB3D XM_001489914 XP_001489964 0.21887 0.028999 
RELL2 XM_001503977 XP_001504027 -0.15318 0.03434 
RHBG XM_001500143 XP_001500193 0.542523 0.030661 
RPS15A CD468996 NULL 0.457876 0.025843 
RPS15A CD467047 NULL 0.776104 0.026463 
RPS27A NULL NULL 0.243014 0.037853 
RPS3A XM_001490864 NULL -1.03708 0.027548 
S100A9 XM_001493485 XP_001493535 0.219545 0.023185 
SCARB2 XM_001491232 XP_001491282 0.182691 0.041357 
SLC16A10 XM_001502292 XP_001502342 -0.20701 0.049061 
SLC25A1 XM_001488569 XP_001488619 0.397017 0.031063 
SLC2A2 AJ715983 NP_001075348 0.506324 0.016794 
SLC38A5 XM_001493333 XP_001493383 0.228724 0.037214 
SLC9A8 XM_001501184 XP_001501234 0.237754 0.016015 
SPTA1 XM_001490255 XP_001490305 0.128038 0.038389 
SSFA2 XM_001501268 NULL -0.23099 0.031803 
ST6GALNAC1 XM_001491565 XP_001491615 -0.15578 0.042985 
TBX6 XR_036396 NULL -0.19838 0.037551 
TCTN3 XM_001500642 XP_001500692 -0.21303 0.025011 
TOR2A XM_001501467 XP_001501517 0.379833 0.014873 
TP53 EF627477 NULL 0.33727 0.038955 
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Gene symbol NCBI accession RefSeq accession Log fold change Pvalue 
TRAF6 NULL NULL -0.46026 0.038984 
TRIM50 XM_001504491 XP_001504541 0.346829 0.048596 
TSPAN18 XM_001490050 XP_001490100 -0.16211 0.03481 
TTBK2 AB292108 NP_001075250 0.462038 0.033517 
TXNDC9 XM_001490270 XP_001490320 0.152967 0.040947 
UBC XM_001499082 XP_001499132 0.336627 0.040326 
UNC13B XM_001504528 NULL -0.1499 0.043334 
UPK2 XM_001503043 XP_001503093 -0.17234 0.025518 
WDR36 XM_001503571 XP_001503621 -0.41988 0.038431 
YIPF2 NULL NULL -0.13495 0.026752 
 
 
 
Table A-10: List of differentially expressed genes (pvalue<0.05) for control horses after 
allergen exposure compared to baseline. ** Represents genes with pvalue<0.05 and fold 
change ≥ 0.58 or ≤ -0.58 selected for qPCR. 
 
Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
ABCC8 XM_001501642 XP_001501692 -0.28736 0.02648 
ACTG1 BM735136 NULL 0.382464 0.036253 
ADA XM_001500443 XP_001500493 -0.65874 0.042177 
AGT DN510402 NULL -0.55413 0.031435 
ALDOB XM_001504011 XP_001504061 0.478568 0.047262 
ALG3 XM_001497526 XP_001497576 0.515755 0.037369 
AMPD1 NULL NULL 0.954384 0.005189 
ANKRD46 XM_001492490 XP_001492540 -0.25017 0.008314 
ANKS3 NULL NULL -0.41365 0.008631 
APIP XM_001493072 XP_001493122 -0.17689 0.042824 
ARSA XM_001490463 XP_001490513 -0.37952 0.020896 
ARX XM_001493047 NULL -0.44152 0.024878 
ASB1 XM_001496907 XP_001496957 0.260529 0.049957 
ASCC3L1 XM_001492679 XP_001492729 0.251776 0.024469 
ATAD2 XM_001497188 XP_001497238 0.723817 0.023879 
ATF7 XM_001504543 XP_001504593 0.566171 0.04658 
ATG7 XM_001493002 XP_001493052 0.184386 0.039075 
ATP5C1 NULL NULL 0.54808 0.01767 
ATPIF1 DN507063 XP_001504043 0.215821 0.021334 
BCOR XM_001488901 NULL -0.18082 0.02417 
BHMT XM_001504652 XP_001504702 0.297368 0.009834 
BLCAP XM_001502351 XP_001502401 0.529198 0.024666 
BTBD1 CX601378 NULL 0.359597 0.045596 
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Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
C12orf48 XM_001497513 XP_001497563 -0.22759 0.025501 
C12orf53 XM_001496868 XP_001496918 0.318913 0.008198 
C12orf60 XM_001497318 XP_001497368 -0.10904 0.047529 
C14orf50 XM_001493918 XP_001493968 0.112401 0.035554 
C17orf68 XM_001503195 XP_001503245 0.194422 0.04506 
C1QA XM_001504261 XP_001504311 -0.24793 0.035635 
C1QTNF8 CX602825 NULL -0.14524 0.042302 
C21orf56 XM_001488132 XP_001488182 0.129936 0.021444 
C2orf47 NULL NULL 0.234285 0.022549 
C2orf50 XM_001503531 XP_001503581 0.230749 0.042411 
C3orf37 XM_001495046 XP_001495096 0.157194 0.046541 
C3orf52 XM_001501326 XP_001501376 -0.43246 0.025775 
C5orf21 XM_001503716 XP_001503766 -0.47471 0.000374 
C6orf192 XM_001503393 XP_001503443 0.225104 0.019186 
C7orf23 DN508473 NULL -0.36892 0.006763 
CASP4 XM_001499070 XP_001499120 -0.23161 0.049906 
CATSPER1 XM_001491133 XP_001491183 0.554645 0.017303 
CBFB XM_001496237 XP_001496287 -0.12229 0.028415 
CBLN3 XM_001488806 XP_001488856 -0.12933 0.019709 
CCBP2 XM_001497290 XP_001497340 0.145647 0.042516 
CCDC106 XM_001496086 XP_001496136 0.236705 0.027563 
CCNYL1 XM_001498888 XP_001498938 0.159102 0.046413 
CD40LG XM_001490011 XP_001490061 0.13724 0.036134 
CDC42 XM_001493198 XP_001493248 -0.48628 0.025385 
CDIPT XM_001501701 XP_001501751 0.32878 0.01138 
CHAT XM_001494138 XP_001494188 -0.19806 0.038428 
CHCHD6 XM_001492700 XP_001492750 0.153303 0.046125 
CHEK1 XM_001505083 XP_001505133 0.22364 0.03904 
CHST8 XM_001489047 XP_001489097 -0.21969 0.022875 
CLPX XM_001498202 XP_001498252 -0.2739 0.024605 
CNOT10 XM_001491886 XP_001491936 0.454001 0.006565 
CNPY4 XM_001505053 XP_001505103 0.116868 0.048801 
CNTNAP5 XM_001489205 XP_001489255 -0.24302 0.0394 
COX5B XM_001493723 XP_001493773 0.118438 0.049893 
CPEB1 XM_001498253 XP_001498303 0.343802 0.027005 
CPN2 XM_001498855 NULL 0.364045 0.035331 
CREB3L2 XM_001499610 XP_001499660 0.158716 0.044214 
CREBBP XM_001499349 XP_001499399 0.48091 0.022536 
CYP11B2 XM_001505011 NULL -0.23419 0.025429 
CYP2C19 XM_001502162 XP_001502212 0.256779 0.040061 
CYP2F1 XM_001498170 XP_001498220 -0.33643 0.026136 
DCBLD1 XM_001502824 XP_001502874 0.200435 0.032127 
DDB2 XM_001490725 XP_001490775 -0.22609 0.024481 
DDN XM_001491707 XP_001491757 0.347831 0.017498 
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Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
C12orf48 XM_001497513 XP_001497563 -0.22759 0.025501 
C12orf53 XM_001496868 XP_001496918 0.318913 0.008198 
C12orf60 XM_001497318 XP_001497368 -0.10904 0.047529 
C14orf50 XM_001493918 XP_001493968 0.112401 0.035554 
C17orf68 XM_001503195 XP_001503245 0.194422 0.04506 
C1QA XM_001504261 XP_001504311 -0.24793 0.035635 
C1QTNF8 CX602825 NULL -0.14524 0.042302 
C21orf56 XM_001488132 XP_001488182 0.129936 0.021444 
C2orf47 NULL NULL 0.234285 0.022549 
C2orf50 XM_001503531 XP_001503581 0.230749 0.042411 
C3orf37 XM_001495046 XP_001495096 0.157194 0.046541 
C3orf52 XM_001501326 XP_001501376 -0.43246 0.025775 
C5orf21 XM_001503716 XP_001503766 -0.47471 0.000374 
C6orf192 XM_001503393 XP_001503443 0.225104 0.019186 
C7orf23 DN508473 NULL -0.36892 0.006763 
CASP4 XM_001499070 XP_001499120 -0.23161 0.049906 
CATSPER1 XM_001491133 XP_001491183 0.554645 0.017303 
CBFB XM_001496237 XP_001496287 -0.12229 0.028415 
CBLN3 XM_001488806 XP_001488856 -0.12933 0.019709 
CCBP2 XM_001497290 XP_001497340 0.145647 0.042516 
CCDC106 XM_001496086 XP_001496136 0.236705 0.027563 
CCNYL1 XM_001498888 XP_001498938 0.159102 0.046413 
CD40LG XM_001490011 XP_001490061 0.13724 0.036134 
CDC42 XM_001493198 XP_001493248 -0.48628 0.025385 
CDIPT XM_001501701 XP_001501751 0.32878 0.01138 
CHAT XM_001494138 XP_001494188 -0.19806 0.038428 
CHCHD6 XM_001492700 XP_001492750 0.153303 0.046125 
CHEK1 XM_001505083 XP_001505133 0.22364 0.03904 
CHST8 XM_001489047 XP_001489097 -0.21969 0.022875 
CLPX XM_001498202 XP_001498252 -0.2739 0.024605 
CNOT10 XM_001491886 XP_001491936 0.454001 0.006565 
CNPY4 XM_001505053 XP_001505103 0.116868 0.048801 
CNTNAP5 XM_001489205 XP_001489255 -0.24302 0.0394 
COX5B XM_001493723 XP_001493773 0.118438 0.049893 
CPEB1 XM_001498253 XP_001498303 0.343802 0.027005 
CPN2 XM_001498855 NULL 0.364045 0.035331 
CREB3L2 XM_001499610 XP_001499660 0.158716 0.044214 
CREBBP XM_001499349 XP_001499399 0.48091 0.022536 
CYP11B2 XM_001505011 NULL -0.23419 0.025429 
CYP2C19 XM_001502162 XP_001502212 0.256779 0.040061 
CYP2F1 XM_001498170 XP_001498220 -0.33643 0.026136 
DCBLD1 XM_001502824 XP_001502874 0.200435 0.032127 
DDB2 XM_001490725 XP_001490775 -0.22609 0.024481 
DDN XM_001491707 XP_001491757 0.347831 0.017498 
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Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
DDR2 XM_001492493 XP_001492543 0.525399 0.014439 
DDX11 XM_001490596 XP_001490646 -0.21617 0.025034 
DKFZp686D0972 XM_001495321 XP_001495371 0.334511 0.020193 
DMRTC2 XM_001499585 XP_001499635 0.272045 0.003553 
DOCK1 XM_001489764 XP_001489814 0.285689 0.049323 
DPP7 XM_001492340 XP_001492390 0.621615 0.021717 
DRD2 XM_001501996 XP_001502046 0.158282 0.027737 
E4F1 XM_001498135 XP_001498185 -0.34871 0.006322 
ECHDC3 XM_001499215 XP_001499265 -0.17476 0.045254 
EFCAB6 XM_001487867 XP_001487917 0.200027 0.023574 
EIF2B4 XM_001502278 XP_001502328 -0.47666 0.033778 
EIF2S3 XM_001494201 XP_001494251 -0.17337 0.027287 
ELAVL1 XM_001497883 XP_001497933 0.558273 0.025783 
ELOF1 XM_001490341 XP_001490391 -0.18687 0.040113 
EMR3 XM_001495605 XP_001495655 0.458319 0.046023 
EPO AB100030 NP_001075294 0.178845 0.031493 
EXOC8 XM_001494038 XP_001494088 -0.66813 0.021026 
FAM107A XM_001488861 XP_001488911 -0.25554 0.017673 
FAM91A1 XM_001497901 XP_001497951 0.220126 0.041142 
FANCD2 XM_001494041 XP_001494091 -0.18318 0.033523 
FASTKD2 XM_001498513 XP_001498563 0.314497 0.03658 
FBXL11 XM_001497095 XP_001497145 -0.23001 0.019622 
FBXO11 XM_001498271 XP_001498321 0.137258 0.049045 
FERMT1 XM_001493949 XP_001493999 -0.19588 0.025881 
FGA BM780427 NULL -0.21398 0.005842 
FGF2 NULL NULL 0.133195 0.042356 
FLJ21865 XM_001490670 XP_001490720 -0.19076 0.041819 
FLJ46321 N/A N/A 0.202494 0.024876 
FLJ46321 XM_001488510 NULL -0.2933 0.030105 
FLJ46321 N/A N/A 0.168935 0.039239 
FLVCR1 XM_001488684 XP_001488734 -0.31062 0.005169 
FMO3 XM_001495951 XP_001496001 0.206273 0.014022 
FOLH1 XM_001489017 XP_001489067 0.185224 0.030348 
FOXN4 XM_001496911 XP_001496961 -0.36655 0.005968 
GATA2 XM_001488164 XP_001488214 0.446997 0.048959 
GEMIN8 XM_001489578 NULL 0.291336 0.024218 
GLCCI1 XM_001495201 XP_001495251 0.785274 0.017472 
GOLPH3 XM_001500613 XP_001500663 0.31076 0.046624 
GPR151 XM_001503885 XP_001503935 0.280873 0.021988 
GPX3 NM_001115158 NP_001108630 -0.28061 0.04535 
GRHL2 XM_001493287 XP_001493337 0.910797 0.01957 
HBE1 XM_001504191 XP_001504241 -0.17099 0.013871 
HCK CD465568 NULL -0.26801 0.007001 
HECA XM_001495962 XP_001496012 0.158119 0.040098 
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HIBADH XM_001499874 XP_001499924 -0.54107 0.017333 
HIST1H4J XM_001498048 XP_001498098 0.195906 0.020184 
HLA-DRB1 XM_001495531 XP_001495581 -0.22221 0.017836 
HMGB2 NULL NULL 0.246214 0.008762 
HMGN1 NULL NULL 0.22359 0.04144 
HTR7 XM_001501255 XP_001501305 0.17498 0.048014 
HTRA4 XM_001491574 XP_001491624 -0.18611 0.0271 
IFI44 XM_001497882 XP_001497932 -0.33711 0.025669 
IGFBP6 NULL NULL -0.33601 0.022968 
IIP45 XM_001489888 XP_001489938 -0.23947 0.016327 
IL1RL1 XM_001491350 XP_001491400 -0.32791 0.038072 
KCNC4 XM_001496175 NULL 0.418141 0.025487 
KCNE4 XM_001495661 XP_001495711 -0.1476 0.027269 
KCNIP1 XM_001503162 XP_001503212 0.29794 0.018114 
KIAA0652 XM_001489922 NULL 0.20253 0.017528 
KIF2A XM_001493976 XP_001494026 0.30307 0.017625 
KITLG XM_001491749 XP_001491799 0.150915 0.047963 
KLF4 XM_001492981 NULL -0.20009 0.04385 
KLRD1 XM_001494069 XP_001494119 0.169488 0.043248 
LCA5 XM_001503637 XP_001503687 0.503378 0.020068 
LHFPL1 XM_001488695 XP_001488745 0.348849 0.044286 
LILRB4 XM_001489413 XP_001489463 0.162521 0.031188 
LINGO2 XM_001498518 XP_001498568 -0.29399 0.012915 
LIPG XM_001499159 XP_001499209 0.280005 0.014571 
LIPJ XM_001501539 XP_001501589 0.187562 0.029423 
LOC340156 XM_001488066 XP_001488116 0.844356 0.0325 
LOC4951 XM_001494035 XP_001494085 -0.1814 0.041105 
LOC651536 XM_001502913 XP_001502963 0.191004 0.036871 
LOC728447 XM_001494321 XP_001494371 0.37434 0.049943 
LOC728464 XM_001502209 XP_001502259 -0.19277 0.023366 
LRRC39 XM_001488705 XP_001488755 0.262233 0.020636 
LRRN2 XM_001489200 XP_001489250 0.189625 0.007082 
LYK5 XM_001495479 XP_001495529 -0.22873 0.042064 
MAOB AB178283 NP_001075302 0.159384 0.049059 
MAP1LC3B XM_001500241 NULL -0.25273 0.048179 
MAP2K6 XM_001498752 XP_001498802 0.123403 0.044617 
MC3R XM_001489123 XP_001489173 -0.42292 0.035993 
MFSD11 XM_001492704 XP_001492754 -0.13936 0.043888 
MGC23985 XM_001503845 XP_001503895 0.160148 0.040733 
MGC50722 XM_001498447 XP_001498497 0.260469 0.011222 
MOCOS XM_001497515 XP_001497565 0.169281 0.011422 
MPST CX605060 NULL 0.171037 0.027473 
MRPL11 XM_001496069 XP_001496119 -0.1725 0.012575 
MRPL15 CX598344 NULL -0.4632 0.049464 
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MRPL55 DN509267 XP_001494804 -0.43127 0.004726 
MTERFD2 XM_001497592 XP_001497642 0.161427 0.01816 
MYOZ2 XM_001503234 XP_001503284 0.210234 0.015215 
MYST2 XM_001502506 XP_001502556 0.2297 0.024376 
NADK XM_001503443 XP_001503493 -0.26861 0.036858 
NDUFB5 DN508847 XP_001495558 0.197419 0.03774 
NFYC XM_001503250 XP_001503300 0.206316 0.016469 
NKIRAS2 XM_001495362 XP_001495412 -0.27577 0.022311 
NLRP1** XM_001502829 XP_001502879 0.879117 0.038263 
NME1-NME2 DN510443 NULL -0.19402 0.009184 
NOC3L CX603641 NULL 0.288471 0.017359 
NPAL1 DN510209 NULL -0.5065 0.010381 
NPM1 NULL NULL -0.18544 0.022126 
NPR3 XM_001500398 XP_001500448 -0.16671 0.017961 
NPTXR CX594481 NULL -0.25043 0.047288 
NR1H4 XM_001496056 XP_001496106 -0.20849 0.049551 
NR2E3 XM_001494954 XP_001495004 0.275625 0.022754 
NTAN1 NULL NULL 0.160111 0.034946 
NUDT4 XM_001495348 XP_001495398 0.356541 0.045166 
NUDT8 XM_001492186 NULL 0.410626 0.032351 
NULL CX603838 NULL -0.26316 0.003618 
NULL DN510982 NULL -0.34284 0.003826 
NULL CX597518 NULL 0.32561 0.004362 
NULL XM_001491511 NULL -0.38713 0.00611 
NULL DN508304 NULL -0.17229 0.007647 
NULL DN509075 NULL -0.18996 0.007979 
NULL XR_036258 NULL -0.35068 0.011203 
NULL CX598059 NULL -0.34524 0.011675 
NULL CX602673 NULL -0.20763 0.011809 
NULL XM_001495673 NULL 0.26954 0.01203 
NULL DN509646 NULL -0.27243 0.012771 
NULL XM_001499091 XP_001499141 -0.30197 0.012947 
NULL CX605794 NULL -0.25747 0.013891 
NULL DN510407 NULL -0.22756 0.015263 
NULL CX603890 NULL -0.3292 0.015421 
NULL CX602249 NULL -0.40041 0.015669 
NULL XR_036349 NULL -0.17858 0.016135 
NULL CX604190 NULL -0.355 0.016504 
NULL CX604012 NULL 0.287679 0.016893 
NULL DN510417 NULL 0.403233 0.017168 
NULL DN509230 NULL -0.34225 0.017823 
NULL CX602423 NULL 0.356203 0.020874 
NULL CX602962 NULL -0.32357 0.021541 
NULL CX605229 NULL -0.16713 0.021921 
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NULL DN511060 NULL -0.20142 0.022355 
NULL CX602999 NULL 0.372858 0.023793 
NULL XM_001491766 NULL -0.20418 0.024842 
NULL CX605497 NULL 0.166509 0.027773 
NULL DN510227 NULL -0.30624 0.028065 
NULL CX597125 NULL -0.15902 0.028866 
NULL XM_001503568 NULL 0.253451 0.031333 
NULL CX603914 NULL -0.18911 0.032286 
NULL CD536420 NULL -0.13801 0.032654 
NULL CX604033 NULL -0.26169 0.03318 
NULL DN509048 NULL -0.34883 0.033232 
NULL CX602671 NULL -0.51486 0.034018 
NULL DN509184 NULL -0.38082 0.03435 
NULL DN507905 NULL 0.354473 0.034748 
NULL CD470590 NULL -0.55033 0.040211 
NULL CX604149 NULL 0.220966 0.041461 
NULL CD528773 NULL -0.27521 0.043312 
NULL CD470227 NULL -0.46914 0.043705 
NULL CX600034 NULL -0.96456 0.045322 
NULL CX599655 NULL 0.222764 0.045956 
NULL DN506142 NULL 0.199536 0.046189 
NULL CX594703 NULL 0.208985 0.046428 
NULL DN509452 NULL 0.230574 0.046692 
NULL CX601539 NULL 0.148762 0.047775 
NULL CD467057 NULL -0.25517 0.047784 
NULL DN504828 NULL -0.40229 0.047866 
NULL BI960932 NULL 0.357004 0.047919 
NULL CX603562 NULL 0.351948 0.049321 
NULL CX603403 NULL -0.21629 0.049484 
OPA3 DN509316 NULL -0.8072 0.000239 
OR10A4 XM_001500066 XP_001500116 0.190027 0.047697 
OR10C1 XM_001489021 XP_001489071 0.12307 0.04753 
OR11H6 XM_001502302 XP_001502352 0.268459 0.045998 
OR13H1 XM_001491485 NULL 0.240546 0.039581 
OR1F1 XM_001499014 XP_001499064 0.173465 0.039443 
OR1L1 XM_001501254 XP_001501304 0.216243 0.048029 
OR1N2 XM_001497814 XP_001497864 0.45279 0.018868 
OR2B11 XM_001504074 XP_001504124 0.447462 0.027603 
OR2D3** XM_001500110 XP_001500160 0.854773 0.003415 
OR2L8 XM_001499162 NULL -0.50719 0.023318 
OR2T33 XM_001497754 NULL 0.175891 0.022634 
OR2T33 XM_001491345 NULL -0.2515 0.033996 
OR2W1 XM_001494282 XP_001494332 0.174815 0.02704 
OR4C11 XM_001495311 XP_001495361 0.242508 0.027577 
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OR4C16 XM_001494914 XP_001494964 -0.32212 0.042627 
OR4F15 XM_001501753 XP_001501803 0.230348 0.014142 
OR4K13 XM_001501955 XP_001502005 0.260309 0.030299 
OR4P4 XM_001495187 XP_001495237 0.542067 0.014848 
OR51A7 XM_001497708 XP_001497758 0.423374 0.038104 
OR51G2 XM_001498435 NULL 0.348326 0.002337 
OR51I1 XM_001503971 XP_001504021 0.288524 0.025677 
OR52E8 XM_001498450 XP_001498500 0.291408 0.011323 
OR52J3 XM_001498495 NULL 0.20133 0.040383 
OR5A2 XM_001495642 XP_001495692 0.216045 0.024005 
OR5BU1 XM_001495626 XP_001495676 0.510988 0.007688 
OR5P2 XM_001500307 XP_001500357 0.335611 0.012578 
OR6C1 XM_001490296 XP_001490346 0.206577 0.028519 
OR6C2 XM_001489553 NULL 0.265508 0.010738 
OR6C2 XM_001491120 XP_001491170 0.202785 0.01975 
OR6C70 XM_001490802 XP_001490852 0.28592 0.029728 
OR7E24 XM_001493590 XP_001493640 0.543819 0.034561 
OR8B3 XM_001501921 NULL 0.648596 0.013265 
OR8B3 XM_001501664 XP_001501714 0.340618 0.024416 
P2RX3 XM_001504914 XP_001504964 -0.35219 0.007107 
P4HA2 XM_001502946 XP_001502996 -0.73316 0.040654 
PANK3 XM_001503241 XP_001503291 0.220359 0.044781 
PCDHGB3 XM_001502136 XP_001502186 0.360144 0.033932 
PCK2 XM_001489336 XP_001489386 0.311448 0.015789 
PCSK2 XM_001491591 XP_001491641 0.349811 0.017213 
PDCD1LG2 XM_001492097 XP_001492147 0.147122 0.026782 
PDE3B XM_001501420 XP_001501470 0.177111 0.022396 
PFDN1 XM_001499395 XP_001499445 -0.25215 0.034877 
PGRMC1 DN509190 NULL -0.21395 0.049152 
PIK3R1 XM_001491571 XP_001491621 -0.68522 0.026548 
PIK3R4 XM_001496778 XP_001496828 0.257827 0.043563 
PITPNB XM_001499699 XP_001499749 -0.249 0.039968 
PITPNC1 XM_001499960 XP_001500010 -0.17096 0.024152 
PLUNC XM_001498706 XP_001498756 0.294584 0.034644 
PPP2CA XR_036429 NULL 0.652938 0.034851 
PPP6C XM_001500587 XP_001500637 0.441911 0.032121 
PQLC3 XM_001502263 XP_001502313 0.115683 0.04322 
PRCC XM_001500494 XP_001500544 -0.28742 0.04078 
PRKCDBP XM_001499633 XP_001499683 -0.41415 0.040801 
PRKCQ XM_001499872 XP_001499922 -0.32081 0.048945 
PSME4 XM_001497080 XP_001497130 -0.27736 0.004814 
PTP4A2 NULL NULL 0.207895 0.033241 
QRSL1 XM_001503943 XP_001503993 -0.32415 0.012343 
QSOX1 XM_001488615 XP_001488665 -0.28399 0.028888 
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RBM35B XM_001498872 XP_001498922 -0.18307 0.048584 
RGS5 XM_001492029 XP_001492079 0.119258 0.04492 
RING1 XM_001493382 XP_001493432 -0.2514 0.048376 
RNF152 XM_001489933 XP_001489983 -0.14793 0.019968 
RPL37 BI961238 XP_001499005 -0.39546 0.016148 
RPL7 XM_001491982 XP_001492032 -0.67362 0.032564 
RPRM XM_001491352 XP_001491402 0.177594 0.048717 
RQCD1 XM_001491531 XP_001491581 0.523039 0.045376 
SELO XM_001496075 XP_001496125 0.174708 0.038087 
SERF2 XM_001500420 XP_001500470 0.215438 0.012303 
SERINC5 XM_001503874 XP_001503924 -0.38581 0.02252 
SERTAD1 XR_036272 NULL -0.19328 0.028736 
SH3BGRL XM_001501152 XP_001501202 0.14636 0.023908 
SH3GL1 XM_001494308 NULL 0.420738 0.025007 
SHROOM2 XM_001488393 XP_001488443 0.131121 0.046404 
SIGLEC14 XM_001496296 XP_001496346 -0.32211 0.036327 
SLC16A1 XM_001495158 XP_001495208 0.188788 0.036625 
SLC16A14 XM_001497261 XP_001497311 -0.20989 0.029197 
SLC18A1 XM_001490140 XP_001490190 0.261434 0.02371 
SLC35A4 XM_001504164 XP_001504214 0.232301 0.018334 
SLC39A13 XM_001491132 XP_001491182 -0.294 0.036139 
SLC39A9 XM_001500384 XP_001500434 0.224154 0.020065 
SLC6A8 XM_001491633 XP_001491683 0.465186 0.030494 
SLC7A4 BI961888 XP_001492952 0.398226 0.02824 
SLC7A7 CD535752 NULL -0.38915 0.013448 
SLMO1 XM_001489476 XP_001489526 0.162967 0.048988 
SOX4 NULL NULL 0.219273 0.027637 
SPHK1 XM_001491689 XP_001491739 0.222634 0.04825 
SURF4 XM_001499090 XP_001499140 0.156427 0.029156 
SYF2 XM_001501117 XP_001501167 0.185125 0.010552 
TAAR8 XM_001503349 XP_001503399 -0.3475 0.006339 
TEX11 XM_001490344 XP_001490394 0.22371 0.026907 
TFAM XM_001503382 XP_001503432 0.286302 0.019479 
TFE3 XM_001494896 XP_001494946 0.297885 0.045961 
TGM3 CD469900 NULL -0.25928 0.027262 
THAP3 XM_001491823 XP_001491873 -0.30618 0.007553 
THSD1 XR_035821 NULL -0.13005 0.049763 
TICAM1 XM_001493990 XP_001494040 -0.11966 0.032748 
TM2D2 XM_001491499 XP_001491549 -0.26594 0.032277 
TMCO6 XM_001504162 XP_001504212 0.183063 0.032356 
TMEM167 XM_001504639 NULL 0.290951 0.039732 
TMEM171 XM_001504691 XP_001504741 0.305715 0.015251 
TMEM5 NULL NULL -0.55048 0.007448 
TMEM58 XM_001494838 XP_001494888 -0.56743 0.012298 
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TMEM71 XM_001499201 XP_001499251 0.348118 0.035967 
TMEM95 XM_001503064 XP_001503114 0.166907 0.045127 
TMOD3 XM_001499393 XP_001499443 0.139338 0.030561 
TMPRSS11E2 XM_001501361 XP_001501411 -0.47637 0.04511 
TNFRSF10A XM_001503050 XP_001503100 -0.2383 0.011352 
TPR NULL NULL -0.20522 0.01265 
TRH XM_001491273 XP_001491323 0.153682 0.043842 
TRIM39 XM_001492176 XP_001492226 0.379216 0.04574 
TSPO XM_001503143 XP_001503193 0.251579 0.043451 
TTR XM_001495182 XP_001495232 0.214415 0.012757 
TUBA3C XM_001488340 XP_001488390 -0.29746 0.017159 
UACA XM_001495340 NULL -0.19096 0.041346 
UBC XM_001499082 XP_001499132 -0.3403 0.044822 
UBE2G2 XM_001490079 NULL 0.715065 0.037124 
UBXD8 XM_001502650 XP_001502700 0.468242 0.000969 
UGCGL1 XM_001504931 XP_001504981 0.103581 0.044813 
UPK2 XM_001503043 XP_001503093 0.242261 0.009669 
USP32 XM_001503781 XP_001503831 0.183872 0.038464 
USP6NL XM_001489534 XP_001489584 -0.27901 0.045073 
USP8 XM_001501926 XP_001501976 -0.23152 0.038994 
VN1R1 XM_001490632 NULL 0.34542 0.030136 
VPS29 XM_001495099 XP_001495149 0.20264 0.04716 
VPS35 XM_001490225 XP_001490275 0.251023 0.035081 
VTN XM_001504123 XP_001504173 0.231365 0.029878 
XKRX XM_001492403 XP_001492453 0.429293 0.035877 
ZC3H12D XM_001495556 XP_001495606 -0.1269 0.024606 
ZCCHC9 XM_001504642 XP_001504692 0.171532 0.047382 
ZDHHC17 DN510703 NULL -0.39825 0.036697 
ZKSCAN4 DN509499 NULL -0.32777 0.014806 
ZNF234 XM_001500100 XP_001500150 -0.1708 0.048093 
ZNF407 NULL NULL -0.44057 0.004587 
ZNF512 XM_001502165 XP_001502215 0.275094 0.047046 
ZNF575 XM_001499856 XP_001499906 0.331743 0.039215 
TFE3 XM_001494896 XP_001494946 0.297885 0.045961 
TGM3 CD469900 NULL -0.25928 0.027262 
THAP3 XM_001491823 XP_001491873 -0.30618 0.007553 
THSD1 XR_035821 NULL -0.13005 0.049763 
TICAM1 XM_001493990 XP_001494040 -0.11966 0.032748 
TM2D2 XM_001491499 XP_001491549 -0.26594 0.032277 
TMCO6 XM_001504162 XP_001504212 0.183063 0.032356 
TMEM167 XM_001504639 NULL 0.290951 0.039732 
TMEM171 XM_001504691 XP_001504741 0.305715 0.015251 
TMEM5 NULL NULL -0.55048 0.007448 
TMEM58 XM_001494838 XP_001494888 -0.56743 0.012298 
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ABCA13 XM_001496546 XP_001496596 1.037721 0.012461 
ABCA4 XM_001491597 XP_001491647 -0.20234 0.046607 
ABI2 XM_001497656 XP_001497706 0.579302 0.005247 
ABO XM_001491153 XP_001491203 0.486945 0.006452 
ACCN5 XM_001500739 XP_001500789 0.771025 0.028665 
ACSS2 XM_001501341 XP_001501391 -0.46807 0.039853 
ACTA2 XM_001503035 XP_001503085 0.703496 0.02659 
ACTR2 XM_001494389 XP_001494439 -2.07064 0.001165 
ADAM28 XM_001491580 XP_001491630 -0.56749 0.046506 
AGT DN510402 NULL -0.60305 0.02028 
AGTRAP XM_001492019 XP_001492069 -0.79757 0.043198 
AKAP14 XM_001491634 NULL 0.267078 0.049638 
ALDOA NULL NULL -0.36301 0.044038 
ALKBH3 XM_001489694 XP_001489744 -0.1968 0.029472 
ALKBH6 XM_001492599 XP_001492649 -0.33154 0.021518 
ALPL XM_001504312 XP_001504362 0.560444 0.017596 
ALS2CR8 XM_001497530 XP_001497580 -0.27154 0.046495 
AP1G1 XM_001500479 NULL 1.055121 0.012305 
APPL1 XM_001491548 XP_001491598 0.334809 0.01894 
ARL6 XM_001504416 XP_001504466 0.243138 0.046286 
ARPM1 XM_001491136 XP_001491186 0.473668 0.027702 
ART3 XM_001490592 XP_001490642 -0.33842 0.008631 
ASB11 XM_001489836 XP_001489886 -0.67643 0.048175 
ATF4 XM_001499993 XP_001500043 -0.21397 0.039679 
ATG3 CD528901 NULL -0.72757 0.038941 
ATG7 XM_001493002 XP_001493052 0.348071 0.040517 
ATM XM_001501161 XP_001501211 -0.45027 0.001899 
ATOH1 XM_001495691 XP_001495741 -0.23704 0.025404 
ATP11B XM_001496792 XP_001496842 -0.27704 0.039211 
ATP6AP1 XM_001494850 NULL -0.37601 0.017738 
AVPR1B XM_001489521 XP_001489571 -0.15627 0.018305 
B4GALT3 XM_001503814 XP_001503864 -0.41842 0.024535 
bA16L21.2.1 XM_001491058 XP_001491108 0.468213 0.039446 
BAG4 XM_001493179 XP_001493229 0.212958 0.014436 
BAZ1A XM_001490894 XP_001490944 -0.5496 0.017181 
BCKDK XM_001500782 XP_001500832 -0.31719 0.037365 
BDKRB1 XM_001489223 XP_001489273 -0.52687 0.028964 
BHLHB9 XM_001504604 XP_001504654 0.522902 0.000104 
BMPR1A XM_001500907 XP_001500957 0.540654 0.012881 
BMS1 XM_001489945 XP_001489995 -0.38849 0.033776 
BMX XM_001490091 XP_001490141 -0.32058 0.040133 
BSDC1 XM_001503784 XP_001503834 -0.23987 0.009126 
BTBD16 XM_001495476 XP_001495526 0.252625 0.017797 
BTBD6 NULL NULL -0.7423 0.009073 
C11orf41 XM_001492058 XP_001492108 -0.43351 0.012116 
C11orf60 XM_001502961 XP_001503011 0.367626 0.01651 
C12orf34 XM_001496801 NULL -0.58296 0.020218 
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C12orf57 CX604375 XP_001497722 -0.1585 0.041625 
C14orf68 XM_001488578 NULL -0.31614 0.006199 
C17orf49 NULL NULL 0.722099 0.015115 
C17orf63 XM_001504183 XP_001504233 -0.69946 0.030039 
C17orf68 XM_001503195 XP_001503245 0.359327 0.009729 
C17orf75 XM_001504001 XP_001504051 -0.35747 0.02246 
C18orf22 XM_001496059 XP_001496109 0.234633 0.036686 
C19orf45 XM_001496690 XP_001496740 -0.3325 0.016977 
C1orf182 XM_001495120 NULL 0.701534 0.043444 
C1QA XM_001504261 XP_001504311 -0.49162 0.033785 
C20orf152 XM_001501888 XP_001501938 -0.22185 0.036937 
C3orf37 XM_001495046 XP_001495096 0.248819 0.018123 
C3orf63 XM_001490512 XP_001490562 0.238418 0.033175 
C4orf20 XM_001490682 XP_001490732 -0.49584 0.04532 
C4orf26 XM_001490823 XP_001490873 0.33728 0.036499 
C5orf21 XM_001503716 XP_001503766 -0.67135 0.033617 
C6orf166 XM_001500351 XP_001500401 0.437393 0.005069 
C8orf37 XM_001490155 XP_001490205 -0.33855 0.01189 
C8orf70 XM_001491870 XP_001491920 -0.29263 0.047506 
C8orf80 XM_001492998 XP_001493048 0.223111 0.032251 
C9orf131 XM_001498113 XP_001498163 -0.42936 0.006311 
CALR3 XM_001502873 XP_001502923 -1.72919 0.045369 
CAPN9 XM_001494410 XP_001494460 -0.3399 0.032075 
CASC5 XM_001501097 XP_001501147 -0.29271 0.01074 
CASR XM_001502152 XP_001502202 0.427202 0.047735 
CBLN3 XM_001488806 XP_001488856 -0.29656 0.03575 
CBS XM_001490849 NULL 1.186991 0.006148 
CCDC25 XM_001492881 XP_001492931 0.735653 0.01888 
CCDC86 XM_001501625 XP_001501675 -0.36668 0.043493 
CCDC99 XM_001503223 XP_001503273 -0.26275 0.039019 
CCL11 AJ251188 NP_001075340 0.242455 0.020013 
CCL4 CD536661 XP_001503938 -0.30715 0.007157 
CCT7 XM_001488366 XP_001488416 -1.00489 0.028476 
CD164** BM414616 NULL 0.623907 0.030197 
CD200R2 XM_001501232 XP_001501282 -0.31167 0.046973 
CD300E XM_001492757 XP_001492807 0.27282 0.035827 
CD82 XM_001489923 XP_001489973 -0.56017 0.032673 
CDC42SE1 XM_001491452 NULL 0.715237 0.04539 
CDS2 XM_001496234 XP_001496284 0.331344 0.048142 
CEACAM1 DN510800 NULL -0.19695 0.011575 
CFB XM_001492552 XP_001492602 0.250238 0.029272 
CGGBP1 NULL NULL -0.57567 0.033939 
CHAT XM_001494138 XP_001494188 -0.42505 0.020786 
CHCHD1 XM_001503907 XP_001503957 -0.27602 0.039856 
CHD1 XM_001504605 XP_001504655 0.413024 0.012356 
CLCF1 XM_001495767 XP_001495817 -0.60471 0.031767 
CLEC4G XM_001496849 XP_001496899 -0.49977 0.005775 
CLPX XM_001498202 XP_001498252 -0.35828 0.015643 
CLRN1 XM_001489624 XP_001489674 -0.50704 0.043534 
CNTN5 XM_001499420 XP_001499470 -0.48395 0.018772 
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COPS3 XM_001489781 XP_001489831 1.317346 0.006002 
COQ5 XM_001488871 XP_001488921 -0.362 0.040116 
COX7B2 XM_001496055 NULL 0.418043 0.003373 
CRTAC1 XM_001501238 XP_001501288 -0.344 0.017977 
CRYGS XM_001499197 XP_001499247 -0.32412 0.018514 
CTDSPL2 XM_001502847 XP_001502897 -0.28197 0.046758 
CTNNA1 XM_001504256 XP_001504306 0.347933 0.01988 
CYP11A1 NM_001082521 NULL -0.26564 0.012307 
CYP2B6 XM_001498389 XP_001498439 -0.9925 0.039791 
CYP2F1 XM_001498170 XP_001498220 -0.58941 0.04966 
D2HGDH XM_001503152 XP_001503202 -0.35464 0.015085 
DAO XM_001500936 XP_001500986 0.604679 0.005247 
DARC XM_001490641 XP_001490691 -0.43282 0.037625 
DCP1B XM_001489775 NULL -0.43519 0.028676 
DCP2 XM_001503544 XP_001503594 0.520618 0.00031 
DDT NULL NULL 0.365224 0.028522 
DECR2 XM_001495338 XP_001495388 0.421156 0.001778 
DHCR7 XM_001497598 XP_001497648 -0.32826 0.040516 
DLEU7 XM_001488517 XP_001488567 0.32917 0.042681 
DLX6 XM_001494576 XP_001494626 -0.2854 0.049404 
DMAP1 XM_001496404 XP_001496454 0.128217 0.006903 
DNAJB5 XM_001498146 XP_001498196 -0.34425 0.015034 
DUT XM_001499877 XP_001499927 0.536045 0.018876 
DZIP1 XM_001492095 XP_001492145 0.427997 0.016201 
ECM2 XM_001491513 XP_001491563 -0.31136 0.025311 
EEF1A1 NULL NULL -0.36645 0.041193 
EEF1E1 XM_001490875 XP_001490925 0.390926 0.040527 
EFNA3 XM_001498265 XP_001498315 -0.58867 0.003751 
EIF2C1 XM_001503662 NULL -0.28284 0.019496 
EIF3CL DN509049 NULL -0.69744 0.009602 
EIF3CL CX603489 NULL -0.3145 0.017678 
ELAVL1** XM_001497883 XP_001497933 1.018199 0.006986 
EMP2 XM_001492271 NULL 0.391436 0.026733 
EMR3 XM_001495605 XP_001495655 0.487905 0.048778 
ENO3 NULL NULL -0.38754 0.018971 
ERBB2 XM_001501105 XP_001501155 -0.81754 0.039115 
EXOC8 XM_001494038 XP_001494088 -1.19338 0.008229 
FAM107B XM_001498585 XP_001498635 -0.37907 0.002294 
FAM45A CX598831 NULL 1.481584 0.024642 
FBXL10 DN504171 NULL -0.55947 0.035738 
FBXL11 XM_001497095 XP_001497145 -0.34449 0.008827 
FBXL15 XM_001499655 XP_001499705 -0.24886 0.043512 
FBXL22 XM_001499127 NULL -0.31008 0.017224 
FCF1 XM_001490976 XP_001491026 -0.31983 0.048569 
FES XM_001498763 NULL -0.45435 0.035789 
FEZ2 XM_001499974 XP_001500024 0.173831 0.038165 
FGA BM780427 NULL -0.43454 0.021822 
FLJ12993 XM_001493769 XP_001493819 -0.46767 0.00952 
FLJ20254 XM_001502643 XP_001502693 0.340071 0.010832 
FLJ25006 XM_001501927 XP_001501977 -0.31047 0.013722 
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FLJ31818 XM_001500571 XP_001500621 0.289857 0.008696 
FLJ40243 XM_001496447 XP_001496497 0.406214 0.035389 
FLJ46321 #N/A #N/A -0.43179 0.011405 
FLJ46321 #N/A #N/A -0.29692 0.01998 
FLRT2 XM_001495071 XP_001495121 0.302181 0.013902 
FMO3 XM_001495951 XP_001496001 0.523709 0.009847 
FN3KRP XM_001490260 XP_001490310 0.318488 0.022715 
FOXP4 XM_001501047 XP_001501097 0.316174 0.022606 
FRYL NULL NULL -0.34467 0.005715 
FTL XM_001488775 XP_001488825 -0.35257 0.038442 
GABRA2 XM_001496096 XP_001496146 0.495879 0.035691 
GATAD1 XM_001493322 XP_001493372 0.522085 0.037253 
GBA XM_001498650 XP_001498700 0.270754 0.026967 
GBA2 XM_001497746 XP_001497796 0.163072 0.01766 
GEMIN6 XM_001500469 XP_001500519 -0.13552 0.041607 
GMIP XM_001503515 XP_001503565 -0.15845 0.029161 
GOLPH3 XM_001500613 XP_001500663 0.418452 0.043142 
GORASP1 XM_001498286 XP_001498336 -0.17059 0.015596 
GPRC6A XM_001504147 XP_001504197 -0.45449 0.01586 
GRINA XM_001493306 XP_001493356 0.539736 0.049361 
GTSE1 XM_001488648 XP_001488698 -0.48555 0.046174 
HBB XM_001504190 XP_001504240 1.436502 0.0228 
HDAC3 XM_001503978 XP_001504028 0.198928 0.042852 
HFE XM_001505039 XP_001505089 0.677802 0.024956 
HIST1H3B XM_001493440 XP_001493490 0.173631 0.049382 
HIST2H2AB XM_001488506 XP_001488556 -0.13196 0.018501 
HNRPDL AY246721 NULL -0.43276 0.016786 
HRAS XM_001488899 NULL 0.406556 0.019443 
HSD11B2 AF126744 NP_001075395 -0.39177 0.043871 
HSPBP1 NULL NULL -0.49075 0.030163 
HSPE1 NULL NULL 1.359839 0.039948 
HTR4 AY263357 NULL -0.28813 0.026755 
IDH3G XM_001493411 XP_001493461 -0.23873 0.045309 
IFNW1 XM_001497115 XP_001497165 -0.12699 0.039297 
IFT57 XM_001503311 XP_001503361 -0.46961 0.027765 
IGSF21 XM_001498665 XP_001498715 -0.39913 0.033873 
IGSF8 XM_001491262 XP_001491312 0.480286 0.046656 
IL1RL1 XM_001491350 XP_001491400 -0.538 0.038873 
IL3 XM_001504454 NULL -0.50156 0.035707 
ILK XM_001504599 XP_001504649 -0.30422 0.01894 
ING5 XM_001497795 XP_001497845 -0.35798 0.040122 
INTS12 XM_001503610 XP_001503660 -0.31402 0.006822 
ITGAL XM_001496070 XP_001496120 -0.33171 0.022815 
JAK2 XM_001500499 XP_001500549 -0.51016 0.010581 
JMJD3 XR_036443 NULL 0.324232 0.048903 
KCNH8 XM_001495463 XP_001495513 -0.4725 0.015057 
KCTD11 NULL NULL -0.52284 0.03645 
KDELC1 XM_001493228 XP_001493278 0.372368 0.016248 
KIAA0226 XM_001499814 XP_001499864 0.827202 0.038863 
KIAA0907 XM_001499401 XP_001499451 0.148796 0.049374 
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KIAA1853 XM_001490434 XP_001490484 -0.32549 0.038302 
KIF2A XM_001493976 XP_001494026 1.04902 0.001648 
KIF5B XM_001493254 XP_001493304 -0.23622 0.046619 
KL XM_001495612 XP_001495662 -0.37402 0.019868 
KLK8 XM_001497389 XP_001497439 0.245556 0.025008 
KLRD1 XM_001494069 XP_001494119 0.260962 0.034785 
KLRK1 XM_001499819 XP_001499869 -0.35753 0.044149 
KRTAP10-7 XM_001490330 XP_001490380 -0.4848 0.026736 
KTELC1 XM_001500712 XP_001500762 0.357019 0.031305 
LAMP1 XM_001495652 XP_001495702 -0.68662 0.025885 
LAT XM_001502343 XP_001502393 1.094573 0.04829 
LBP XM_001499815 XP_001499865 0.27448 0.038729 
LDHB XM_001502203 XP_001502253 -0.3092 0.026803 
LHX6 XM_001501453 NULL -0.3683 0.038979 
LHX9 XM_001492961 NULL 0.238433 0.026941 
LILRB3 XM_001488558 XP_001488608 -0.10361 0.048875 
LMBR1L XM_001504157 XP_001504207 -0.49004 0.005773 
LOC255809 XM_001490886 NULL -0.30213 0.0277 
LOC283677 XM_001494312 XP_001494362 -0.50036 0.008356 
LOC401934 XM_001496605 NULL 0.225593 0.044584 
LOC729533 XM_001489563 NULL 0.55112 0.028664 
LONRF1 XM_001494722 XP_001494772 0.368876 0.005907 
LRMP XM_001498588 XP_001498638 -0.37691 0.036073 
LRRC15 XM_001500569 XP_001500619 -0.7499 0.045015 
LRRC25 XM_001500641 XP_001500691 1.076904 0.002838 
LRRC36 XM_001496409 XP_001496459 1.085917 0.043118 
LRRC41 NULL NULL 0.311386 0.029295 
LYNX1 XM_001496732 XP_001496782 -0.43004 0.019176 
MAGED1 CX595349 NULL -0.2497 0.048527 
MAL XM_001494676 NULL -0.42252 0.003718 
MAL XM_001494113 XP_001494163 -0.48321 0.020482 
MAML1 XM_001497397 XP_001497447 0.419366 0.022563 
MAP4K3 XM_001499556 XP_001499606 0.279908 0.012328 
MARK2 NULL NULL -1.27109 0.009214 
MAT2A XM_001497416 XP_001497466 -0.23636 0.022092 
MC3R XM_001489123 XP_001489173 -0.55662 0.024977 
MCM8 XM_001496114 XP_001496164 0.302788 0.035381 
MEIS3 XM_001503175 XP_001503225 0.230872 0.03966 
MMD XM_001500221 XP_001500271 0.260309 0.035177 
MNDA XM_001490503 XP_001490553 0.263727 0.043212 
MPP5 XM_001499684 XP_001499734 -0.25067 0.033853 
MPZL3 XM_001500915 XP_001500965 0.445297 0.040927 
MRFAP1 CX594991 NULL -0.67634 0.048577 
MRPL1 XM_001491866 XP_001491916 -0.18196 0.020208 
MRPL21 CX604559 XP_001499094 0.994656 0.012171 
MRPL47 XM_001495484 XP_001495534 0.306573 0.016678 
MSRB2 XM_001495858 NULL -0.38218 0.013082 
MTERFD2 XM_001497592 XP_001497642 0.242095 0.043465 
MTFR1 XM_001495100 XP_001495150 -0.54029 0.011643 
MTHFD2L XM_001490173 XP_001490223 -0.32808 0.037074 
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MTNR1A XM_001490171 XP_001490221 -0.16377 0.018636 
MX2 U55216 NP_001075961 -0.42476 0.012707 
MXD4 XM_001488540 XP_001488590 -0.4782 0.047791 
MYEOV2 XM_001497339 XP_001497389 0.801473 0.030051 
MYLIP XM_001493152 XP_001493202 0.602705 0.000216 
MYO1B XM_001502243 XP_001502293 -0.76223 0.027856 
NAE1 XM_001496095 XP_001496145 0.308608 0.0113 
NAGA XM_001502709 XP_001502759 0.342072 0.028904 
NARG1 XM_001502496 XP_001502546 -0.30179 0.017191 
NBPF6 XM_001491713 NULL -0.16598 0.032227 
NDUFA3 XM_001488784 NULL -0.4914 0.025004 
NFYA XM_001500879 XP_001500929 0.196692 0.034159 
NHLRC1 XM_001496559 XP_001496609 0.425955 0.027616 
NID1 NULL NULL -0.27056 0.040337 
NID2 XM_001497325 XP_001497375 -0.16267 0.040769 
NKIRAS2 XM_001495362 XP_001495412 -0.48614 0.049914 
NMBR XM_001502752 XP_001502802 -0.22195 0.03695 
NNMT XM_001500480 XP_001500530 0.444659 0.040034 
NOTCH3 NULL NULL -0.2651 0.015905 
NPEPPS XM_001498919 XP_001498969 0.172038 0.024811 
NPTXR CX594481 NULL -0.46787 0.031628 
NSD1 XM_001502429 XP_001502479 0.531832 0.031273 
NULL CX601100 NULL -0.67773 0.00164 
NULL BM735205 NULL -0.7024 0.003485 
NULL XM_001499091 XP_001499141 -0.79201 0.003809 
NULL DN507943 NULL -0.64088 0.003851 
NULL DN508635 NULL -0.48034 0.004784 
NULL CX601827 NULL -1.08591 0.005241 
NULL CD468792 NULL -0.57139 0.005412 
NULL CX604012 NULL 0.363557 0.005468 
NULL DN504496 NULL 0.332039 0.0057 
NULL CX602321 NULL 0.500311 0.005783 
NULL CX602251 NULL -0.60126 0.006089 
NULL DN506707 NULL -0.34604 0.008084 
NULL CX598059 NULL -0.41728 0.009811 
NULL DN505730 NULL 0.409894 0.010636 
NULL CX593209 NULL 0.145297 0.011794 
NULL CX605433 NULL -0.45932 0.012188 
NULL XM_001498676 XP_001498726 -0.42284 0.012976 
NULL XM_001499079 XP_001499129 -0.28088 0.014014 
NULL CX603887 NULL 0.343868 0.014105 
NULL CX603684 NULL -0.36693 0.015477 
NULL CX595318 NULL 0.264926 0.015884 
NULL DN508766 NULL -0.44952 0.016605 
NULL XM_001500257 NULL 0.447962 0.017507 
NULL CX603713 NULL -0.35958 0.018491 
NULL DN510407 NULL -0.24818 0.018983 
NULL CD464196 NULL 0.558409 0.019886 
NULL NULL NULL 0.35697 0.019998 
NULL DN508159 NULL -0.56657 0.020105 
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NULL BM735424 NULL 1.520936 0.020466 
NULL XM_001503536 XP_001503586 -0.54449 0.021203 
NULL CX593935 NULL -0.42233 0.02156 
NULL CX596903 NULL 0.464739 0.021816 
NULL XM_001490812 NULL -0.39431 0.022622 
NULL CX604190 NULL -0.62638 0.024814 
NULL CX602929 NULL 0.271464 0.025325 
NULL CD467522 NULL -0.45779 0.025506 
NULL DN509048 NULL -0.75683 0.026148 
NULL DN510495 NULL -0.18871 0.027206 
NULL CD465619 NULL 1.250059 0.028296 
NULL CX599439 NULL -0.38836 0.028907 
NULL XR_036039 NULL 0.413724 0.029429 
NULL XM_001498663 NULL -0.2136 0.02979 
NULL CX600740 NULL -0.67915 0.032207 
NULL DN509646 NULL -0.3427 0.033119 
NULL DN504061 NULL 0.126985 0.035378 
NULL CX599268 NULL 0.241347 0.036262 
NULL CX603914 NULL -0.32499 0.037032 
NULL CX601732 NULL -0.42339 0.037134 
NULL CX601151 NULL 0.248239 0.03816 
NULL XR_036258 NULL -0.56344 0.039309 
NULL XM_001496940 NULL -0.45673 0.039553 
NULL CX602249 NULL -0.58671 0.039715 
NULL CD528873 NULL -0.28557 0.039772 
NULL CX604208 NULL -0.24671 0.04007 
NULL XM_001492225 XP_001492275 -0.3243 0.040092 
NULL XM_001503568 NULL 0.345419 0.04114 
NULL CX605182 NULL -0.20818 0.041375 
NULL XM_001493134 NULL 0.272965 0.042045 
NULL CX594596 NULL -0.95861 0.042623 
NULL DN507767 NULL -0.56498 0.043055 
NULL XM_001496228 XP_001496278 0.112603 0.043923 
NULL CX597119 NULL -0.55971 0.045049 
NULL DN509404 NULL 0.328628 0.045736 
NULL NULL NULL 0.289731 0.046468 
NULL NULL NULL 0.322679 0.046653 
NULL NULL NULL 0.134845 0.046877 
NULL DN509184 NULL -0.68031 0.047685 
NULL BM780537 NULL 1.344317 0.048789 
NULL DN510522 NULL -0.33785 0.048892 
NULL CX596762 NULL -0.71837 0.049943 
NUP85 XM_001496162 XP_001496212 0.30659 0.033569 
ODZ3 NULL NULL 0.30416 0.027222 
OMG XM_001504036 XP_001504086 0.903839 0.036137 
OR12D2 XM_001499509 NULL 0.315713 0.028131 
OR13C8 XM_001493303 XP_001493353 0.596551 0.038654 
OR1N1 XM_001501095 XP_001501145 -0.47512 0.006692 
OR2D3 XM_001500110 XP_001500160 0.725878 0.027357 
OR2D3 XM_001499982 XP_001500032 0.447959 0.041069 
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OR2G3 XM_001491712 XP_001491762 -0.32043 0.039956 
OR2L2 XM_001497233 XP_001497283 -0.40817 0.020941 
OR2T1 XM_001502542 XP_001502592 -0.44488 0.045203 
OR2T4 XM_001504685 XP_001504735 1.089059 0.026307 
OR2T4 XM_001490238 NULL -0.3494 0.031239 
OR4A16 XM_001495905 NULL 0.489512 0.028438 
OR4A47 XM_001495702 XP_001495752 -0.465 0.040039 
OR4D1 XM_001503470 NULL -0.80203 0.01943 
OR4D9 XM_001495337 NULL 0.348727 0.026342 
OR51F1 XM_001497409 XP_001497459 -0.45656 0.001096 
OR52A1 XM_001498165 XP_001498215 -0.31527 0.045603 
OR52E8 XM_001496727 XP_001496777 -0.41831 0.005041 
OR5AT1 XM_001488321 XP_001488371 -0.89421 0.014204 
OR5B3 XM_001497677 XP_001497727 -0.66089 0.029936 
OR6C2 XM_001491344 XP_001491394 0.728612 0.014376 
OR6C2 XM_001489614 XP_001489664 -0.63834 0.021204 
OR6C2 XM_001489573 XP_001489623 -0.38728 0.023382 
OR6F1 XM_001497005 XP_001497055 -0.39749 0.002335 
OR7G2 XM_001494401 XP_001494451 -0.47589 0.001555 
OR8B3 XM_001502010 XP_001502060 0.337228 0.010235 
OR8B3 XM_001501965 XP_001502015 -0.44819 0.02263 
OR8B3 XM_001501664 XP_001501714 0.415064 0.024793 
OR8B3 XM_001501870 XP_001501920 -0.37101 0.035763 
OR8G2 XM_001501835 XP_001501885 -0.38882 0.007602 
OR9I1 XM_001497370 XP_001497420 -0.29027 0.024997 
OR9I1 XM_001497800 XP_001497850 0.284142 0.025185 
OSBPL11 XM_001501564 XP_001501614 0.337289 0.008461 
OTOA XM_001498662 XP_001498712 -0.38073 0.032787 
PAFAH1B3 XM_001501179 XP_001501229 -0.39568 0.021092 
PAIP1 NULL NULL -0.61037 0.00168 
PAMCI XM_001491284 XP_001491334 -0.28221 0.028922 
PASK XM_001497609 XP_001497659 0.262052 0.006837 
PAX2 XM_001499985 XP_001500035 0.5136 0.038219 
PAX5 XM_001504306 XP_001504356 -0.67071 0.0113 
PBXIP1 NULL NULL -0.56141 0.034118 
PCDHGA1 XM_001502164 XP_001502214 0.295804 0.044348 
PDCD1LG2 XM_001492097 XP_001492147 0.333714 0.042233 
PDCD5** CX600347 NULL 0.595991 0.034822 
PEO1 XM_001499940 XP_001499990 0.908884 0.01853 
PEX1 XM_001493365 XP_001493415 -0.33281 0.036541 
PFDN1 XM_001499395 XP_001499445 -0.25002 0.031685 
PGRMC1 DN509190 NULL -0.6774 0.047156 
PHLDB2 XM_001501356 XP_001501406 -0.34437 0.039855 
PHOX2A XM_001499157 XP_001499207 -0.48986 0.044225 
PIBF1 XM_001496359 XP_001496409 0.579437 0.038817 
PIGW XM_001503800 XP_001503850 0.605626 0.005669 
PIK3R1** XM_001491571 XP_001491621 -1.45857 0.000769 
PIWIL4 XM_001498511 XP_001498561 -0.37208 0.005277 
PLA2G4B XM_001500747 XP_001500797 0.238702 0.028487 
PLAC8 DN503804 NULL -0.25129 0.024623 
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PLCL1 XM_001500272 XP_001500322 0.384306 0.021737 
PLCXD2 XM_001501392 XP_001501442 -0.32069 0.036216 
PLEK2 XM_001499816 XP_001499866 -0.69179 0.022386 
PNKD CX600626 NULL -0.4653 0.023308 
POLL XM_001499802 XP_001499852 -0.96154 0.024432 
POLR1C XM_001502041 XP_001502091 0.543719 0.030209 
POLR2C XM_001494211 XP_001494261 -0.44105 0.007487 
POLR2H XM_001498245 XP_001498295 -0.24263 0.030994 
PPAPDC3 XM_001498987 XP_001499037 -0.24863 0.036815 
PPCDC XM_001491716 XP_001491766 -0.44417 0.002218 
PPM1M XM_001492660 NULL 0.189241 0.04209 
PQBP1 XM_001494409 XP_001494459 -0.28915 0.02038 
PRIMA1 XM_001495263 XP_001495313 0.27794 0.037698 
PRKAB1 XM_001490253 XP_001490303 -0.49682 0.009982 
PRKAR1A NULL NULL -0.29288 0.019041 
PRPF4 XM_001488863 XP_001488913 -0.24401 0.011598 
PRPSAP2 XM_001488362 XP_001488412 -0.13886 0.029364 
PRSS27 XM_001498358 XP_001498408 -0.24355 0.049024 
PSMA1 XM_001504944 XP_001504994 1.403976 0.033914 
PSMA2 XM_001495200 XP_001495250 -0.17599 0.043855 
PSTK XM_001490298 XP_001490348 -0.32289 0.047575 
PTCRA XM_001497178 XP_001497228 0.511121 0.043665 
PTGS2 AB041771 NULL -0.61131 0.003264 
PTPRA XM_001497046 XP_001497096 -0.49236 0.039803 
PTPRM NULL NULL 0.242835 0.026959 
PWWP2B XM_001488078 XP_001488128 -0.32772 0.007807 
RAB10 XM_001502813 XP_001502863 0.541243 0.049004 
RAB39 XM_001501007 XP_001501057 0.465332 0.031408 
RAB9A XM_001488986 XP_001489036 0.288793 0.029713 
RAD51C XM_001500643 XP_001500693 0.427758 0.037929 
RAG1AP1 XM_001498337 XP_001498387 -0.29493 0.022318 
RASGEF1C XM_001501051 XP_001501101 0.309668 0.019989 
RCL1 XM_001491924 XP_001491974 -0.45125 0.012265 
RCN1 NULL NULL -0.44143 0.005236 
RCN2 XM_001493149 XP_001493199 1.128578 0.011424 
RECQL NULL NULL -0.35707 0.048399 
RHBDD1 XM_001496411 XP_001496461 -0.25906 0.020625 
RIT2 XM_001497798 XP_001497848 0.384162 0.047161 
RNASET2 XM_001489592 XP_001489642 -0.33638 0.035311 
RNF6 NULL NULL 0.290255 0.018977 
RNH1 XM_001488475 XP_001488525 -0.52832 0.027001 
ROR2 XM_001495538 XP_001495588 -0.15183 0.034363 
RPAP2 XM_001492375 XP_001492425 1.616473 0.04193 
RPL13A XM_001491876 XP_001491926 1.157148 0.005014 
RPL9 XM_001498163 XP_001498213 -0.11745 0.033947 
RPS15A CD467047 NULL -0.82898 0.009938 
RPS18 NULL NULL -0.52733 0.032222 
RSU1 XM_001498053 XP_001498103 -0.23718 0.020765 
RUSC2 XM_001504521 XP_001504571 -0.38864 0.006565 
RXFP1 XM_001500397 XP_001500447 0.479782 0.036678 
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RYBP XM_001493974 XP_001494024 0.551866 0.037589 
S100A2 CX598422 XP_001494717 -0.28614 0.000633 
SAAL1 XM_001501683 XP_001501733 -0.42161 0.009864 
SAMM50 XM_001487978 XP_001488028 -0.46664 0.016864 
SCO2 XM_001490346 XP_001490396 -0.5202 0.020918 
SCYL1BP1 CX603672 NULL 0.476634 0.016104 
SDHB XM_001488214 XP_001488264 -0.4021 0.037353 
SEC14L2 XM_001498151 XP_001498201 -0.31864 0.016432 
SEMA6D XM_001502470 NULL 1.611118 0.041064 
SENP5 XM_001499415 XP_001499465 -0.2666 0.021735 
SERPINA10 XM_001495713 XP_001495763 -0.22057 0.016413 
SERPINB5 XM_001490854 XP_001490904 0.290265 0.034924 
SERPINB7 XM_001491729 XP_001491779 -0.6862 0.009143 
SESN2 XM_001503991 XP_001504041 0.380826 0.032296 
SFT2D2 XM_001490765 NULL -0.36743 0.014426 
SH2D4B XM_001501404 XP_001501454 -1.04133 0.041784 
SHCBP1 XM_001490125 XP_001490175 0.251866 0.018841 
SIGLEC10 XM_001496570 XP_001496620 1.824777 0.033051 
SLBP XM_001488379 XP_001488429 -0.41802 0.025112 
SLC12A3 XM_001502571 XP_001502621 -0.27332 0.008323 
SLC19A2 XM_001491417 XP_001491467 -0.33836 0.026902 
SLC22A18 XM_001492540 XP_001492590 0.376234 0.038742 
SLC25A13 XM_001494425 XP_001494475 -0.44461 0.007677 
SLC26A9 XM_001490825 XP_001490875 0.432121 0.033086 
SLC29A3 XM_001502808 XP_001502858 -0.49362 0.027257 
SLC2A3 XM_001498757 XP_001498807 -0.46009 0.049435 
SLC30A9 XM_001494445 XP_001494495 -0.5714 0.017555 
SLC36A2 XM_001501324 XP_001501374 -0.21357 0.03344 
SLC39A9 XM_001500384 XP_001500434 0.278338 0.049063 
SLC7A4 XM_001488939 XP_001488989 -0.43406 0.039078 
SLC7A7 CD535752 NULL -0.91116 0.004926 
SLC9A8 XM_001501184 XP_001501234 -0.49589 0.006665 
SNAI2 XM_001488056 XP_001488106 0.227857 0.034827 
SP3 XM_001495258 XP_001495308 0.397893 0.034462 
SPATS2 NULL NULL 0.359554 0.045724 
SPRY3 XM_001498267 XP_001498317 0.43798 0.036341 
SPSB3 XM_001497802 XP_001497852 0.296659 0.020542 
SRD5A2 XM_001501522 XP_001501572 0.446924 0.019614 
SSRP1 XM_001497090 XP_001497140 -0.21896 0.028055 
STAMBPL1 XM_001503046 XP_001503096 0.648776 0.048185 
STARD8 XM_001496620 XP_001496670 -0.15655 0.023873 
STMN2 XM_001490291 XP_001490341 -0.4201 0.005985 
TAAR8 XM_001503349 XP_001503399 -0.37331 0.039089 
TATDN1 CX598673 NULL -0.33175 0.049004 
TBC1D16 XM_001490266 XP_001490316 -0.51957 0.03238 
TBP XM_001499329 XP_001499379 -0.57815 0.035184 
TBX5 NULL NULL -0.41324 0.007684 
TCAP XM_001501165 XP_001501215 -0.43643 0.049727 
TCERG1 NULL NULL 0.367793 0.021478 
TFPI2 XM_001492769 XP_001492819 0.523447 0.020102 
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THAP3 XM_001491823 XP_001491873 -0.42859 0.016419 
THEM4 XR_036022 NULL -0.20629 0.018377 
THNSL1 XM_001495489 XP_001495539 0.892391 0.04134 
THUMPD2 XM_001499458 XP_001499508 -0.22917 0.011271 
TIMM17B CX602842 XP_001494391 -0.72716 0.015399 
TLOC1 XM_001494700 XP_001494750 0.615924 0.004561 
TMEM107 CX602840 XP_001504860 -0.49671 0.019149 
TMEM186 XM_001490868 XP_001490918 -0.17676 0.04649 
TMEM58 XM_001494838 XP_001494888 -0.58807 0.04332 
TMEM61 XM_001492579 XP_001492629 -0.84275 0.046517 
TMEM66 XM_001494229 XP_001494279 -0.64837 0.03537 
TMPO XM_001496532 XP_001496582 0.592739 0.002712 
TMPRSS11B XM_001497493 XP_001497543 0.322418 0.039678 
TMPRSS11E2 XM_001501361 XP_001501411 -0.49099 0.018928 
TMPRSS11F XM_001497462 XP_001497512 -0.18015 0.04736 
TNFRSF11A XM_001490290 NULL -0.60134 0.021882 
TNNI1 NULL NULL -0.42858 0.029371 
TNNI3 AY819020 NP_001075373 -0.14174 0.048887 
TOR3A XM_001494447 XP_001494497 0.368171 0.022678 
TP53BP1 XM_001503090 XP_001503140 -0.53399 0.022722 
TP53BP2 XM_001489738 XP_001489788 -0.59972 0.001774 
TPM2 NULL NULL 0.410223 0.039612 
TPM3 XM_001496060 XP_001496110 0.790491 0.049503 
TPPP XM_001490990 NULL -0.13979 0.031393 
TPR NULL NULL -0.3308 0.039404 
TRAF3IP3 XM_001490981 NULL -0.11419 0.038281 
TRAT1 XM_001501680 NULL -0.36617 0.027302 
TSC1 XM_001498348 XP_001498398 -0.25102 0.041166 
TSPAN17 XM_001492295 NULL 0.293128 0.034302 
TSPAN17 NULL NULL -0.22306 0.04522 
TSPAN4 XM_001494692 XP_001494742 -0.76231 0.045128 
TSSK1B XM_001495808 XP_001495858 -0.39324 0.038658 
TTC17 XM_001489510 XP_001489560 -0.26205 0.049193 
TTC29 XM_001500442 XP_001500492 0.222961 0.017177 
TTC32 XM_001503379 XP_001503429 -0.36951 0.011026 
TTN NULL NULL -0.3528 0.036569 
TUBGCP2 NULL NULL 0.316341 0.002595 
TYRP1 NM_001081840 NULL -0.64773 0.009289 
UBC XM_001499082 XP_001499132 -0.50371 0.016492 
UBE2N XM_001495374 XP_001495424 -1.40564 0.009958 
UBR1 NULL NULL 0.34222 0.04028 
UGCGL2 XR_035970 NULL 1.321114 0.008578 
UNC93B1 XR_035965 NULL 0.395064 0.002776 
UNK XM_001492039 XP_001492089 -0.64874 0.006525 
USF2 XM_001491920 NULL -0.48562 0.040525 
USO1 XM_001490004 XP_001490054 -0.74932 0.028564 
USP26 XM_001490646 XP_001490696 -0.20627 0.043552 
USP37 XM_001491830 XP_001491880 0.278041 0.019774 
VAMP4 XM_001496519 XP_001496569 -0.61482 0.006003 
VAX2 XM_001492525 XP_001492575 -0.11692 0.034143 
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VN1R4 XM_001495698 NULL -0.76408 0.008464 
VN1R4 XM_001495663 XP_001495713 -0.52895 0.008648 
VPS25 DN506327 NULL -0.4429 0.024473 
VPS8 XM_001498641 XP_001498691 -0.44364 0.038505 
VTCN1 XM_001496634 XP_001496684 0.826387 0.039715 
VWA3A XM_001491541 NULL 0.196857 0.038463 
WASF3 XM_001491084 XP_001491134 -0.26094 0.019494 
WDR1 XM_001501013 XP_001501063 0.178524 0.0446 
WDR19 XM_001498365 XP_001498415 -0.31339 0.030455 
WDR36 XM_001503571 XP_001503621 0.71301 0.045841 
WDR52 XM_001501172 XP_001501222 -0.32261 0.013713 
WIPF2 XM_001500432 XP_001500482 0.580661 0.013572 
ZFYVE26 XM_001500061 XP_001500111 -0.24851 0.013307 
ZNF24 XM_001496673 XP_001496723 0.493909 0.027197 
ZNF384 XM_001492314 XP_001492364 -0.14402 0.048108 
ZNF385B XM_001501085 XP_001501135 -0.27851 0.03744 
ZNF454 XM_001501556 XP_001501606 -0.48612 0.045934 
ZNF571 XM_001493743 XP_001493793 0.382406 0.011424 
ZNF704 XM_001491115 XP_001491165 -0.28161 0.040396 
ZNF709 XM_001496693 XP_001496743 0.271299 0.015172 
ZSWIM6 XM_001492480 XP_001492530 -0.4768 0.039998 
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39509 XM_001487921 XP_001487971 -0.21501 0.008258 
ABCA4 XM_001491597 XP_001491647 -0.24088 0.020179 
ABCC1 DQ418453 NP_001075232 -0.37076 0.004618 
ACAA1 XM_001488559 XP_001488609 0.439247 0.014224 
ACCN5 XM_001500739 XP_001500789 0.697107 0.045548 
ACTR2 XM_001494389 XP_001494439 -1.92631 0.002144 
ADCY4 XM_001489040 XP_001489090 0.394923 0.025122 
AGPAT1 XM_001492068 XP_001492118 -0.52109 0.046043 
AGTRL1 XM_001504912 XP_001504962 -0.15371 0.048224 
AHRR XM_001490918 XP_001490968 0.404589 0.017294 
AJAP1 XM_001492529 XP_001492579 0.41276 0.043132 
ALDOB XM_001504011 XP_001504061 -0.61132 0.020628 
ALKBH3 XM_001489694 XP_001489744 -0.25528 0.006483 
ALKBH6 XM_001492599 XP_001492649 -0.31432 0.028275 
ARHGAP11A XM_001503656 XP_001503706 -0.27127 0.049702 
ARID5B XM_001503500 XP_001503550 -0.36463 0.02885 
ART3 XM_001490592 XP_001490642 -0.24265 0.049635 
ATF7 XM_001504543 XP_001504593 -0.69194 0.005127 
ATG9B XM_001495054 XP_001495104 -0.43453 0.008089 
ATOH1 XM_001495691 XP_001495741 -0.26671 0.01328 
ATP11B XM_001496792 XP_001496842 -0.2865 0.033604 
ATP5G1 XM_001499269 XP_001499319 -0.13855 0.025869 
ATP6AP1 XM_001494850 NULL -0.36204 0.02178 
AUP1 XR_036315 NULL 0.193886 0.021566 
B4GALT3 XM_001503814 XP_001503864 -0.4411 0.018534 
BHLHB3 CX604838 NULL -0.26255 0.008899 
BHLHB9 XM_001504604 XP_001504654 0.278385 0.018121 
BMS1 XM_001489945 XP_001489995 -0.40133 0.028896 
BTBD16 XM_001495476 XP_001495526 0.31356 0.004471 
BTN3A3 XM_001492121 XP_001492171 -0.4129 0.022899 
C10orf11 XM_001503070 XP_001503120 -0.27753 0.028051 
C10orf35 XM_001503697 XP_001503747 -0.33961 0.047171 
C11orf41 XM_001492058 XP_001492108 -0.37076 0.028522 
C17orf49 NULL NULL 1.108573 0.000595 
C17orf63 XM_001504183 XP_001504233 -0.7154 0.02688 
C17orf75 XM_001504001 XP_001504051 -0.40659 0.010759 
C1orf149 XM_001498954 XP_001499004 0.113634 0.039654 
C1orf182 XM_001495120 NULL 0.701324 0.0435 
C2 XM_001492501 XP_001492551 0.298633 0.038245 
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C20orf149 NULL NULL 1.015525 0.048434 
C4orf35 XM_001502161 XP_001502211 0.605399 0.044016 
C6orf128 XM_001495299 XP_001495349 0.312798 0.036258 
C7orf42 XM_001499915 XP_001499965 -0.23991 0.044483 
C8orf33 XM_001494951 NULL -0.37805 0.017016 
C9orf125 XM_001504009 XP_001504059 0.414458 0.037869 
C9orf23 DN510873 XP_001498436 -0.6268 0.000469 
CASC5 XM_001501097 XP_001501147 -0.23901 0.032447 
CASR XM_001502152 XP_001502202 0.445185 0.039913 
CATSPERB XM_001494573 XP_001494623 -0.32921 0.042172 
CBS XM_001490849 NULL 1.088121 0.01086 
CCDC142 XM_001498892 XP_001498942 -0.3235 0.045393 
CCDC38 XM_001496074 XP_001496124 0.492362 0.022565 
CCDC68 XM_001488458 XP_001488508 -0.14245 0.021078 
CCL11 AJ251188 NP_001075340 0.225497 0.029067 
CCL5 AF506970 NP_001075332 0.739873 0.035852 
CCL8 AF506972 NP_001075333 0.395796 0.034808 
CCNG1 XM_001503358 XP_001503408 0.322989 0.045921 
CDC23 XM_001504289 XP_001504339 0.357997 0.034333 
CHMP2A XM_001495629 XP_001495679 0.531585 0.036436 
CLRN1 XM_001489624 XP_001489674 -0.58661 0.021593 
CLRN2 XM_001498507 XP_001498557 -0.22687 0.044594 
CNIH2 XM_001491221 NULL -0.18796 0.033759 
CNTNAP5 XM_001489205 XP_001489255 0.421424 0.044733 
COPS3 XM_001489781 XP_001489831 1.695628 0.00079 
COPS7B XM_001498509 XP_001498559 -0.80484 0.022268 
CORO1C XM_001500961 XP_001501011 -0.19039 0.037091 
COX18 XM_001488484 XP_001488534 -0.33021 0.027109 
COX5A DN504112 XP_001491906 0.225113 0.039324 
COX7C XM_001504630 NULL 0.84929 0.019084 
CREB3L2 XM_001499610 XP_001499660 -0.23417 0.011386 
CRTAC1 XM_001501238 XP_001501288 -0.34228 0.018482 
CTDSPL2 XM_001502847 XP_001502897 -0.46335 0.002379 
CYP39A1 XM_001498174 XP_001498224 -0.22456 0.047946 
DAPP1 DN504745 NULL 0.375578 0.037677 
DCP2 XM_001503544 XP_001503594 0.307228 0.018115 
DDN XM_001491707 XP_001491757 -0.58105 0.002249 
DDR1 XM_001490798 XP_001490848 0.179244 0.023285 
DDT NULL NULL 0.523196 0.002997 
DECR2 XM_001495338 XP_001495388 0.244986 0.048646 
DLX6 XM_001494576 XP_001494626 -0.35271 0.017734 
DMAP1 XM_001496404 XP_001496454 0.16191 0.001128 
  
256 
Table A-12 Continued 
 
Gene symbol NCBI accession RefSeq accession Log fold change Pvalue 
DMRTC2 XM_001499585 XP_001499635 -0.25159 0.044309 
DNAJB5 XM_001498146 XP_001498196 -0.34228 0.015538 
DNAJC16 XM_001489768 XP_001489818 -0.21894 0.040372 
DNAJC21 XM_001497983 XP_001498033 0.257368 0.049391 
DNASE1L3 XM_001491051 XP_001491101 1.059955 0.041287 
DZIP1 XM_001492095 XP_001492145 0.508085 0.005456 
EEF1A1 NULL NULL 1.077461 0.04369 
EFNA3 XM_001498265 XP_001498315 -0.50762 0.010359 
EIF2C1 XM_001503662 NULL -0.2827 0.019545 
EMID2** XM_001492651 XP_001492701 1.179418 0.005997 
ENDOGL1 XM_001488144 XP_001488194 -0.22543 0.033927 
ETAA1 XM_001492658 XP_001492708 0.280771 0.047149 
ETFDH XM_001500342 XP_001500392 -0.12258 0.046647 
EXOC5 XM_001491407 XP_001491457 -0.29879 0.011841 
EYA4 XM_001504359 NULL -0.6815 0.005129 
FAM107B XM_001498585 XP_001498635 -0.29336 0.013603 
FAM108B1 XM_001488520 XP_001488570 -0.31686 0.028521 
FARSA XM_001504881 XP_001504931 0.153892 0.009352 
FBXL15 XM_001499655 XP_001499705 -0.28166 0.024202 
FBXL22 XM_001499127 NULL -0.29888 0.02106 
FBXO2 XM_001492274 XP_001492324 0.349863 0.047672 
FBXO30 XM_001502353 XP_001502403 -0.20567 0.03598 
FCF1 XM_001490976 XP_001491026 -0.42613 0.011148 
FERMT2 XM_001494661 XP_001494711 -0.42347 0.048057 
FGFR2 XM_001491765 XP_001491815 -0.28711 0.044411 
FLJ11171 XM_001498320 XP_001498370 -0.50677 0.030762 
FLJ12993 XM_001493769 XP_001493819 -0.4646 0.009925 
FLJ46321 XM_001488510 NULL 0.958958 0.005997 
FLJ46321 N/A N/A -0.21903 0.044957 
FPRL1 XM_001489967 XP_001490017 -0.30868 0.009139 
FRK XM_001504096 XP_001504146 0.437822 0.040077 
FTH1 XM_001488238 NULL -0.18888 0.046372 
GALNT5 XM_001491135 XP_001491185 0.130806 0.042747 
GAPVD1 XR_036393 NULL 0.679605 0.008361 
GBA XM_001498650 XP_001498700 0.368033 0.004092 
GBA2 XM_001497746 XP_001497796 0.177416 0.010756 
GCC1 XM_001502547 XP_001502597 0.798215 0.043716 
GJB1 AY286490 NP_001075360 -0.24453 0.035921 
GPAM XM_001496479 XP_001496529 -0.34893 0.031211 
GPBAR1 XM_001491146 XP_001491196 -0.44605 0.02938 
GPR110 XM_001498273 XP_001498323 -0.45149 0.023833 
GPR152 XM_001491968 XP_001492018 -0.95856 0.013787 
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GPR161 XM_001493957 XP_001494007 -0.32022 0.047479 
GPR31 XM_001489448 XP_001489498 -0.27566 0.013579 
GRHL2** XM_001493287 XP_001493337 -1.44125 0.000166 
GRIA4 XM_001500730 NULL 0.193427 0.044726 
GSG1L XM_001502403 XP_001502453 -0.25204 0.02885 
GTPBP2 XM_001497559 XP_001497609 -0.23995 0.015556 
GZMK XM_001497014 XP_001497064 0.140809 0.048632 
H3F3A CD468247 NULL 0.62422 0.032925 
HBB XM_001504190 XP_001504240 1.414061 0.024735 
HCK** CD465568 NULL 0.59042 0.019787 
HIST1H2BI XM_001498344 XP_001498394 -0.27937 0.04005 
HK1 CX601616 NULL -0.18104 0.046972 
HLA-DRB1 XM_001495531 XP_001495581 0.531712 0.000256 
HOXB1 XM_001499152 XP_001499202 -0.29727 0.005543 
HRAS XM_001488899 NULL 0.562831 0.002187 
HS3ST2 XM_001500813 XP_001500863 0.374906 0.033424 
HSPE1 NULL NULL 1.82398 0.008014 
HTATSF1 DN506841 NULL -0.33914 0.047444 
HTT XM_001488793 XP_001488843 -0.55307 0.032434 
IDE XM_001501035 XP_001501085 -0.17776 0.011112 
IGFBP6 NULL NULL 0.687531 0.008746 
IGFBP7 XM_001491171 XP_001491221 0.492022 0.048569 
IL22RA2 XM_001503573 XP_001503623 -0.33945 0.023025 
IMP5 XM_001496121 NULL 0.314868 0.021224 
INSR XM_001496584 XP_001496634 -0.25966 0.027761 
INTS12 XM_001503610 XP_001503660 -0.2701 0.017283 
IQGAP2 XM_001503963 XP_001504013 -0.17378 0.012993 
IRF4 XM_001487865 XP_001487915 -0.40285 0.044287 
ITGBL1 XM_001494267 XP_001494317 0.684289 0.038352 
JMJD2C XM_001492601 XP_001492651 0.215892 0.045166 
KCNA1 XM_001494973 XP_001495023 -0.42141 0.047751 
KCNE3 XM_001498182 XP_001498232 -0.27853 0.028716 
KCNH8 XM_001495463 XP_001495513 -0.48107 0.013556 
KCTD15 XM_001489117 XP_001489167 -1.35609 0.033293 
KIAA0141 XM_001503967 XP_001504017 0.443343 0.024048 
KIAA0515 XM_001498956 XP_001499006 -0.21349 0.022052 
KIAA1166 XM_001504860 XP_001504910 0.348703 0.036559 
KIF17 XM_001504329 XP_001504379 0.444891 0.017319 
KITLG XM_001491749 XP_001491799 -0.4293 0.003208 
KLHDC8B XM_001498158 XP_001498208 -0.28733 0.030014 
KRTAP26-1 XM_001495932 XP_001495982 -0.63053 0.048573 
LIPG XM_001499159 XP_001499209 -0.32741 0.028016 
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LMAN1L XM_001493866 XP_001493916 -0.51913 0.028414 
LMBR1L XM_001504157 XP_001504207 -0.40519 0.018797 
LOC152485 XM_001500552 XP_001500602 0.724353 0.04312 
LOC345222 XM_001490014 XP_001490064 -0.22755 0.028129 
LOC401498 XM_001498934 XP_001498984 -0.46916 0.029612 
LOC644444 XM_001502201 XP_001502251 -0.14474 0.040538 
LOC648672 XM_001488728 XP_001488778 -0.23577 0.037284 
LOC728772 XM_001491967 XP_001492017 0.580286 0.041238 
LOC728937 NULL NULL 0.49753 0.042804 
LOC730491 XM_001488498 XP_001488548 -0.32795 0.021633 
LOC731062 X75612 CAA53284 0.90197 0.012465 
LONRF1 XM_001494722 XP_001494772 0.309904 0.017531 
LRFN2 XM_001496300 XP_001496350 -0.2559 0.033191 
LRPAP1 CX602308 NULL 0.156946 0.022387 
LRPPRC XM_001498869 XP_001498919 -0.31371 0.024851 
LRRC41 NULL NULL 0.286663 0.042943 
LRRC8D XM_001493936 XP_001493986 0.413924 0.03701 
LYPLA1 XM_001489457 NULL -0.30844 0.037274 
MAL XM_001494676 NULL -0.4395 0.002748 
MAL2 XM_001496457 XP_001496507 0.315626 0.032243 
MAML1 XM_001497397 XP_001497447 0.451541 0.015019 
MAN2A2 NULL NULL -0.38682 0.029215 
MB NULL NULL -0.22733 0.02535 
MBOAT4 XM_001494172 XP_001494222 -0.36283 0.034479 
MECR BM735250 NULL -0.17506 0.047716 
MED7 DN510032 NULL -0.1466 0.043135 
MGC23985 XM_001503845 XP_001503895 -0.31588 0.036821 
MGC24975 XM_001495805 NULL -0.32261 0.035594 
MGC4655 XM_001496288 XP_001496338 -0.47118 0.011122 
MGC50722 XM_001498447 XP_001498497 -0.47108 0.019641 
MICB AB126064 NULL -0.23536 0.011169 
MLZE XM_001498324 XP_001498374 -0.32635 0.024704 
MRPL21 CX604559 XP_001499094 1.061571 0.008074 
MRPL47 XM_001495484 XP_001495534 0.257987 0.039781 
MVP XM_001501685 XP_001501735 -0.39093 0.025236 
MYEOV2 XM_001497339 XP_001497389 0.909018 0.01544 
MYL2 NULL NULL 0.382941 0.045384 
MYLIP XM_001493152 XP_001493202 0.374966 0.010823 
NAT1 XM_001487857 XP_001487907 0.542205 0.005775 
NBPF6 XM_001491713 NULL -0.16287 0.035219 
NCAPG2 XR_035925 NULL 0.378977 0.046848 
NDUFA12L XM_001494417 XP_001494467 -0.24762 0.040189 
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NEB NULL NULL -0.1953 0.008036 
NENF NULL NULL 0.755207 0.005771 
NKAIN1 XM_001500148 XP_001500198 -0.26922 0.048009 
NLE1 XM_001503942 XP_001503992 0.456578 0.004181 
NMD3 XM_001493928 XP_001493978 0.144493 0.043712 
NPEPPS XM_001498919 XP_001498969 0.156847 0.038691 
NQO1 XM_001497333 XP_001497383 0.163082 0.01344 
NR1I3 XM_001503792 XP_001503842 -0.28748 0.04936 
NUDCD3 XM_001495776 XP_001495826 1.15546 0.01093 
NULL DN510495 NULL -0.29115 0.001519 
NULL CX601100 NULL -0.63069 0.002934 
NULL CD528461 NULL -0.55488 0.003523 
NULL DN505730 NULL 0.466296 0.00446 
NULL XM_001498676 XP_001498726 -0.45457 0.008256 
NULL DN504496 NULL 0.308781 0.009264 
NULL CX593935 NULL -0.47838 0.010519 
NULL CX598740 NULL -0.44108 0.011666 
NULL XM_001501528 NULL -0.37123 0.012526 
NULL CD469043 NULL -0.36502 0.012804 
NULL CX604150 NULL -0.48215 0.013588 
NULL CD465841 NULL 1.03321 0.013937 
NULL CD465619 NULL 1.377777 0.016941 
NULL DN509075 NULL 0.334493 0.017014 
NULL CX599557 NULL 0.184822 0.018528 
NULL XM_001499079 XP_001499129 -0.26389 0.01992 
NULL XM_001502810 NULL 0.465699 0.020151 
NULL CD468792 NULL -0.4564 0.021556 
NULL CD535786 NULL -0.39812 0.022838 
NULL XM_001500869 NULL 0.604523 0.022854 
NULL XM_001500257 NULL 0.425431 0.023123 
NULL CX601539 NULL -0.36929 0.025992 
NULL CX597518 NULL -0.27243 0.028562 
NULL XR_035913 NULL 0.727238 0.030052 
NULL CD465531 NULL 0.570342 0.030387 
NULL DN505697 NULL 0.4977 0.030721 
NULL XM_001491362 XP_001491412 0.500122 0.034607 
NULL CX604208 NULL -0.24763 0.039409 
NULL CD466767 NULL -0.65138 0.039784 
NULL XM_001498702 NULL -0.19587 0.039845 
NULL CX592735 NULL 1.06049 0.040585 
NULL CX595725 NULL -0.17242 0.041027 
NULL XM_001493892 NULL -0.4473 0.044512 
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NULL CD468899 NULL 0.461399 0.044934 
NULL DN507862 NULL -0.2436 0.045068 
NULL DN509644 NULL -0.27954 0.045367 
NULL CD528231 NULL -0.15912 0.0458 
NULL CD471233 NULL -0.28895 0.046984 
NULL CX602929 NULL 0.236282 0.048182 
OBSL1 CX603384 NULL 0.168987 0.016025 
ODAM XM_001502141 XP_001502191 0.810894 0.04895 
OR11L1 XM_001498040 NULL -0.28901 0.039886 
OR13A1 XM_001497194 XP_001497244 -0.40502 0.02689 
OR1L6 XM_001500920 XP_001500970 0.339785 0.022104 
OR1N1 XM_001501095 XP_001501145 -0.38801 0.022541 
OR1N2 XM_001497814 XP_001497864 -0.46837 0.039316 
OR2B11 XM_001491893 XP_001491943 -0.37587 0.02802 
OR2L2 XM_001497233 XP_001497283 -0.3471 0.045558 
OR2L8 XM_001499037 NULL -1.05989 0.040685 
OR2T33 XM_001491345 NULL 0.455463 0.034616 
OR2W1 XM_001494282 XP_001494332 -0.27689 0.010633 
OR4A16 XM_001495905 NULL 0.461048 0.037763 
OR4C13 XM_001494731 XP_001494781 -0.25656 0.032483 
OR4D9 XM_001495337 NULL 0.411979 0.010305 
OR4F15 XM_001502286 XP_001502336 -0.34222 0.048646 
OR4F6 XM_001501987 XP_001502037 -0.33232 0.009043 
OR51E2 XM_001497263 XP_001497313 -0.39032 0.030857 
OR51F1 XM_001497409 XP_001497459 -0.32001 0.014553 
OR51I1 XM_001503971 XP_001504021 -0.69163 0.00464 
OR51I2 XM_001498875 XP_001498925 -0.42474 0.045744 
OR52E8 XM_001496727 XP_001496777 -0.40421 0.006407 
OR52H1 XM_001499184 XP_001499234 -0.3512 0.037118 
OR56A4 XM_001504516 XP_001504566 -0.51377 0.00155 
OR5AN1 XM_001495188 NULL -0.37522 0.016805 
OR5P2 XM_001500473 XP_001500523 0.520624 0.039874 
OR6F1 XM_001497005 XP_001497055 -0.31343 0.012326 
OR7D4 XM_001492422 XP_001492472 -0.36321 0.04777 
OR7G2 XM_001494401 XP_001494451 -0.31478 0.024895 
OR8B3 XM_001501921 NULL -0.67414 0.04426 
OR8G2 XM_001504708 XP_001504758 0.612418 0.006317 
OTUD7A XM_001492427 XP_001492477 -0.57488 0.048103 
PA2G4 XM_001504804 XP_001504854 0.180606 0.017067 
PAIP1 NULL NULL -0.45554 0.013471 
PARP12 XM_001496539 XP_001496589 0.386746 0.031737 
PARP9 XM_001500274 XP_001500324 -0.30472 0.037685 
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PCK1 XM_001489771 XP_001489821 -0.28663 0.011703 
PCP2 XM_001497385 XP_001497435 0.283109 0.042493 
PDCD2 NULL NULL 0.31781 0.00807 
PDIA5 XM_001500185 XP_001500235 0.377488 0.048379 
PHIP XM_001499042 XP_001499092 0.147767 0.044369 
PIGK XM_001496963 XP_001497013 -0.44345 0.037795 
PLA2G5 XM_001504348 XP_001504398 0.649197 0.04346 
PLCZ1 XM_001497766 XP_001497816 0.138929 0.01243 
PLD1 XM_001493497 XP_001493547 0.486716 0.030553 
PON3 XM_001493457 XP_001493507 0.515501 0.03836 
PPAPDC3 XM_001498987 XP_001499037 -0.23789 0.044791 
PPP1R14C XM_001494839 NULL 0.285711 0.045361 
PPP1R3B XM_001494371 XP_001494421 0.15679 0.019555 
PRAME XM_001493673 XP_001493723 -0.39663 0.021684 
PRL AY373339 NP_001075365 -0.17547 0.046162 
PRPF4 XM_001488863 XP_001488913 -0.279 0.004759 
PRPSAP2 XM_001488362 XP_001488412 -0.16628 0.010856 
PSD4 XM_001495883 XP_001495933 -0.2094 0.04351 
PTPRM NULL NULL 0.226717 0.037424 
PXDN XM_001503042 XP_001503092 0.116257 0.032477 
RAB39 XM_001501007 XP_001501057 0.549373 0.012879 
RAB39B XM_001494307 XP_001494357 -0.10424 0.027871 
RAB3GAP1 XM_001489470 XP_001489520 -0.30066 0.032446 
RALGDS XM_001499958 NULL -0.38399 0.021835 
REG3G XM_001498156 XP_001498206 -0.26075 0.04973 
RNF214 XM_001502611 XP_001502661 -0.56143 0.031646 
RNF5 XM_001493452 XP_001493502 0.406873 0.034111 
RPL13A XM_001491876 XP_001491926 1.098955 0.007167 
RPLP1 BM735439 XP_001495775 1.129718 0.034464 
RPS3A XM_001490864 NULL -2.85316 0.012516 
RS1 XM_001491183 XP_001491233 0.315318 0.021948 
RSPO1 NM_001109680 NULL -0.14898 0.037349 
RWDD2A XM_001503673 XP_001503723 -0.39351 0.001959 
S100A2 CX598422 XP_001494717 -0.19795 0.01097 
SAMHD1 XM_001499498 XP_001499548 -0.27837 0.046675 
SAMM50 XM_001487978 XP_001488028 -0.40458 0.035037 
SAP30 XM_001496719 NULL -0.2628 0.042692 
SCAPER XM_001493099 XP_001493149 -0.12499 0.04387 
SCARF1 XM_001502293 XP_001502343 0.20805 0.046395 
SENP8 XM_001494920 XP_001494970 -0.41429 0.007808 
SERF2 XM_001500420 XP_001500470 -0.36623 0.006826 
SERINC5 XM_001503874 XP_001503924 0.530289 0.017862 
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SERPINA10 XM_001495713 XP_001495763 -0.1858 0.039105 
SET XM_001500465 XP_001500515 -0.27252 0.031999 
SF3B3 XM_001500830 XP_001500880 -0.34426 0.049369 
SFT2D2 XM_001490765 NULL -0.47 0.002692 
SGSM1 XM_001496176 XP_001496226 0.686988 0.034193 
SH2D1A XM_001500705 XP_001500755 0.843763 0.022965 
SH3BGRL XM_001501152 XP_001501202 -0.27699 0.017623 
SIGLEC14 XM_001496296 XP_001496346 0.558058 0.023767 
SLC12A3 XM_001502571 XP_001502621 -0.27738 0.007552 
SLC19A1 XM_001489728 XP_001489778 -0.13466 0.019581 
SLC19A2 XM_001491417 XP_001491467 -0.51867 0.001575 
SLC19A3 XM_001494151 XP_001494201 -0.15146 0.02431 
SLC22A10 XM_001502945 XP_001502995 -0.34629 0.045415 
SLC25A1 XM_001488569 XP_001488619 0.909841 0.035852 
SLC25A13 XM_001494425 XP_001494475 -0.47302 0.005013 
SLC25A21 XM_001492015 XP_001492065 0.684545 0.005823 
SLC35B2 XM_001497724 XP_001497774 -0.41621 0.02852 
SLC38A3 XM_001493826 XP_001493876 -0.37242 0.029497 
SLC5A9 XM_001493060 XP_001493110 0.348062 0.049513 
SLC6A8 XM_001491633 XP_001491683 -0.64555 0.015277 
SLC7A4 XM_001488939 XP_001488989 -0.44285 0.035664 
SLITRK2 XM_001489935 XP_001489985 -0.14116 0.047933 
SNTB2 XM_001497135 XP_001497185 -0.25643 0.045952 
SPDYA XM_001501882 XP_001501932 -0.41586 0.023565 
SPHK1 XM_001491689 XP_001491739 -0.70335 0.023337 
SRPR XM_001505096 XP_001505146 -0.49765 0.043499 
SSRP1 XM_001497090 XP_001497140 -0.19474 0.047947 
ST6GALNAC1 XM_001491565 XP_001491615 -0.40615 0.008992 
STEAP2 XM_001490032 XP_001490082 -0.44215 0.010366 
STX4 XM_001500858 XP_001500908 -0.32273 0.034489 
SYNE1 XM_001494275 XP_001494325 -0.26684 0.004585 
TBC1D16 XM_001490266 XP_001490316 -0.54206 0.026315 
TBX5 NULL NULL -0.52174 0.0013 
TEGT XM_001504223 XP_001504273 0.468953 0.043829 
TFF1 XM_001492483 NULL 0.441392 0.032853 
TFPI2 XM_001492769 XP_001492819 0.759563 0.001558 
THOP1 XM_001493535 XP_001493585 -0.14155 0.049053 
TIMM50 XM_001497601 XP_001497651 -0.44141 0.008628 
TMEM165 XR_035951 NULL 0.669001 0.021421 
TMEM16B XM_001495269 NULL 0.927352 0.04374 
TMEM34 XM_001501751 XP_001501801 -0.49327 0.005171 
TMEM5 NULL NULL 0.436213 0.029007 
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TMEM71 XM_001499201 XP_001499251 -0.48856 0.005713 
TMEM95 XM_001503064 XP_001503114 -0.39681 0.011393 
TMLHE XM_001498280 XP_001498330 -0.33467 0.037921 
TNNI2 NULL NULL 0.139645 0.026048 
TPPP XM_001490990 NULL -0.19321 0.004547 
TRIM56 XM_001492494 XP_001492544 0.320604 0.043302 
TSC22D2 XM_001490871 XP_001490921 0.195608 0.04065 
TSGA13 XM_001498542 XP_001498592 -0.13727 0.029294 
TTC17 XM_001489510 XP_001489560 -0.33285 0.015094 
TTC25 XM_001496697 XP_001496747 0.30507 0.029763 
TTLL9 XM_001498331 XP_001498381 -0.18292 0.015844 
TYRP1 NM_001081840 NULL -0.66742 0.007644 
UBE2N XM_001495374 XP_001495424 -1.74569 0.002091 
UBTD2 XM_001499628 XP_001499678 0.483573 0.008712 
UGT2A2 XM_001494284 XP_001494334 -0.15248 0.046386 
UNC93B1 XR_035965 NULL 0.282473 0.024055 
UPK2 XM_001503043 XP_001503093 -0.40456 0.002742 
USF2 XM_001491920 NULL -0.47331 0.045332 
USP1 XM_001500051 XP_001500101 -0.49472 0.001116 
USP38 XM_001502129 XP_001502179 -0.21656 0.004716 
USP42 XM_001493859 XP_001493909 -0.19497 0.016539 
USP54 XM_001503894 XP_001503944 -0.30721 0.047272 
VIPR1 XM_001501612 XP_001501662 -0.28388 0.035524 
VN1R4 XM_001495698 NULL -0.57247 0.040558 
VPS33B XM_001498840 XP_001498890 -0.33929 0.034143 
VSNL1 XM_001503420 XP_001503470 -0.31373 0.042909 
VTCN1 XM_001496634 XP_001496684 0.783792 0.049895 
WDR21A XM_001488663 XP_001488713 -0.41757 0.028748 
WDR52 XM_001501172 XP_001501222 -0.26123 0.040596 
ZCCHC11 XM_001490378 NULL 0.473504 0.03041 
ZDHHC19 XM_001489984 XP_001490034 -0.38606 0.018775 
ZNHIT1 XM_001504461 XP_001504511 1.509699 0.015572 
ZNRF2 XM_001499541 NULL 0.810946 0.049486 
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Table B-1: List of differentially expressed genes (pvalue <0.05 and fold change cut off 
of 1.2) for the allergen avoidance group at the 6-month time point compared to the 
baseline.  
 
Gene symbol NCBI accession RefSeq accession Log fold change Pvalue 
ABCD2 XM_001500065.1 NP_005155.1 0.543212126 0.00314231 
ABLIM2 XM_001500021.1 NP_115808.3 0.677512087 0.020290061 
ARPC1B gnl|UG|Eca#S38804028 NP_005711.1 -0.376571797 0.028054279 
ATAD2 XM_001497188.1 NP_054828.2 -0.354280817 0.024231517 
BCDIN3D PLT2-K07-M13.rgy.ab1 NP_859059.1 0.289543332 0.009246751 
BMPER CT020026B20C12.ab1 NP_597725.1 0.403951188 0.043768533 
C11orf49 XM_001504556.1 NP_001003678.1 -0.33955333 0.020296705 
C4orf20 XM_001490682.1 NP_060829.1 0.409527582 0.023476216 
C9orf32 gnl|UG|Eca#S36623675 NP_054783.2 0.311728573 0.02509001 
C9orf58 XM_001499384.1 NP_113614.1 0.331954857 0.025187153 
CCR8 XM_001501979.1 NP_005192.1 0.613960619 0.039725657 
CEACAM21 XM_001499625.1 NP_001091976.1 -0.384337534 0.027788263 
CES7 XM_001493427.1 NP_659461.1 0.285658878 0.044231286 
CHI3L1 XM_001496500.1 NP_001267.2 -0.272012954 0.0318671 
CNR1 XM_001503748.1 NP_057167.2 0.363496686 0.036363576 
COL1A1 gnl|UG|Eca#S38811517 NP_000079.2 -0.336239966 0.041266243 
COL5A1 XR_036195.1 NP_000084.3 -0.498584475 0.001203738 
CYP26A1 XM_001502498.1 NP_000774.2 0.580617922 0.038492287 
DDIT4L XM_001497203.1 NP_660287.1 0.620062855 0.043476285 
EXDL1 XM_001503479.1 NP_689809.2 0.263419084 0.002082851 
FAM55D XM_001500547.1 NP_001071107.1 0.769514223 0.045056788 
FBXO3 XM_001503169.1 NP_036307.2 0.28718879 0.003587882 
GLMN XM_001492771.1 NP_444504.1 0.331989739 0.02605657 
HEG1 XM_001500006.1 NP_065784.1 -0.339816247 0.039705444 
IDH2 gnl|UG|Eca#S36647263 NP_002159.2 0.501759049 0.039440607 
IFNA5 XM_001497241.1 NP_002160.1 -0.308724595 0.00895384 
LOC390667 XM_001497697.1 NP_001013680.1 -0.298598347 0.028592265 
LOC401498 XM_001498934.1 NP_997723.2 -0.411060422 0.010703433 
LOC651536 XM_001493483.1 XP_945805.1 -0.666988701 0.029417463 
LOC731062 XM_001492904.1 XP_001131736.1 0.319183634 0.018260396 
LRRN2 XM_001489200.1 NP_006329.2 -0.340379568 0.01728978 
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MICB XM_001489019.1 NP_005922.1 -0.265053257 0.034926214 
MMP16 gnl|UG|Eca#S38813088 NP_005932.2 0.559137515 0.037595674 
MSH6 XM_001497961.1 NP_000170.1 0.320836095 0.02735467 
NECAP1 XM_001498661.1 NP_056324.2 -0.347999738 0.01778941 
NULL PLT13-N11-M13.rgy.ab1 NULL -0.406730322 0.031608479 
NULL PLT23-K17-M13R.ab1 NULL -0.369398293 0.016401671 
NULL PLT28-N04-M13R.ab1 NULL -0.366478368 0.005094035 
NULL CT020011B20C03.ab1 NULL -0.313842563 0.026635145 
NULL PLT23-I09-M13R.ab1 NULL -0.291604956 0.049176711 
NULL GENE:6874 NULL -0.283947524 0.04959469 
NULL gnl|UG|Eca#S36628683 NULL 0.970314344 0.028420189 
NULL gnl|UG|Eca#S36643246 NULL 0.921816067 0.046960164 
NULL gnl|UG|Eca#S36637094 NULL 0.736564792 0.042292168 
NULL CT020015B20G04.ab1 NULL 0.475961622 0.038686166 
NULL GENE:3536 NULL 0.457990106 0.040744011 
NULL CT020026A20B09.ab1 NULL 0.377637901 0.048473522 
NULL gnl|UG|Eca#S36631924 NULL 0.376598008 0.025966309 
NULL gnl|UG|Eca#S36648412 NULL 0.373080403 0.007888671 
NULL CT02039A2G09.f1 NULL 0.360645843 0.020379178 
NULL gnl|UG|Eca#S36621081 NULL 0.357902459 0.007940736 
NULL CT020009A10C05.ab1 NULL 0.355663859 0.037079901 
NULL CT020026B20C09.ab1 NULL 0.336328697 0.043696084 
NULL gnl|UG|Eca#S36643360 NULL 0.306007238 0.020165834 
NULL CT020003B10F09.ab1 NULL 0.300084051 0.04183679 
NULL gnl|UG|Eca#S36656141 NULL 0.29112614 0.028379226 
NULL CT020019B10E05.ab1 NULL 0.286928357 0.047067626 
NULL PLT14-I23-M13.rgy.ab1 NULL 0.27483269 0.035968507 
OR2G3 XM_001494102.1 NP_001001914.1 0.307988982 0.013632558 
OR4D9 XM_001497973.1 NP_001004711.1 0.351569639 0.014130893 
OR4F15 XM_001501753.1 NP_001001674.1 0.267059362 0.025106721 
OR5B12 XM_001497597.1 NP_001004733.1 0.491741981 0.008103244 
OR5K1 XM_001503633.1 NP_001004736.2 0.262952948 0.030612798 
PLCD4 57.1D7.ab1 NP_116115.1 0.408784512 0.031807758 
RBM39 gnl|UG|Eca#S38807635 NP_909122.1 0.273556978 0.002457149 
RER1 gnl|UG|Eca#S38802589 NP_008964.3 0.29532706 0.021686433 
RNF126 HL010007000_PLT_E05_37_035.ab1 NP_919442.1 0.775341424 0.015551486 
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SART3 gnl|UG|Eca#S36643775 NP_055521.1 0.715509095 0.00852801 
SLC10A6 gnl|UG|Eca#S38816407 NP_932069.1 0.552355404 0.021698064 
SLC25A1 XM_001488569.1 NP_005975.1 0.456004235 0.048270947 
SLC25A20 XM_001494717.1 NP_000378.1 0.266579915 0.046006043 
ST18 XM_001488723.1 NP_055497.1 0.272580956 0.047967511 
TANC1 XM_001492390.1 NP_203752.1 0.290972244 0.042981327 
TCP11 XM_001488694.1 NP_001087197.1 0.350016094 0.018556604 
TMEM119 XM_001497020.1 NP_859075.1 -0.381115876 0.028157787 
TMEM146 XM_001495780.1 NP_689997.3 0.296576744 0.046247313 
TMEM20 XM_001500819.1 NP_694958.1 0.310930821 0.014345293 
TMEM32 gnl|UG|Eca#S36644504 NP_775741.1 0.337175928 0.018749655 
TPH1 XM_001504954.1 NP_004170.1 2.560315857 0.032021814 
TXNRD3 XM_001492751.1 XP_001129642.1 0.370439929 0.027706263 
UQCRB gnl|UG|Eca#S36649002 NP_006285.1 0.643201539 0.030838074 
VIM gnl|UG|Eca#S36646726 NP_003371.2 0.29369645 0.012811472 
WHSC2 XR_035785.1 NP_005654.2 0.831955918 0.033870998 
ZBTB41 XM_001492621.1 NP_919290.2 0.467702871 0.009727874 
#N/A gnl|UG|Eca#S38817907-5 #N/A -0.320492001 0.007206627 
     
 
 
 
Table B-2: List of differentially expressed genes (pvalue <0.05 and fold change cut off 
of 1.2) for the allergen avoidance group at the 12-month time point compared to the 
baseline.  
 
Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
ABCD2 XM_001500065.1 NP_005155.1 0.40969935 0.045783307 
ACVR1C XM_001492118.1 NP_660302.2 0.291369039 0.027678903 
ACVR2A XM_001487856.1 NP_001607.1 0.290823504 0.011215241 
ACY1 XM_001492838.1 NP_000657.1 0.467900827 0.038050363 
ALOX5AP gnl|UG|Eca#S36633997 NP_001620.2 -0.351566627 0.04693036 
ANKS6 XM_001494967.1 NP_775822.3 -0.291347267 0.011006065 
ARL6IP1 gnl|UG|Eca#S36627808 NP_055976.1 -0.394492117 0.045079062 
ASPH gnl|UG|Eca#S38812993 NP_004309.2 -0.305085935 0.028897772 
ATG5 XM_001503938.1 NP_004840.1 0.402235148 0.022017641 
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B4GALT3 XM_001496370.1 NP_003770.1 -0.847461482 0.038340565 
BTC XM_001490427.1 NP_001720.1 -0.609231561 0.00395858 
C11orf77 XM_001489899.1 NP_776172.1 -0.455146038 0.017998903 
C1orf101 XM_001493885.1 NP_776168.1 0.589928364 0.030102937 
C20orf112 XR_036251.1 NP_542183.1 -0.397186329 0.006774664 
C20orf149 XM_001492738.1 NP_077275.1 -0.404123179 0.013764418 
C5AR1 gnl|UG|Eca#S38812641 NP_001727.1 -0.457864356 0.016127144 
C7orf30 gnl|UG|Eca#S38815874 NP_612455.1 -0.399516428 0.005881025 
CALR gnl|UG|Eca#S38803287 NP_004334.1 0.343841179 0.015603193 
CBLB gnl|UG|Eca#S38808556 NP_733762.2 -0.447426274 0.033829988 
CD99 gnl|UG|Eca#S38802284 NP_002405.1 -0.461838978 0.033074303 
CENPE XR_036279.1 NP_001804.2 -0.294970116 0.028019544 
COL5A1 XR_036195.1 NP_000084.3 0.509763626 0.028522014 
COLEC10 XM_001496392.1 NP_006429.1 0.3438898 0.04355867 
COX7A2L gnl|UG|Eca#S38810038 NP_004709.2 -0.824165853 0.004657017 
CYHR1 CT02037A2H11.f1.ab1 NP_116076.1 -0.307511615 0.01007686 
CYP46A1 XM_001488041.1 NP_006659.1 -0.460089861 0.020815775 
DDC XM_001498321.1 NP_000781.1 -0.462577585 0.006834673 
DGAT1 gnl|UG|Eca#S38802930 NP_036211.2 -0.323169318 0.018287914 
EIF3CL gnl|UG|Eca#S36653864 XP_001132506.1 -0.299479208 0.044982147 
ENTPD4 XM_001492944.1 NP_004892.1 -0.421062419 0.045081081 
FOXJ3 XM_001503156.1 NP_055762.3 -0.263461621 0.013186881 
GABRD XM_001495250.1 NP_000806.2 0.369108427 0.018001073 
GNL1 gnl|UG|Eca#S38804347 NP_005266.2 0.354121187 0.032106865 
HES7 XM_001504807.1 NP_115969.2 -0.360550084 0.043853143 
HK3 XM_001498546.1 NP_002106.1 -0.311041866 0.037821183 
HMGB3 gnl|UG|Eca#S38802843 NP_005333.2 -0.300867993 0.023191301 
HP1BP3 gnl|UG|Eca#S38817368 NP_057371.2 0.273742855 0.048254151 
IMPACT XM_001494845.1 NP_060909.1 -0.559858234 0.041418476 
ITGA9 gnl|UG|Eca#S38809311 NP_002198.2 0.678002428 0.030125014 
IZUMO1 XM_001489113.1 NP_872381.1 -0.539087838 0.031990288 
KCNH1 PLT27-L02-M13R.ab1 NP_758872.1 -0.591165082 0.047605705 
KCNJ1 XM_001502563.1 NP_000211.1 -0.337393485 0.034155051 
KIAA0922 XM_001499727.1 NP_056011.2 -0.361871265 0.047419125 
LASS4 XM_001497105.1 NP_078828.1 0.395596357 0.013145545 
LOC651536 XM_001492876.1 XP_945805.1 -0.632623667 0.00451103 
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LPXN XM_001504694.1 NP_004802.1 0.34023857 0.032394747 
LYG1 XM_001490374.1 NP_777558.1 -0.441822398 0.035412525 
Magmas SM0055-3_H03_15.ab1 NP_057153.8 -0.625081511 0.02961981 
MCM2 XM_001488780.1 NP_004517.2 0.44615205 0.033032606 
MMEL1 gnl|UG|Eca#S36656591 NP_258428.1 0.578569043 0.027829084 
NAGK gnl|UG|Eca#S38810098 NP_060037.2 -0.936832447 0.046628265 
NFKBIZ gnl|UG|Eca#S38808389 NP_113607.1 -0.275592895 0.041197522 
NNT gnl|UG|Eca#S38807862 NP_036475.3 -0.651475697 0.004067085 
NULL gnl|UG|Eca#S36623227 NULL -1.360892039 0.007639309 
NULL gnl|UG|Eca#S36654383 NULL -0.992605919 0.033239645 
NULL CT02038B2H06.f1.ab1 NULL -0.939596001 0.04486265 
NULL gnl|UG|Eca#S36646192 NULL -0.833187459 0.033745737 
NULL Un0130.1-277067:31850-32161:+ NULL -0.725541772 0.028161699 
NULL CT020018B10B01.ab1 NULL -0.680779948 0.043954501 
NULL CT020027B20F07.ab1 NULL -0.664459257 0.01414391 
NULL gnl|UG|Eca#S36648412 NULL -0.641702962 0.003848606 
NULL SM0050-1_A07_01.ab1 NULL -0.641137965 0.01685251 
NULL gnl|UG|Eca#S36640829 NULL -0.622977727 0.03555097 
NULL CT020014A10H02.ab1 NULL -0.5866769 0.009861336 
NULL gnl|UG|Eca#S36654519 NULL -0.585329082 0.022046166 
NULL HL02016A1E03.ab1 NULL -0.564230003 0.038813648 
NULL gnl|UG|Eca#S36642828 NULL -0.532377921 0.021864062 
NULL PLT19-P12-M13.rgy.ab1 NULL -0.525777683 0.044093419 
NULL PLT21-E09-M13R.ab1 NULL -0.512571794 0.035504693 
NULL PLT32-I04-M13R.ab1 NULL -0.500980851 0.034005617 
NULL CT020023B20H02.ab1 NULL -0.490294472 0.001643801 
NULL CT020008A10F11.ab1 NULL -0.471270424 0.045189182 
NULL CT020010A10D08.ab1 NULL -0.463108383 0.030037042 
NULL gnl|UG|Eca#S36646700 NULL -0.443609218 0.04386729 
NULL HL02020B1F01.ab1 NULL -0.433672813 0.02666155 
NULL CT020007B10C10.ab1 NULL -0.420944123 0.022998606 
NULL HL02022A1F03.ab1 NULL -0.39433484 0.033672853 
NULL gnl|UG|Eca#S36654359 NULL -0.381586079 0.03643111 
NULL HL01015B1D11.ab1 NULL -0.372343078 0.037761263 
NULL CT02039A2G10.f1 NULL -0.370536944 0.028623979 
NULL gnl|UG|Eca#S36649669 NULL -0.364902676 0.019739539 
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NULL CT020021A10F04.ab1 NULL -0.363042932 0.022901469 
NULL CT020005A10_PLT_H05_40_046.ab1 NULL -0.356228059 0.047351836 
NULL gnl|UG|Eca#S36644977 NULL -0.337704434 0.018890025 
NULL CT02038A2B04.f1.ab1 NULL -0.332412978 0.018893431 
NULL SM0053-1_F09_11.ab1 NULL -0.332407881 0.033205166 
NULL gnl|UG|Eca#S36655383 NULL -0.329006526 0.034382763 
NULL CT020022A10D01.ab1 NULL -0.308752861 0.049057862 
NULL PLT11-P20-M13.rgy.ab1 NULL -0.305522448 0.021260029 
NULL gnl|UG|Eca#S36645566 NULL -0.300543534 0.042242311 
NULL HL02020B2H10.ab1 NULL -0.299012177 0.049686307 
NULL CT020012A20A10.ab1 NULL -0.296980144 0.021225474 
NULL CT020020A20D04.ab1 NULL -0.282193277 0.02041472 
NULL gnl|UG|Eca#S36653234 NULL -0.275654193 0.048194285 
NULL gnl|UG|Eca#S36626566 NULL -0.27136633 0.028709229 
NULL CT020003A10_PLT_H07_56_063.ab1 NULL -0.262602224 0.026219512 
NULL gnl|UG|Eca#S36647872 NULL 0.533754875 0.0484944 
NULL PLT14-H13-M13.rgy.ab1 NULL 0.35358225 0.003500126 
NULL PLT25-P19-M13R.ab1 NULL 0.330403885 0.041989336 
NULL GENE:19132 NULL 0.275109569 0.034854859 
NULL PLT29-G23-M13R.ab1 NULL 0.274790248 0.002505995 
NULL CT020020B20D02.ab1 NULL 0.267412744 0.030670913 
NULL gnl|UG|Eca#S36646288 NULL 0.261141729 0.022576852 
OLFM3 XM_001488106.1 NP_477518.1 -1.215618638 0.034524701 
OR10G7 XM_001491717.1 NP_001004463.1 0.368643912 0.014457974 
OR10G9 XM_001504677.1 NP_001001953.1 0.336078291 0.046647953 
OR1E1 XM_001501011.1 NP_003544.2 -0.307998169 0.012266409 
OR1F1 XM_001497945.1 NP_036492.1 0.393202854 0.002551987 
OR2F2 XM_001503021.1 NP_001004685.1 -0.317604272 0.016481163 
OR2T1 XM_001496591.1 NP_112166.1 -0.273516536 0.00483788 
OR2T1 XM_001488476.1 NP_112166.1 0.294382964 0.003772257 
OR2Y1 XM_001494154.1 NP_001001657.1 -0.284367365 0.021366227 
OR4A15 XM_001490213.1 NP_001005275.1 -0.519685212 0.0425957 
OR4P4 XM_001488616.1 NP_001004124.1 0.287336502 0.038577359 
OR52A5 XM_001504149.1 NP_001005160.1 0.283370289 0.019615661 
OR6C2 XM_001489614.1 NP_473446.1 -0.41802156 0.021947461 
OR6N2 XM_001490459.1 NP_001005278.1 -0.284979532 0.032580901 
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OR7A17 XM_001494078.1 NP_112163.1 -0.343628694 0.020952282 
OR8S1 XM_001490794.1 NP_001005203.2 0.288700567 0.004044799 
PAPPA2 XM_001498222.1 NP_064714.2 -0.582260453 0.049565939 
PES1 gnl|UG|Eca#S36631489 NP_055118.1 -0.653893375 0.014009811 
PITPNB gnl|UG|Eca#S38813557 NP_036531.1 -0.277173914 0.049711508 
PNLIPRP1 XM_001497716.1 NP_006220.1 -0.331005349 0.009197281 
PPM1A gnl|UG|Eca#S38807088 NP_066283.1 -0.30480297 0.033081891 
PPM1F XM_001491065.1 NP_055449.1 -0.343607969 0.025012125 
PQLC1 XM_001494788.1 NP_079354.2 -1.31338984 0.041362933 
PRICKLE4 XM_001501174.1 NP_037529.3 -0.363642629 0.034920256 
PROM2 CT02040B1G11.f1.ab1 NP_653308.1 -0.461571851 0.039715859 
PSCD1 gnl|UG|Eca#S38812041 NP_059430.2 -0.449073598 0.048580054 
PTTG1IP gnl|UG|Eca#S36644223 NP_004330.1 -0.529919075 0.032791313 
RAB38 XM_001489498.1 NP_071732.1 -0.502473944 0.048613667 
RALGDS CT02034A1D05.f1.ab1 NP_006257.1 -0.319527164 0.025028705 
RASGEF1A XM_001490265.1 NP_660356.2 -0.619346879 0.017324711 
RAVER1 gnl|UG|Eca#S38803970 NP_597709.2 0.349038972 0.018726222 
RPL29 gnl|UG|Eca#S36654195 NP_000983.1 -0.30938851 0.001484597 
SCYL1 gnl|UG|Eca#S36644614 NP_065731.3 -0.445199637 0.012151429 
SIGLEC5 XM_001497073.1 NP_003821.1 -0.404780394 0.0394426 
SLC2A2 gnl|UG|Eca#S36656765 NP_000331.1 -0.486633155 0.015343175 
SLC44A4 XM_001492369.1 NP_079533.2 0.464773938 0.039763669 
SMCR8 XM_001488509.1 NP_658988.2 0.285088783 0.018253681 
SNRPG HL010001001_HL010_E09_69_067.ab1 NP_003087.1 -0.271854597 0.032751433 
SRCAP gnl|UG|Eca#S38810945 NP_006653.2 -0.294838444 0.04308922 
TCEA1 XM_001489406.1 NP_006747.1 0.491390838 0.033216647 
TCP11L1 XM_001492539.1 NP_060863.2 0.363327472 0.036354286 
TMED4 XR_036138.1 NP_872353.2 -0.265628834 0.013800977 
TMEM86B XM_001489645.1 NP_776165.2 0.511078446 0.033635612 
TMEM97 gnl|UG|Eca#S36645870 NP_055388.2 -0.38294 0.03388555 
TNFSF4 XM_001492820.1 NP_003317.1 0.598301343 0.031701916 
TRSPAP1 gnl|UG|Eca#S38817207 NP_060316.1 0.513620933 0.048994823 
TTC1 gnl|UG|Eca#S38810759 NP_003305.1 -0.447531969 0.005199526 
UCRC gnl|UG|Eca#S36652606 NP_037519.2 -0.44626764 0.027284228 
ULBP3 XM_001495280.1 NP_078794.1 -0.441949677 0.035434647 
VAT1 XM_001496194.1 NP_006364.2 0.26822596 0.030230202 
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XPO7 XM_001490507.1 NP_001093632.1 1.236593078 0.041144528 
ZDHHC18 XM_001500713.1 NP_115659.1 0.275813669 0.042122786 
#N/A gnl|UG|Eca#S36657275-5 #N/A -0.560442757 0.01853162 
#N/A gnl|UG|Eca#S38809257Con #N/A 0.374512249 0.009033948 
 
 
 
Table B-3: List of differentially expressed genes (pvalue <0.05 and fold change cut off 
of 1.2) for the treatment group at the 6-month time point compared to the baseline.  
 
Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
ACSM5 XM_001488143.1 NP_060358.2 0.739795183 0.015316929 
AGXT2L2 gnl|UG|Eca#S38810526 NP_699204.1 -0.515388946 0.030155412 
ALDH18A1 XR_036392.1 NP_001017423.1 -0.374921374 0.035600462 
ATAD2 XM_001497188.1 NP_054828.2 -0.735905575 0.031827353 
C1orf101 XM_001493885.1 NP_776168.1 -1.451517094 0.011137653 
COPB2 gnl|UG|Eca#S38809205 NP_004757.1 0.454695781 0.042822909 
FLJ12993 XM_001493769.1 NP_001073975.1 -0.314912101 0.049840755 
ITGA9 gnl|UG|Eca#S38809311 NP_002198.2 -0.649043176 0.023983129 
MC5R XM_001490598.1 NP_005904.1 0.442723598 0.020721254 
MFSD7 XM_001488157.1 NP_115595.2 -0.827526786 0.016306331 
NULL CT02042A1C04.f1.ab1 NULL -1.520223013 0.03924965 
NULL CT020018A20F12.ab1 NULL -0.971435263 0.040183324 
NULL gnl|UG|Eca#S36645692 NULL -0.680466351 0.036672763 
NULL CT020010B10C07.ab1 NULL -0.494719269 0.047457817 
NULL HL01015B2D01.ab1 NULL -0.481382276 0.03113615 
NULL PLT13-N10-M13.rgy.ab1 NULL -0.402842368 0.033017123 
NULL gnl|UG|Eca#S36631680 NULL -0.349867276 0.01966565 
NULL CT02038A2G04.f1.ab1 NULL -0.291083523 0.018663776 
NULL PLT25-P19-M13R.ab1 NULL -0.276235302 0.039766821 
NULL gnl|UG|Eca#S36648438 NULL 0.965201075 0.028865786 
NULL SM0049-3_B09_03.ab1 NULL 0.475300715 0.020100789 
OR2T4 XM_001487944.1 NP_001004696.1 -0.82464822 0.022325799 
OR4A47 XM_001495702.1 NP_001005512.2 -1.066751575 0.017889806 
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PITPNB gnl|UG|Eca#S38813557 NP_036531.1 0.260712929 0.023882242 
RHOG XM_001496655.1 NP_001656.2 -0.887180953 0.04005589 
RUVBL2 gnl|UG|Eca#S38802810 NP_006657.1 -1.05131447 0.026372273 
SCG5 gnl|UG|Eca#S38817793 NP_003011.1 -2.142916489 0.046514415 
THOC4 XM_001489439.1 XP_001134346.1 -0.920545861 0.014848621 
TMEM86B XM_001489645.1 NP_776165.2 -0.418218971 0.004210093 
UBE2G2 XM_001490079.1 NP_003334.2 -0.323545409 0.011366118 
ZNF423 XM_001491336.1 NP_055884.2 -0.469505686 0.047100168 
 
 
 
Table B-4: List of differentially expressed genes (pvalue <0.05 and fold change cut off 
of 1.2) for the treatment group at the 12-month time point compared to the baseline.  
 
Gene Symbol NCBI accession RefSeq accession 
Log fold 
change Pvalue 
ACTL7B XM_001492641.1 NP_006677.1 0.302918202 0.01217914 
APOE XR_036412.1 NP_000032.1 0.310599988 0.036883944 
ATP11A XM_001497096.1 NP_056020.2 -0.337743215 0.026938917 
ATP8A2 XM_001492094.1 NP_057613.4 0.344086701 0.016074615 
BANK1 XM_001497747.1 NP_060405.3 0.494542628 0.02996333 
C14orf172 gnl|UG|Eca#S38806821 NP_689520.2 0.304748 0.001728088 
C16orf35 XM_001496679.1 NP_001070818.1 -0.306521565 0.008785123 
C2orf66 XM_001500103.1 NP_998773.1 -0.736508874 0.039020891 
C6orf136 XM_001489684.1 NP_001103408.1 0.278247739 0.036952674 
C9orf58 XM_001499384.1 NP_113614.1 0.329767229 0.015163379 
CASR gnl|UG|Eca#S38808589 NP_000379.2 0.266674186 0.008222488 
CLEC9A CT02040B1A04.f1.ab1 NP_997228.1 0.786406638 0.004948974 
D15Wsu75e XM_001500344.1 NP_056519.1 -0.288245791 0.03931723 
DBNDD1 XM_001488503.1 NP_001036075.1 0.309203657 0.0299733 
DGAT2 gnl|UG|Eca#S38813894 NP_115953.2 -0.278654126 0.021050866 
EDIL3 gnl|UG|Eca#S38810337 NP_005702.3 0.379304087 0.03414137 
EPB41L5 XM_001492466.1 NP_065960.2 0.26395503 0.011585303 
FAHD1 XM_001497855.1 NP_112485.1 -0.504821137 0.045547497 
FAM14A gnl|UG|Eca#S38806857 NP_114425.1 0.321211605 0.004283862 
GAPDH XR_035875.1 NP_002037.2 -0.335626721 0.027297636 
IPO13 XM_001496543.1 NP_055467.2 -0.374947984 0.006946382 
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ITGA9 gnl|UG|Eca#S38809311 NP_002198.2 -0.616233248 0.011042576 
KLRC1 XM_001494234.1 NP_002250.1 0.332014225 0.004155855 
MCM4 gnl|UG|Eca#S38812968 NP_005905.2 -0.405488793 0.01305292 
MCM5 gnl|UG|Eca#S38805899 NP_006730.2 0.377731922 0.033241646 
MTA2 gnl|UG|Eca#S38811148 NP_004730.2 0.43431311 0.009210879 
NULL CT02034B2C11.f1.ab1 NULL -0.435011035 0.028349656 
NULL PLT7-A17-M13.rgy.ab1 NULL -0.352116773 0.019118938 
NULL SM0049-1_C06_06.ab1 NULL -0.327381154 0.046064752 
NULL gnl|UG|Eca#S36623681 NULL -0.278208242 0.024749417 
NULL gnl|UG|Eca#S36646288 NULL -0.271386729 0.017190892 
NULL CT020007B20G07.ab1 NULL -0.270694792 0.04095818 
NULL HL010008000_PLT_A03_17_017.ab1 NULL 1.554327386 0.017236597 
NULL CT020020B10C01.ab1 NULL 0.601976634 0.0157602 
NULL HL01019B2D08.ab1 NULL 0.522761238 0.049273337 
NULL CT020027A20A06.ab1 NULL 0.435078451 0.026515836 
NULL Un0595.1-16114:6979-10788:- NULL 0.43309721 0.019510688 
NULL CT020020B10H03.ab1 NULL 0.418351547 0.027166219 
NULL CT020010B20B04.ab1 NULL 0.41453717 0.046928578 
NULL HL020003000_PLT_B02_10_013.ab1 NULL 0.397544208 0.006285186 
NULL CT020017B10B08.ab1 NULL 0.395252221 0.006121267 
NULL gnl|UG|Eca#S36625500 NULL 0.380809512 0.005449418 
NULL CT020026B20C09.ab1 NULL 0.378078674 0.024265649 
NULL HL02017A1B03.ab1 NULL 0.376273682 0.021739018 
NULL GENE:22350 NULL 0.343244068 0.023666006 
NULL CT02032A2E05.f1.ab1 NULL 0.336940934 0.003297009 
NULL gnl|UG|Eca#S36630542 NULL 0.311618149 0.042315911 
NULL gnl|UG|Eca#S36654519 NULL 0.305935266 0.021731965 
NULL PLT29-B21-M13R.ab1 NULL 0.282926868 0.004463238 
NULL gnl|UG|Eca#S36644914 NULL 0.28048793 0.030036968 
NULL Un0435.1-19795:12872-13609:+ NULL 0.275631338 0.009613747 
NULL CT020026A20B09.ab1 NULL 0.27500797 0.027482192 
NULL XM_001491658.1 NULL 0.272364574 0.007943113 
OR10V1 XM_001492887.1 NP_001005324.1 -0.287004699 0.040998633 
OR11H6 XM_001505127.1 NP_001004480.1 -0.281997553 0.04471254 
OR51F2 XM_001497442.1 NP_001004753.1 -0.326967497 0.047984931 
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OR52D1 XM_001498223.1 NP_001005163.1 0.276158958 0.005627777 
OR52J3 XM_001498056.1 NP_001001916.2 0.334842743 0.000461248 
OR5B12 XM_001497640.1 NP_001004733.1 -0.458151485 0.000235412 
PDYN XM_001497665.1 NP_077722.1 0.292041589 0.022025175 
PFDN1 gnl|UG|Eca#S38810689 NP_002613.2 0.317254271 0.04058558 
RXRB gnl|UG|Eca#S38808035 NP_068811.1 0.318720726 0.031988907 
SCYL1 gnl|UG|Eca#S36644614 NP_065731.3 0.543979999 0.008591795 
SERTAD4 XM_001493274.1 NP_062551.1 0.341799246 0.027211507 
SFXN3 XM_001500003.1 NP_112233.2 -0.390777342 0.004469119 
SLC38A6 XM_001492955.1 NP_722518.1 -0.410814677 0.049774426 
SMYD1 XM_001497775.1 NP_938015.1 0.289853177 0.036819805 
SPAG4L XM_001498564.1 NP_542406.2 0.40535083 0.029340174 
STT3A gnl|UG|Eca#S38814116 NP_689926.1 -0.923689246 0.025379712 
TBPL2 XM_001496000.1 NP_950248.1 -0.301787042 0.045153152 
TNFSF4 XM_001492820.1 NP_003317.1 -0.319506354 0.041363125 
TRPC5 XM_001488732.1 NP_036603.1 0.266894848 0.023625828 
ZFYVE9 XM_001493830.1 NP_004790.2 -0.273565869 0.039517398 
ZNF551 XM_001493785.1 NP_612356.1 0.275121901 0.031188756 
#N/A gnl|UG|Eca#S38818598-m85 #N/A 0.275618639 0.022373715 
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Table C-1: List of differentially expressed genes (pvalue <0.05 and fold change cut off 
of 1.5) between the stimulated and the un-stimulated leukocytes at Day 1.  
 
Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
AFF4 XM_001504421 XP_001504471 0.736771554 0.001231228 
ARMC8 XM_001496956 XP_001497006 0.993034946 0.000143926 
ATP6V1C1 XM_001494101 XP_001494151 1.61495745 0.012828436 
AZIN1 XM_001493984 XP_001494034 1.30074439 0.001350399 
AZIN1 XR_035783 NULL 0.97456889 0.011838909 
B3GALT4 XM_001497099 XP_001497149 0.868094259 0.0004303 
B4GALT5 XM_001501176 XP_001501226 0.740378146 0.001318002 
BIRC3 XM_001499875 XP_001499925 1.925939744 0.005072062 
C17orf56 XM_001489994 XP_001490044 1.205522855 0.009628448 
CCL20 XM_001496798 NULL 2.610358728 0.006660321 
CHIC1 XM_001504969 XP_001505019 0.656790617 6.01E-05 
CITED1 XM_001488044 XP_001488094 0.690298431 0.022558711 
CLINT1 CX604855 NULL 1.222249813 0.018676155 
CXorf21 XM_001502412 NULL 0.724386169 0.019306103 
CXXC5 NULL NULL -0.622772728 0.017828615 
DDX58 XM_001497845 XP_001497895 1.012974707 0.028022378 
EDN2 AB079136 NP_001075292 0.71238449 0.025477548 
FAM21C CX603317 NULL 2.12223529 0.002892481 
FAM3A XM_001492203 XP_001492253 0.920262899 0.006131427 
FLJ22662 XM_001497121 XP_001497171 -0.69439459 0.006104455 
FPRL1 XM_001497411 XP_001497461 1.038335127 0.009498748 
GALNT2 XM_001496209 XP_001496259 -1.29368847 0.049578246 
GNAI3 XM_001494890 XP_001494940 1.152377992 0.00116789 
GNB3 XM_001497120 XP_001497170 0.706700578 0.001334301 
GPR109A CD469236 NULL 0.906632573 0.032062321 
GYG1 XM_001491640 XP_001491690 -0.656642951 0.027410007 
HAGHL XM_001497250 XP_001497300 0.865290302 0.000618082 
HIP1R XM_001492795 XP_001492845 0.750215372 0.000570017 
HN1L NULL NULL -1.234627804 0.025963621 
HNRNPA1 XM_001501027 XP_001501077 -1.127468753 0.036793513 
IFNA5 XM_001495486 NULL 1.112483298 0.038252084 
IL1A NM_001082500 NULL 2.413131186 0.03380699 
IL1B XM_001495926 XP_001495976 1.490260424 0.02739791 
IL1RN U92482 NP_001075994 1.876892686 0.000360812 
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INS-IGF2 XM_001492829 NULL 0.718615748 0.009247854 
IVNS1ABP CX604411 NULL -0.77874227 0.006571008 
KCNK2 XM_001488153 XP_001488203 0.904674402 0.032685262 
KCNK7 XM_001493848 XP_001493898 -0.948840153 0.039837617 
KIAA2026 DN508828 NULL 1.252853964 0.003279472 
KIAA2026 NULL NULL 0.83003415 0.006222284 
KIF21A XM_001500023 XP_001500073 0.983154746 0.042016242 
KLRB1 XM_001499255 XP_001499305 0.783208614 0.039042291 
LCP1 CD466266 NULL -0.788551364 0.01608422 
LILRA6 AB120413 NP_001075993 -0.712406497 0.011624887 
LILRB4 XM_001489413 XP_001489463 -0.615096867 0.02846047 
LMBR1L XM_001504157 XP_001504207 0.602115766 0.018912226 
MAPK14 XM_001494719 XP_001494769 -0.59840028 0.011840746 
MMP13 AF034087 NP_001075273 0.628858225 0.031911612 
MPP4 XM_001496932 XP_001496982 1.9042037 0.008789771 
MS4A6A XM_001493201 XP_001493251 -0.660051914 0.01734874 
MTHFD2 XM_001500723 XP_001500773 1.056604193 0.016126532 
NFKBIA NULL NULL 0.841142358 0.016476399 
NLRP13 XM_001490754 XP_001490804 0.623449799 0.031212763 
NUBP1 XR_035869 NULL -0.660362741 0.042452626 
NULL NULL NULL 3.650643824 0.001230412 
NULL BI961791 NULL 1.733094978 0.020336907 
NULL NULL NULL 1.614431528 0.003423183 
NULL NULL NULL 1.422963358 0.002011361 
NULL XM_001489363 NULL 1.402783642 0.005658842 
NULL NULL NULL 1.398857319 0.010660813 
NULL DN508878 NULL 1.392061079 0.0378562 
NULL CD469517 NULL 1.383517701 0.00115628 
NULL CX604543 NULL 1.374177108 0.015431937 
NULL CD465425 NULL 1.273417274 0.000468737 
NULL DN507020 NULL 1.231137808 0.000808902 
NULL CD535494 NULL 1.150001754 0.000533264 
NULL BM414612 NULL 1.10496954 0.021648089 
NULL NULL NULL 1.024929833 0.000965244 
NULL DN508987 NULL 0.965068028 0.018353876 
NULL NULL NULL 0.924807265 0.017895581 
NULL NULL NULL 0.756502529 0.027365545 
NULL XM_001503112 NULL 0.75175176 0.014359124 
NULL NULL NULL 0.740663541 0.000707521 
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NULL NULL NULL 0.685719513 0.047748735 
NULL CX601512 NULL 0.658767096 0.047800289 
NULL NULL NULL 0.647880706 0.012898365 
NULL NULL NULL 0.592962906 0.000124773 
NULL CX604697 NULL 0.58437 0.047801191 
NULL XM_001497251 NULL -1.222264504 0.022010221 
NULL XM_001497156 NULL -1.017644465 0.04531373 
NULL DN509725 NULL -0.940950373 0.030122187 
NULL CX605267 NULL -0.881213651 0.047078064 
NULL CX600791 NULL -0.846206416 0.032060274 
NULL NULL NULL -0.690425434 0.003427915 
NULL NULL NULL -0.683315393 0.003232457 
NULL NULL NULL -0.659463765 0.028386418 
NULL CD468881 NULL -0.65132791 0.037279346 
NULL NULL NULL -0.639249664 0.031076657 
NULL XM_001499111 XP_001499161 -0.583273337 0.035671404 
OLAH XM_001498643 XP_001498693 -0.842955156 0.022441262 
OLR1 XM_001493960 XP_001494010 1.654290003 0.042997441 
OR2W3 XM_001498405 XP_001498455 1.280015075 7.45E-05 
OR8U8 XM_001496341 NULL -0.606710763 0.040760083 
OSBPL11 XM_001501564 XP_001501614 -0.621347908 0.017476482 
OXTR XM_001491665 XP_001491715 0.639764911 0.008698872 
PABPC4 XM_001503450 XP_001503500 0.822893601 0.009078976 
PIK3AP1 XM_001500468 XP_001500518 1.195804752 0.004431402 
PLSCR1 XM_001492309 XP_001492359 -0.768157181 0.00405952 
PODXL XM_001498373 XP_001498423 1.236325872 0.000287089 
PRPF39 XM_001493416 NULL 0.944144709 0.025222003 
PSMB5 XM_001494488 XP_001494538 0.640391481 0.044227039 
PTAFR XM_001503995 XP_001504045 0.684922323 0.002152635 
RAB6IP1 XM_001500797 XP_001500847 0.860114154 0.00686056 
RALGDS NULL NULL 0.581840191 0.034669024 
RASGEF1B NULL NULL 1.308715804 0.01677066 
RGS2 XM_001490543 XP_001490593 -0.998595853 0.00797569 
SCUBE1 XM_001500812 XP_001500862 -0.949584788 0.041363431 
SELP CD467527 NULL -0.613675509 0.029230938 
SERPINB1 M91161 NP_001075416 -0.718289355 0.022790827 
SERPINE2 XM_001495938 XP_001495988 0.866235669 0.043403297 
SLC22A6 XM_001495190 XP_001495240 0.581444932 0.014295459 
SMARCA4 XM_001490624 XP_001490674 0.797659347 0.000547984 
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SUMO2 XM_001499526 XP_001499576 -0.692012317 0.019498782 
TANK XM_001493298 XP_001493348 0.929247306 0.001159495 
TCTE3 XM_001488610 XP_001488660 -0.888890706 0.017066746 
TFCP2 XM_001504307 NULL 1.922040404 0.001358919 
TGM2 XM_001499729 NULL 1.516040134 0.005775403 
TNFAIP3 XM_001504414 XP_001504464 0.595735418 0.024467972 
TRAF3 XM_001490000 XP_001490050 0.634627522 0.002496081 
UBP1 XM_001489950 XP_001490000 1.157457981 0.035246983 
UQCRH CX603785 XP_001495144 0.775721189 0.040370337 
USP13 XM_001496315 XP_001496365 0.639778431 0.017319985 
ZNF462 XM_001493275 XP_001493325 -0.81658804 0.037827707 
ZPBP2 XM_001497917 NULL 0.625513646 0.003179897 
 
 
 
Table C-2: List of differentially expressed genes (pvalue <0.05 and fold change cut off 
of 1.5) between the stimulated and the un-stimulated leukocytes at Week-2.  
 
Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
AACS XM_001493527 XP_001493577 0.697875092 0.007947887 
ALG8 XM_001492875 XP_001492925 -0.728984573 0.048304908 
ALPL XM_001504312 XP_001504362 -0.686710111 0.025516009 
ATP11B XM_001496792 XP_001496842 0.665612005 0.010133154 
ATP6V1C1 XM_001494101 XP_001494151 0.975560628 0.019712683 
BIRC3 XM_001499875 XP_001499925 1.615070966 7.11E-05 
BTN2A1 XM_001492502 XP_001492552 1.206141566 0.018929092 
C11orf49 XR_036183 NULL 0.730436448 0.027136315 
C11orf49 XR_035773 NULL 0.642278149 0.000285858 
C18orf22 XM_001496059 XP_001496109 0.80602411 0.003109621 
C21orf91 XM_001500343 XP_001500393 0.595403623 0.020166088 
CABP2 XM_001498045 NULL 0.718691313 0.045264044 
CAST XM_001503694 XP_001503744 -1.115287256 0.040730863 
CCDC100 XM_001504520 XP_001504570 0.803480114 0.000671344 
CLCN6 XM_001491741 XP_001491791 -0.948193616 0.035580709 
CLDN14 XM_001495856 XP_001495906 0.912178907 0.040836892 
CUL3 XM_001493366 XP_001493416 0.709298728 0.021485139 
CXCL10 XM_001490541 XP_001490591 1.171016563 0.01448367 
CXCL3 XM_001489197 XP_001489247 0.654880213 0.013169831 
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DDX58 XM_001497845 XP_001497895 1.353450442 0.000135334 
EDN2 AB079136 NP_001075292 0.729300071 0.034286293 
ELL2 XR_036497 NULL 0.766178866 0.00996606 
FAM21C CX603317 NULL 0.681328551 0.007521442 
FAM89A NULL NULL -1.392747977 0.015022384 
GCN5L2 XM_001495089 XP_001495139 -0.778986964 0.043977187 
GLB1L XM_001493157 XP_001493207 -0.907075214 0.017892875 
GPR31 XM_001489448 XP_001489498 0.75204151 0.002582712 
GRB7 XM_001501037 XP_001501087 0.788591024 0.030267131 
HLF XM_001500211 XP_001500261 0.631119475 0.012749438 
ICAM2 XM_001495313 XP_001495363 -0.946848255 0.034909114 
ID3 XM_001504221 XP_001504271 -0.978905753 0.048206851 
IL1A NM_001082500 NULL 2.585107345 0.00267813 
IL1B XM_001495926 XP_001495976 1.117415389 0.003005676 
IL1RN U92482 NP_001075994 1.735601259 0.008432987 
IMPG2 XM_001503461 XP_001503511 0.580153251 0.014373984 
INDO XM_001490681 XP_001490731 0.699291416 0.020064572 
KCNA3 XM_001494050 XP_001494100 -0.781951055 0.021939954 
KCNJ2 XM_001498612 XP_001498662 1.146143623 0.009018466 
KIF21A XM_001500023 XP_001500073 0.981764562 0.006683527 
KLHL20 XM_001493014 XP_001493064 0.698686792 0.004861024 
LIG4 XM_001493890 XP_001493940 -0.795900702 0.04039123 
LMBR1L XM_001504157 XP_001504207 0.664735066 0.00043301 
LOC388630 CX592898 NULL -0.630465559 0.046103315 
LOC728772 XM_001491967 XP_001492017 0.853607511 0.032762529 
LOC730422 DN507079 NP_001108413 2.084691798 0.000570065 
MCM6 XM_001489698 XP_001489748 -1.193710812 0.044163362 
MEF2A CD464185 NULL 0.640787956 0.048692709 
MEIS2 XM_001503626 XP_001503676 -0.612615011 0.0420056 
NFKBIA NULL NULL 0.76992866 0.012265461 
NR2F6 XM_001499719 XP_001499769 -1.301052643 0.042924624 
NT5C2 XM_001499520 XP_001499570 1.018978363 0.033684678 
NULL CD470350 NULL 1.746563419 0.001395949 
NULL XM_001489363 NULL 1.665159892 5.30E-06 
NULL CD469517 NULL 1.555468456 0.000114922 
NULL DN508878 NULL 1.355154756 0.00526598 
NULL BI961791 NULL 1.226659197 0.001107059 
NULL CD469043 NULL 1.223220171 0.00356743 
NULL CD465425 NULL 1.170032197 0.006003242 
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NULL BM414612 NULL 1.069382494 0.004701095 
NULL DN508987 NULL 0.948631459 0.007527228 
NULL CD465947 NULL 0.873054658 0.000692472 
NULL CX604697 NULL 0.73798422 0.009839182 
NULL CD536657 NULL 0.659792997 0.03513463 
NULL BM734930 NULL 0.629887182 0.034901723 
NULL CX602249 NULL 0.617207288 0.041069387 
NULL CX604543 NULL 0.607069351 0.02211025 
NULL CX606039 NULL 0.590691432 0.017643889 
NULL XM_001499351 NULL -1.034739544 0.048989989 
NULL CX604033 NULL -0.875177731 0.030203368 
NULL DN509057 NULL -0.743127321 0.013027874 
NULL CD467035 NULL -0.601842855 0.018924587 
OR13D1 XM_001493177 XP_001493227 0.596492155 0.038405249 
OR2W3 XM_001498405 XP_001498455 0.686014534 0.001182582 
OR7A5 XM_001496119 NULL -1.411614429 0.041144358 
OR7E24 XM_001493162 NULL 0.799036252 0.005243035 
OR8U8 XM_001496341 NULL -1.53019112 0.004005738 
PICALM XM_001490412 XP_001490462 0.647383297 0.010620606 
PIK3AP1 XM_001500468 XP_001500518 0.893155484 0.003328656 
PLD5 XM_001492999 XP_001493049 -0.659744978 0.031305064 
PLEK XM_001492113 XP_001492163 1.229628257 0.02832517 
PNRC2 XM_001504200 NULL 1.053665318 0.006980435 
PODXL XM_001498373 XP_001498423 0.687422164 0.002950615 
PRRC1 XM_001504480 XP_001504530 -1.076634396 0.041794071 
PSCDBP XM_001491278 XP_001491328 1.272818912 0.000351192 
PTAFR XM_001503995 XP_001504045 0.822485473 0.007125783 
RASGEF1B NULL NULL 0.848567319 0.012791089 
RETN XM_001497441 XP_001497491 0.580805519 0.030795519 
RGS2 XM_001490543 XP_001490593 -0.658435263 0.004267861 
RNF19A XM_001492262 XP_001492312 0.930427638 0.001547354 
RNF24 XM_001496498 NULL 1.927467483 0.048862351 
RPAP2 XM_001492375 XP_001492425 -1.173849673 0.02198338 
SHARPIN XM_001495880 NULL 0.746428938 0.015341767 
SLC35D2 XM_001494155 XP_001494205 -0.940151368 0.023497194 
SMARCA4 XM_001490624 XP_001490674 0.96693218 0.000817632 
SNX10 CD467781 NULL 0.973375468 0.046955258 
SOD2 AB001693 NP_001075986 1.64600987 0.003318969 
SPATA4 XM_001493009 XP_001493059 -0.740639785 0.00537563 
  
281 
Table C-2 Continued 
 
Gene symbol NCBI accession RefSeq accession Log fold change Pvalue 
STAMBPL1 XM_001503046 XP_001503096 0.966996845 0.035484165 
TFCP2 XM_001504307 NULL 1.31403059 0.000400086 
TMLHE XM_001498280 XP_001498330 -0.667880002 0.003929976 
TPR XM_001487879 NULL 0.615968645 0.020129579 
TREM1 XM_001500981 XP_001501031 0.618781248 0.013385432 
UBP1 XM_001489950 XP_001490000 0.992715894 0.000908657 
USP13 XM_001496315 XP_001496365 0.664360613 0.004791727 
WDR51A XR_036062 NULL 0.701553019 0.048494841 
YTHDF1 XM_001492553 XP_001492603 0.788093149 0.013563092 
ZNF462 XM_001493275 XP_001493325 -1.309843924 0.040337679 
ZNF784 XM_001490354 XP_001490404 0.960078462 0.000240908 
ZSWIM6 XM_001492480 XP_001492530 -0.635315737 0.0319159 
 
 
 
Table C-3: List of differentially expressed genes (pvalue <0.05 and fold change cut off 
of 1.5) between the stimulated and the un-stimulated leukocytes at Week-4.  
 
Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
ACTR2 XM_001494389 XP_001494439 -1.442565254 0.003314642 
ADA XM_001500443 XP_001500493 -0.875944536 0.024130993 
ARHGDIB XM_001501778 XP_001501828 -0.637499858 0.038167737 
ARPC4 CD528440 NULL -0.920637046 0.033625217 
BIRC3 XM_001499875 XP_001499925 1.280228588 0.006797131 
C14orf104 XM_001496267 XP_001496317 1.746290565 0.036210752 
C5orf36 XM_001503712 XP_001503762 -0.603469059 0.044885869 
CXCL2 AF053497 NULL 0.740888242 0.029366444 
CYP26A1 XM_001502498 XP_001502548 -0.644005452 0.012248082 
DDX58 XM_001497845 XP_001497895 0.849356831 0.049516409 
EDEM3 XM_001490885 XP_001490935 -0.944580951 0.031360262 
EDN2 AB079136 NP_001075292 0.607993768 0.025940492 
EIF4A1 XM_001504774 XP_001504824 1.071830095 0.048047913 
FGL2 XM_001488486 XP_001488536 -0.66421589 0.03392253 
GABRB3 XM_001493048 XP_001493098 -0.587994546 0.035456941 
IL1A NM_001082500 NULL 2.572395297 0.000756361 
IL1B XM_001495926 XP_001495976 0.951317235 0.044939967 
IL1RN U92482 NP_001075994 1.729878284 0.027841748 
KCNJ10 XM_001491211 XP_001491261 0.639116173 0.001835555 
KCNJ2 XM_001498612 XP_001498662 0.652178111 0.015169015 
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Gene symbol NCBI accession RefSeq accession Log fold change Pvalue 
KIAA1434 CD466056 NULL -0.652669269 0.043516761 
KIF21A XM_001500023 XP_001500073 0.780286691 0.014437963 
LILRB4 CD467691 NULL 0.7487236 0.002005286 
LOC730796 XM_001497173 XP_001497223 -1.864425085 0.015808519 
LYPLA1 NULL NULL -0.581273371 0.030319939 
LYZL6 XM_001494897 XP_001494947 -0.730179609 0.020052288 
MEF2A CD464185 NULL 0.899356423 0.025180504 
NULL CX605267 NULL 2.025224021 0.014351557 
NULL XM_001499351 NULL 1.81497192 0.032856806 
NULL BI961791 NULL 1.594257497 0.007960216 
NULL BM414612 NULL 1.075807382 0.017516782 
NULL CD469517 NULL 0.947058826 0.002164067 
NULL CX602603 NULL 0.589551174 0.028049872 
NULL CD536079 NULL -0.896364101 0.045862387 
NULL CD465841 NULL -0.849233215 0.012961625 
NULL CD467057 NULL -0.795731345 0.026775678 
NULL CD528135 NULL -0.598270955 0.007291102 
OPA3 DN509316 NULL -1.044739656 0.03591177 
OR1A1 XM_001502552 XP_001502602 0.592219414 0.007588206 
PLAU XM_001502951 XP_001503001 0.704530429 0.022173188 
PLEK XM_001492113 XP_001492163 1.102544441 0.013744419 
PODXL XM_001498373 XP_001498423 0.613394511 0.013782635 
POLR1D XM_001493249 NULL -1.2136447 0.023244224 
POLR1E XM_001504281 XP_001504331 -0.862395043 0.025176069 
PSCDBP XM_001491278 XP_001491328 0.627090082 0.031605316 
RGS2 XM_001490543 XP_001490593 -0.779635039 0.003267522 
RPS25 XM_001503063 XP_001503113 -0.778312468 0.027655033 
SCG5 XM_001501620 XP_001501670 -1.140674466 0.010563301 
SCYL1 CX602064 NULL -0.780474666 0.044981942 
SELL XM_001491555 XP_001491605 -0.648639128 0.023712227 
TFCP2 XM_001504307 NULL 0.982984015 0.020718816 
TGM2 XM_001499729 NULL -1.223681514 0.04554654 
TNNT3 XM_001492908 NULL 0.625029157 0.015217817 
TREM1 XM_001500981 XP_001501031 0.69132632 0.016773534 
TSC22D3 XM_001491157 XP_001491207 -0.624588592 0.01369984 
TTBK2 NULL NULL -0.822268707 0.046272344 
USP13 XM_001496315 XP_001496365 0.630416799 0.003463127 
VIM CX604176 NULL -0.756968459 0.036629821 
ZC3HAV1 XM_001499163 NULL -0.613778865 0.038877421 
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Gene symbol NCBI accession RefSeq accession Log fold change Pvalue 
ZNF211 XM_001494387 XP_001494437 -1.043226236 0.00886443 
ZNF407 CX599900 NULL -1.052235826 0.041966686 
ZNF407 NULL NULL -0.765018041 0.020102759 
 
 
 
Table C-4: List of differentially expressed genes (pvalue <0.05 and fold change cut off 
of 1.5) between the stimulated and the un-stimulated leukocytes at Week-8. 
 
Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
AK3 DN510426 NULL -0.661739522 0.037256069 
ARMC8 XM_001496956 XP_001497006 0.846242545 0.000494223 
ARRDC3 XM_001504616 XP_001504666 -0.819339052 0.024527401 
BIRC3 XM_001499875 XP_001499925 2.264968369 9.56E-05 
C11orf49 XM_001494248 XP_001494298 0.763452177 0.023052929 
C11orf49 XR_036183 NULL 0.663628353 0.012780599 
C11orf49 XR_036493 NULL 0.656792724 0.03831742 
C18orf22 XM_001496059 XP_001496109 1.328615535 0.001417922 
CCL20 XM_001496798 NULL 1.107191516 0.006865372 
CFDP1 XM_001498771 XP_001498821 0.773997841 0.009567496 
CHCHD2 XM_001499574 XP_001499624 -0.591928204 0.003264909 
CSNK1G3 XM_001504513 NULL -0.598403293 0.020198351 
CUL3 XM_001493366 XP_001493416 0.979939517 0.008525381 
CXCL10 XM_001490541 XP_001490591 1.575531659 0.000560746 
CXCL2 AF053497 NULL 0.917729157 0.002791755 
DCTN3 DN509108 XP_001503748 -0.584589224 0.040841778 
DDX58 XM_001497845 XP_001497895 1.792685698 4.00E-06 
EDEM3 XM_001490885 XP_001490935 -0.746385317 0.0292086 
EDN2 AB079136 NP_001075292 0.870137472 0.005503041 
FAM21C CX603317 NULL 1.094500398 0.008875332 
GBP1 XM_001494991 XP_001495041 1.161217967 0.021352266 
GDI2 XM_001500009 XP_001500059 -0.623018754 0.043096298 
GPR109A CD469236 NULL 0.834857357 0.006961215 
GPR31 XM_001489448 XP_001489498 0.717358629 0.009769871 
GPR84 XM_001504570 XP_001504620 1.164376829 6.80E-05 
HEXIM2 XM_001495090 XP_001495140 -1.014570409 0.021517129 
HNRNPU CD528363 NULL -0.858937088 0.020943577 
HSPE1 NULL NULL -1.329874116 0.010472361 
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Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
IFNA5 XM_001495486 NULL 0.645616128 0.00248139 
IL1A NM_001082500 NULL 3.829758886 1.78E-08 
IL1B XM_001495926 XP_001495976 2.162329197 0.0020009 
IL1RN U92482 NP_001075994 2.473567181 0.000714063 
INDO XM_001490681 XP_001490731 1.815170687 5.71E-05 
INS-IGF2 XM_001492829 NULL 0.752345604 0.000182068 
IVNS1ABP CX604411 NULL -0.926549023 0.002796688 
KCNJ2 XM_001498612 XP_001498662 1.27988629 0.001459713 
KIAA1434 CD466056 NULL -0.79780471 0.007438089 
KIF21A XM_001500023 XP_001500073 1.268932109 0.000251705 
KLRB1 XM_001499255 XP_001499305 0.611917454 0.007104291 
KMO XM_001492701 XP_001492751 0.617044902 0.005072262 
LILRA6 AB120413 NP_001075993 -0.698036649 0.004198966 
LILRB4 XM_001489413 XP_001489463 -0.624058776 0.014811842 
LMBR1L XM_001504157 XP_001504207 0.89806684 0.001025308 
LOC730422 DN507079 NP_001108413 2.797778782 1.70E-05 
LOC730803 CD471754 NULL 0.741306132 0.000501277 
MPP4 XM_001496932 XP_001496982 1.169375876 0.003034343 
NDUFA10 XM_001500579 XP_001500629 1.46144557 0.035064978 
NFKBIA NULL NULL 0.909828808 0.001027568 
NPBWR2 XM_001495569 NULL 0.752061566 0.000326237 
NULL CD469043 NULL 1.927062928 0.004635845 
NULL XM_001489363 NULL 1.788861079 0.000157873 
NULL DN508878 NULL 1.788274041 7.03E-07 
NULL CD470350 NULL 1.753720715 0.004053683 
NULL BI961791 NULL 1.65394905 0.006544702 
NULL CD469517 NULL 1.522912202 2.92E-05 
NULL BM414612 NULL 1.146132093 0.007689025 
NULL DN508987 NULL 1.113626273 0.00016679 
NULL CD465425 NULL 1.036822143 0.004148771 
NULL BI961659 NULL 1.018131402 0.014146126 
NULL CX604697 NULL 0.962484971 0.000347426 
NULL CD536657 NULL 0.947982933 0.010354492 
NULL DN507662 NULL 0.875493921 0.014686101 
NULL CX604543 NULL 0.867957213 0.000213978 
NULL CD467650 NULL 0.759172053 0.038807186 
NULL DN509862 NULL 0.672955815 0.030058649 
NULL CD470694 NULL 0.594570216 0.00690229 
NULL CX604033 NULL -0.946244491 0.01018918 
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Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
NULL CX601537 NULL -0.740174279 0.018614933 
NULL CX599471 NULL -0.681775599 0.034322327 
NXF1 AB302133 NP_001091076 -0.611574648 0.047492306 
OLR1 XM_001493960 XP_001494010 1.328882722 0.036496251 
OPA3 DN509316 NULL -0.863751882 0.005823285 
PGM1 XM_001499673 XP_001499723 0.698336921 0.001334788 
PIK3AP1 XM_001500468 XP_001500518 0.985168148 0.009981568 
PLAU XM_001502951 XP_001503001 0.619602346 0.013212908 
PLEK XM_001492113 XP_001492163 1.760980001 0.000304627 
PODXL XM_001498373 XP_001498423 1.099337807 0.004288463 
PPFIA4 XM_001495820 XP_001495870 -0.708426479 0.048413006 
PSCDBP XM_001491278 XP_001491328 0.806746862 0.005992711 
PSMB5 XM_001494488 XP_001494538 0.637221712 0.002647985 
PTAFR XM_001503995 XP_001504045 0.777576077 0.001461637 
RASGEF1B NULL NULL 0.712141042 0.007503619 
RGS2 XM_001490543 XP_001490593 -0.94991284 0.000494958 
RHOG XM_001496655 XP_001496705 0.734130137 0.01977316 
RNASET2 XM_001489592 XP_001489642 -0.713822838 0.02170683 
RNF19A XM_001492262 XP_001492312 0.864644553 0.029098453 
RSPH3 XM_001491976 XP_001492026 1.700046358 0.023920608 
SELL XM_001491555 XP_001491605 -0.948017951 0.015346515 
SHPRH XM_001502347 XP_001502397 -0.707018169 0.023369506 
SLC15A2 XM_001500375 XP_001500425 0.644046096 0.000764652 
SLC39A13 XM_001491132 XP_001491182 -0.774930279 0.029339313 
SMARCA4 XM_001490624 XP_001490674 0.942879067 0.005320191 
SNX10 CD467781 NULL 1.380222938 0.006243751 
SOD2 AB001693 NP_001075986 1.759764413 0.009343792 
TANK XM_001493298 XP_001493348 1.109704488 0.003522222 
TFCP2 XM_001504307 NULL 2.056293477 4.33E-06 
TPI1 XM_001497472 XP_001497522 0.597111927 0.003084807 
TRAF6 NULL NULL -0.726515334 0.013804121 
UBP1 XM_001489950 XP_001490000 0.823570172 0.015037027 
UMPS XM_001500039 XP_001500089 0.590924746 0.010610914 
USP13 XM_001496315 XP_001496365 0.589099914 0.006317992 
VAPB XM_001490076 XP_001490126 0.609593867 0.000700642 
VNN1 XM_001503387 NULL -0.957757395 0.037100202 
ZNF211 XM_001494387 XP_001494437 -0.631307968 0.007563067 
ZNF268 XM_001494533 XP_001494583 -0.818874188 0.010320922 
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Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
ZNF329 XM_001495088 XP_001495138 -0.652394347 0.043973111 
ZNF350 XM_001495722 XP_001495772 0.984133366 0.047129427 
ZNF784 XM_001490354 XP_001490404 1.061232126 0.001565597 
ZNRF2 XM_001499541 NULL -0.636871587 0.018607074 
  
 
 
Table C-5: List of differentially expressed genes (pvalue <0.05 and fold change cut off 
of 1.5) between the stimulated leukocytes at week-2 compared to day 1. 
 
Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
AADAT XM_001498966 XP_001499016 -0.599841058 0.019685724 
ACADVL XM_001504761 XP_001504811 -1.651823215 0.017418466 
AFF3 XM_001492324 XP_001492374 -1.901706459 0.011746588 
ARFGEF1 XM_001494559 XP_001494609 -1.514649073 0.007706563 
ARMC8 XM_001496956 XP_001497006 -0.625057636 0.007458776 
ARPC3 XR_036238 NULL -0.627643399 0.027328242 
ATP6V1C1 XM_001494101 XP_001494151 -1.45038984 0.000571598 
AZIN1 XM_001493984 XP_001494034 -1.004918935 0.047897784 
AZIN1 XR_035783 NULL -0.795232016 0.004857066 
B3GNT2 XM_001495317 XP_001495367 -1.442155249 0.00052999 
BANF2 XM_001494025 NULL -0.859837701 0.036637416 
BIRC3 XM_001499875 XP_001499925 -1.517216835 0.024332028 
BTBD8 XM_001492459 XP_001492509 -1.415130725 0.009584908 
C12orf35 XM_001503113 XP_001503163 0.750719425 0.032286184 
C17orf56 XM_001489994 XP_001490044 -0.851436055 0.003568557 
C1orf190 XM_001495298 XP_001495348 -1.378103612 0.01276244 
CA12 EF397505 NP_001093230 -0.608655561 0.005510256 
CBS XM_001490849 NULL -1.322477266 0.000607311 
CCL20 XM_001496798 NULL -2.009916209 0.00065999 
CLEC4E XM_001492794 XP_001492844 -0.601616897 0.031106152 
CLINT1 CX604855 NULL -0.855821145 0.001653176 
CPT1B XM_001490719 XP_001490769 -1.120076377 0.002317933 
CRTC3 XM_001498594 XP_001498644 1.038409832 0.003098911 
CXCR4 XM_001490165 XP_001490215 0.979364609 0.00165446 
CYP2E1 NM_001111303 NULL -0.63583653 0.019451826 
DBN1 XM_001498360 XP_001498410 -1.006602239 0.04053832 
EEF1A1 XM_001489416 XP_001489466 1.119913132 0.001026975 
FAM14A XM_001495656 XP_001495706 -0.644261163 0.008598707 
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Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
FAM21C CX603317 NULL -1.455950406 0.012888314 
FPRL1 XM_001497411 XP_001497461 -0.692646035 0.031678634 
FYB XM_001496939 XP_001496989 -1.163563477 0.000975345 
GIMAP7 NULL NULL 0.826658955 0.018917044 
GIMAP7 NULL NULL 0.814249777 0.01133128 
GNPDA1 XM_001503958 XP_001504008 -1.5737722 0.037194312 
HIP1R XM_001492795 XP_001492845 -0.611008399 0.001101656 
HLA-DQB1 XM_001492617 XP_001492667 0.906897149 0.007864025 
HLA-DRA XM_001494553 XP_001494603 0.827114849 0.003035121 
IFITM1 CD465069 XP_001488655 -1.310679673 0.011558093 
INDO XM_001490681 XP_001490731 1.049008421 0.02751077 
KCNK2 XM_001488153 XP_001488203 -1.048962482 0.016000341 
KIF2A XM_001493976 XP_001494026 -0.864738995 0.015725822 
KRT15 XM_001496858 XP_001496908 -2.008355664 0.011479337 
LMOD3 XM_001498577 XP_001498627 1.96990071 0.007936875 
LOC651894 CD466713 NULL -0.832969568 0.028204696 
LOC653214 XM_001496996 NULL 0.598815897 0.00648256 
LOC730422 DN507079 NP_001108413 -0.885191791 0.024265709 
LOC92270 XM_001503822 XP_001503872 0.628738747 0.001985344 
MPP4 XM_001496932 XP_001496982 -1.312866861 0.005152038 
MRPL21 CX604559 XP_001499094 -0.680057552 0.01325242 
MTHFD2L XM_001490173 XP_001490223 -0.649925322 0.033817178 
NULL CD470175 NULL -1.357598817 0.023588974 
NULL CX604543 NULL -1.041540848 0.003411092 
NULL CX593205 NULL -0.794532952 0.043331451 
OLFM4 XM_001493449 XP_001493499 -0.823812846 0.02530932 
OR10G2 XM_001498059 XP_001498109 -0.95779856 0.010799608 
OR2W3 XM_001498405 XP_001498455 -0.781737412 0.003195667 
OR52D1 XM_001498223 NULL -1.109021342 0.002134949 
PGM1 XM_001499673 XP_001499723 -0.612126571 0.005268821 
PIK3AP1 XM_001500468 XP_001500518 -0.758539591 0.001008768 
PLA2G5 XM_001504348 XP_001504398 -1.858163792 0.003357951 
RASGEF1B NULL NULL -0.679248186 0.01957803 
RETN XM_001497441 XP_001497491 -0.827955159 0.002938616 
RNF144B XM_001494349 XP_001494399 -0.711980364 0.045847975 
RPS25 XM_001503063 XP_001503113 0.890919203 0.044256309 
RPSA DN504853 NULL 0.749437571 0.03611253 
RPSA NULL NULL 0.746273817 0.001529256 
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Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
S100A12 CD535886 XP_001494448 -1.532241077 0.026458394 
S100A8 XM_001493589 XP_001493639 -1.417147546 0.01751323 
S100A8 XM_001494358 XP_001494408 -0.982696069 0.047182232 
SDCBP XR_036510 NULL -1.789133353 0.001510222 
SDCBP XM_001496872 XP_001496922 -1.497244159 0.03342175 
SERPINB1 M91161 NP_001075416 -1.00147438 0.046329777 
SYT2 XM_001495156 NULL -1.080907123 0.001177288 
TANK XM_001493298 XP_001493348 -0.818562526 0.030943308 
TFCP2 XM_001504307 NULL -1.085022963 0.044891734 
TFEC XM_001501723 XP_001501773 -0.798728598 0.000734221 
THBS1 XM_001503599 XP_001503649 0.624917399 0.024624249 
TMSB4X XM_001488854 XP_001488904 1.023105536 0.04769547 
TRAK1 XM_001497614 XP_001497664 -0.964215761 0.013584595 
TSPO XM_001503143 XP_001503193 -0.822048322 0.012614901 
TTBK2 AB292108 NP_001075250 1.096359411 0.047205166 
TTBK2 AY237113 NULL 0.873142625 0.047749764 
TUBA1A XM_001491832 XP_001491882 0.580964062 0.004679956 
ZFP14 XM_001493293 NULL 1.052025934 0.016778616 
 
 
 
Table C-6: List of differentially expressed genes (pvalue <0.05 and fold change cut off 
of 1.5) between the stimulated leukocytes at week-4 compared to day 1. 
 
Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
ABCB10 XM_001496372 XP_001496422 1.161280858 0.019254903 
ABHD6 XM_001489265 XP_001489315 0.650778103 0.030679937 
ABI1 XM_001494640 XP_001494690 -0.767737493 0.003962405 
ACADVL XM_001504761 XP_001504811 -1.879594703 0.014211782 
AFF4 XM_001504421 XP_001504471 -0.954288105 0.002818212 
ALPL XM_001504312 XP_001504362 0.89254865 0.025561207 
ANXA5 XM_001503130 XP_001503180 -0.643605893 0.006481538 
ANXA7 XM_001503861 XP_001503911 -0.650895201 0.035981336 
ARFGEF1 XM_001494559 XP_001494609 -1.799871891 0.003416439 
ARHGAP1 XM_001489971 XP_001490021 1.463670456 0.002538143 
ARHGEF3 XM_001490400 XP_001490450 1.092489183 0.023071976 
ATP11B XM_001496792 XP_001496842 -0.753303804 0.004651174 
ATP13A2 XM_001488576 XP_001488626 1.524868826 0.008006548 
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ATP1B3 XM_001494313 XP_001494363 -0.747397509 0.002454295 
ATP6V0E1 CX602201 XP_001502972 0.702958792 0.031368646 
ATP6V1C1 XM_001494101 XP_001494151 -1.89525501 0.00024631 
ATXN2 XM_001491014 XP_001491064 0.964185712 0.010402414 
AZIN1 XM_001493984 XP_001494034 -1.482429489 0.012098411 
AZIN1 XR_035783 NULL -0.947558216 0.005818344 
BIRC3 XM_001499875 XP_001499925 -1.05168096 0.025969003 
BLCAP XM_001502351 XP_001502401 -0.665611044 0.003561071 
BTBD8 XM_001492459 XP_001492509 -1.759125712 0.004509461 
C10orf112 XM_001497827 XP_001497877 -1.069586233 0.006710267 
C14orf104 XM_001496267 XP_001496317 1.78482992 0.005691124 
C16orf78 XM_001488683 XP_001488733 1.216013897 0.028518142 
C21orf66 XM_001494782 XP_001494832 0.659321985 0.008569989 
CA12 EF397505 NP_001093230 -0.829216321 0.036543231 
CACHD1 XM_001500703 XP_001500753 -1.123583473 0.048271085 
CACNG1 XM_001499847 XP_001499897 0.741109289 0.005422058 
CBLB XM_001503354 XP_001503404 1.513523424 0.016415187 
CCL20 XM_001496798 NULL -1.31502122 0.001798704 
CD47 XM_001501702 XP_001501752 -0.62802743 0.020389544 
CDC2 XM_001502198 XP_001502248 -0.757883093 0.002952177 
CDK3 XM_001491903 XP_001491953 -0.84103389 0.011362206 
CHIC1 XM_001504969 XP_001505019 -0.586615158 0.022967356 
CLCA2 XM_001496218 XP_001496268 1.467135987 0.01348303 
CLIC5 XM_001502577 XP_001502627 0.794455478 0.029767639 
CLINT1 CX604855 NULL -0.910798085 0.006945032 
CNP XM_001495565 XP_001495615 -0.662740956 0.011407858 
COL3A1 AF117954 NULL 0.753124137 0.021760872 
CXXC5 NULL NULL 1.237148399 0.023742178 
DPM3 XM_001494606 XP_001494656 1.407031607 0.020593666 
DZIP1 XM_001492095 XP_001492145 -0.784317436 0.010056089 
EDN2 AB079136 NP_001075292 -0.777616848 0.035669238 
EMR3 XM_001495205 XP_001495255 -0.62598915 0.036379305 
ERCC3 XM_001488507 XP_001488557 1.171594418 0.032766119 
EXOSC4 XR_036511 NULL 0.664744484 0.00208116 
FAM21C CX603317 NULL -1.63507073 0.002486198 
FBXO15 XM_001493325 XP_001493375 0.761524442 0.02191545 
FPRL1 XM_001497411 XP_001497461 -1.229928848 0.003793493 
FYB XM_001496939 XP_001496989 -1.056103323 0.019260887 
GALNT2 XM_001496209 XP_001496259 1.678343053 0.021105045 
  
290 
Table C-6 Continued 
 
Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
GK XM_001488392 XP_001488442 -0.636607299 0.014233248 
GPR137 XM_001489414 XP_001489464 0.6577204 0.021086949 
GPR84 XM_001504570 XP_001504620 -0.943360847 0.026265726 
HSPC152 CX600330 XP_001489771 1.125263352 0.048425048 
IFITM1 CD465069 XP_001488655 -1.277246242 0.009153732 
IFNGR2 XR_036253 NULL -0.654109666 0.019799342 
JAK2 XM_001500499 XP_001500549 0.629148847 0.034449 
KCNJ2 XM_001498612 XP_001498662 -1.260930457 0.042137556 
KCNK2 XM_001488153 XP_001488203 -0.955331639 0.020296789 
KCNK7 XM_001493848 XP_001493898 0.968250664 0.01938093 
KIAA0460 XM_001489478 XP_001489528 -0.662138964 0.029710588 
KIF2A XM_001493976 XP_001494026 -0.964276977 0.005081501 
KY XM_001498469 XP_001498519 0.670285539 0.042327107 
LHFPL1 XM_001488695 XP_001488745 0.722807015 0.010884967 
LOC643596 XM_001492183 NULL 0.9263886 0.007054456 
LOC651894 CD466713 NULL -0.952000303 0.000688254 
LOC730422 DN507079 NP_001108413 -1.902043561 0.003593265 
LRMP XM_001498588 XP_001498638 -0.834436784 0.029000685 
LRRC23 XM_001497546 XP_001497596 1.894459 0.019468393 
MAL XM_001494547 XP_001494597 0.917596672 0.005975176 
MAPK10 XM_001495324 XP_001495374 0.852832015 0.002361373 
MTHFD2L XM_001490173 XP_001490223 -0.596670218 0.032990439 
NFKBIA NULL NULL -0.770999382 0.019251318 
NICN1 XM_001497632 XP_001497682 0.728131151 0.002068504 
NT5C2 XM_001499520 XP_001499570 -0.995060761 0.021949558 
NUBP1 XR_035869 NULL 1.399692908 0.023958098 
NULL CX604543 NULL -1.483857197 0.001851788 
NULL DN508878 NULL -1.247637922 0.009305107 
NULL CX606039 NULL -1.023196843 0.003736644 
NULL XR_036509 NULL -0.981207915 0.039788418 
NULL CD465425 NULL -0.950307718 0.006110222 
NULL DN508978 NULL -0.925169145 0.048204521 
NULL DN510428 NULL -0.908166329 0.03181999 
NULL XR_036280 NULL -0.903209125 0.023578169 
NULL CD469043 NULL -0.843652508 0.038041206 
NULL CX602378 NULL -0.810701847 0.045863924 
NULL CD528850 NULL -0.743187436 0.014108027 
NULL CD528482 NULL -0.727772627 0.035418894 
NULL CX601512 NULL -0.68960818 0.001654285 
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NULL CD468881 NULL -0.652960578 0.00062913 
NULL DN507234 NULL -0.640263416 0.00768336 
NULL DN508304 NULL -0.600152376 0.026311831 
NULL CX602785 NULL -0.592140719 0.001939824 
NULL CD468898 NULL -0.581370148 0.018228267 
NULL CD470175 NULL 2.154640616 0.007565129 
NULL CX605267 NULL 1.99496677 0.014646028 
NULL XM_001499351 NULL 1.826194049 0.011733461 
NULL XM_001497251 NULL 1.605571026 0.008928497 
NULL CX600194 NULL 1.557605331 0.014299339 
NULL XM_001498195 XP_001498245 1.492323065 0.045499211 
NULL DN509725 NULL 1.126940549 0.008703142 
NULL XM_001502325 XP_001502375 0.853830526 0.012400068 
NULL CX603299 NULL 0.768572762 0.011388289 
NULL XM_001497110 XP_001497160 0.679230586 0.036510202 
NULL CX593935 NULL 0.582608209 0.026898811 
OR1J4 XM_001501393 XP_001501443 0.68007645 0.001907715 
OR2S2 XM_001493425 XP_001493475 1.031860512 0.03330239 
OR52B4 XM_001496909 XP_001496959 0.740666567 0.006783273 
OR52D1 XM_001498223 NULL -1.216183234 0.031932653 
OR5B2 XM_001497992 XP_001498042 -0.823284405 0.002921001 
OR6C68 XM_001504060 XP_001504110 -0.606378761 0.045664355 
ORM2 XM_001488149 XP_001488199 -0.590570964 0.01759447 
PERQ1 XM_001505064 XP_001505114 1.305957671 0.001043103 
PGM1 XM_001499673 XP_001499723 -0.850064767 0.004344601 
PICALM XM_001490412 XP_001490462 -1.068610719 6.40E-05 
PIK3AP1 XM_001500468 XP_001500518 -0.980084989 0.007484601 
PIM1 XM_001500225 XP_001500275 1.3762541 0.045883745 
PLA2G10 XM_001489049 XP_001489099 -0.660352777 0.035772003 
PLA2G5 XM_001504348 XP_001504398 -1.843177878 0.004780698 
PPP4R1 XR_035855 NULL 1.147376507 0.000620105 
PRPF39 XM_001493416 NULL -0.710937356 0.006095941 
RAB18 XM_001494294 XP_001494344 -0.622147197 0.005824465 
RAP1B XM_001493406 XP_001493456 -0.99904749 0.01038233 
RASGEF1B NULL NULL -0.93326973 0.008852046 
RETN XM_001497441 XP_001497491 -0.995230551 0.014098611 
RNF144A XM_001503614 XP_001503664 1.671011302 0.015927157 
RNF181 DN504657 NULL 0.846822667 0.012766161 
RNF19A XM_001492262 XP_001492312 -0.686283743 0.004148708 
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RPAP2 XM_001492375 XP_001492425 1.387119963 0.024836054 
RTKN XM_001500407 XP_001500457 1.382375189 0.008040411 
S100P BM734933 XP_001501447 -1.354950417 0.029387967 
SAA1 NM_001081853 NULL -0.620685226 0.022778935 
SCG5 XM_001501620 XP_001501670 -1.071491568 0.008619687 
SDCBP XR_036510 NULL -1.907925119 0.014369212 
SDCBP XM_001496872 XP_001496922 -1.787542663 0.020917757 
SELO XM_001496075 XP_001496125 1.211623034 0.009311136 
SERPINB1 M91161 NP_001075416 -1.335315655 0.017392239 
SH3BGRL XM_001501152 XP_001501202 -0.890131925 0.003219365 
SLC35D2 XM_001494155 XP_001494205 1.211854003 0.003445215 
SMARCA4 XM_001490624 XP_001490674 -0.702730217 0.041540223 
SMC2 XM_001503998 XP_001504048 0.876809335 0.007564097 
SNX3 XM_001503983 XP_001504033 -0.903569952 0.001465001 
SPAG4L XM_001498564 XP_001498614 0.665504638 0.049353951 
SPINLW1 XM_001500671 NULL -0.605375297 0.026425219 
SUMF1 XM_001496576 XP_001496626 1.554337784 0.022789518 
TAF4B XM_001495354 XP_001495404 0.664136735 0.046405627 
TANK XM_001493298 XP_001493348 -0.969842651 0.045667353 
TCTN3 XM_001500642 XP_001500692 -0.876988261 0.004960816 
TFCP2 XM_001504307 NULL -0.99590272 0.000813443 
TFEC XM_001501723 XP_001501773 -0.895921872 0.003425299 
TLK1 XM_001498377 XP_001498427 0.930789411 0.005914872 
TMEM139 XM_001489983 XP_001490033 0.854682638 0.000356726 
TMLHE XM_001498280 XP_001498330 0.791435845 0.017887668 
TRAF3 XM_001490000 XP_001490050 -0.60527754 0.004209033 
TREM1 XM_001500981 XP_001501031 0.734073069 0.001192172 
TSPO XM_001503143 XP_001503193 -0.968851092 0.006787871 
UBL7 XM_001494059 XP_001494109 -1.135296214 0.009790008 
UNC119 CX601468 XP_001504190 0.685298012 0.028585415 
UNC45B NULL NULL 1.587404768 0.015616724 
USP22 XM_001488603 XP_001488653 0.823866683 0.021871856 
VPS54 XM_001493998 XP_001494048 1.61469506 0.021503377 
WBP1 CX600458 NULL -0.79674945 0.012115691 
YIPF4 XM_001500250 XP_001500300 -0.785103711 0.003076969 
ZCCHC4 XM_001499564 XP_001499614 0.630560054 0.01936207 
ZNF423 XM_001491336 XP_001491386 0.748528672 0.02733138 
ZNF462 XM_001493275 XP_001493325 1.446451666 0.015667213 
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ACADVL XM_001504761 XP_001504811 -2.087284003 0.000847443 
ARFGEF1 XM_001494559 XP_001494609 -1.610113438 0.003378656 
ARRB2 XM_001502964 XP_001503014 0.606058556 0.043532194 
ASNSD1 XM_001499046 XP_001499096 1.077796478 0.033549869 
ATP11B XM_001496792 XP_001496842 -0.822230159 0.016452645 
ATP1B3 XM_001494313 XP_001494363 -0.648695613 0.005482556 
ATP6V1C1 XM_001494101 XP_001494151 -1.202587628 0.034009971 
ATRX XM_001502685 XP_001502735 -0.616259946 0.039278326 
BCL2A1 XM_001487956 XP_001488006 0.955041415 0.044290947 
BTBD8 XM_001492459 XP_001492509 -0.924766866 0.038558138 
C11orf58 XR_036382 NULL 0.653065607 0.023198729 
C7orf34 XM_001490979 NULL 0.601862595 0.046129133 
CASP4 XM_001499070 XP_001499120 0.600992949 0.046434391 
CCL20 XM_001496798 NULL -0.778462967 0.005110509 
CD69 XM_001499388 XP_001499438 0.740935237 0.004646201 
CDK3 XM_001491903 XP_001491953 -0.664564519 0.04827149 
CLINT1 CX604855 NULL -0.981385555 0.006492774 
DEK XM_001496593 XP_001496643 0.931423833 0.015238457 
DNAJC10 XM_001498066 XP_001498116 0.77186899 0.041010184 
EEF1A1 NULL NULL 1.095967951 0.024315896 
EHHADH XM_001498736 XP_001498786 -0.766644773 0.026279904 
EML3 XM_001494714 XP_001494764 0.791210587 0.019950462 
EMR3 XM_001495205 XP_001495255 -0.646968248 0.030763809 
FAM21C CX603317 NULL -1.555535197 0.048848611 
FAM3A XM_001492203 XP_001492253 -0.945540312 0.040937953 
FAM45A CX598831 NULL 0.639509616 0.033204238 
FGF17 XM_001490190 XP_001490240 0.592744908 0.029997885 
FOXN1 XM_001504134 XP_001504184 -0.689854717 0.027621125 
FYB XM_001496939 XP_001496989 -0.982925809 0.020545064 
GIMAP7 NULL NULL 1.04459567 0.010520798 
GIMAP7 NULL NULL 0.825287594 0.0283829 
GPR84 XM_001504570 XP_001504620 -0.620613813 0.031937423 
GRHL2 XM_001493287 XP_001493337 -0.821895236 0.006017268 
HLA-DQB1 XM_001492617 XP_001492667 0.800585287 0.000840462 
HLA-DRA XM_001494553 XP_001494603 0.893882438 0.023371877 
HLA-DRB1 XM_001495531 XP_001495581 0.68056067 0.027745738 
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HOXA11 XM_001499702 NULL 0.683219088 0.039182344 
HSPA8 AF411802 NULL 1.058149497 0.033203756 
IFITM1 CD465069 XP_001488655 -1.11443803 0.022143739 
IL7R EF035169 NP_001075411 0.685082157 0.03278201 
INDO XM_001490681 XP_001490731 1.481234967 0.019946121 
KIF2A XM_001493976 XP_001494026 -1.306312758 0.008457702 
LOC339457 XM_001495309 NULL -0.653234193 0.022665678 
LOC651894 CD466713 NULL -0.930651515 0.02515162 
LOC653214 XM_001496996 NULL 0.63790332 0.016630539 
LOC730422 DN507079 NP_001108413 -1.396569217 0.005032256 
MAP4K4 XM_001491720 XP_001491770 0.786029617 0.027023591 
MC3R XM_001489123 XP_001489173 0.794228461 0.035617852 
MMP1 AF148882 NP_001075316 -1.383265349 0.018457835 
NULL CD528482 NULL -1.001419634 0.036841621 
NULL CX606039 NULL -0.950759774 0.01062028 
NULL CD466166 NULL -0.825130352 0.036207037 
NULL CX604543 NULL -0.749051439 0.036238202 
NULL CX602785 NULL -0.61274206 0.0012007 
NULL CD469036 NULL -0.612438036 0.024935751 
NULL CX593205 NULL -0.610547975 0.02273951 
NULL CD528850 NULL -0.604770805 0.046956995 
NULL DN508293 XP_001504999 1.64644475 0.02100169 
NULL CD465991 XP_001503681 1.258970823 0.006486919 
NULL CD465610 NULL 0.972664732 0.022041409 
NULL CD536657 NULL 0.938773528 0.039296938 
NULL CX605248 NULL 0.905460231 0.03371701 
NULL DN507426 NULL 0.772989861 0.048495289 
NULL CD469128 NULL 0.608263541 0.000200687 
NULL DN509978 NULL 0.597142053 0.040207122 
OR52D1 XM_001498223 NULL -0.6527913 0.018588612 
OR5B2 XM_001497992 XP_001498042 -1.06714031 0.044328516 
ORM2 CD536428 XP_001488234 0.743300485 0.049920887 
OXTR XM_001491665 XP_001491715 -0.680126049 0.047532481 
PAIP1 NULL NULL 0.665814841 0.01745315 
PGM1 XM_001499673 XP_001499723 -0.737188302 0.00474333 
PLA2G5 XM_001504348 XP_001504398 -1.43726865 0.015664865 
PRPF39 XM_001493416 NULL -0.846397133 0.003751746 
PTPRZ1 XM_001501199 XP_001501249 -0.674121723 0.019505069 
RAD50 XM_001504442 XP_001504492 -0.658976212 0.021970309 
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RASSF2 BM735017 NULL -0.586614888 0.026433264 
RHOG XM_001496655 XP_001496705 -0.877560931 0.034669375 
RNF149 XM_001491820 XP_001491870 -0.633153847 0.048241295 
RNF17 XM_001488530 XP_001488580 -0.613166043 0.032459796 
RPL10 NULL NULL 0.860666446 0.025198181 
RPL28 CD464415 XP_001495815 0.855569252 0.023662502 
RPL31 XM_001489469 XP_001489519 1.146218833 0.010572086 
RPL36A NULL NULL 0.701082298 0.003860024 
RPL37A XM_001500265 XP_001500315 0.784064991 0.014120044 
RPL7 XM_001491982 XP_001492032 1.389483366 0.030492423 
RPLP1 BM735439 XP_001495775 0.791525336 0.016447705 
RPS2 XR_036216 NULL 0.626066785 0.01084341 
RPS25 XM_001503063 XP_001503113 1.365923741 0.028074188 
RPS3A XM_001501474 XP_001501524 1.350921423 0.044803898 
RPSA XM_001497103 XP_001497153 1.331451612 0.041836193 
S100A13 CX601420 XP_001494839 0.66414564 0.037215882 
S100A8 XM_001493589 XP_001493639 -1.413323341 0.015480451 
S100A8 XM_001494358 XP_001494408 -0.801027911 0.016183703 
SCYL1 CX602064 NULL -0.790557375 0.046564998 
SDCBP XR_036510 NULL -1.077260645 0.0490504 
SEC61G XM_001498680 NULL 0.759066217 0.036271045 
SERPINB1 M91161 NP_001075416 -1.145077426 0.030318397 
SGCE XM_001493182 XP_001493232 -0.644246152 0.030496341 
SHFM1 XM_001494095 XP_001494145 0.616331664 0.014870371 
SNX3 XM_001503983 XP_001504033 -0.732013342 0.041336429 
SPCS1 XM_001501306 NULL 0.589014524 0.032431208 
TFCP2 XM_001504307 NULL -0.687762496 0.034288891 
TFEC XM_001501723 XP_001501773 -0.604147246 0.016938484 
TOR2A XM_001501467 XP_001501517 1.14341584 0.016151657 
TOR3A XM_001494447 XP_001494497 -0.922058318 0.026579156 
TRIM47 DN510014 NULL -0.688295223 0.019260471 
TSPO XM_001503143 XP_001503193 -0.706198165 0.04877139 
TUBA1A XM_001491832 XP_001491882 0.865009711 0.014219178 
UBL7 XM_001494059 XP_001494109 -1.243838638 0.016938105 
USP48 XM_001504296 XP_001504346 -0.730407902 0.002124971 
WIPI1 XM_001499325 XP_001499375 -0.689463493 0.025966418 
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APPENDIX D 
 
Table D-1: Differentially expressed genes. List of differentially expressed genes for 
each comparison is shown in the table. Genes were considered differentially expressed 
with p<0.05 and fold change >1.5 
 
Biological sample Time point  Differentially expressed genes 
Blood leukocytes 
Birth (B-T0) Up: 119 Down: 149 
Week-2(B-T2) Up: 93 Down: 87 
Week-4(B-T4) Up: 191 Down: 128 
Nasal epithelial cells 
Birth (N-T0) Up: 360 Down: 141 
Week-2(N-T2) Up: 228 Down: 348 
Week-4(N-T4) Up: 108 Down: 159 
 
 
 
 
 
 
 
 
 
Figure D-1: Biological processes associated with DE genes in blood leukocytes at two-
week time point. Graphical representation of top fifteen statistically significant processes 
associated with the DE genes in blood leukocytes at week-two a) represents biological 
processes at week-two (T2) associated with down-regulated (colored green bars) and b) 
up-regulated (colored red bars) genes. The Y-axis represents the biological processes 
and the X-axis represents the p value displayed as -log2 (p value). 
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Figure D-2: Biological processes associated with DE genes in blood leukocytes at four-
week time point. Graphical representation of top fifteen statistically significant processes 
associated with the DE genes in blood leukocytes at week-four a) represents biological 
processes at week-four (T4) associated with down-regulated (colored green bars) and b) 
up-regulated (colored red bars) genes. The Y-axis represents the biological processes 
and the X-axis represents the p value displayed as -log2 (p value). 
 
 
 
 
 
 
 
Figure D-3: Biological processes associated with DE genes in nasal epithelium at two-
week time point. Graphical representation of top fifteen statistically significant processes 
associated with the DE genes in nasal epithelium at week-two a) represents biological 
processes at week-two (T2) associated with down-regulated (colored green bars) and b) 
up-regulated (colored red bars) genes. The Y-axis represents the biological processes 
and the X-axis represents the p value displayed as -log2 (p value). 
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Figure D-4: Biological processes associated with DE genes in nasal epithelium at four-
week time point. Graphical representation of top fifteen statistically significant processes 
associated with the DE genes in nasal epithelium at week-four a) represents biological 
processes at week-four (T4) associated with down-regulated (colored green bars) and b) 
up-regulated (colored red bars) genes. The Y-axis represents the biological processes 
and the X-axis represents the p value displayed as -log2 (p value). 
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Table D-2: Linear discriminant analysis of infected versus control foals at week two 
(blood leukocytes). The five ten one-, two-, and three-gene LDA classifiers are shown in 
the table below.  ε bolstered represents the bolstered resubstitution error for the respective 
gene classifier and  Δ ε bolstered represents the decrease in error for each feature set 
relative to its highest ranked subset of genes.  
 
1 feature 2 feature 3 feature εbolstered Δεbolstered 
LSM10 
     0.1218   
PRRT2 
     0.1693   
GENE:21056     0.1735   
HL02022A1G02.ab1     0.1835   
gnl|UG|Eca#S36646929     0.1864   
PLEK2 
 
HSPD1 
   0.0313   
LSM10 
 
DDX47 
   0.0696 0.0522 
PLEK2 
 
DDX47 
   0.0705   
AEBP1 
 GENE:7122   0.0728   
CX604379 
 
EXOSC9 
   0.0772 0.1092 
PLEK2 
 
DDX47 
 
HSPD1 
 0.026 0.0053 
EXOSC9 
 
PRRT2 
 GENE:7122 0.0279   
PLEK2 
 
ANKRD50 
 
HSPD1 
 0.0329 -0.0016 
GLT25D2 
 
MXRA5 
 
CENTA2 
 0.0345   
EXOSC9 
 
PRRT2 
 
HSPD1 
 0.0346   
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Table D-3: Linear discriminant analysis of infected versus control foals at week four 
(blood leukocytes). The five ten one-, two-, and three-gene LDA classifiers are shown in 
the table below.  ε bolstered represents the bolstered resubstitution error for the respective 
gene classifier and  Δ ε bolstered represents the decrease in error for each feature set 
relative to its highest ranked subset of genes.  
 
1 feature 2 feature 3 feature εbolstered Δεbolstered 
LOC731041 
     0.0463   
POLE3 
     0.1115   
ZNF420 
     0.115   
RPL10A 
     0.1158   
CD163 
     0.1222   
RPL10A 
     0.0315   
LOC731041 
 
CD163 
   0.0316 0.0147 
ZNF420 
 
KRT4 
   0.0361 0.0789 
SRM 
 
LOC731041 
   0.0368 0.0782 
ZNF420 
 
LOC731041 
   0.0373 0.0777 
ZNF420 
 
KRT4 
 
PROCR 
 0.0046 0.0315 
RPL10A 
 
ZNF420 
 
PRDM4 
 0.0092 0.0223 
ZNF420 
 
RAB19 
 
KRT4 
 0.0105 0.0256 
ZNF420 
 
LOC731041 
 
MAP3K14 
 0.0119 0.0254 
CEP55 
 
ZNF420 
 
LOC731041 
 0.0151 0.0222 
 
 
 
 
 
 
 
 
 
 
 
 
  
301 
Table D-4: Linear discriminant analysis of infected versus control foals at week two 
(nasal epithelial cells). The top five one-, two-, and three-gene LDA classifiers are 
shown in the table below.  ε bolstered represents the bolstered resubstitution error for the 
respective gene classifier and  Δ ε bolstered represents the decrease in error for each feature 
set relative to its highest ranked subset of genes.  
 
1 feature 2 feature 3 feature εbolstered Δεbolstered 
YY1 
     0.0973   
MXRA8 
     0.1246   
CX605699 
     0.1444   
SH2B3 
     0.1542   
GABRB3 
     0.1561   
CX604514 
 
AHSA1 
   0.0317 0.1477 
CX601639 
 
AHSA1 
   0.0339 0.1455 
CT020001B10_PLT_A08_57_056.ab1 OBP2B    0.0393   
MAGEA10 
 
MXRA8 
   0.0406 0.084 
AHSA1 
 
GORASP2 
   0.0443 0.1351 
CX604514 
 
AHSA1 
 
GORASP2 
 0.013 0.0187 
CX604514 
 
AHSA1 
 
SERPINB
2 
 
0.0178 0.0139 
CX604514 
 
ZADH2 
 
AHSA1 
 0.019 0.0127 
NPPA 
 
MAGEA10 
 
MXRA8 
 0.0191 0.0215 
CT020001B10_PLT_A08_57_056.ab1 CT020013A10H12.ab1 OBP2B  0.0192 0.0201 
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Table D-5: Linear discriminant analysis of infected versus control foals at week four 
(nasal epithelial cells). The top five one-, two-, and three-gene LDA classifiers are 
shown in the table below.  ε bolstered represents the bolstered resubstitution error for the 
respective gene classifier and  Δ ε bolstered represents the decrease in error for each feature 
set relative to its highest ranked subset of genes.  
 
1 feature 2 feature 3 feature εbolstered Δεbolstered 
UQCR 
     0.1591   
LMBR1L 
     0.1729   
COX7B 
     0.1831   
SLC35E4 
     0.1851   
DN508139 
     0.1931   
UQCR 
 
SCAPER 
   0.0565 0.1026 
OR2L2 
 
DN508139 
   0.0794 0.1137 
COL28A1 
 
DN508139 
   0.0806 0.1125 
SLC35E4 
 
MGAT4C 
   0.0832 0.1019 
CX605849 
 
DN508139 
  0.0877 0.1054 
OR2L2 
 
COL28A1 
 
DN508139 
 0.0397 0.0397 
KIAA1553 
 
UQCR 
 
SCAPER 
 0.0447 0.0118 
OR2L2 
 
DN508139 
 
DN508139 
 0.0452 0.0342 
UQCR 
 
CLDN3 
 
SCAPER 
 0.0455 0.011 
UQCR 
 
ZNF709 
 
SCAPER 
 0.0463 0.0102 
 
 
 
 
Section D-1  
Temporal changes in blood leukocytes 
Two weeks after birth the gene expression profile from the blood leukocytes suggest 
possible exposure to R. equi. At this time point the up-regulated genes were mainly 
involved in lipid biosynthesis and metabolic processes, processes that could play a role 
in disease progression.  
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Evidence for a role of lipid-related genes is present for Mycobacterium tuberculosis 
infection. Mycobacterium tuberculosis obtains nourishment from lipids as a major 
source of carbon (Rachman et al., 2006). Host lipids also play an important role during 
infection because they appear to be the primary carbon source for M. tuberculosis in vivo 
(Jain et al., 2007). A more recent study observed up-regulation of host genes associated 
with lipid metabolism and synthesis, causing a progression in granuloma formation (Kim 
et al., 2010). R. equi and Mycobacterium tuberculosis share significant genomic 
similarity (47% sequence homology to Mycobacterium tuberculosis) and this homology 
may be reflected in the pathogenesis (Rahman et al., 2005). We therefore propose that a 
similar mechanism could be involved in foal lungs due to R. equi stimulation of innate 
immunity. Targeting pathways leading to lipid biosynthesis and metabolism may 
therefore be of therapeutic value to control R. equi growth and hence pneumonia 
progression.  
 
Four weeks after birth, gene expression profiles from blood leukocytes suggest that 
protective host immune responses are being activated due to pathogen exposure. These 
findings support our belief that foals have already been exposed to R. equi, and are 
therefore activating appropriate immune responses against the pathogen. Animals that 
are more susceptible can be expected to show differences in their profiles. In response to 
R. equi, up-regulation of genes involved in B cell differentiation and iron homeostasis 
are protecting against this intracellular pathogen by limiting iron requirements of the 
pathogen.  
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The hemochromatosis (HFE) and aconitase 1(ACO1) genes are involved in iron 
homeostasis. Hemochromatosis protein is linked to peptide presentation pathway 
abnormalities and functions to regulate iron absorption by regulating interaction of the 
transferrin receptor with transferrin (de Almeida et al., 2005). Lack of iron confers 
protection within macrophages to the pathogens whose virulence is dependent on iron 
availability (Moalem et al., 2004). Up-regulation of the HFE gene could therefore be a 
host defense response to limit iron availability to R. equi. Since the HFE gene product 
regulates iron homeostasis via transferrin regulation, this gene is also a good candidate 
to be studied for its possible role in R. equi pneumonia.  
 
Section D-2  
Temporal changes in nasal epithelium  
At two weeks of age, the gene expression profiles of nasal epithelial cells suggest up-
regulation of genes involved in wound healing, negative regulation of T-cell 
proliferation, and regulation of IFN-γ production. This would suggest increased 
protective immune responses at this time point, due to exposure to the pathogen.  
 
CD276/B7-H3 (associated with regulation of IFN-γ production processes) is involved in 
controlling the immune system beyond adaptive immune responses. Epithelial cells on 
nasal mucosa express B7-H3 and expression is also induced on T cells, NK cells, APC 
like dendritic cells (DC), and macrophages (Flies and Chen, 2007). It regulates 
proliferation of CD4+ and CD8+ T cells, selectively stimulates IFN-γ production in 
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vitro, and has both T cell stimulatory and inhibitory roles (Yi and Chen, 2009). There is 
evidence that B7-H3 enhances TCR-mediated proliferation of T lymphocytes, generates 
cytotoxic T lymphocytes, and releases IFN-γ from CD4+ cells (Saatian et al., 2004). A 
B7-H3 deficiency in mice was reported to increase stimulation of T cells compared to 
wild type mice, and the B7-H3 deficient mice showed enhanced differentiation of T cells 
into Th-1 subsets (Suh et al., 2003). Another study reported no stimulatory function of 
B7-H3 in T cell proliferation or IFN-γ production (Steinberger et al., 2004). Based on 
our study its exact role in R. equi susceptibility is unclear, but it will be a potential 
candidate for future research.  
 
From linear discriminant analysis, the three-gene classifiers, CX604515, AHSA1, and 
GORASP2 could discriminate R. equi infected foals from healthy foals at birth with the 
lowest misclassification error. Activator of heat shock 90 kDa protein ATPase homolog 
1 (AHSA1/AHA1) activates heat shock protein 90). Heat shock proteins have 
immunological functions and roles in stress (Tobian et al., 2005). The golgi reassembly 
stacking protein 2 (GORASP2) gene-product is involved in stacking of golgi cisternae 
and may play a role in intracellular transport of some transmembrane proteins.  
 
Four weeks after birth, expression profiles of nasal epithelial cells suggested that genes 
are being modulated (up or down) to initiate protective immune responses to restrict 
bacterial growth. The down-regulated genes were associated with regulation of body 
fluids and heme biosynthesis. Gene products associated with regulation of body fluids 
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include SAA1: Serum amyloid A, an equine acute phase protein that is increased during 
infectious and non-infectious inflammation (Hulten and Demmers, 2002). In 2005 
Cohen et al. (2005b) studied SAA concentrations in serum samples. They found that 
concentration of this protein in foals with R. equi pneumonia was not a good marker for 
either screening or diagnosis due to variability of results. The translocator protein 
(TSPO) gene is associated with heme biosynthesis processes in susceptible foals. 
Proposed functions of TSPO include host defenses such as immunosuppression, immune 
cell reactivity, and apoptosis of immune cells (Veenman et al., 2007). Impaired host 
defense against Mycobacterium bovis is due to stimulation of TSPO present on 
macrophages/lymphocytes (Veenman et al., 2007). Since Mycobacterium bovis is also an 
intracellular bacterium, it will be interesting to further explore its role in R. equi related 
pneumonia. 
 
Up-regulated genes at N-T4 were associated with various biological processes, of which 
rabGTPases signaling appeared to be of particular interest. Intracellular bacterium target 
Rab to colonize vacuolar compartments in cells of the host. Hence, Rab may provide a 
mechanism for how bacteria manipulate host cell functions to avoid destruction in 
lysosomes (Brumell and Scidmore, 2007).  
 
Section D-3  
Protocol for RNA extraction from nasal epithelial cells 
Unless otherwise stated, all procedures are carried out at room temperature. 
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1. Before collecting cells, prepare one 1.5 ml microcentrifuge tube per sample with 
1.5ml RNAlater. 
2. Place the brush head into the microcentrifuge tube. 
3. Remove brush head from RNAlater and gently scrap away cells from brush 
using a 10ul tip. 
4. Spin the tubes at 5000g at 4 deg C for 5 minutes. 
5. Remove the supernatant. 
6. Add 1ml PBS to wash the pellet. Spin at 2000g for 5 minutes. 
7. Remove supernatant and add another 1ml of PBS (Repeat step 6). 
8. Add 350μl extraction buffer (RLT) supplemented with 1% (v/v) β-
mercaptoethanol. (Cell lysates can be stored in RLT buffer at -80ºC for several 
months).  
9. Disrupt the cells by homogenizing using 20gz needle on ice. 
10. Centrifuge for 2 min at 14 000 rpm to homogenize. 
11. Add 1 volume (usually 350 μl) of 70% ethanol to column eluate and mix well by 
pipetting. Do not centrifuge. 
12. Apply the whole volume of the sample (up to 700 μl) to one RNeasy mini spin 
column sitting on a 2-ml collection tube and centrifuge for 15 sec at 14 000 rpm. 
13. Perform on-column Dnase digestion step (RNeasy mini kit procedure) 
14. Transfer the RNeasy column into a new 2 ml collection tube. Pipette 500 μl of 
buffer RPE onto RNeasy column and centrifuge for 15 sec at 14000 rpm. 
15. Repeat step 9. 
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16. Transfer RNeasy column into a new 2-ml collection tube. Centrifuge for 2 min at 
14000 rpm as (to ensure that all the ethanol is washed out from column 
membrane). 
17. Transfer RNeasy column into a 1.5 ml collection tube and pipette 30μl of Rnase-
free water directly onto the middle of the RNeasy membrane without touching it 
with the tip. Incubate at room temperature for 1 min then centrifuge for 1 min at 
14 000 rpm. 
18. After centrifugation put the tubes immediately on ice and use the samples 
immediately or store them at -80ºC for later usage. 
19. For RNA cleanup follow RNeasy Minelute Cleanup (eluted in 14ul of water) 
 
 
 
Table D-6a: Down-regulated genes from blood leukocytes at T0. The result for each 
biological process is listed in this table. For each process listed in second column the 
associated DE genes are presented in the third column of the table. The final column 
shows the p-value associated with each process.  
 
Count Biological process Genes Pvalue 
1 Cartilage development 
CHAD 
COL9A1 
IHH 
BMP1 
 
0.0021 
2 Endosome to lysosome transport VAMP7 
SNX1 
 
0.005 
3 Regulation of tyrosine phosphorylation of Stat3 protein JAK2 
PPP2R1A 
 
0.005 
4 Tyrosine phosphorylation of Stat3 protein JAK2 
PPP2R1A 
 
0.0058 
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Table D-6a Continued 
 
Count Biological process Genes Pvalue 
5 Regulation of growth 
TFCP2L1 
CHAD 
CDKN2AIP 
UBE2E3 
LTBP4 
PPP2R1A 
LRP12 
 
0.0277 
6 Cartilage condensation  
CHAD 
BMP1 
 
 
0.0078 
7 Lysosomal transport VAMP7 
SNX1 
 
0.0111 
8 Chondrocyte differentiation COL9A1 
IHH 
 
0.0111 
9 Peptide cross-linking COL3A1 
EGFLAM 
 
1.36E-02 
10 Cell activation  
JAK2 
VAMP7 
IL27RA 
FGA 
RPL22 
COL3A1 
CBLB 
 
1.42E-02 
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Table D-6a Continued 
 
Count Biological process Genes Pvalue 
11 Cellular developemental process 
DBN1 
TFCP2L1 
PRAME 
EMX1 
ERCC3 
NDC80 
BBS10 
SOHLH1 
UNC45B 
SPATA9 
LTBP4 
PPP2R1A 
SCUBE1 
IHH 
BMP1 
JAK2 
RPL22 
ZNF423 
COL9A1 
 
1.46E-02 
12 Negative regulation of immune response IL27RA 
COL3A1 
 
1.50E-02 
13 Growth 
TFCP2L1 
CHAD 
CDKN2AIP 
UBE2E3 
LTBP4 
NUBP1 
PPP2R1A 
LRP12 
 
1.63E-02 
14 Purine ribonucleotide metabolic process 
ATP13A5 
ERCC3 
PRPS1 
ATP13A2 
 
1.71E-02 
15 Vacuolar transport VAMP7 
SNX1 
 
1.94E-02 
16 Regulation of tyrosine phosphorylation of STAT protein JAK2 
PPP2R1A 
 
1.94E-02 
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Table D-6a Continued 
 
Count Biological process Genes Pvalue 
17 Ribonucleotide metabolic process 
ATP13A5 
ERCC3 
PRPS1 
ATP13A2 
 
0.0209 
18 Regulation of cellular component size 
CHAD 
CDKN2AIP 
LTBP4 
NEBL 
NUBP1 
PPP2R1A 
 
0.0219 
19 Negative regulation of immune system 
IL27RA 
COL3A1 
CBLB 
 
0.0222 
20 Platelet activation FGA 
COL3A1 
 
0.0242 
21 Tyrosine phosphorylation of STAT protein JAK2 
PPP2R1A 
 
0.0259 
22 Cytoskeleton organization 
DBN1 
NEBL 
KLHL20 
DES 
TUBGCP3 
FHDC1 
NDC80 
 
0.0270 
23 Regulation of JAK-STAT cascade JAK2 
PPP2R1A 
 
0.0277 
24 Cell growth 
CHAD 
CDKN2AIP 
LTBP4 
NUBP1 
PPP2R1A 
 
0.0280 
 
 
 
 
 
 
 
  
312 
Table D-6a Continued 
 
Count Biological process Genes Pvalue 
25 Cell differentiation 
DBN1 
TFCP2L1 
PRAME 
EMX1 
ERCC3 
SOHLH1 
UNC45B 
SPATA9 
LTBP4 
PPP2R1A 
SCUBE1 
BMP1 
IHH 
JAK2 
RPL22 
ZNF423 
COL9A1 
 
0.0318 
26 Mitotic sister chromatid segregation SMC2 
NDC80 
 
0.0332 
27 Sister chromatid segregation SMC2 
NDC80 
 
0.0352 
28 Regulation of cell size 
CHAD 
CDKN2AIP 
LTBP4 
NUBP1 
PPP2R1A 
 
0.03
57 
29 ATP metabolic process 
ATP13A5 
ERCC3 
ATP13A2 
 
0.0384 
30 Tissue development 
TFCP2L1 
CHAD 
ERCC3 
SCUBE1 
IHH 
BMP1 
JAK2 
COL9A1 
COL3A1 
 
0.0390 
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Table D-6a Continued 
 
Count Biological process Genes Pvalue 
31 Alpha-beta T cell activation RPL22 
CBLB 
 
0.0412 
32 Blood coagulation 
FGA 
SCUBE1 
COL3A1 
 
0.0432 
33 Regulation of cell growth 
CHAD 
CDKN2AIP 
LTBP4 
PPP2R1A 
 
0.0449 
34 Negative regulation of DNA binding ZNF462 
JAK2 
 
0.0455 
35 Peptidyl-serine modification GALNT2 
EGFLAM 
 
0.0455 
36 Regulation of biological quality 
DBN1 
RXFP3 
CDKN2AIP 
NDC80 
BBS10 
NUBP1 
COL3A1 
CHAD 
NEBL 
LTBP4 
PPP2R1A 
SCUBE1 
JAK2 
FGA 
COL9A1 
SNCAIP 
 
0.0455 
37 Coagulation 
FGA 
SCUBE1 
COL3A1 
 
0.0449 
38 Regulation of anatomical structure size 
CHAD 
CDKN2AIP 
LTBP4 
NEBL 
NUBP1 
PPP2R1A 
 
0.0479 
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Table D-6a Continued 
 
Count Biological process Genes Pvalue 
39 Purine ribonucleoside triphosphate 
ATP13A5 
ERCC3 
ATP13A2 
 
0.0483 
40 Ribonucleoside triphosphate metabolic 
ATP13A5 
ERCC3 
ATP13A2 
 
0.0496 
 
 
 
Table D-6b: Up-regulated genes from blood leukocytes at T0. The result for each 
biological process is listed in this table. For each process listed in second column the 
associated DE genes are presented in the third column of the table. The final column 
shows the p-value associated with each process.  
 
Count Biological process Genes pvalue 
1 Synaptic vesicle exocytosis 
STX4 
CPLX3 
RAB3A 
 
3.09E-05 
2 Cell differentiation 
HOXA7 
THOC5 
ACTC1 
ACTG1 
PMP22 
ADAD1 
PHOX2A 
KCNH1 
CEBPB 
GSN 
VASP 
HDAC4 
SLITRK4 
RAB3A 
SPI1 
TOB1 
CSRP2 
TSSK2 
 
9.30E-05 
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Table D-6b Continued 
 
Count Biological process Genes Pvalue 
3 Muscle cell differentiation 
KCNH1 
HDAC4 
ACTC1 
ACTG1 
CSRP2 
 
0.0001 
4 Cell development 
CEBPB 
KCNH1 
GSN 
VASP 
HDAC4 
ACTC1 
ACTG1 
SLITRK4 
ADAD1 
RAB3A 
PHOX2A 
CSRP2 
 
0.0001 
5 Cellular development process 
HOXA7 
THOC5 
ACTC1 
ACTG1 
PMP22 
ADAD1 
PHOX2A 
KCNH1 
CEBPB 
GSN 
VASP 
HDAC4 
SLITRK4 
RAB3A 
SPI1 
TOB1 
CSRP2 
TSSK2 
 
0.0002 
6 Synaptice vesicle transport 
STX4 
CPLX3 
RAB3A 
 
0.0004 
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Table D-6b Continued 
 
Count Biological process Genes Pvalue 
7 Cellular component assembly involved in morphogenesis 
ACTC1 
ACTG1 
PMP22 
 
0.0005 
8 Neurotransmitter secretion 
STX4 
CPLX3 
RAB3A 
 
0.0009 
9 Muscle organ development 
KCNH1 
HDAC4 
ACTC1 
ACTG1 
BVES 
CSRP2 
 
0.0012 
10 Striated muscle tissue development 
KCNH1 
HDAC4 
ACTC1 
ACTG1 
CSRP2 
 
0.0014 
11 Muscle tissue development  
KCNH1 
HDAC4 
ACTC1 
ACTG1 
CSRP2 
 
0.0017 
12 Response to fungus 
CARD9 
S100A12 
 
0.0018 
13 Establishment of localization in cell 
THOC5 
ACTC1 
CHML 
TSPO 
RAB3A 
SEC22B 
RAB27B 
STX4 
CPLX3 
TOB1 
SRP19 
STX11 
 
0.002 
14 Regulation of neurotransmitter secretion 
CPLX3 
RAB3A 
 
0.0025 
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Table D-6b Continued 
 
Count Biological process Genes Pvalue 
15 Regulation of interleukin-6 biosynthetic process 
CEBPB 
CARD9 
 
0.0025 
16 Interleukin-6 biosynthetic process 
CEBPB 
CARD9 
 
0.0030 
17 Exocytosis 
STX4 
RAB27B 
CPLX3 
RAB3A 
 
0.0032 
18 Cellular localization 
THOC5 
ACTC1 
CHML 
TSPO 
RAB3A 
SEC22B 
RAB27B 
STX4 
CPLX3 
TOB1 
SRP19 
STX11 
 
0.0033 
19 Membrane fusion 
STX4 
STX11 
RAB3A 
 
0.0033 
20 Regulation of neurotransmitter transport 
CPLX3 
RAB3A 
 
0.0034 
21 Myotube differentiation 
KCNH1 
HDAC4 
 
0.0034 
22 Myofibril assembly 
ACTC1 
ACTG1 
 
0.0039 
23 Striated muscle cell development 
ACTC1 
ACTG1 
 
0.0044 
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Table D-6b Continued 
 
Count Biological process Genes Pvalue 
24 Intracellular transport 
THOC5 
ACTC1 
CHML 
TSPO 
SEC22B 
STX4 
SRP19 
TOB1 
STX11 
 
0.0048 
25 Regulation of multicellular organismal 
CEBPB 
HOXA7 
THOC5 
HDAC4 
CARD9 
RAB3A 
PHOX2A 
SPI1 
CPLX3 
TOB1 
 
0.0050 
26 Regulation of neurotransmitter levels 
STX4 
CPLX3 
RAB3A 
 
0.0050 
27 Muscle cell development 
ACTC1 
ACTG1 
 
0.0055 
28 Skeletal muscle fiber development 
KCNH1 
HDAC4 
CSRP2 
 
0.0057 
29 Actomyosin structure organization 
ACTC1 
ACTG1 
 
0.0060 
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Table D-6b Continued 
 
Count Biological process Genes Pvalue 
30 Protein transport- 
CHML 
TSPO 
RAB3A 
SEC22B 
RAB7L1 
RAB27B 
STX4 
SRP19 
TOB1 
STX11 
 
0.0062 
31 System development 
HOXA7 
THOC5 
ACTC1 
ACTG1 
BVES 
PMP22 
PHOX2A 
KCNH1 
CEBPB 
GSN 
VASP 
HDAC4 
NDP 
SLITRK4 
RAB3A 
SPI1 
TOB1 
CSRP2 
 
0.0062 
32 Neurotransmitter transport 
STX4 
CPLX3 
RAB3A 
 
0.0063 
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Table D-6b Continued 
 
Count Biological process Genes Pvalue 
33 Organ development 
CEBPB 
KCNH1 
HOXA7 
GSN 
THOC5 
VASP 
HDAC4 
ACTC1 
ACTG1 
NDP 
BVES 
RAB3A 
PHOX2A 
SPI1 
CSRP2 
 
0.0064 
34 Macromolecule localization 
OSBPL2 
THOC5 
CHML 
TSPO 
RAB3A 
SEC22B 
RAB7L1 
RAB27B 
STX4 
TOB1 
SRP19 
STX11 
 
0.0065 
35 Establishment of protein localization 
CHML 
TSPO 
RAB3A 
SEC22B 
RAB7L1 
RAB27B 
STX4 
SRP19 
TOB1 
STX11 
 
0.0068 
 
  
321 
Table D-6b Continued 
 
Count Biological process Genes Pvalue 
36 Muscle fiber development 
KCNH1 
HDAC4 
CSRP2 
 
0.0071 
37 Tissue development 
KCNH1 
HOXA7 
GSN 
VASP 
HDAC4 
ACTC1 
ACTG1 
CSRP2 
 
0.0096 
38 Multicellular organismal development 
HOXA7 
THOC5 
ACTC1 
ACTG1 
BVES 
PMP22 
ADAD1 
PHOX2A 
KCNH1 
CEBPB 
GSN 
VASP 
HDAC4 
NDP 
SLITRK4 
 
RAB3A 
 
SP11 
 
TOB1 
CSRP2 
TSSK2 
 
0.0096 
39 Regulation of exocytosis 
RAB27B 
RAB3A 
 
0.0101 
40 Negative regulation of cell differentiation 
HOXA7 
THOC5 
HDAC4 
TOB1 
 
0.0106 
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Table D-7a: Down-regulated genes from blood leukocytes at T2. The result for each 
biological process is listed in this table. For each process listed in second column the 
associated DE genes are presented in the third column of the table. The final column 
shows the p-value associated with each process.  
 
Count Biological process Genes Pvalue  
1 Mitotic sister chromatid segregation 
KIAA0892 
NCAPG 
 
0.0086 
2 Sister chromatid segregation 
KIAA0892 
NCAPG 
 
0.0091 
3 RNA splicing 
FRG1 
PHF5A 
SNRPD3 
LSM10 
 
0.0152 
4 Ribonucleoprotein complex biogenesis 
EXOSC9 
FRG1 
SNRPD3 
 
0.0212 
5 mRNA processing 
FRG1 
PHF5A 
SNRPD3 
LSM10 
 
0.0217 
6 DNA packaging 
NCAPG 
SHPRH 
 
0.0284 
7 rRNA processing 
EXOSC9 
FRG1 
 
0.0284 
8 RNA processing 
EXOSC9 
FRG1 
PHF5A 
SNRPD3 
LSM10 
 
0.0307 
9 rRNA metabolic process 
EXOSC9 
FRG1 
 
0.0311 
10 Regulation of lipase activity 
PPP2R4 
HRH1 
 
0.0311 
11 Lipoprotein metabolic process 
LIPG 
CHM 
 
0.032 
12 mRNA metabolic process 
FRG1 
PHF5A 
 
0.0353 
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13 Chromosome segregation 
KIAA0892 
NCAPG 
 
0.0387 
14 DNA conformation channge 
NCAPG 
SHPRH 
 
0.0397 
15 Nuclear division  
KIAA0892 
LMLN 
NCAPG 
 
0.0543 
16 Mitosis 
KIAA0892 
LMLN 
NCAPG 
 
0.0543 
17 Ribosome biogenesis 
EXOSC9 
FRG1 
 
0.0557 
18 Organelle fission 
KIAA0892 
LMLN 
NCAPG 
 
0.0584 
19 M phase of mitotic cell cycle 
KIAA0892 
LMLN 
NCAPG 
 
0.0591 
20 Response to nutrient 
LIPG 
AACS 
 
0.0639 
21 Regulation of hydrolase activity 
CHM 
PPP2R4 
HRH1 
 
0.0771 
22 Potassium ion transport 
SLC24A5 
KCNJ8 
 
0.0839 
23 Cell division 
KIAA0892 
LMLN 
NCAPG 
 
0.0895 
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Table D-7b: Up-regulated genes from blood leukocytes at T2. The result for each 
biological process is listed in this table. For each process listed in second column the 
associated DE genes are presented in the third column of the table. The final column 
shows the p-value associated with each process.  
 
Count Biological process Genes Pvalue 
1 Isoprenoid biosynthetic process 
DHRS9 
HMGCR 
 
0.0019 
2 Steroid metabolic process 
DHRS9 
CYP21A2 
OSBPL8 
HMGCR 
 
0.0028 
3 Cellular lipid metabolic process 
AGPAT5 
DHRS9 
CYP21A2 
OSBPL8 
PIGP 
CRYL1 
HMGCR 
 
0.0028 
4 Lipid biosynthetic process 
AGPAT5 
DHRS9 
CYP21A2 
PIGP 
HMGCR 
 
0.0029 
5 Purine ribonucleoside metabolic process 
HMGCR 
QTRTD1 
 
0.0033 
6 Purine nucleoside metabolic process 
HMGCR 
QTRTD1 
 
0.0033 
7 Lipid metabolic process  
AGPAT5 
DHRS9 
CYP21A2 
OSBPL8 
PIGP 
CRYL1 
HMGCR 
 
0.0071 
8 Ribonucleoside metabolic process 
HMGCR 
QTRTD1 
 
0.0073 
9 Isoprenoid metabolic process 
DHRS9 
HMGCR 
 
0.0077 
10 nucleoside metabolic process 
HMGCR 
QTRTD1 
 
0.0128 
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11 Phospholipid biosynthetic process 
AGPAT5 
PIGP 
 
0.0318 
12 Steroid biosynthetic process 
CYP21A2 
HMGCR 
 
0.0348 
13 Phospholipid metabolic process 
AGPAT5 
PIGP 
 
0.0886 
14 Organophosphate metabolic process 
AGPAT5 
PIGP 
 
0.0986 
15 Sexual reproduction  
ZPBP 
HMGCR 
GDF9 
 
0.0998 
 
 
 
Table D-8a: Down-regulated genes from blood leukocytes at T4. The result for each 
biological process is listed in this table. For each process listed in second column the 
associated DE genes are presented in the third column of the table. The final column 
shows the p-value associated with each process.  
 
Count Biological processes Genes Pvalue 
1 Spinal cord oligodendrocyte 
cell differentiation NKX2-2 
ASCL1 
 
5.53E-05 
2 Oligodendrocyte cell fate 
specification NKX2-2 
ASCL1 
 
5.53E-05 
3 Glial cell fate specification 
NKX2-2 
ASCL1 
 
5.53E-05 
4 Oligodendrocyte cell fate 
commitment NKX2-2 
ASCL1 
 
5.53E-05 
5 Spinal cord oligodendrocyte 
cell fate specification NKX2-2 
ASCL1 
 
5.53E-05 
6 Succinyl-CoA metabolic 
process SUCLA2 
SUCLG2 
 
0.0002 
7 Glial cell fate commitment 
NKX2-2 
ASCL1 
 
0.0005 
8 Regulation of neuron 
differentiation LRRC4C 
MAG 
NKX2-2 
ASCL1 
 
0.0031 
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9 Oligodendrocyte development 
NKX2-2 
ASCL1 
 
0.0035 
10 Cell differentiation in spinal 
cord  NKX2-2 
ASCL1 
 
0.0035 
11 Regulation of neurogenesis 
LRRC4C 
MAG 
NKX2-2 
ASCL1 
 
0.0084 
12 Neuromuscular junction 
development NRD1 
UTRN 
 
0.0087 
13 Oligodendrocyte 
differentiation NKX2-2 
ASCL1 
 
0.0087 
14 Glial cell development 
NKX2-2 
ASCL1 
 
0.0096 
15 Neuron fate commitment 
NKX2-2 
ASCL1 
 
0.0096 
16 central nervous system neuron 
EPHB1 
ASCL1 
 
0.0096 
17 cell development 
REC8 
TFCP2L1 
LRRC4C 
ZBTB16 
ASCL1 
UTRN 
NKX2-2 
MAG 
EPHB1 
NRD1 
 
0.0105 
18 spinal cord development 
NKX2-2 
ASCL1 
 
0.0106 
19 tricarboxylic acid cycle 
SUCLA2 
SUCLG2 
 
0.0116 
20 acetyl-CoA catabolic process 
SUCLA2 
SUCLG2 
 
0.0116 
21 coenzyme catabolic process 
SUCLA2 
SUCLG2 
 
0.0126 
22 developmental maturation 
REC8 
 
0.0131 
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23 regulation of nervous system 
development LRRC4C 
MAG 
NKX2-2 
ASCL1 
 
0.0138 
24 central nervous system neuron 
EPHB1 
ASCL1 
 
0.0148 
25 cofactor catabolic process 
SUCLA2 
SUCLG2 
 
0.0160 
26 female pregnancy 
HPGD 
TFCP2L1 
SULT1E1 
 
0.0166 
27 regulation of cell development 
LRRC4C 
MAG 
NKX2-2 
ASCL1 
 
0.0174 
28 acetyl-CoA metabolic process 
SUCLA2 
SUCLG2 
 
0.0197 
29 cell fate specification 
NKX2-2 
ASCL1 
 
0.0197 
30 cytokinesis 
BIN3 
CNTROB 
 
0.0237 
31 aerobic respiration 
SUCLA2 
SUCLG2 
 
0.0251 
32 cell morphogenesis 
TFCP2L1 
BIN3 
LRRC4C 
MAG 
BBS7 
EPHB1 
 
0.0260 
33 protein processing 
CPE 
C4BPA 
CAPN1 
 
0.0272 
34 cell fate commitment 
NKX2-2 
TCF3 
ASCL1 
 
0.0281 
35 regulation of axonogenesis 
LRRC4C 
MAG 
 
0.0327 
36 protein maturation CPE 
 
0.0350 
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37 cellular component 
morphogenesis TFCP2L1 
BIN3 
LRRC4C 
MAG 
BBS7 
EPHB1 
 
0.0381 
38 regulation of neuron 
projection LRRC4C 
MAG 
 
0.0445 
39 glial cell differentiation 
NKX2-2 
ASCL1 
 
0.0445 
40 cell projection morphogenesis 
LRRC4C 
MAG 
BBS7 
EPHB1 
 
0.0504 
 
 
 
Table D-8b: Up-regulated genes from blood leukocytes at T4. The result for each 
biological process is listed in this table. For each process listed in second column the 
associated DE genes are presented in the third column of the table. The final column 
shows the p-value associated with each process.  
 
Count Biological process  Genes pvalue 
1 Embryonic digit morphogenesis 
GNA12 
GLI3 
 
0.0083 
2 Embryonic organ morphogenesis 
PROX1 
GLI3 
 
0.0093 
3 Negative regulation of epithelial cell proliferation 
RUNX3 
KRT4 
 
0.0093 
4 Spinal cord development 
PROX1 
GLI3 
 
0.0141 
5 Lung development 
PROX1 
GLI3 
  BMPR2 
0.0158 
6 Negative regulation of transport 
TRAT1 
GNAI2 
ARL6IP5 
FAF1 
 
0.0167 
7 Regulation of cell cycle 
PROX1 
 
0.0172 
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8 Respiratory tube development 
PROX1 
GLI3 
BMPR2 
 
0.0173 
9 Cellular iron ion homeostasis 
HFE 
ACO1 
 
0.0182 
10 Respiratory system development 
PROX1 
GLI3 
BMPR2 
 
0.0195 
11 Cellular response to starvation 
BMPR2 
HFE 
 
0.0211 
12 Nuclear-transcribed mRNA catabolic process 
PAN3 
RBM8A 
 
0.0211 
13 Protein modification process 
GRK5 
BMPR2 
PAN3 
UBE2I 
CDKL1 
PMM2 
HLCS 
CCNT1 
P4HA2 
NEK2 
PCNP 
ST8SIA1 
ALG2 
MAP3K14 
GAD1 
GNAI2 
TAOK3 
 
0.0222 
14 Iron ion homeostasis 
HFE 
ACO1 
 
0.0227 
15 Camera-type eye morphogenesis 
PROX1 
GLI3 
 
0.026 
16 Nuclear-transcribed mRNA catabolic 
PAN3 
RBM8A 
 
0.0277 
17 Odontogenesis of dentine-containing tooth 
GLI3 
AMBN 
 
0.0294 
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18 Response to starvation 
BMPR2 
 
0.0294 
19 Embryonic organ development 
PROX1 
GLI3 
 
0.0330 
20 Macromolecule modification 
GRK5 
BMPR2 
PAN3 
UBE2I 
CDKL1 
PMM2 
HLCS 
CCNT1 
P4HA2 
NEK2 
PCNP 
ST8SIA1 
ALG2 
MAP3K14 
GAD1 
GNAI2 
TAOK3 
 
0.0331 
21 Bone mineralization 
BMPR2 
AMBN 
 
0.0349 
22 Actin filament organization 
PROX1 
ARPC4 
ARPC5L 
 
0.0353 
23 Cellular response to nutrient levels 
BMPR2 
HFE 
 
0.0368 
24 mRNA catabolic process 
PAN3 
RBM8A 
 
0.0368 
25 Tube development 
PROX1 
GLI3 
BMPR2 
BBS5 
 
0.0380 
26 Regulation of protein import into nucleus 
GLI3 
FAF1 
 
0.0408 
27 Regulation of cyclin-dependent protein 
CDC6 
CCNT1 
 
0.0428 
28 Epithelial cell differentiation PROX1 
 
0.0432 
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29 Actin filament polymerization 
ARPC4 
ARPC5L 
 
0.0449 
30 Epithelium development 
PROX1 
DMBT1 
GLI3 
KRT4 
 
0.0456 
31 Regulation of cellular component 
PROX1 
ARPC5L 
FAF1 
 
0.0457 
32 B cell differentiation 
DCLRE1C 
IL2RG 
 
0.0491 
33 Antigen processing and presentation 
PROCR 
HFE 
 
0.0491 
34 Protein amino acid phosphorylation 
GRK5 
BMPR2 
PAN3 
CCNT1 
NEK2 
CDKL1 
MAP3K14 
GNAI2 
TAOK3 
 
0.0518 
35 Interspecies interaction between 
DMBT1 
UBE2I 
CCNT1 
SPEN 
IL2RG 
 
0.0518 
36 Protein amino acid glycosylation 
ALG2 
ST8SIA1 
PMM2 
 
0.0533 
37 Glycosylation 
ALG2 
ST8SIA1 
PMM2 
 
0.0533 
38 Macromolecule glycosylation 
ALG2 
ST8SIA1 
PMM2 
 
0.0533 
39 Cellular defense response 
TRAT1 
 
0.0535 
40 Odontogenesis  0.0557 
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Table D-9: List of differentially expressed genes (pvalue <0.05 and fold change cut off 
of 1.5) between the affected and the unaffected foals from blood leukocytes at birth. 
 
Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
ABCB10 XM_001496372 XP_001496422 -1.522481717 0.003156131 
ACADVL XM_001504761 XP_001504811 0.901272857 0.023283085 
ACTC1 XM_001503650 XP_001503700 0.622197552 0.009610891 
ACTG1 XM_001487824 XP_001487874 0.687288844 0.007623722 
ADAD1 XM_001503028 XP_001503078 0.60602188 0.027378802 
AKAP9 XR_036011 NULL -0.802540398 0.023602559 
AMZ1 XM_001492380 XP_001492430 -0.730530981 0.021308767 
ANKRD10 XM_001496718 XP_001496768 0.807406888 0.047847196 
ARF3 XM_001504136 XP_001504186 -0.684753825 0.016468376 
ARHGAP1 XM_001489971 XP_001490021 -0.786564378 0.013045788 
ARMC9 XM_001495098 XP_001495148 0.624324393 0.012766311 
ATF4 NULL NULL 0.727088156 0.014060121 
ATP13A2 XM_001488576 XP_001488626 -1.548655689 0.00782911 
ATP13A5 XM_001498779 XP_001498829 -0.637994023 0.029526287 
AURKC XM_001501997 XP_001502047 0.719072491 0.010124505 
BBS10 XM_001488843 XP_001488893 -1.034576923 0.010443723 
BCMO1 XM_001499593 XP_001499643 -0.779765514 0.044749297 
BMP1 XM_001490465 XP_001490515 -0.777785796 0.035909583 
BRI3BP XM_001493505 XP_001493555 -0.597763284 0.042605735 
BVES XM_001503931 XP_001503981 0.649323393 0.041745944 
C11orf49 CD528548 NP_001093883 0.878315891 0.01865831 
C11orf49 XR_035773 NULL 0.868351106 0.03417004 
C11orf49 XM_001504556 XP_001504606 0.640691012 0.024405146 
C11orf49 XR_036183 NULL 0.582168227 0.029149313 
C12orf57 CX604375 XP_001497722 0.818085845 0.029819354 
C12orf62 XM_001504244 NULL 0.690036532 0.028337127 
C14orf105 XM_001496486 XP_001496536 0.864715965 0.046449978 
C14orf43 XR_035847 NULL 0.625522097 0.017656989 
C15orf21 XR_035959 NULL 0.639346271 0.018260101 
C16orf78 XM_001488683 XP_001488733 -1.677504406 0.010737236 
C18orf19 XM_001488709 XP_001488759 -1.17282182 0.01369973 
C1orf86 XM_001495164 XP_001495214 -2.030232074 0.002533635 
C2orf42 XM_001492837 XP_001492887 -0.903203925 0.02092908 
C5orf30 XM_001504598 XP_001504648 -0.759126552 0.014760365 
C7orf31 XM_001498834 XP_001498884 -0.698931067 0.016417536 
C9orf52 NULL NULL 0.723924053 0.008753612 
CARD9 XM_001496216 XP_001496266 0.705711141 0.008625631 
CBLB XM_001503354 XP_001503404 -1.370705081 0.044257806 
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CC2D1A XR_036084 NULL -0.893623584 0.044553683 
CCDC25 XM_001492881 XP_001492931 0.815060748 0.029013163 
CCDC56 XM_001493268 XP_001493318 0.682068712 0.034750671 
CD99L2 NULL NULL 0.827808729 0.021303852 
CDAN1 NULL NULL -1.272231301 0.039209144 
CDK2AP2 CX594512 NULL 1.049718151 0.027878357 
CDKN2AIP XM_001491626 NULL -1.329129282 0.001080992 
CEBPB CX605423 NULL 0.667972368 0.032229854 
CHAD NULL NULL -2.503411503 0.0069877 
CHML XM_001491347 XP_001491397 0.708094215 0.037483441 
CLPX XM_001498202 XP_001498252 -1.297168438 0.024119705 
CNBP XM_001504974 XP_001505024 -0.994942386 0.047939445 
CNOT6 XM_001500848 XP_001500898 -0.696433103 0.006387514 
COL3A1 AF117954 NULL -0.704862657 0.021207748 
COL9A1 CX605273 NULL -0.795098338 0.025378887 
CPLX1 XM_001488011 XP_001488061 -0.664168141 0.041519617 
CPLX3 XM_001493846 XP_001493896 0.631167371 0.012343181 
CREB3 XR_036492 NULL -0.969029193 0.013209177 
CSRP2 DN508692 XP_001489207 0.906642761 0.018317778 
CST11 XM_001491723 XP_001491773 -2.731500887 0.00540897 
CUEDC2 XM_001498878 XP_001498928 -0.67696995 0.012335056 
CXorf36 XM_001490751 XP_001490801 0.864505838 0.013142682 
CYP2B6 XM_001498423 XP_001498473 -0.907469641 0.013625083 
DBN1 XM_001498360 XP_001498410 -2.012820167 0.004826148 
DDT XM_001489369 XP_001489419 0.903804782 0.046885091 
DES XM_001492002 XP_001492052 -0.600627459 0.043119663 
DNTTIP2 XM_001491388 XP_001491438 0.968249056 0.005153026 
EGFLAM XM_001499382 XP_001499432 -0.610634583 0.027941388 
EMR1 XM_001496454 XP_001496504 -0.631221162 0.025719867 
EMX1 XM_001491947 XP_001491997 -0.897235784 0.039211738 
ENPP5 XM_001502620 XP_001502670 -0.693124786 0.046822185 
ERCC3 XM_001488507 XP_001488557 -1.188478791 0.013511478 
FAM3C CX603884 NULL -0.607867065 0.012265239 
FAM83C XM_001501577 XP_001501627 0.974123457 0.031592622 
FGA BM780427 NULL -0.665213353 0.040351304 
FHDC1 XM_001501253 XP_001501303 -0.768160098 0.044649192 
FILIP1 XM_001503595 XP_001503645 0.791246118 0.026489848 
GALNT2 XM_001496209 XP_001496259 -1.809968873 0.007554082 
GLRA2 XM_001489464 XP_001489514 -0.662502348 0.029280425 
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GOLGA7 XM_001490279 XP_001490329 -0.90529579 0.041389813 
GSN U31699 NP_001075422 0.914541879 0.003675405 
GSTO1 XM_001499377 XP_001499427 0.780389597 0.00693771 
GZMB AM183299 NP_001075350 0.779950329 0.029017827 
HDAC4 XM_001497151 XP_001497201 0.608480982 0.012794377 
HDLBP XM_001502985 XP_001503035 -0.639252649 0.012543945 
HN1L NULL NULL -0.887943569 0.02023213 
HOXA7 XM_001499485 XP_001499535 0.729172864 0.011052482 
HTR3E XM_001497129 XP_001497179 -0.638022949 0.009233634 
IFITM1 CD465069 XP_001488655 0.711230302 0.011640268 
IHH XM_001491778 XP_001491828 -0.714841373 0.039810098 
IL27RA NULL NULL -0.95938214 0.019656252 
ING5 XM_001497795 XP_001497845 0.629538835 0.017695541 
INTS10 XM_001488562 XP_001488612 -0.614457092 0.023868351 
IQCF1 XM_001492952 NULL 1.136365164 0.040843757 
JAK2 XM_001500499 XP_001500549 -0.665788127 0.036663078 
KCNH1 NULL NULL 0.729327604 0.036860455 
KIAA1671 XM_001496100 XP_001496150 0.584708507 0.043126379 
KLHL20 XM_001493014 XP_001493064 -0.611939984 0.016770335 
LAPTM5 XM_001503920 XP_001503970 0.887760158 0.032743447 
LILRB4 XM_001489413 XP_001489463 0.617797169 0.024823215 
LOC130074 CX603739 XP_001504975 -0.751620222 0.026871046 
LOC348751 XM_001502768 XP_001502818 -0.98525902 0.044604284 
LOC442388 XM_001497709 XP_001497759 -0.581122895 0.034941904 
LOC651536 XM_001492588 NULL -0.605228104 0.033234864 
LRGUK XM_001498102 XP_001498152 0.697014041 0.032402976 
LRP12 XM_001494687 XP_001494737 -0.697442719 0.02669819 
LRRC23 XM_001497546 XP_001497596 -2.120128088 0.000971804 
LTBP4 NULL NULL -0.711473254 0.045515496 
MAP1LC3B XM_001493613 XP_001493663 -0.685757126 0.027611451 
MET CX603152 NULL -0.758574781 0.03476553 
MGC50722 XM_001498447 XP_001498497 -0.698113916 0.007357438 
MTAP XM_001495991 XP_001496041 0.99870131 0.003737323 
NARFL XM_001496246 XP_001496296 0.754130129 0.024830181 
NDC80 XM_001492535 XP_001492585 -1.024091435 0.039873926 
NDP XM_001490351 XP_001490401 0.696997455 0.036657447 
NEBL XM_001496364 XP_001496414 -1.48846536 0.039488705 
NLRP13 XM_001490754 XP_001490804 0.888155115 0.035959263 
NUBP1 XR_035869 NULL -1.684632869 0.002788328 
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NULL CX594111 NULL 1.000655406 0.013816981 
NULL CD467944 NULL 0.950169391 0.012740142 
NULL XM_001498970 NULL 0.921133159 0.013130607 
NULL DN507341 NULL 0.89610717 0.021323145 
NULL CD469043 NULL 0.749399338 0.036566827 
NULL CD528850 NULL 0.630558535 0.021685068 
NULL CX600948 NULL 0.611322518 0.014384755 
NULL CX600791 NULL -1.35155731 0.009502707 
NULL XM_001497251 NULL -1.112742623 0.003650484 
NULL CX600585 NULL -1.009681056 0.015361551 
NULL XM_001499189 NULL -0.99487445 0.033004253 
NULL XR_035972 NULL -0.978774712 0.0089167 
NULL XM_001489861 XP_001489911 -0.934577051 0.018195029 
NULL XM_001490009 NULL -0.73262925 0.044400263 
NULL XM_001491180 XP_001491230 -0.729432625 0.0036063 
NULL CX605044 NULL -0.614822777 0.04981404 
NULL CX593054 NULL -0.605222621 0.019060131 
NULL CX592395 NULL -0.602290635 0.039202967 
NULL XM_001496183 XP_001496233 -0.591688473 0.04836191 
OLAH XM_001498643 XP_001498693 -0.674704441 0.031676262 
OR4A16 XM_001490392 XP_001490442 0.653326814 0.021098789 
OR4K15 XM_001502087 XP_001502137 0.941719294 0.04388778 
OR51G2 XM_001498239 XP_001498289 -1.197862377 0.041200636 
OR5D14 XM_001494979 XP_001495029 -0.642174291 0.041844404 
OSBPL2 CX598426 NULL 0.613023914 0.046657096 
PARD6A XM_001498013 XP_001498063 0.876695706 0.040284707 
PDHB XM_001489051 XP_001489101 -0.845803576 0.007267214 
PDP2 XM_001496151 XP_001496201 -0.793325814 0.024579976 
PHOX2A XM_001499157 XP_001499207 0.651382374 0.0474398 
PLA2G2F XM_001501686 XP_001501736 -0.59752463 0.030788559 
PLD5 XM_001492999 XP_001493049 -0.828774696 0.027651709 
PMP22 CX595068 NULL 0.654807846 0.027389336 
POLD4 XM_001497352 XP_001497402 0.651250647 0.031066347 
PPP1R2 XM_001491737 XP_001491787 0.618139669 0.033786061 
PPP2R1A XM_001496260 XP_001496310 -0.610448566 0.027754824 
PRAME XM_001493673 XP_001493723 -0.651626092 0.015159623 
PRPF18 XM_001498739 XP_001498789 -0.767099557 0.041883146 
PRPF40B NULL NULL -0.710240414 0.028447653 
PRPS1 XM_001496452 XP_001496502 -0.683869051 0.008400077 
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PSKH2 XM_001489877 XP_001489927 -0.590348516 0.016646816 
RAB27B XM_001487851 XP_001487901 0.644456196 0.031204257 
RAB38 XM_001489498 XP_001489548 -0.612629047 0.031917447 
RAB3A XM_001503228 XP_001503278 0.796919996 0.042028926 
RAB7L1 XM_001490736 XP_001490786 0.813846764 0.020621332 
RAPH1 XM_001497711 XP_001497761 0.842937083 0.021728695 
RFXANK XM_001503453 NULL 0.754674467 0.024953545 
RG9MTD1 XR_036450 NULL -1.118019154 0.027238049 
RPAP1 XM_001503411 NULL -0.620997182 0.036390989 
RPAP2 XM_001492375 XP_001492425 -1.379780399 0.044837386 
RPL22 CX605634 NULL -0.74979204 0.014943077 
RPS27A NULL NULL 0.82564823 0.044835487 
RXFP3 XM_001498125 XP_001498175 -0.76063494 0.005603248 
S100A12 CD535886 XP_001494448 0.990596593 0.021916997 
S100A8 XM_001493589 XP_001493639 0.63897673 0.010271841 
SCN4B XM_001502720 XP_001502770 -0.616263269 0.04380285 
SCUBE1 XM_001500812 XP_001500862 -1.414001903 0.048196995 
SDPR XM_001502303 XP_001502353 1.524486532 0.002019344 
SEC22B CX606051 XP_001501277 0.683421352 0.033324448 
SERPINB1 M91161 NP_001075416 0.757844511 0.020101086 
SFMBT1 XM_001492162 XP_001492212 -0.63344528 0.017762201 
SLC2A4RG XM_001492979 XP_001493029 0.742830148 0.030544217 
SLC35D2 XM_001494155 XP_001494205 -0.706969785 0.016322033 
SLC43A2 XM_001502290 XP_001502340 -0.984821681 0.035316119 
SLC7A4 XM_001488218 XP_001488268 0.895561033 0.006688317 
SLC7A4 XR_036162 NULL 0.688296445 0.049590682 
SLITRK4 XM_001490209 XP_001490259 0.61196064 0.042242472 
SMC2 XM_001503998 XP_001504048 -0.616404023 0.019650268 
SMPX NULL NULL 0.631892092 0.020585721 
SNCAIP XM_001504535 XP_001504585 -0.833751075 0.004663087 
SNX1 EF397509 NULL -0.703330712 0.006209154 
SOHLH1 XM_001498247 XP_001498297 -0.583529068 0.039215078 
SPATA9 XM_001504610 XP_001504660 -0.683793601 0.049722137 
SPI1 XM_001491380 XP_001491430 0.899636967 0.019534518 
SRP19 XM_001503550 XP_001503600 0.74581405 0.017523659 
SRR XM_001504357 XP_001504407 -0.707012981 0.026784075 
STX11 XM_001502432 XP_001502482 1.055050992 0.004410196 
STX4 XM_001500858 XP_001500908 0.631260279 0.048415445 
SULT2A1 XM_001487871 XP_001487921 -0.676260682 0.037176082 
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SUMF1 XM_001496576 XP_001496626 -1.002503848 0.022002055 
TCTE3 XM_001488610 XP_001488660 -1.093154066 0.018066472 
TFCP2L1 XM_001498814 XP_001498864 -0.768680399 0.006497138 
THOC5 XM_001499034 XP_001499084 0.812645546 0.036552415 
TMEM2 XM_001489726 XP_001489776 0.69954791 0.022231162 
TOB1 XM_001503158 XP_001503208 0.704725533 0.046209742 
TSPO XM_001503143 XP_001503193 0.85276228 0.023505648 
TSSK2 XM_001489006 XP_001489056 0.656252757 0.019436282 
TUBGCP3 XM_001497010 XP_001497060 -0.676601693 0.022195001 
UBE2E3 XM_001497741 XP_001497791 -0.689896865 0.008389007 
UHRF1BP1 XM_001498458 XP_001498508 0.776616759 0.016476293 
UMOD XM_001488179 XP_001488229 -0.736600076 0.040685821 
UNC45B NULL NULL -1.322813389 0.023183771 
VAMP7 XM_001498227 XP_001498277 -0.664586098 0.01374208 
VASP NULL NULL 0.724741729 0.007598145 
ZCCHC16 XM_001488714 XP_001488764 0.688498471 0.013570475 
ZNF182 XM_001501391 XP_001501441 -0.661674129 0.047936578 
ZNF226 XR_036324 NULL 0.96101549 0.048960251 
ZNF264 XM_001492159 XP_001492209 0.784328199 0.016232432 
ZNF423 XM_001491336 XP_001491386 -0.71004126 0.022938436 
ZNF462 XM_001493275 XP_001493325 -1.26585732 0.010720258 
 
 
 
 
Table D-10: List of differentially expressed genes (pvalue <0.05 and fold change cut off 
of 1.5) between the affected and the unaffected foals from blood leukocytes at week-2. 
 
Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
AACS XM_001493527 XP_001493577 -0.72554489 0.030617728 
ADAMDEC1 XM_001491607 XP_001491657 0.674077059 0.025630896 
AEBP1 CX603424 NULL -0.777809664 0.008218916 
AGPAT5 XM_001495033 XP_001495083 0.902337995 0.018605436 
AMZ1 XM_001492380 XP_001492430 -0.620366362 0.044609579 
ANKRD50 XM_001502891 XP_001502941 0.731885196 0.024325397 
ARHGAP11A XM_001503656 XP_001503706 0.671819441 0.009123263 
ASB5 XM_001492958 XP_001493008 -0.760489141 0.026324409 
BTD XM_001494901 XP_001494951 0.692110218 0.020796682 
C13orf1 XM_001488590 XP_001488640 1.0131063 0.040576108 
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C14orf140 XM_001491724 XP_001491774 0.683981542 0.038679422 
C15orf44 XM_001497803 XP_001497853 -0.759673253 0.03836822 
C16orf72 XM_001490783 XP_001490833 -0.861095054 0.009975494 
C1orf62 XM_001493547 XP_001493597 0.668014846 0.049629074 
C20orf94 XM_001495300 XP_001495350 -0.637047796 0.04356551 
C21orf70 NULL NULL 1.102323581 0.004098597 
C2orf60 XM_001502779 XP_001502829 0.640462922 0.021326395 
C4orf22 XM_001492815 XP_001492865 0.679215952 0.036980733 
C5orf37 XM_001504673 XP_001504723 0.674457914 0.011135657 
CACNB2 XM_001497017 XP_001497067 0.958617546 0.002267408 
CACNG3 XM_001501201 XP_001501251 -0.879242373 0.029964138 
CAMK1D XM_001499103 XP_001499153 0.705264281 0.015947479 
CENTA2 XM_001504020 XP_001504070 -0.590886198 0.027026232 
CEP192 XM_001490884 NULL -0.853455989 0.036168146 
CHM XM_001500825 XP_001500875 -0.933734768 0.032535793 
CLCA2 XM_001496218 XP_001496268 -0.788624762 0.017107988 
CNKSR3 XM_001493771 XP_001493821 -0.706886084 0.031665762 
CRNKL1 XM_001489795 NULL 0.615174666 0.043822694 
CRYL1 XM_001488972 XP_001489022 0.689884118 0.011069559 
CST8 XM_001491551 XP_001491601 -0.875056149 0.039513274 
CYP21A2 XM_001491922 XP_001491972 1.064524789 0.035587436 
CYP2C18 XM_001502256 XP_001502306 -0.678186128 0.010695019 
DDX18 NULL NULL -0.85162656 0.037689935 
DDX47 XM_001501444 XP_001501494 0.681498892 0.012816292 
DHRS9 XM_001497633 XP_001497683 0.615176779 0.018225767 
DIDO1 XM_001491593 XP_001491643 -0.744185199 0.010653202 
DNAH2 XM_001495846 NULL -1.060455206 0.036124645 
EHD2 XM_001503200 XP_001503250 0.754746252 0.010570599 
EXOSC9 XM_001503119 XP_001503169 -0.930154126 0.038897905 
FAM53C XM_001504275 XP_001504325 -0.633062091 0.020270886 
FAM55C XM_001503412 XP_001503462 -0.601986037 0.041772985 
FLJ46481 XM_001499734 XP_001499784 -0.609195651 0.048565196 
FRG1 XM_001489630 XP_001489680 -0.600862611 0.038983822 
GABPA XR_036314 NULL 0.647109576 0.030150666 
GBAS XM_001493226 XP_001493276 1.68849694 0.014052715 
GDF9 XM_001504427 XP_001504477 0.737468862 0.047173128 
GLT25D2 XM_001489756 XP_001489806 -0.697696741 0.01147901 
GMPPB XM_001494187 XP_001494237 -0.712917959 0.026286979 
GPR87 XM_001489247 XP_001489297 -0.586382239 0.014947221 
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GRPEL2 XM_001503782 XP_001503832 0.848462089 0.028033358 
HDHD1A XM_001488459 XP_001488509 0.591686148 0.037073927 
HEBP2 XM_001503590 XP_001503640 0.667160065 0.0342125 
HIST2H2AA4 CX603409 XP_001488204 0.738002808 0.038396082 
HMGCR XM_001504678 XP_001504728 0.678907621 0.008240531 
HNRPAB XM_001499029 XP_001499079 1.033551532 0.038357121 
HRH1 DQ681103 NP_001075388 -0.989025512 0.020323069 
HSPD1 XM_001502665 XP_001502715 0.66368848 0.019353124 
IHPK3 XM_001497932 XP_001497982 -0.802911222 0.004355956 
IMPDH2 XM_001494550 XP_001494600 -0.591455282 0.024789857 
KCNJ8 XM_001502229 XP_001502279 -1.035812591 0.024806367 
KIAA0460 XM_001489478 XP_001489528 1.352452817 0.035612132 
KIAA0892 XM_001503477 XP_001503527 -0.632646763 0.021002053 
KLHL2 XM_001498031 XP_001498081 -0.62216799 0.033910232 
KLK1 AY290704 NP_001075362 -0.750103253 0.046262651 
KRT13 XM_001496876 XP_001496926 -0.60259676 0.028006062 
KRT23 XM_001497479 XP_001497529 0.635396798 0.039521605 
LGALS3 DN506570 NULL -0.668513986 0.027895779 
LIPG XM_001499159 XP_001499209 -0.839139166 0.037984955 
LMLN XM_001499880 XP_001499930 -0.687903776 0.043202676 
LOC647024 XM_001496845 NULL 0.651542448 0.037735846 
LOC731848 XM_001490664 NULL 0.645230804 0.038918497 
LRRC32 XM_001494868 XP_001494918 -0.670232464 0.021334099 
LSM10 XM_001499047 XP_001499097 -0.85220108 0.007007341 
MED29 XM_001497555 XP_001497605 -0.613728099 0.045638989 
MMP7 XM_001498809 XP_001498859 -0.84269001 0.008027363 
MNDA XM_001490503 XP_001490553 -0.631020899 0.049034476 
MRPL40 XM_001488462 XP_001488512 0.64823975 0.028851079 
MTERFD1 XM_001490437 XP_001490487 0.756942384 0.03628174 
MXRA5 XM_001500228 XP_001500278 -0.625232292 0.019498305 
NCAPG XR_036336 NULL -0.77827476 0.016590509 
NULL CX604379 NULL -1.098070909 0.012462016 
NULL CX601609 NULL -1.07005894 0.00674355 
NULL XM_001503112 NULL -0.898076939 0.041979768 
NULL CD469526 NULL -0.769291998 0.017362102 
NULL AW260823 NULL -0.688548257 0.044390525 
NULL XM_001498856 XP_001498906 -0.600126118 0.027026568 
NULL CX604802 NULL -0.599349826 0.04363699 
NULL CD464486 NULL -0.584683002 0.047939659 
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NULL DN509596 NULL 0.976336716 0.026426804 
NULL CX594703 NULL 0.910829827 0.028742552 
NULL CX600364 NULL 0.807012414 0.022943073 
NULL CD528740 NULL 0.771652352 0.02940802 
NULL CX600981 NULL 0.73574549 0.011630911 
NULL XM_001498676 XP_001498726 0.72731217 0.029067119 
NULL DN503867 NULL 0.714703071 0.011442931 
NULL CX595746 NULL 0.685704186 0.040396142 
NULL CX606013 NULL 0.672423188 0.035500837 
NULL CX600772 NULL 0.623763027 0.040570204 
OR2W1 XM_001494282 XP_001494332 0.698038515 0.017990243 
OR4A15 XM_001495944 NULL -0.87414825 0.0268891 
OR4F16 XM_001502069 XP_001502119 0.777416324 0.017700794 
OR7A10 XM_001493265 XP_001493315 0.984070755 0.017341 
OSBPL8 XM_001491827 XP_001491877 0.798807958 0.005824794 
OSCAR NULL NULL 0.794470797 0.047685196 
P4HB XM_001489491 XP_001489541 -0.871093248 0.007967631 
PDE11A XM_001500621 XP_001500671 0.725605803 0.010807397 
PHF5A XM_001502490 XP_001502540 -0.615030668 0.040574665 
PI3 BM734843 XP_001503236 0.63207267 0.035996543 
PIGP XM_001493083 NULL 0.611478941 0.023165056 
PLEK2 XM_001499816 XP_001499866 -0.795496712 0.00917385 
PPP2R4 XM_001499731 XP_001499781 -0.656648407 0.047238736 
PRRT2 XM_001496325 XP_001496375 -0.811857158 0.016145111 
QTRTD1 XM_001501053 XP_001501103 0.931189423 0.001721637 
RAB39 XM_001501007 XP_001501057 0.736318608 0.018653711 
RAPGEF1 XM_001499272 XP_001499322 0.885580245 0.022452879 
RAPH1 XM_001497711 XP_001497761 -0.597421656 0.044153867 
RASL11A XM_001491587 XP_001491637 -0.623787216 0.031346302 
RHBDD3 XM_001499400 XP_001499450 -0.816565469 0.032317308 
RIOK2 XM_001504606 XP_001504656 -0.665750137 0.013661682 
RY1 CX599215 XP_001490747 0.582617927 0.045381358 
S100A8 XM_001493589 XP_001493639 0.626710318 0.038798705 
SHPRH XM_001502347 XP_001502397 -0.72368165 0.047278162 
SLC24A5 XM_001502401 XP_001502451 -0.84992871 0.033046352 
SNRPD3 DN508752 XP_001489110 -0.697387336 0.016940627 
TEK XM_001497116 XP_001497166 0.787741354 0.014292019 
TFPI2 XM_001492769 XP_001492819 0.916758134 0.014108727 
TMEM90A XM_001490537 XP_001490587 0.788711016 0.015588121 
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TMEM98 XM_001503985 XP_001504035 -0.614555194 0.023025361 
TRAF7 XR_036252 NULL 0.865000653 0.02922601 
VPS13D XM_001490932 XP_001490982 -0.712064314 0.026703383 
VSTM2A XM_001498645 XP_001498695 -0.61881097 0.048003937 
WDR16 XM_001504842 XP_001504892 -0.598652452 0.014630963 
WDR90 XM_001497075 XP_001497125 -1.147768165 0.01090289 
XRCC3 NULL NULL 0.686822519 0.007897402 
ZER1 XM_001500385 XP_001500435 0.680061032 0.043508235 
ZFP36L2 NULL NULL 0.664914342 0.047563354 
ZNF384 XM_001492314 XP_001492364 -0.69763729 0.044935558 
ZPBP XM_001496847 XP_001496897 0.657813419 0.037813488 
ZYX CX602081 NULL 0.927692683 0.021156171 
 
 
 
 
Table D-11: List of differentially expressed genes (pvalue <0.05 and fold change cut off 
of 1.5) between the affected and the unaffected foals from blood leukocytes at week-4. 
 
Gene Symbol NCBI accession RefSeq accession Log fold change Pvalue 
ABHD11 XM_001493693 XP_001493743 0.824432151 0.01683871 
ACO1 XM_001497806 XP_001497856 1.136674395 0.027261528 
ACSM1 XM_001493842 XP_001493892 -1.205818791 0.013995359 
ACTRT1 XM_001500549 XP_001500599 -0.908930759 0.03487858 
ALG2 NULL NULL 0.898576415 0.033543806 
AMBN XM_001488980 XP_001489030 0.693908477 0.044976625 
AMTN XM_001488949 XP_001488999 -0.672977135 0.046689522 
ANKRD44 XM_001500129 NULL 0.673019657 0.041133566 
ANKRD55 XM_001493668 XP_001493718 0.646250949 0.033824786 
ARHGAP1 XM_001489971 XP_001490021 -0.707295394 0.049296303 
ARL6IP5 XM_001498624 XP_001498674 0.668509416 0.039764869 
ARPC4 CD528440 NULL 0.835056066 0.007559072 
ARPC5L XM_001502042 XP_001502092 0.872911244 0.011008949 
ASCL1 XM_001497332 NULL -0.674414983 0.037221269 
ASCL3 XM_001504908 XP_001504958 -0.603224494 0.041007398 
BBS5 XM_001497722 XP_001497772 1.325015617 0.007329683 
BBS7 XM_001503097 XP_001503147 -1.06064282 0.015497735 
BIN3 XM_001490921 XP_001490971 -0.914487452 0.04207251 
BMPR2 XM_001497300 XP_001497350 0.781985453 0.013847916 
C10orf78 XM_001497644 XP_001497694 -0.730783412 0.040503406 
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C11orf63 XM_001501476 XP_001501526 -0.591156139 0.044800468 
C12orf40 XM_001501387 NULL 0.659184294 0.040382775 
C18orf24 XM_001499477 XP_001499527 -0.757619598 0.016200898 
C1orf123 CX593878 XP_001489591 0.828927528 0.035616484 
C1orf89 XM_001488699 XP_001488749 0.786037797 0.01404909 
C2orf44 XM_001501451 XP_001501501 0.926586862 0.033159663 
C4BPA XM_001492532 XP_001492582 -0.6757353 0.034734034 
C9orf117 XM_001500138 XP_001500188 0.618962069 0.045839285 
CAPN1 DN506160 NULL -0.658404724 0.042214151 
CBARA1 XM_001503797 XP_001503847 -1.13304612 0.000842687 
CBX7 XM_001499938 XP_001499988 0.981449203 0.047091849 
CCNT1 AF190905 NP_001075315 1.014017948 0.043345906 
CD163 XM_001492693 XP_001492743 0.874794175 0.02903147 
CDC6 XM_001497757 XP_001497807 0.765859809 0.020497884 
CDKL1 XM_001496680 XP_001496730 0.850717165 0.028567976 
CENTA2 XM_001504020 XP_001504070 0.761549991 0.045635333 
CEP55 XM_001502456 XP_001502506 -1.231715977 0.049450497 
CILP2 XR_036360 NULL 0.599404607 0.045188824 
CLIC2 XM_001494262 XP_001494312 0.768038142 0.015996986 
CNOT6 XM_001500848 XP_001500898 -0.724794156 0.015861262 
CNTROB XM_001504801 XP_001504851 -0.891468692 0.049142737 
COL28A1 XM_001494969 XP_001495019 0.670835285 0.030154821 
COLQ XM_001496422 XP_001496472 -0.836694034 0.019009154 
CPE XR_036288 NULL -0.925864549 0.024684604 
CRTAC1 XM_001501238 XP_001501288 0.767143469 0.02541414 
CYP2B6 XM_001498389 XP_001498439 -0.693056116 0.046602376 
DACH2 XM_001500765 XP_001500815 0.635695161 0.02847851 
DCDC2 XM_001495171 XP_001495221 0.653784358 0.025454344 
DCI XM_001498154 XP_001498204 -0.670046472 0.044823437 
DCLRE1C XM_001498475 XP_001498525 0.749791653 0.024574643 
DDX43 XM_001497841 XP_001497891 0.900852542 0.033177947 
DKFZP566E164 XM_001489668 XP_001489718 -0.701713945 0.01477661 
DMBT1 XM_001488880 NULL 0.752024082 0.019218885 
DPP7 XM_001492340 XP_001492390 0.869147143 0.03601938 
ECGF1 NULL NULL 1.012926327 0.014382867 
EFHB XM_001493851 XP_001493901 0.665052898 0.044798473 
EPHB1 XM_001498502 XP_001498552 -0.713059954 0.01827056 
FAF1 XM_001494368 XP_001494418 0.839815191 0.047701914 
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FAM105A XM_001499903 XP_001499953 -0.636009046 0.036634639 
FAM139A XM_001490518 XP_001490568 -0.78933682 0.014383001 
FAT3 XM_001491911 XP_001491961 -0.91151198 0.028531857 
FDFT1 XR_036232 NULL 1.175862043 0.019215251 
FLJ20674 XM_001489301 XP_001489351 -0.735471225 0.031460958 
FLJ25770 XM_001491036 XP_001491086 1.422616274 0.044374148 
FLJ33590 XM_001495043 XP_001495093 0.75074796 0.009179796 
FLJ46321 #N/A #N/A 1.194637748 0.02635805 
FOXK1 XM_001492851 XP_001492901 -0.674312971 0.044232219 
FSCN1 NULL NULL -0.594237692 0.049900959 
FXC1 XM_001499687 XP_001499737 -0.645918346 0.047874691 
GAD1 XM_001498256 XP_001498306 0.765048783 0.041510819 
GATA1 XM_001493845 XP_001493895 -0.892349008 0.009059292 
GCSH DN505906 NULL 0.630305503 0.030401077 
GLI3 XM_001495075 XP_001495125 0.876439175 0.025513856 
GNA12 XM_001492404 XP_001492454 0.717780408 0.039278073 
GNAI2 XM_001496327 XP_001496377 0.879424075 0.049022977 
GNGT2 XM_001502316 XP_001502366 0.634366814 0.02499616 
GOLGA4 XM_001489013 XP_001489063 0.653425889 0.043649168 
GOLIM4 XM_001494089 XP_001494139 0.690956125 0.037710658 
GRK5 XM_001496354 XP_001496404 0.816355464 0.01386985 
GZMB AM183299 NP_001075350 0.921569337 0.020418076 
HAPLN1 CX603704 NULL 0.600347281 0.029777436 
HFE XM_001505027 XP_001505077 0.784461939 0.033433178 
HINT1 NULL NULL 0.587550998 0.038438089 
HIST1H2AE XM_001495023 XP_001495073 0.743516921 0.011562785 
HLCS XM_001493178 XP_001493228 0.663388523 0.03916721 
HNRNPL CD536575 NULL 0.853732296 0.043587695 
HPGD DQ385611 NP_001075255 -0.686883502 0.019465575 
HSPB1 XM_001504478 XP_001504528 0.852506892 0.015553825 
HTR3E XM_001497129 XP_001497179 -0.769744752 0.032584633 
HYI XM_001496743 XP_001496793 0.6155182 0.044043481 
IL17REL XM_001489299 XP_001489349 1.159521978 0.048756448 
IL2RG CD528508 NULL 1.115919806 0.001547772 
INCA1 XM_001502893 XP_001502943 -0.788368523 0.005989588 
ITGA3 XM_001502583 XP_001502633 -0.651131662 0.044016236 
JMJD5 XM_001502536 XP_001502586 -0.665871511 0.044055892 
JTV1 XM_001493465 NULL 1.372689206 0.019269937 
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KCND3 XM_001498710 XP_001498760 0.718470634 0.031318295 
KCNF1 XM_001503533 XP_001503583 1.045189101 0.010358685 
KIAA0802 XM_001488953 XP_001489003 -0.789617392 0.014104903 
KIAA1522 XM_001499821 XP_001499871 0.906374088 0.006776329 
KRT4 XM_001504474 XP_001504524 0.758488228 0.031325828 
LAMC3 XM_001499397 XP_001499447 0.66779874 0.04092658 
LIN37 XM_001492756 XP_001492806 0.856195902 0.016480941 
LOC253012 XM_001493648 XP_001493698 -0.778010565 0.032145741 
LOC646262 XM_001501473 NULL -0.627564117 0.041829378 
LOC653604 XM_001491369 XP_001491419 0.882282461 0.041349545 
LOC730415 XM_001494779 NULL 0.981775272 0.024315085 
LOC731041 XM_001503445 XP_001503495 1.298620634 0.010694653 
LRRC4C XM_001488162 XP_001488212 -0.914852808 0.026656916 
MAG XM_001491638 XP_001491688 -0.799026669 0.026907538 
MAP3K14 XM_001488264 XP_001488314 0.83987315 0.007262049 
MAP3K7IP2 XM_001502154 XP_001502204 1.09390485 0.002437077 
MEMO1 XM_001500302 NULL 0.601409126 0.036826515 
MICAL2 XM_001504929 NULL 0.637072408 0.033386071 
MMP2 XM_001493281 XP_001493331 -1.0253689 0.015163324 
MYBL2 XM_001500357 XP_001500407 -0.857075737 0.022193169 
MYH7 XM_001489572 XP_001489622 -1.402560989 0.010461775 
MYOM3 XM_001501292 XP_001501342 0.728215721 0.018461048 
MYPN XM_001503598 XP_001503648 -0.65640054 0.039165919 
NAGLU NULL NULL -0.630091211 0.049659021 
NAP1L4 XM_001496107 XP_001496157 -0.600171823 0.030755596 
NEK2 XM_001489608 XP_001489658 0.850644472 0.040888305 
NKRF XM_001491762 XP_001491812 0.660887292 0.014169 
NKX2-2 XM_001489173 XP_001489223 -0.584352598 0.041738966 
NONO XM_001492800 XP_001492850 -0.744486991 0.014763985 
NRD1 XM_001491249 XP_001491299 -0.741767508 0.022413151 
NSUN4 XM_001495067 XP_001495117 -0.748933921 0.014692122 
NULL DN508672 NULL -1.269558684 0.032475356 
NULL CD528771 NULL -1.0529431 0.034606894 
NULL XM_001488168 NULL -0.867020044 0.018622789 
NULL CX602249 NULL -0.857369732 0.023630254 
NULL CX597420 NULL -0.848206579 0.009950008 
NULL DN504031 NULL -0.744222424 0.014677933 
NULL DN505256 NULL -0.732271667 0.045276634 
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NULL CD535168 NULL -0.619713689 0.042228039 
NULL DN503870 NULL 1.079727231 0.049273076 
NULL CX604280 NULL 1.078121699 0.009844696 
NULL CX598059 NULL 0.986189189 0.025239381 
NULL DN510694 NULL 0.925682438 0.031445614 
NULL CX600400 NULL 0.819793405 0.010064804 
NULL XM_001488796 NULL 0.795635899 0.025737808 
NULL DN510044 NULL 0.758233493 0.045926298 
NULL XM_001502267 NULL 0.741574552 0.022801843 
NULL DN507862 NULL 0.739793209 0.03707351 
NULL CD465106 NULL 0.709931469 0.022586261 
NULL CX605585 NULL 0.656995272 0.037610036 
NULL CD466566 NULL 0.644238493 0.029758414 
NULL XM_001492610 XP_001492660 0.640316815 0.040630205 
NULL BI395111 NULL 0.618441602 0.043597554 
NULL CX601928 NULL 0.597679343 0.033249989 
OGDH XM_001496616 XP_001496666 -0.913042692 0.018003571 
OPA3 DN509316 NULL 0.798085734 0.040692222 
OR13G1 XM_001497057 XP_001497107 0.709579595 0.026301096 
OR1F1 XM_001499023 XP_001499073 0.789782396 0.009673188 
OR1J4 XM_001501063 XP_001501113 -0.70595534 0.036851303 
OR2L2 #N/A #N/A -0.641878932 0.032461194 
OR5AC2 XM_001502484 XP_001502534 0.731490897 0.032080733 
OR6C2 XM_001490746 XP_001490796 0.671904668 0.040858071 
OR6M1 XM_001501603 XP_001501653 -0.715514166 0.011801507 
OR7E24 XM_001493551 XP_001493601 -0.642636316 0.024989668 
P4HA2 XM_001502946 XP_001502996 1.033549394 0.044062027 
PAFAH1B3 NULL NULL 0.646462584 0.022564484 
PAN3 XM_001492258 XP_001492308 0.77973085 0.005868645 
PCDH17 XM_001493601 XP_001493651 0.83560144 0.031176001 
PCNP NULL NULL 0.615589796 0.03018974 
PDE7B XM_001503536 XP_001503586 0.815677777 0.011166386 
PLCXD1 XM_001492383 NULL 0.638766202 0.036536752 
PMM2 XM_001492888 XP_001492938 0.629383623 0.015834635 
POLE3 XM_001501741 XP_001501791 0.597046509 0.030627274 
PPFIBP1 XM_001502834 XP_001502884 -0.760921186 0.028110712 
PPP1R13B XM_001492437 XP_001492487 -0.695417478 0.022822972 
PRDM4 XM_001499385 XP_001499435 1.000346191 0.036545211 
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PRKD1 XM_001489357 XP_001489407 -0.669132824 0.044888979 
PROCR XM_001499210 XP_001499260 0.639203304 0.021145432 
PROX1 XM_001488438 NULL 0.810062595 0.009406178 
PRR6 XM_001503454 XP_001503504 0.70887894 0.041039238 
PSCD4 XM_001499462 XP_001499512 -0.921045731 0.010584851 
PTGFR DQ385610 NP_001075275 0.894626241 0.018569989 
PTPN2 XM_001491015 XP_001491065 -0.87428708 0.047912292 
PXMP2 XM_001493509 NULL 0.769523277 0.0137058 
RAB19 XM_001498572 XP_001498622 0.756853978 0.017856061 
RAB21 XM_001490408 XP_001490458 0.681004859 0.030582558 
RANGAP1 XM_001500278 NULL 0.682166075 0.045748163 
RBBP6 CX600655 NULL -1.068891294 0.022225204 
RBM26 CX605135 NULL -0.582683787 0.034388628 
RBM8A XM_001499584 XP_001499634 0.800715532 0.033272762 
RCN1 NULL NULL 0.631689222 0.020945528 
REC8 XM_001489288 XP_001489338 -0.740685088 0.01346746 
RPL10 NULL NULL -0.679156156 0.021766591 
RPL10A DN509254 NULL -0.761116722 0.009473794 
RPL7 XM_001491982 XP_001492032 0.708588824 0.046120855 
RTN4IP1 XM_001501887 XP_001501937 -0.906856973 0.013453879 
RUNX3 XM_001501145 XP_001501195 0.770106513 0.046225233 
S100A9 XM_001493530 XP_001493580 -0.836522783 0.014063895 
SAA1 NM_001081853 NULL -0.821241693 0.01004916 
SAPS3 NM_001113235 NULL 0.609683578 0.043396702 
SCN4B XM_001502720 XP_001502770 0.743310176 0.043523389 
SEC61G XM_001498680 NULL 0.801415531 0.010060894 
SERP1 DN511021 NULL -0.867831292 0.028627955 
SERTAD4 XM_001493274 XP_001493324 -0.624122725 0.041721335 
SFRS15 XM_001498724 XP_001498774 0.783509317 0.034910913 
SFRS2IP NULL NULL 0.776238743 0.035882467 
SH3KBP1 XR_035923 NULL 0.622309871 0.043784292 
SH3TC2 XM_001501557 XP_001501607 0.762141952 0.049308748 
SLC28A3 XM_001489024 XP_001489074 -0.666797922 0.029887233 
SLK XM_001497698 XP_001497748 -0.956653955 0.035654257 
SPATA20 XM_001499679 XP_001499729 0.600810343 0.042037587 
SPEN CD535806 NULL 0.754233621 0.006286923 
SPINT1 XM_001501036 XP_001501086 -0.867038431 0.04471486 
SRM XM_001490359 XP_001490409 -0.710928231 0.013574664 
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ST13 XM_001502270 XP_001502320 0.758904906 0.014737918 
ST18 XM_001488723 XP_001488773 -0.785890475 0.01241326 
ST8SIA1 XM_001502320 XP_001502370 0.897676848 0.012424287 
STX8 XM_001503237 XP_001503287 1.030427866 0.046142217 
SUCLA2 XM_001489977 XP_001490027 -0.819681389 0.028231525 
SUCLG2 XM_001495004 XP_001495054 -0.97874017 0.041212985 
SULT1E1 XM_001498087 NULL -0.616668073 0.04154673 
SYNE2 XR_036037 NULL 0.874062362 0.034937932 
TAOK3 XM_001490545 NULL 0.790960579 0.010197744 
TARSL2 XM_001491099 XP_001491149 -0.812502627 0.034735104 
TAS2R9 XM_001496057 XP_001496107 -0.629382627 0.02285544 
TBC1D22B XM_001500276 XP_001500326 0.741567124 0.035699003 
TCF3 NULL NULL -0.742334375 0.023431604 
TFCP2L1 XM_001498204 XP_001498254 -0.653297252 0.038843455 
THADA XM_001498963 XP_001499013 -0.665159584 0.019449541 
TMEM185A XM_001499720 XP_001499770 -0.601190523 0.019957981 
TOLLIP XM_001488094 XP_001488144 -0.660499417 0.012481292 
TOMM40L XM_001503794 XP_001503844 -0.656591402 0.029678745 
TPM3 NULL NULL 0.77977646 0.01944537 
TRAT1 XM_001501680 NULL 0.624713298 0.022395282 
TRIM37 XM_001503728 XP_001503778 0.894801778 0.046877981 
TRMU XM_001488665 XP_001488715 0.913905861 0.022340473 
UBAP2 NULL NULL 1.172151708 0.04411146 
UBC CD470796 NULL 0.658150291 0.03181527 
UBE2I NULL NULL 0.608852001 0.047141504 
UFC1 CX601567 XP_001503885 -1.553873074 0.046275104 
USP4 XM_001497962 XP_001498012 -0.852701426 0.02669579 
UTRN XR_036182 NULL -0.748313949 0.022686422 
ZBTB16 XM_001502114 XP_001502164 -0.696715068 0.041271055 
ZBTB25 XM_001499182 XP_001499232 -0.652316612 0.036311795 
ZNF420 XM_001497154 XP_001497204 -0.720812554 0.006799315 
ZNF445 XM_001496613 XP_001496663 -0.58188432 0.046913612 
ZNF7 XM_001495225 XP_001495275 -0.628032812 0.037661295 
ZNF709 XM_001495842 XP_001495892 0.587432338 0.049223648 
ZNF791 XM_001490211 XP_001490261 -0.654520882 0.04998415 
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39509 XM_001487921 XP_001487971 0.793861403 0.025134599 
A26C1A XM_001497713 XP_001497763 1.075175923 0.014680301 
AACS XM_001493527 XP_001493577 0.682515573 0.04531751 
ACMSD XM_001489267 XP_001489317 -0.602542753 0.04732682 
ADAM32 XM_001490591 XP_001490641 -0.916891529 0.000853704 
AMPH XM_001494195 XP_001494245 0.90161222 0.024233325 
ANAPC10 XM_001501957 XP_001502007 0.728195302 0.043759224 
ANP32E XR_035813 NULL 1.083410208 0.036931548 
ANXA6 XM_001503675 XP_001503725 1.162891857 0.022133563 
AP4S1 XM_001489582 XP_001489632 0.860416348 0.001953339 
APOA1BP XM_001500314 XP_001500364 -0.863312078 0.039334602 
AQP3 AM182511 NULL -0.88185452 0.012152189 
ARG1 XM_001503285 XP_001503335 0.615482701 0.020901431 
ARHGAP18 XM_001503227 XP_001503277 0.927528868 0.033406013 
ASB10 XM_001495177 XP_001495227 0.720011764 0.038442363 
ASCL3 XM_001504908 XP_001504958 0.833601735 0.030677006 
ATP5G3 XM_001499935 XP_001499985 -0.865052013 0.01128912 
ATP6V1F CX603584 XP_001502835 1.081723873 0.022565474 
BAG3 XM_001496279 XP_001496329 1.455376368 0.033978391 
BBS10 XM_001488843 XP_001488893 -0.590771318 0.032253704 
BCL7C XM_001501077 XP_001501127 0.929104434 0.018136744 
BLK XM_001497947 XP_001497997 0.830760387 0.025783394 
BMP10 XM_001491616 XP_001491666 0.689692153 0.024181214 
BNIP3 NULL NULL 0.698013935 0.032062375 
BOC XM_001501187 XP_001501237 0.700781483 0.003820581 
BOLA2 XM_001495385 NULL -0.636107014 0.029490999 
BRMS1 XM_001491327 XP_001491377 0.608698903 0.024557096 
BTBD2 NULL NULL 0.636264523 0.018747932 
BTN1A1 XM_001492530 XP_001492580 0.941358416 0.023179345 
C10orf38 XM_001498537 XP_001498587 0.735653166 0.019457784 
C14orf124 XM_001488725 XP_001488775 -0.616552581 0.026921856 
C14orf49 XM_001498945 XP_001498995 -0.711439248 0.045306352 
C14orf73 XM_001491747 XP_001491797 0.749396125 0.033735186 
C1orf125 XM_001488358 XP_001488408 -0.614871664 0.027102789 
C1orf128 XM_001504214 XP_001504264 0.923585439 0.040134716 
C1orf159 XM_001496587 XP_001496637 0.803968845 0.010873305 
C1orf186 XM_001489497 XP_001489547 0.872783937 0.037242038 
C1orf216 XM_001503671 XP_001503721 -0.588014423 0.025343041 
C3orf14 XM_001490221 NULL 0.894485008 0.028271034 
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C3orf23 XM_001501325 XP_001501375 -0.632233583 0.016688672 
C3orf64 XM_001498735 NULL 0.698128434 0.020027336 
C3orf68 CX603098 XP_001491485 1.19602234 0.038952862 
C4orf36 XM_001494175 NULL -0.842806546 0.003686987 
C5orf24 XM_001504379 XP_001504429 0.818369005 0.038165009 
C6orf105 XM_001495069 XP_001495119 -0.650505413 0.034698714 
C6orf12 XM_001490388 NULL -0.629339992 0.014571457 
C6orf70 XM_001488580 XP_001488630 0.61352066 0.027417037 
C6orf72 XM_001495513 XP_001495563 0.86109621 0.02631759 
CAB39 XM_001494866 XP_001494916 0.603249606 0.041339336 
CALCA NM_001081854 NULL 1.18284334 0.021429391 
CALM3 CX605038 NULL 0.730503282 0.030677938 
CAMK2A XM_001501480 XP_001501530 -0.584695813 0.013136929 
CARS XM_001492495 XP_001492545 0.662332205 0.022099055 
CASP1 AF090119 NP_001075311 -0.744081199 0.010022903 
CASP6 XM_001502919 XP_001502969 0.719193942 0.029022585 
CCDC49 XM_001501527 XP_001501577 0.796377792 0.006251021 
CCL19 XM_001492856 NULL 1.33834668 0.031616495 
CCL20 XM_001496798 NULL -0.5808208 0.014988685 
CD300C XM_001497431 XP_001497481 0.679192312 0.034974567 
CD3EAP XM_001502587 XP_001502637 1.581353089 0.027576083 
CD53 XM_001498018 NULL 0.648927836 0.024650919 
CD74 AB032166 NP_001093240 0.622947605 0.01476552 
CDC34 XM_001488127 XP_001488177 0.851750039 0.041332086 
CDH3 XM_001496960 XP_001497010 0.63364907 0.030444985 
CECR5 XM_001489609 XP_001489659 1.112109527 0.035626197 
CEP68 XM_001494458 XP_001494508 1.379606057 0.003140165 
CES1 XM_001491526 XP_001491576 1.212305639 0.008899001 
CGI-96 XM_001503030 XP_001503080 -0.66156703 0.028739111 
CGNL1 XM_001500558 XP_001500608 0.836344372 0.001585353 
CIB2 XM_001492446 XP_001492496 -0.609357361 0.015470955 
CKAP2 XM_001488323 XP_001488373 0.817155838 0.028127283 
CLCA1 AY524856 NP_001075268 0.839125726 0.046194323 
CLDN3 XR_036494 NULL 0.581103035 0.027314303 
CNTROB XM_001504801 XP_001504851 -1.29769536 0.007858427 
COG5 XM_001492486 XP_001492536 1.186853432 0.010629538 
COL9A2 XM_001498093 XP_001498143 0.65995549 0.011054014 
CORT XM_001490564 XP_001490614 0.71180909 0.004801545 
COX6A2 XM_001500332 XP_001500382 1.193135715 0.001625285 
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CUGBP1 XM_001492089 XP_001492139 1.158379903 0.003947484 
CYP46A1 XM_001488041 XP_001488091 -0.597130538 0.019067384 
CYTL1 XM_001499643 XP_001499693 0.845872533 0.036307835 
DCLRE1C XM_001498475 XP_001498525 0.925577317 0.015199968 
DCN AF038127 NP_001075394 0.766086745 0.021892121 
DCP2 XM_001503544 XP_001503594 -0.604281694 0.018552636 
DEFB113 XM_001498655 NULL 0.625462234 0.028940603 
DEPDC7 XM_001492566 XP_001492616 0.783027756 0.012793169 
DGAT2 XM_001495302 XP_001495352 0.660882089 0.023900723 
DHODH XM_001497851 XP_001497901 1.122207249 0.000578554 
DHX34 XM_001503157 XP_001503207 -0.60564385 0.031977878 
DIAPH3 XM_001493869 XP_001493919 -0.645789084 0.009602191 
DIXDC1 XM_001501796 XP_001501846 0.954190002 0.044568378 
DKFZP564J0863 XM_001488081 XP_001488131 -0.716365868 0.027311965 
DKFZP564O0823 XM_001490542 XP_001490592 0.950536437 0.040570432 
DKFZP566E164 XM_001489668 XP_001489718 0.70783266 0.012755736 
DNASE1L3 XM_001491051 XP_001491101 0.687040411 0.031043406 
DPP6 XM_001504680 XP_001504730 0.804147805 0.014127905 
DUS3L NULL NULL 0.61916278 0.0418401 
DUSP22 XM_001489269 XP_001489319 -0.683171965 0.041313033 
DYX1C1 XM_001500868 XP_001500918 0.661298556 0.004097737 
EBF2 XM_001493967 XP_001494017 0.649052792 0.01600998 
EBNA1BP2 BM735407 NULL 1.086986812 0.038746171 
EEF1A1 NULL NULL -0.784274846 0.005685074 
EHD2 XM_001503200 XP_001503250 -0.653983138 0.005966117 
EIF3K XM_001497212 XP_001497262 0.850467988 0.043135846 
EIF4E3 XM_001494186 NULL 0.914854485 0.037685775 
EIF4G3 AY484519 NP_001075231 0.831393819 0.017217161 
ENO2 XM_001497578 XP_001497628 -0.619954481 0.006896585 
EPB41 XM_001503955 XP_001504005 0.776419465 0.025622812 
ERAS XM_001493930 XP_001493980 0.588761915 0.047492734 
ERN1 XM_001495274 XP_001495324 1.531045896 0.038320754 
ESCO1 XM_001491258 XP_001491308 -0.623339599 0.017507502 
EXT1 XM_001496434 XP_001496484 1.014506466 0.032669057 
FAM64A XM_001504737 XP_001504787 0.668319112 0.025847709 
FANCG XM_001498082 XP_001498132 0.664289271 0.040538804 
FANCI XM_001499443 XP_001499493 0.636264733 0.009151394 
FASN XM_001491292 XP_001491342 -0.734508103 0.043437048 
FBF1 XM_001491921 XP_001491971 -0.725494056 0.009356722 
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FBXO24 XM_001505057 XP_001505107 0.744713185 0.025868533 
FGF14 XM_001493005 XP_001493055 -0.692184046 0.049141443 
FGF6 XM_001494335 XP_001494385 0.664357496 0.047177609 
FHAD1 XM_001489144 XP_001489194 0.813724168 0.015419794 
FICD XM_001501073 XP_001501123 0.693201399 0.033943236 
FKBP8 XM_001503329 XP_001503379 -0.852231819 0.015395673 
FLJ14154 XM_001502091 XP_001502141 0.87181905 0.042011577 
FOS XM_001491972 XP_001492022 -0.662927282 0.049851004 
FRK XM_001504096 XP_001504146 0.811793708 0.047214325 
FSD1L XM_001492739 XP_001492789 0.664435713 0.038383173 
GGA2 XM_001500946 XP_001500996 0.622531176 0.048598535 
GGTLA1 XM_001489252 XP_001489302 -0.593035199 0.006382838 
GJA5 XM_001499011 XP_001499061 0.69622699 0.010240205 
GLUL NULL NULL 0.928282132 0.006744328 
GLUL NULL NULL 0.85724721 0.036213361 
GNA13 XM_001494363 XP_001494413 1.498991668 0.041984327 
GNB2L1 NULL NULL 0.683718441 0.03638908 
GNG12 XM_001499698 NULL 0.81094982 0.003367794 
GNGT2 XM_001502316 XP_001502366 0.948897099 0.04810129 
GOLGA3 XM_001493410 XP_001493460 0.765920916 0.009155926 
GOT1 XM_001501044 XP_001501094 -0.605169797 0.007415579 
GPATCH4 XM_001500345 XP_001500395 0.667875781 0.027379246 
GSDM1 XM_001500788 XP_001500838 0.620432727 0.005087997 
GSN U31699 NP_001075422 0.664504832 0.006907027 
GUCA1B XM_001501305 XP_001501355 1.205194371 0.009654883 
HAMP BM780870 XP_001491660 0.816602516 0.003239989 
HAX1 XM_001496771 XP_001496821 1.178501949 0.039053957 
HDAC11 XM_001489622 XP_001489672 0.882022735 0.041259725 
HDAC8 XM_001488346 XP_001488396 0.743014634 0.022832223 
HEATR5B XM_001501052 XP_001501102 0.612873919 0.049769976 
HEY2 XM_001503138 XP_001503188 0.895992654 0.037743457 
HLA-B AY225157 NULL 0.783300915 0.030522313 
HMOX1 XM_001498885 XP_001498935 0.760132956 0.037433476 
HNRPDL XM_001491342 XP_001491392 0.859814702 0.045230745 
HOXB1 XM_001499152 XP_001499202 -0.770014369 0.025932441 
HPX XM_001504590 XP_001504640 0.739295827 0.041567623 
HSPA1A XM_001492096 XP_001492146 0.864345476 0.032784537 
HSPBP1 NULL NULL 0.92318642 0.03112715 
IFIT5 XM_001491815 XP_001491865 0.607277418 0.014023483 
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IFT172 XM_001502188 XP_001502238 0.601776762 0.036029254 
IL13RA2 XM_001490946 XP_001490996 0.774163159 0.02389608 
IL7 XM_001491850 XP_001491900 -0.883488785 0.046657251 
IMPA2 XM_001491556 XP_001491606 -0.590423171 0.007567366 
INMT XM_001500503 XP_001500553 0.670653238 0.004491636 
INTS1 NULL NULL 0.959425872 0.016046688 
IQCA XM_001496502 XP_001496552 0.839771004 0.003893102 
IRF2BP2 CX596722 NULL 0.603403928 0.017346397 
ITGA11 XM_001495868 XP_001495918 0.664193578 0.04571672 
IVL XM_001493161 NULL 0.637947905 0.041696095 
KCTD14 XM_001494397 XP_001494447 0.824586119 0.031219384 
KIAA1024 XM_001503096 XP_001503146 0.684829195 0.030307156 
KIAA2018 XM_001502865 XP_001502915 0.948916624 0.019335485 
KLK4 XM_001497520 XP_001497570 0.932156606 0.020869561 
KLRC1 XM_001494279 NULL 1.489533271 0.025309721 
KLRC1 XM_001494234 NULL 0.877536075 0.030172848 
KNG1 XM_001499339 XP_001499389 0.583628714 0.03192535 
KPNA4 NULL NULL 1.048286688 0.004499596 
LAMA4 XR_036481 NULL -1.244378846 0.002768756 
LARS2 XM_001500836 XP_001500886 0.679129676 0.034595173 
LCN2 XM_001501148 XP_001501198 0.742878665 0.008636251 
LGALS3 XM_001495733 XP_001495783 1.462088497 0.001364186 
LINGO2 XM_001498518 XP_001498568 0.762514347 0.01722562 
LMNA XM_001499921 XP_001499971 0.918397464 0.024484183 
LOC124220 XM_001498514 XP_001498564 -0.671586964 0.007839637 
LOC149478 XM_001496251 NULL 0.882018652 0.002468681 
LOC389117 XM_001494114 XP_001494164 0.917831109 0.008326509 
LOC401397 NULL NULL 0.70619741 0.006328081 
LOC550631 XM_001498215 XP_001498265 1.152459276 0.002409509 
LOC648044 XM_001504889 XP_001504939 0.615692483 0.049381685 
LOC650536 XM_001500011 XP_001500061 1.093984358 0.001635941 
LOC650536 XM_001500854 XP_001500904 -0.746919459 0.018695192 
LOC729059 XM_001504243 NULL -0.601165158 0.024126868 
LOC730855 AF345995 NULL 1.481132418 0.002599962 
LRMP XM_001498588 XP_001498638 0.595445618 0.032169612 
LRRC45 XM_001487864 XP_001487914 -0.756284769 0.007087316 
LRSAM1 XM_001501598 XP_001501648 0.603337203 0.035584322 
LTBP3 NULL NULL 1.25097694 0.002580806 
LYPD2 XM_001496755 XP_001496805 1.32989038 0.014317774 
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M-RIP XM_001488526 XP_001488576 0.755652344 0.023573221 
MAGIX NULL NULL 0.825679169 0.011044482 
MAP7D1 NULL NULL 1.207964977 0.014802669 
MEST XM_001503034 XP_001503084 0.872589204 0.036271959 
MFSD1 XM_001488381 XP_001488431 1.040286886 0.010889705 
MGC45438 XM_001499691 XP_001499741 0.738281231 0.038049564 
MITD1 XM_001490447 XP_001490497 0.756543941 0.040994621 
MMRN1 XM_001496961 XP_001497011 -0.599533727 0.038683453 
MOSC2 XM_001488982 XP_001489032 0.823748577 0.011375121 
MOSPD1 XM_001488097 XP_001488147 0.59655954 0.039332953 
MPND CX595878 NULL 0.599861977 0.042529829 
MRLC2 XM_001494011 XP_001494061 1.213599054 0.02670087 
MRPL12 XM_001488528 NULL 0.887644261 0.04475687 
MRPL20 NULL NULL -0.592098262 0.014599042 
MRPS18A XM_001502158 XP_001502208 0.744373744 0.024622658 
MSMB XM_001493992 NULL 0.98207406 0.014584801 
MTHFSD XM_001500142 XP_001500192 0.825578675 0.007003781 
MYOM2 XM_001495857 XP_001495907 0.916809813 0.016294686 
MYOZ3 XM_001503704 XP_001503754 0.915143294 0.008661734 
N4BP3 XM_001502111 XP_001502161 0.67760423 0.024940695 
NANP XM_001490677 XP_001490727 -0.882636891 0.047620031 
NCF2 XM_001490231 XP_001490281 0.888709121 0.038261743 
NCOA7 DN510980 NULL 1.18154241 0.029240481 
NDUFA9 XM_001494601 XP_001494651 0.758859212 0.034616241 
NEDD1 XM_001495034 XP_001495084 -0.739511338 0.043595567 
NFASC XM_001489228 XP_001489278 0.813766588 0.049797843 
NKTR NULL NULL 0.598515139 0.032152684 
NOM1 XM_001496962 XP_001497012 0.887801886 0.048238482 
NOS3 XM_001504649 XP_001504699 -0.681474999 0.035505546 
NPLOC4 XM_001489864 XP_001489914 -0.629539592 0.009410239 
NPS XM_001489691 NULL 0.710706637 0.016007717 
NQO2 XM_001491053 XP_001491103 0.995348142 0.003501292 
NULL CD467511 NULL 1.437611457 0.02524405 
NULL CD465749 NULL 1.435496262 0.044529418 
NULL DN508302 NULL 1.116840395 0.043450202 
NULL XM_001496150 NULL 1.084021791 0.036585472 
NULL XM_001490838 XP_001490888 1.079145142 0.030242978 
NULL CX601287 NULL 0.973135161 0.010885815 
NULL CD466975 NULL 0.970526157 0.049350524 
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NULL XM_001495624 NULL 0.918857018 0.034290677 
NULL CD535881 NULL 0.918802139 0.047905361 
NULL CX604881 NULL 0.820441548 0.000764123 
NULL XM_001498667 NULL 0.785857337 0.005018975 
NULL CX604518 NULL 0.737329398 0.042693979 
NULL XR_036280 NULL 0.730224193 0.047666581 
NULL CD536744 NULL 0.70432886 0.015628323 
NULL CX594922 NULL 0.697547992 0.010821008 
NULL XM_001502801 NULL 0.688044625 0.043270306 
NULL XM_001498856 XP_001498906 0.680127909 0.015610148 
NULL CX605947 NULL 0.668737435 0.026867486 
NULL XM_001501195 XP_001501245 0.593542833 0.048546905 
NULL XM_001503948 NULL 0.589049148 0.036305871 
NULL CX601980 NULL 0.580560854 0.036525541 
NULL CD536656 NULL -0.941443808 0.013727597 
NULL CX604893 NULL -0.898406093 0.028844396 
NULL DN508075 NULL -0.886875638 0.024081816 
NULL CD465327 NULL -0.753356222 0.039195307 
NULL BI395121 NULL -0.743151355 0.029328222 
NULL CX601278 NULL -0.736027477 0.04764657 
NULL CD536578 NULL -0.699730642 0.010759686 
NULL XM_001488796 NULL -0.684030434 0.023101672 
NULL DN509542 NULL -0.642509166 0.021201315 
NULL XM_001496183 XP_001496233 -0.641376662 0.031447975 
NULL DN510541 NULL -0.633703324 0.014361923 
NULL DN510227 NULL -0.627038981 0.028426111 
NULL CX601417 NULL -0.61573787 0.024288442 
NULL XM_001493134 NULL -0.600043106 0.022123532 
NULL XM_001495803 NULL -0.597661713 0.009454129 
NULL CX599004 NULL -0.586407875 0.011892391 
NUP188 XM_001499796 XP_001499846 0.786697972 0.006083986 
ODZ2 XM_001503295 NULL -0.637396603 0.012974163 
ODZ3 XM_001492508 NULL -0.614633097 0.005181163 
OR10J5 XM_001490887 XP_001490937 0.848465468 0.045157337 
OR12D2 XM_001490772 XP_001490822 0.879570821 0.020617748 
OR1F1 XM_001499014 XP_001499064 -0.884661036 0.033155361 
OR1J4 XM_001501342 NULL -1.004656597 0.012195071 
OR4F16 XM_001502031 XP_001502081 -0.605456222 0.003857688 
OR56B4 XM_001504553 XP_001504603 -0.807771968 0.012146897 
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OR6C2 XM_001490627 XP_001490677 0.878366666 0.029304792 
OR8U8 XM_001496063 XP_001496113 -0.711278124 0.047814059 
ORM2 XM_001488131 XP_001488181 -0.593239239 0.039846115 
OSAP XM_001502525 XP_001502575 0.726329478 0.003915527 
OSBPL10 XM_001490635 XP_001490685 0.76306215 0.023420877 
OSGIN2 XM_001488667 XP_001488717 -0.876652222 0.003632846 
P4HB XM_001489491 XP_001489541 1.041391575 0.040982584 
PAK4 XM_001497143 XP_001497193 0.724795018 0.011218107 
PALB2 XM_001501015 XP_001501065 0.612857168 0.047154537 
PARD6A XM_001498013 XP_001498063 -1.037912625 0.044060499 
PARP3 XM_001492912 XP_001492962 -0.728794027 0.032851176 
PCSK1 XM_001504608 XP_001504658 0.611083241 0.035501845 
PHACTR3 XM_001491669 NULL 0.982147052 0.01349672 
PHF11 XM_001489978 NULL -0.670738979 0.030489716 
PIB5PA XM_001497367 NULL -1.297378836 0.015636553 
PKIA NULL NULL 0.633595191 0.022771772 
POGK XM_001490105 XP_001490155 0.789127381 0.019917355 
POLR2F XM_001501259 XP_001501309 0.800020693 0.031755044 
PREP NULL NULL -0.624165568 0.006745959 
PRKCE XM_001499053 XP_001499103 1.107485626 0.039123203 
PRND NM_001091537 NULL 0.725009179 0.006748466 
PRR15 XM_001500279 XP_001500329 0.665518938 0.026036314 
PSCD4 XM_001499462 XP_001499512 1.108935856 0.010518118 
PSMC1 NULL NULL 1.063183499 0.04108997 
PSMD3 XM_001500781 NULL 1.08349634 0.041542667 
PTMA XM_001498434 XP_001498484 0.914568693 0.047426787 
RAB2B XM_001505161 XP_001505211 1.093991374 0.031954427 
RAD9A XM_001491881 XP_001491931 -0.911419243 0.017405289 
RAPGEF2 XM_001498831 XP_001498881 0.697129525 0.019372894 
RASAL2 XM_001498432 XP_001498482 -0.650247801 0.014760315 
RASD2 XM_001499945 XP_001499995 0.658440472 0.021030883 
RASSF8 XM_001502654 XP_001502704 0.688682605 0.013211244 
RCE1 XM_001496896 XP_001496946 -0.643550477 0.018921751 
REC8 XM_001489288 XP_001489338 1.155040235 0.027187404 
RENBP XM_001491837 XP_001491887 -0.629686183 0.004747208 
RGS19 XM_001495344 XP_001495394 0.581309328 0.030669808 
RGS20 XM_001488849 XP_001488899 0.835246916 0.038745333 
RNF167 XM_001504749 XP_001504799 0.629410096 0.032014304 
ROR1 XM_001499661 XP_001499711 1.161436143 0.026477321 
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RPL37 BI961238 XP_001499005 0.808632353 0.02006983 
RPL4 CD467413 NULL 0.839683603 0.029757763 
RPS25 XM_001503063 XP_001503113 -0.601461207 0.026748125 
RPS3A NULL NULL -0.693396543 0.04890535 
RTKN2 XM_001502301 XP_001502351 1.009846358 0.047123126 
S100A11 BI961023 XP_001493486 0.872119914 0.047026034 
S100A2 CX598422 XP_001494717 -0.743181373 0.021979447 
S100A5 XM_001493675 XP_001493725 0.8299638 0.037744978 
S100A8 XM_001493507 XP_001493557 0.790055028 0.021918481 
S100A9 XM_001493530 XP_001493580 0.884664501 0.019256606 
SAP130 XM_001504933 NULL 0.826106608 0.010547452 
SCN4B XM_001502720 XP_001502770 0.753207203 0.025524634 
SDC2 CX605958 NULL -0.684257372 0.048945866 
SDCCAG1 NULL NULL 0.583550376 0.010404048 
SDCCAG8 XM_001491918 XP_001491968 0.695236629 0.032847543 
SDF2L1 XM_001493091 XP_001493141 0.59351772 0.039286147 
SEMA6D XM_001502470 NULL -1.593190504 0.033031932 
SETD8 XM_001492985 XP_001493035 -0.788515138 0.014593012 
SF3B2 XM_001495191 XP_001495241 0.874265847 0.023223542 
SGCD XM_001503564 XP_001503614 0.590153597 0.009802713 
SGPL1 XM_001502792 XP_001502842 -0.692512775 0.007172296 
SIM2 XM_001493207 NULL 1.023350646 0.008149913 
SIN3A XM_001491348 XP_001491398 -0.614358146 0.015511108 
SIX4 XM_001497919 XP_001497969 0.5806122 0.012577787 
SLC23A1 XM_001497642 XP_001497692 0.899562588 0.029880842 
SLC25A20 XM_001494717 XP_001494767 0.707175904 0.010108105 
SLC35F3 XM_001493414 XP_001493464 1.179668925 0.002671981 
SLC41A3 NULL NULL -0.594064702 0.037423476 
SLC7A6OS XM_001499093 XP_001499143 -0.644136729 0.008809386 
SLCO1B3 XM_001498036 XP_001498086 -0.973073255 0.008115858 
SLITRK6 XM_001490198 XP_001490248 0.622511404 0.043503366 
SLMAP XM_001489585 XP_001489635 -1.332462281 0.046019981 
SMOC2 NULL NULL 0.647352618 0.045213086 
SMTNL1 XM_001497023 XP_001497073 0.681229626 0.049140476 
SMYD1 XM_001497775 NULL 0.595799971 0.013001788 
SNAI2 XM_001488056 XP_001488106 -0.651183949 0.017180648 
SNAI3 XM_001487991 XP_001488041 0.749377969 0.02776628 
SNCA XM_001496904 XP_001496954 -0.65243193 0.032176449 
SPECC1 XM_001504877 XP_001504927 0.953195401 0.031960627 
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SPON2 XR_035777 NULL 0.729540402 0.006776469 
SS18L2 XM_001501559 XP_001501609 1.202744658 0.044401513 
TAL2 XM_001493399 XP_001493449 1.295734395 0.016481736 
TBC1D9 XM_001501060 XP_001501110 0.94412618 0.02363108 
TBL3 XM_001498025 XP_001498075 -0.673649982 0.011412327 
TDRD7 XM_001495552 XP_001495602 0.710363783 0.02456347 
TDRD9 XM_001492897 XP_001492947 0.826804023 0.017164146 
TERF1 XM_001492421 XP_001492471 0.968671681 0.033068104 
TFDP1 XM_001498959 XP_001499009 0.972179037 0.017469466 
TIFA XM_001503466 XP_001503516 0.774908902 0.020021701 
TLK2 XR_036378 NULL -0.654228258 0.011999707 
TLN2 XM_001500242 XP_001500292 0.581905381 0.02557653 
TMEM189-UBE2V1 XM_001501224 XP_001501274 0.707575887 0.00416749 
TMEM29B XM_001494608 XP_001494658 -0.581161606 0.038656476 
TMEM69 XM_001495815 XP_001495865 0.737446096 0.043788024 
TMOD1 XM_001504126 XP_001504176 1.35837228 0.004130751 
TOMM20 CX605644 XP_001491687 0.979154088 0.038537021 
TPM1 NULL NULL 0.710815839 0.021819587 
TPPP3 CX596053 XP_001496480 -0.72741117 0.039437277 
TRAF3IP2 XM_001504045 XP_001504095 1.062069857 0.015251821 
TRIM50 XM_001504491 XP_001504541 0.774928706 0.016373599 
TRPM7 DQ329355 NULL -0.630754677 0.013403424 
TRUB1 XM_001495127 XP_001495177 0.735161042 0.010254325 
TRY1 XM_001499280 NULL 0.608030767 0.018101239 
TTC30B XM_001500596 NULL -0.664177063 0.031612473 
TTC35 XM_001494974 XP_001495024 0.658176182 0.028704898 
TTLL9 XM_001498331 XP_001498381 0.806528387 0.009523638 
TXNDC6 XM_001496991 NULL -0.908928625 0.000851235 
UBASH3B CD468821 NULL -0.602108777 0.029358745 
UBR5 XR_036042 NULL 0.692622189 0.044677523 
UQCR DN508330 NULL 0.738552307 0.025632613 
USP4 XM_001497962 XP_001498012 -0.687467919 0.017587134 
VAMP7 XM_001498227 XP_001498277 1.5621274 0.017048316 
VPS37A XM_001488521 XP_001488571 -0.617532472 0.028391898 
VTCN1 NULL NULL 0.733444514 0.048639587 
VWA2 XM_001498009 XP_001498059 -1.303048746 0.003579255 
WBP4 XM_001502215 NULL 0.637576061 0.046379065 
WDR81 XM_001502333 XP_001502383 1.027664638 0.032012018 
WWP1 XM_001488288 XP_001488338 -0.692367224 0.018650042 
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XBP1 DN507369 NULL 1.05872584 0.021922233 
XRN2 XM_001489295 XP_001489345 0.653526296 0.022542424 
YPEL2 XM_001503736 XP_001503786 -0.833039127 0.036964088 
YTHDF2 XM_001500333 XP_001500383 0.779949833 0.010022103 
ZBTB32 XM_001492255 XP_001492305 0.593337827 0.03327712 
ZC3H12D XM_001495556 XP_001495606 -0.785748368 0.008716475 
ZC3H7B XM_001500311 XP_001500361 0.964421484 0.035326523 
ZCCHC3 XM_001497984 XP_001498034 0.584494521 0.049137829 
ZDHHC20 XM_001489587 XP_001489637 0.61651159 0.006563921 
ZER1 XM_001500385 XP_001500435 0.770838104 0.020572734 
ZFP3 XM_001504742 XP_001504792 1.045650043 0.014217491 
ZFR XR_036244 NULL 0.609710371 0.040616811 
ZMAT3 XM_001494925 XP_001494975 -0.606974118 0.027902822 
ZNF256 XM_001493473 NULL 0.898464666 0.03398908 
ZNF260 XM_001494454 NULL 0.760864477 0.036507009 
ZNF420 XM_001497154 XP_001497204 1.459606556 0.012555189 
ZNF510 XM_001493815 XP_001493865 0.795028472 0.049739909 
ZNF513 XM_001500900 XP_001500950 0.858573178 0.004841773 
ZNF518B XM_001500984 XP_001501034 0.771606816 0.033862505 
ZNF543 XM_001492239 XP_001492289 0.900710034 0.048871795 
ZNF554 XM_001492592 XP_001492642 0.836045963 0.038032725 
ZNF662 XM_001497214 XP_001497264 0.737492596 0.017533937 
ZNF709 XM_001489853 NULL 1.267656589 0.013208462 
ZNF783 XM_001493065 XP_001493115 0.733980466 0.048341927 
 
 
 
Table D-13: List of differentially expressed genes (pvalue <0.05 and fold change cut off 
of 1.5) between the affected and the unaffected foals from nasal epithelium at week-2. 
 
Gene Symbol NCBI accession RefSeq accession 
Log fold 
change Pvalue 
ACD XR_036166 NULL 0.656969546 0.018694184 
ADAM12 XM_001490047 XP_001490097 -0.619617799 0.022896857 
AFTPH XM_001494716 XP_001494766 0.908173221 0.04711376 
AGR3 XM_001496142 XP_001496192 -1.094971903 0.02255331 
AHSA1 XM_001493748 XP_001493798 0.873321819 0.000918768 
AMOTL1 XM_001497365 XP_001497415 1.195381118 0.001040596 
AMPD1 NULL NULL -0.725576546 0.04035028 
ANKRD38 XM_001500075 XP_001500125 0.628376914 0.017075064 
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Log fold 
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ARHGEF16 XM_001497662 XP_001497712 0.719557642 0.035773593 
ASIP XM_001501139 XP_001501189 0.664137957 0.010371725 
ATCAY XM_001493413 XP_001493463 0.631517924 0.00796608 
ATP13A2 XM_001488576 XP_001488626 0.638108153 0.039016004 
B3GALNT1 XM_001493799 XP_001493849 -0.587269304 0.033200782 
BAG3 XM_001496279 XP_001496329 0.782158388 0.04752626 
BANK1 XM_001497747 XP_001497797 0.771094113 0.002766097 
BC37295_3 XM_001491403 NULL 0.642002578 0.011480864 
BCMO1 XM_001499593 XP_001499643 0.779476158 0.023487728 
BPIL3 XM_001498600 XP_001498650 0.689217207 0.014628253 
BSND XM_001488199 XP_001488249 0.670074336 0.026111785 
C10orf72 XM_001494453 XP_001494503 0.79770732 0.041200056 
C11orf49 XR_035773 NULL 1.780417817 0.046457675 
C14orf102 XM_001494144 XP_001494194 0.680739829 0.041294352 
C17orf49 XM_001503003 XP_001503053 0.598204584 0.015248492 
C1orf31 XM_001493392 NULL 0.721282054 0.041180889 
C1orf50 XM_001497377 XP_001497427 0.874358162 0.001560545 
C1orf86 XM_001495164 XP_001495214 0.746449545 0.020649018 
C2orf28 XM_001502475 XP_001502525 0.63399582 0.013244341 
C3orf14 XM_001490221 NULL 0.628348454 0.030751388 
C6orf162 XM_001503730 XP_001503780 0.974777129 0.010378135 
C9orf97 XM_001495421 XP_001495471 0.603941027 0.02294143 
CAMTA1 NULL NULL 1.168952127 0.028339629 
CAMTA2 XM_001504745 XP_001504795 0.844246654 0.01884976 
CAPN5 XM_001494686 XP_001494736 -0.842935825 0.032196214 
CAPZA3 XM_001501974 XP_001502024 1.062774531 0.048241517 
CCDC33 XM_001494109 XP_001494159 0.591554125 0.04033182 
CCDC97 XM_001500237 XP_001500287 1.656412092 0.008032849 
CCKBR XM_001504583 XP_001504633 1.219772332 0.015785376 
CD276 XM_001493661 XP_001493711 0.714361939 0.024061176 
CDC20 XM_001498579 XP_001498629 -0.581747215 0.022992873 
CDC42BPB XM_001491699 XP_001491749 0.644675308 0.01187746 
CHRDL1 XM_001489536 XP_001489586 0.793939665 0.029493466 
CKM XM_001502522 XP_001502572 0.692622098 0.016631303 
CNKSR2 XM_001491941 XP_001491991 -0.760363292 0.016711729 
CNN3 NULL NULL -0.808151628 0.004526051 
CNN3 NULL NULL -0.673697543 0.003440911 
CNTNAP5 XM_001489205 XP_001489255 0.829714632 0.027417868 
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Log fold 
change Pvalue 
COL6A3 CX604376 NULL -0.655606591 0.018701085 
CPEB1 XM_001498253 XP_001498303 -0.581684487 0.035684408 
CPN2 XM_001498855 NULL -0.705079818 0.027046292 
CUGBP1 XM_001492089 XP_001492139 0.891481366 0.025053462 
DBNDD1 XM_001488503 XP_001488553 -0.78061961 0.030383164 
DCUN1D1 XM_001496812 XP_001496862 1.081069094 0.037651757 
DEFB4 AY170305 NP_001075356 -0.790344939 0.045741498 
DGAT2 XM_001495302 XP_001495352 0.876356484 0.020391007 
DHDH XM_001489811 XP_001489861 1.506925571 0.031187588 
DOK7 XM_001488918 XP_001488968 1.064184382 0.030979589 
EEF1A1 NULL NULL -0.726116284 0.033107328 
EID3 XM_001497826 XP_001497876 0.712089006 0.015418257 
EPHA1 XM_001490060 XP_001490110 -0.757549202 0.044929722 
EXOSC1 DN505643 XP_001501548 1.772457037 0.015509273 
EXOSC5 XM_001500340 XP_001500390 0.610663343 0.007419564 
F3 XM_001491449 XP_001491499 0.794775254 0.023084703 
FAM120A XM_001490989 XP_001491039 0.933395044 0.046397106 
FAM120B XM_001488467 XP_001488517 -0.817638187 0.028832059 
FAM127A XM_001487969 XP_001488019 -0.678659967 0.023849592 
FAM12B XM_001505142 NULL -0.759241679 0.006815165 
FAM149A XM_001502897 XP_001502947 0.664592976 0.026874898 
FAM82C XM_001501075 XP_001501125 -0.738568611 0.044353096 
FAM89A NULL NULL 0.948760061 0.012022614 
FAU BM781413 NULL -0.599428204 0.04079038 
FBRS XR_036371 NULL 0.809134518 0.008696324 
FIGF XM_001489992 XP_001490042 0.713725285 0.012106484 
FOXN4 XM_001496911 XP_001496961 0.961532416 0.041899639 
GABRB3 XM_001493048 XP_001493098 1.013628019 0.000715631 
GALE XM_001504206 XP_001504256 0.791711508 0.028331814 
GALNT2 XM_001496209 XP_001496259 0.667694251 0.022322351 
GAPDH XR_036361 NULL 0.763380582 0.022081426 
GLG1 CX604369 NULL 0.706418368 0.034582856 
GLIS2 XM_001502268 XP_001502318 0.636237359 0.028925265 
GLT6D1 XM_001498210 XP_001498260 -0.824301304 0.036094321 
GLUL NULL NULL -0.94149975 0.039562351 
GNG3 XM_001494898 XP_001494948 0.872689405 0.027141699 
GNPDA1 XM_001503958 XP_001504008 -1.595394185 0.038741905 
GORASP2 XM_001498298 XP_001498348 0.581179652 0.038388617 
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Log fold 
change Pvalue 
GPATCH1 XM_001488716 XP_001488766 0.699111686 0.030861246 
GTF2IRD2B XM_001494135 XP_001494185 -0.667976574 0.035189665 
GYPC XM_001489109 NULL 0.645756885 0.009331151 
HFE XM_001497982 XP_001498032 0.870147155 0.046083861 
HMGB2 NULL NULL -0.758829542 0.007560159 
HNRNPA1 XM_001501027 XP_001501077 0.630030488 0.013386394 
HNRPDL XM_001491342 XP_001491392 0.841528649 0.010287355 
HOXB1 XM_001499152 XP_001499202 -0.841899838 0.013512054 
HSDL1 XM_001502194 NULL -0.644128246 0.014358868 
HTR2C XM_001488512 XP_001488562 1.551624544 0.041571962 
ID3 XM_001504221 XP_001504271 0.805536457 0.032631423 
IGSF21 XM_001498665 XP_001498715 1.401863459 0.028204268 
ISLR XM_001493196 XP_001493246 0.632621359 0.012577167 
ITGA5 XM_001504571 XP_001504621 0.911743274 0.010580773 
KIF2C XM_001496793 XP_001496843 0.717088291 0.003601344 
KLHDC3 DN506485 NULL -0.759397246 0.029141841 
KRT33A XM_001497042 XP_001497092 0.801589461 0.024375794 
LAS1L XM_001496190 XP_001496240 1.328026819 0.023914756 
LBX1 XM_001499876 XP_001499926 0.762530574 0.018170101 
LDHD XM_001501313 XP_001501363 0.808678565 0.013161812 
LDOC1L XM_001488133 XP_001488183 -0.986694221 0.034919604 
LILRA6 XM_001489385 XP_001489435 0.946966896 0.005552957 
LIN54 XM_001494255 XP_001494305 0.766460653 0.031548451 
LMNA XM_001499921 XP_001499971 0.744185488 0.027439804 
LOC389117 XM_001494114 XP_001494164 1.329158083 0.015971943 
LOC390667 XM_001497697 XP_001497747 -2.702098418 0.016561616 
LOC440829 XM_001500377 XP_001500427 1.147860523 0.007954244 
LOC440956 XM_001493055 XP_001493105 0.902521159 0.012143395 
LOC442461 XM_001488900 XP_001488950 1.104987082 0.026010156 
LOC642592 NULL NULL 0.911915683 0.008847904 
LOC643596 XM_001492183 NULL 0.863246101 0.012415253 
LOC645161 NULL NULL 0.594646919 0.041700124 
LOC730855 AF345995 NULL 1.286287529 0.000652782 
LOC731062 XM_001492626 NULL 1.047785019 0.043590934 
LPIN1 XM_001502170 XP_001502220 0.715966416 0.049034183 
LRRC20 XM_001503727 XP_001503777 1.06487927 0.001289511 
LRRTM4 XM_001498361 XP_001498411 1.021960189 0.016392528 
MAEA XR_035780 NULL 0.581087868 0.045297113 
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MAGEA10 XM_001491290 XP_001491340 1.150791618 0.02594001 
MED31 XM_001502782 XP_001502832 0.653167586 0.008516081 
MIB1 NULL NULL -0.829371697 0.018482395 
MPFL XM_001497303 NULL 0.769264597 0.016968495 
MRPL49 CD467563 XP_001492066 1.159126002 0.027065692 
MTAP XM_001495991 XP_001496041 0.913009578 0.014401546 
MVD XM_001488033 XP_001488083 0.613940542 0.028237542 
MXRA8 NULL NULL 0.805959487 0.002893374 
MYO19 XM_001501155 NULL 0.742073563 0.035716242 
NCDN XM_001503678 XP_001503728 -0.947536281 0.028235898 
NDUFB3 XM_001503625 XP_001503675 -0.698556061 0.033779904 
NHSL2 XM_001487942 XP_001487992 -0.713666543 0.027646106 
NKAIN3 XM_001496129 XP_001496179 -0.73922743 0.049580039 
NKRF XM_001491762 XP_001491812 0.635685834 0.031128646 
NKX2-2 XM_001489173 XP_001489223 0.936666141 0.034628089 
NPPA X58563 NP_001075970 -0.630541552 0.023569862 
NUBPL XM_001490020 XP_001490070 -0.623257693 0.008816077 
NUDT19 XM_001489815 NULL 0.688263013 0.017058818 
NULL CX605888 NULL -0.953804151 0.022598933 
NULL XM_001503290 XP_001503340 -0.899785605 0.029315514 
NULL BI395121 NULL -0.835740515 0.009234624 
NULL CD465149 NULL -0.810753986 0.003955582 
NULL CX604514 NULL -0.739823271 0.004129966 
NULL CX599268 NULL -0.726975078 0.011751645 
NULL CX603838 NULL -0.724792919 0.037720918 
NULL CX603822 NULL -0.719007561 0.001339616 
NULL CX593567 NULL -0.709427906 0.017311851 
NULL XM_001497660 NULL -0.68855117 0.0119083 
NULL CD470553 NULL -0.679422914 0.023455107 
NULL CX594584 NULL -0.674299114 0.041954976 
NULL DN508935 NULL -0.662010972 0.044621292 
NULL CX601639 NULL -0.660646952 0.015321317 
NULL CX603281 NULL -0.658146559 0.010347549 
NULL DN509644 NULL -0.633744819 0.013981684 
NULL CX595027 NULL -0.628233604 0.013732771 
NULL DN506649 NULL -0.594185602 0.027833019 
NULL CX603737 NULL -0.584074704 0.010601869 
NULL CX598905 NULL -0.583382284 0.043177823 
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NULL XM_001497156 NULL 1.921141825 0.004280134 
NULL DN507748 NULL 1.402291407 0.020693008 
NULL XR_035772 NULL 1.349384445 0.012081833 
NULL XR_035972 NULL 0.988873844 0.048896061 
NULL CX600791 NULL 0.889209952 0.012557901 
NULL CX602835 NULL 0.888998812 0.028908699 
NULL CX595758 NULL 0.872711966 0.01510688 
NULL XM_001491549 XP_001491599 0.828461917 0.015116816 
NULL CX605699 NULL 0.822898579 0.008050584 
NULL DN507307 NULL 0.774029512 0.011063167 
NULL XM_001497251 NULL 0.704061973 0.030681865 
NULL DN509184 NULL 0.692498187 0.009988585 
NULL DN508765 NULL 0.689267067 0.036613834 
NULL DN504005 NULL 0.62871241 0.025938747 
NULL CX604280 NULL 0.620963014 0.024786153 
NULL XM_001503948 NULL 0.61980628 0.021365115 
NULL DN508760 NULL 0.602086688 0.039617624 
NULL CD465531 NULL 0.597759475 0.040196957 
NULL XM_001488352 NULL 0.594957961 0.029610242 
OBP2B XM_001502876 NULL 0.611564524 0.043319422 
OPA3 DN509316 NULL 1.032244761 0.034580764 
OR10H3 XM_001499453 NULL -0.814285673 0.025020519 
OR1A1 XM_001502600 XP_001502650 -0.616293085 0.008761183 
OR2S2 XM_001504440 XP_001504490 -0.725505525 0.004894745 
OR2T33 XM_001498999 NULL 0.609453994 0.014161985 
OR52A5 XM_001498335 XP_001498385 0.642048706 0.046172995 
OR52J3 XM_001498512 NULL -2.88423699 0.03368168 
OR5A1 XM_001497317 NULL 1.488559818 0.027748352 
OR6C2 XM_001490665 XP_001490715 -1.434159465 0.020493842 
OR9Q2 XM_001497753 XP_001497803 0.642949937 0.023980237 
OTUB1 XM_001489294 XP_001489344 0.829445096 0.006281345 
P4HA3 XM_001495901 XP_001495951 0.818038065 0.015979802 
PAFAH1B3 NULL NULL -0.67690706 0.010015666 
PAPPA XM_001487931 XP_001487981 -0.597673972 0.04328644 
PARD6A XM_001498013 XP_001498063 -0.584073733 0.037715939 
PBX1 XM_001493240 XP_001493290 0.59157924 0.013529476 
PDE4DIP XR_036200 NULL 0.699727199 0.006466326 
PDK2 NULL NULL 0.65478013 0.041190275 
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PEX12 XM_001503933 XP_001503983 0.719585685 0.033596403 
PGAM2 XM_001495636 XP_001495686 1.273323829 0.044945218 
PIM1 XM_001500225 XP_001500275 0.782230297 0.047385922 
PLAUR XM_001501873 XP_001501923 0.699689215 0.028757991 
PLEKHB1 XM_001496117 XP_001496167 1.087380054 0.044336809 
PNMT XM_001501154 XP_001501204 0.6539197 0.021327398 
PNOC XM_001493120 XP_001493170 0.785972633 0.013901641 
PODN XM_001493252 XP_001493302 0.840612875 0.01599106 
POU4F2 XM_001501801 XP_001501851 1.426058849 0.039233121 
PPP4R2 XM_001493684 XP_001493734 -0.974287137 0.024015877 
PRPF8 XM_001504332 XP_001504382 0.976827755 0.038569979 
PRR16 XM_001504547 XP_001504597 0.862643677 0.016402338 
PRRC1 XM_001504480 XP_001504530 1.296642935 0.007066774 
PSMA7 XM_001491034 XP_001491084 -0.622297366 0.049949045 
PTH2 XM_001491631 XP_001491681 0.779336798 0.007113905 
QDPR NULL NULL -0.884611783 0.042327943 
RAB19 XM_001498572 XP_001498622 0.730707392 0.010412718 
RAB3IP XM_001494486 XP_001494536 -0.611839451 0.026279794 
RAB7L1 XM_001490736 XP_001490786 0.812919323 0.018331762 
RAD54L2 XM_001495092 XP_001495142 0.823111858 0.017219693 
RAP2C XM_001491906 XP_001491956 0.63498104 0.019195347 
RASL11B XM_001493834 XP_001493884 -0.710382722 0.00692196 
RGS22 XM_001493094 XP_001493144 -0.660077295 0.025979078 
RLBP1L1 XM_001496222 XP_001496272 -0.80206447 0.003081502 
RNF141 XM_001504919 XP_001504969 -1.006188034 0.034746636 
RNF208 XM_001491514 XP_001491564 0.769170826 0.046097862 
RPL24 DN504010 XP_001503467 -0.628381915 0.014017953 
RUNX3 XM_001501145 XP_001501195 1.00710975 0.048311913 
RWDD2B XM_001499640 XP_001499690 0.773181336 0.025988073 
RY1 CX599215 XP_001490747 -0.757533304 0.002943676 
S100A11 BI961023 XP_001493486 0.934188482 0.007838049 
SAP130 XM_001504933 NULL 1.063359722 0.029982418 
SCGB1A1 XM_001487825 XP_001487875 0.748680398 0.025212101 
SCUBE1 XM_001500812 XP_001500862 0.987192781 0.016081166 
SCYE1 XM_001503150 XP_001503200 0.689763201 0.024351772 
SECISBP2 XM_001493820 XP_001493870 0.831585086 0.024694127 
SERPINB10 CD465653 NULL 0.770956657 0.022517937 
SERPINB2 XM_001491808 NULL 0.779884618 0.004768348 
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SEZ6L2 XM_001496356 XP_001496406 0.652943258 0.023510909 
SH2B3 XM_001491066 XP_001491116 0.600097682 0.031979584 
SH3BGR XM_001491925 NULL -0.581664834 0.020954076 
SHB XM_001496517 XP_001496567 -0.822715528 0.049587963 
SLC31A2 XM_001488681 XP_001488731 -0.586337278 0.049270301 
SLC6A12 XM_001490499 XP_001490549 -1.732852539 0.018632826 
SMARCA5 XM_001502026 XP_001502076 0.818034782 0.040482641 
SNTA1 XM_001498897 XP_001498947 0.8294296 0.028040237 
SPCS1 XM_001501306 NULL 0.680129218 0.027177819 
STAT3 XM_001494631 XP_001494681 0.887247365 0.000743008 
SVOPL XM_001496950 XP_001497000 0.669968544 0.039739242 
TANC1 XM_001492390 XP_001492440 0.65394972 0.020851928 
TAP1 XM_001496035 XP_001496085 0.739352332 0.019165206 
TATDN2 XM_001493683 XP_001493733 -0.640102262 0.031234213 
TCF7L1 XM_001497480 XP_001497530 0.655375069 0.02066466 
TCTA XM_001497739 NULL 0.897418245 0.038317218 
TIGD3 XM_001492759 XP_001492809 0.662665139 0.017670498 
TIMM17B CX602842 XP_001494391 0.71519637 0.02189663 
TMEM16B XM_001495269 NULL 0.820285481 0.039293569 
TMEM183A XM_001495801 XP_001495851 -0.720554342 0.027557868 
TMEM82 XM_001489391 XP_001489441 0.675173017 0.015266721 
TMOD1 XM_001504126 XP_001504176 1.350824501 0.00053532 
TPD52L3 XM_001492482 XP_001492532 -0.846619691 0.03142352 
TREH XM_001500995 XP_001501045 0.608711692 0.018626315 
TRIM55 XM_001494869 XP_001494919 0.601147667 0.042591963 
TSGA13 XM_001498542 XP_001498592 0.684163704 0.041572459 
TSR1 XM_001504361 XP_001504411 0.673223149 0.028278009 
UBA7 XM_001497081 XP_001497131 0.798680323 0.0310785 
VKORC1 DN507704 XP_001500839 -0.803460257 0.01789172 
VPREB1 XM_001502296 XP_001502346 0.787349107 0.044326592 
WDR36 XM_001503571 XP_001503621 -1.227377559 0.016543822 
WDR45 XM_001495045 XP_001495095 -0.608004918 0.047830193 
WFIKKN2 XM_001499780 XP_001499830 0.68420186 0.029953197 
YARS XM_001499806 XP_001499856 0.649987292 0.033156852 
YY1 NULL NULL -0.797186972 0.004030764 
ZADH2 XM_001493715 XP_001493765 0.957242907 0.007660384 
ZDHHC1 XM_001496451 XP_001496501 0.788722704 0.024037043 
ZNF280C XM_001491635 XP_001491685 0.902762058 0.002149491 
 
  
366 
Table D-13 Continued 
 
Gene Symbol NCBI accession RefSeq accession 
Log fold 
change Pvalue 
ZNF518B XM_001500984 XP_001501034 0.763095013 0.00740351 
ZNF613 XM_001495866 XP_001495916 0.858922683 0.029197421 
ZNF709 XM_001496676 NULL 0.604876427 0.030614397 
ZNF768 XM_001496047 XP_001496097 1.029166026 0.038296502 
ZNF793 XM_001493662 XP_001493712 0.887183716 0.027163284 
ZSCAN21 XM_001498385 XP_001498435 1.338258736 0.038262999 
 
 
 
Table D-14: List of differentially expressed genes (pvalue <0.05 and fold change cut off 
of 1.5) between the affected and the unaffected foals from nasal epithelium at week-4. 
 
Gene Symbol NCBI accession RefSeq accession 
Log fold 
change Pvalue 
A1CF XM_001501691 XP_001501741 0.832646485 0.008475736 
ABT1 XM_001505089 XP_001505139 -1.340956152 0.028058504 
ACAA1 XM_001488559 XP_001488609 -0.599259628 0.021954768 
ADAMTSL3 XM_001497774 XP_001497824 0.673192244 0.020793411 
ALLC XM_001502861 XP_001502911 -0.629860172 0.0399707 
ANKRD24 XM_001494451 NULL -0.766840939 0.042867721 
APOL6 XM_001499112 XP_001499162 0.927984486 0.021667634 
ARFRP1 XM_001494418 NULL -0.675858211 0.024028676 
ARL13A XM_001492492 XP_001492542 -0.758983522 0.029237818 
ARL6IP1 CD468299 NULL 0.732932792 0.036965874 
ATP1A1 NM_001114532 NULL -0.716243753 0.046996329 
ATP6V1E2 XM_001498882 XP_001498932 -0.639625905 0.038221582 
AUP1 XR_036315 NULL -0.677871977 0.036884568 
BARHL2 XM_001493713 XP_001493763 -0.707829186 0.010255616 
C11orf17 XM_001504906 XP_001504956 0.703475678 0.020682066 
C11orf52 NULL NULL -0.865026707 0.005671981 
C12orf4 NULL NULL 0.619639222 0.026739291 
C13orf33 XM_001495031 XP_001495081 0.687821247 0.024792286 
C17orf83 XM_001503077 XP_001503127 -0.610318513 0.047004149 
C1orf121 XM_001493908 XP_001493958 0.67561054 0.024732358 
C1orf35 XM_001493264 NULL -0.649411995 0.015091344 
C21orf91 XM_001500343 XP_001500393 0.582694424 0.028265653 
C5orf15 DN510151 NULL -1.042525299 0.033545177 
C5orf40 XM_001503539 XP_001503589 0.616200431 0.02263458 
C6orf221 XM_001498118 XP_001498168 0.815726782 0.003178694 
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C7orf28A XM_001493987 XP_001494037 -0.874362548 0.032756702 
C9orf85 XM_001489559 XP_001489609 0.725317641 0.00690778 
CALM3 XM_001493222 NULL 0.770740595 0.009438996 
CAPN1 DN506160 NULL -0.94158798 0.007713713 
CCNG1 XM_001488405 XP_001488455 0.67734665 0.048421213 
CCNG2 XM_001491674 XP_001491724 -1.241657362 0.018497741 
CD33 XM_001496873 XP_001496923 -0.648887819 0.010507107 
CD3G XM_001502838 XP_001502888 1.730160072 0.027925442 
CHST6 XM_001498821 XP_001498871 1.374623399 0.00164069 
CLCA1 AY524856 NP_001075268 -1.045824705 0.029654985 
CLDN3 XR_036494 NULL -0.645549497 0.048170879 
CMBL XM_001501583 XP_001501633 -0.728143213 0.012008076 
COL28A1 XM_001494969 XP_001495019 -0.753460679 0.003954833 
COX7A1 XM_001492779 XP_001492829 0.596383149 0.03175034 
COX7B CX594711 NULL -0.953208059 0.01077352 
CYB561D2 XM_001495830 XP_001495880 0.651061822 0.049786506 
CYB5A CX594722 XP_001493485 -1.037358425 0.010087741 
CYP11B2 XM_001505011 NULL -0.900442413 0.023597412 
CYP2C19 XM_001502162 XP_001502212 0.723343608 0.034332803 
CYP2F1 XM_001498170 XP_001498220 -0.647047136 0.045941176 
DALRD3 XM_001498501 XP_001498551 -0.885722486 0.046784999 
DCK XM_001489225 XP_001489275 0.594122721 0.030622224 
DGCR2 NULL NULL 0.998980412 0.011496334 
DHDH XM_001489811 XP_001489861 -0.912698794 0.002607083 
DMGDH XM_001503911 XP_001503961 -0.58124661 0.012318285 
DPP6 XM_001504680 XP_001504730 0.639589149 0.038518855 
DRG1 XM_001496885 NULL -0.790989946 0.012829095 
EBF2 XM_001493967 XP_001494017 0.680123254 0.030277644 
EGFL6 XM_001489342 XP_001489392 -0.71057822 0.027662423 
ENDOGL1 XM_001488144 XP_001488194 -1.096294216 0.032538391 
ENO1 XM_001494862 XP_001494912 -0.665318417 0.021811995 
ENPP1 CX604920 NULL 0.837131364 0.017560686 
EPHA2 XM_001488739 XP_001488789 -0.5850366 0.048357932 
EPM2A XM_001496670 XP_001496720 0.619608961 0.021463107 
ERC1 XM_001491831 XP_001491881 -0.886302539 0.013715135 
EXT1 XM_001496434 XP_001496484 -1.075444222 0.013044512 
FAIM XM_001495529 XP_001495579 -0.661017724 0.017062522 
FAM13C1 XM_001503399 XP_001503449 0.591687363 0.033483098 
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FAM21C CX603317 NULL 0.602254898 0.035258997 
FAM54B XM_001504118 XP_001504168 -0.606508088 0.019025016 
FASTKD1 XM_001494348 XP_001494398 -0.969695295 0.02545841 
FLJ20160 XM_001501990 XP_001502040 -0.892536429 0.013064446 
FOXP1 DN503968 NULL -0.624439992 0.011483 
FRYL NULL NULL -0.957623249 0.047714411 
GAPDH XM_001502360 XP_001502410 -0.823217483 0.020257953 
GNAT3 XM_001487934 XP_001487984 -0.847804659 0.047339394 
GNB2L1 NULL NULL 0.981080011 0.0030302 
GRAMD1C XM_001501094 XP_001501144 0.805227311 0.010062435 
GSTA1 XM_001503053 XP_001503103 -0.853867865 0.026818494 
GSTM4 CX601710 NULL 1.282766019 0.019971397 
GYS1 XM_001489239 XP_001489289 0.623847039 0.021310691 
H1F0 XM_001501126 XP_001501176 -0.62813259 0.043011576 
HCCS XM_001488423 XP_001488473 1.264818868 0.030002828 
HCRTR2 XM_001503207 XP_001503257 -0.642392375 0.006776825 
HEY2 XM_001503138 XP_001503188 -0.926509745 0.009572611 
HIST1H4J XM_001501708 XP_001501758 -0.826688278 0.042242517 
HSP90AB1 AY383484 NP_001075407 -0.622090752 0.042959672 
HTR1E XM_001503723 XP_001503773 0.700853188 0.013648808 
IFITM3 CX605459 XP_001488671 -0.798407606 0.024211354 
IMPDH2 XM_001494550 XP_001494600 -0.737341281 0.029862585 
INPP5A XM_001488022 XP_001488072 0.755185322 0.048649758 
INPP5F XM_001496265 XP_001496315 0.674966522 0.034717242 
KCNN3 XM_001497582 XP_001497632 -0.828428635 0.010968736 
KCNRG XM_001488550 XP_001488600 0.704151051 0.048556785 
KIAA1553 XM_001503954 XP_001504004 -1.195143719 0.044609018 
KIF2C XM_001496793 XP_001496843 -0.948292019 0.008586719 
LBXCOR1 XM_001498728 NULL -0.661626455 0.009408176 
LENG1 XM_001488396 XP_001488446 -0.626107991 0.03914387 
LIMCH1 XM_001494623 XP_001494673 -1.349227692 0.005874797 
LIN28B XM_001503925 XP_001503975 -1.776635547 0.037298043 
LMBR1L XM_001504157 XP_001504207 -0.593052611 0.042595949 
LMO7 XM_001488279 XP_001488329 0.583802808 0.045353481 
LOC124446 XM_001501754 XP_001501804 -0.866724706 0.041451409 
LOC728780 XM_001504674 XP_001504724 -0.757158723 0.039061296 
LOC729085 XR_036379 NULL 0.678461784 0.035907053 
LRRC15 XM_001500569 XP_001500619 0.689693763 0.048339409 
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LYRM4 CX605171 NULL 0.655867417 0.036665488 
LYSMD4 XR_035862 NULL -0.733594726 0.044530761 
MAGEB16 XM_001488696 XP_001488746 -0.622695779 0.0381295 
MAP2K1 XM_001496420 XP_001496470 0.787575065 0.045455961 
MESP2 XM_001499242 NULL -0.623735646 0.045830675 
MGAT4C XM_001495737 XP_001495787 0.860979516 0.004608274 
MKI67 XM_001489412 XP_001489462 1.01169943 0.044068579 
MRPL21 CX604559 XP_001499094 -1.034579234 0.010308367 
MXI1 XM_001496951 XP_001497001 -0.738855714 0.033110951 
NANOS3 XM_001494819 XP_001494869 -0.614937874 0.040185863 
NBPF6 XM_001497337 NULL 0.608487406 0.037123347 
NOL8 XM_001489687 XP_001489737 -1.543571813 0.014143301 
NONO XM_001492800 XP_001492850 -0.616463186 0.027019073 
NULL XM_001503112 NULL -1.174740052 0.036027527 
NULL CD465327 NULL -1.159813556 0.012179574 
NULL DN508036 NULL -1.054096365 0.034266373 
NULL CX599420 NULL -0.981846219 0.02626958 
NULL CD470845 NULL -0.977777737 0.00619198 
NULL CX604338 NULL -0.922961234 0.008579522 
NULL CX593230 NULL -0.850991777 0.031489335 
NULL CX601522 NULL -0.846585201 0.027092655 
NULL BM414703 NULL -0.775474009 0.016410087 
NULL DN508295 NULL -0.724062199 0.012467506 
NULL CX601641 NULL -0.711086963 0.019963884 
NULL CX605199 NULL -0.673486932 0.005752077 
NULL CX605849 NULL -0.672146284 0.012038211 
NULL XR_036258 NULL -0.658216857 0.045318492 
NULL XM_001496363 XP_001496413 -0.650827063 0.016304912 
NULL XM_001502325 XP_001502375 -0.624090671 0.028234523 
NULL DN504949 NULL -0.584613984 0.014224809 
NULL DN508139 NULL 0.814218578 0.007929484 
NULL CX592100 NULL 0.682515155 0.039915205 
NULL XM_001488836 NULL 0.631965438 0.022524357 
NULL CX600577 NULL 0.618601028 0.023004272 
NULL BI960932 NULL 0.587600399 0.049318147 
NULL CX595091 NULL 0.584213972 0.013822649 
NUP43 XM_001495468 XP_001495518 0.693637301 0.013764025 
OR13C3 XM_001493767 XP_001493817 0.8532832 0.033569935 
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OR2L2 XM_001491169 NULL -0.880001026 0.03980507 
OR2T33 XM_001491604 NULL 0.638186115 0.038510702 
OR52A5 XM_001498335 XP_001498385 -0.91904009 0.005454211 
PATZ1 XM_001496979 XP_001497029 1.012064056 0.022763939 
PDCD2 XR_035769 NULL -0.8718239 0.009651637 
PGBD2 XM_001489628 XP_001489678 -0.712424507 0.018875561 
PHKG1 XM_001493353 XP_001493403 0.593849525 0.025875054 
PIM3 XM_001489277 XP_001489327 0.760014044 0.021386153 
PIP3-E XM_001493835 XP_001493885 -0.907827901 0.044234612 
PNLIPRP3 XM_001497755 XP_001497805 0.764672641 0.016280741 
PPIF XM_001503133 XP_001503183 -1.1290225 0.026632136 
PPM1L NULL NULL -0.751893498 0.031957557 
PTGIR XM_001500857 XP_001500907 0.735222145 0.010329417 
PTH2R XM_001499116 XP_001499166 -0.662387891 0.036334377 
PTPLB XM_001500147 XP_001500197 0.822906174 0.00341293 
QDPR XM_001498522 XP_001498572 0.664223696 0.034470498 
RAB8A CX593996 NULL -1.225994858 0.003683153 
RABAC1 CX605896 NULL -0.583006162 0.031789253 
RABGAP1 XM_001502284 XP_001502334 -1.053200274 0.044050016 
RABGAP1L CX604606 NULL 0.646938991 0.045842495 
RALGDS XM_001494159 NULL -0.628124826 0.034664569 
RASA1 XM_001503763 XP_001503813 -0.648346323 0.038766202 
RFESD XM_001504611 XP_001504661 -0.698905074 0.008368325 
RHBDL3 XM_001501624 XP_001501674 -0.811082785 0.048977433 
RNF125 XM_001495353 XP_001495403 -0.664859632 0.023065159 
RPL10 NULL NULL -0.671277767 0.012879941 
RPL13 XM_001488825 XP_001488875 -0.760386076 0.021152271 
RPL28 CD464415 XP_001495815 -0.657473936 0.009462253 
RPL3L XM_001497904 XP_001497954 -0.851485046 0.016568967 
RPL7A CD535100 NULL -0.972501046 0.005000503 
RPS18 NULL NULL -1.006931347 0.003186254 
RPS2 CD536630 NULL -0.673069241 0.014418029 
S100A11 BI961023 XP_001493486 -0.805591769 0.040404051 
SAA1 BM780732 NULL -0.745340627 0.030636949 
SAMD8 XM_001503968 XP_001504018 0.722574858 0.02194306 
SCAPER XM_001493099 XP_001493149 0.63637674 0.032201637 
SELENBP1 NULL NULL -1.444713323 0.006144535 
SHB XM_001496517 XP_001496567 -1.327035275 0.041358482 
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SIGLEC5 XM_001496694 XP_001496744 0.702159421 0.023251966 
SKP1 XM_001504404 XP_001504454 0.671973889 0.034570903 
SLC26A9 XM_001490825 XP_001490875 0.628557108 0.045214646 
SLC35E4 XM_001497797 XP_001497847 0.86116699 0.003975234 
SLC4A11 XM_001496863 XP_001496913 0.991168621 0.004650469 
SLC9A10 XM_001501303 XP_001501353 -0.825198351 0.005202031 
SMARCA5 XM_001502026 XP_001502076 1.576157971 0.045398111 
SMOX XM_001495369 XP_001495419 1.040094617 0.008716366 
SNAI2 XM_001488056 XP_001488106 0.604557377 0.036071761 
SPACA5B XM_001493471 XP_001493521 0.65972288 0.049159818 
SPRED1 XM_001503617 XP_001503667 0.901968423 0.030022338 
SRR XM_001504357 XP_001504407 -0.958727 0.014125923 
STAMBP XR_035758 NULL 0.583755129 0.025867117 
SUCLG2 XM_001495004 XP_001495054 1.034716329 0.030225375 
SYNPO2 XM_001503239 XP_001503289 -0.718121452 0.046501452 
SYVN1 XM_001492161 XP_001492211 -1.69912096 0.030607827 
TBC1D21 XM_001493579 XP_001493629 0.840322793 0.01302098 
TDRD9 XM_001492897 XP_001492947 -0.729460062 0.023965311 
TEX13A XM_001493678 NULL -1.598003933 0.026460985 
TFE3 XM_001494896 XP_001494946 -1.014575441 0.00674404 
TGM3 CD469900 NULL -0.78195184 0.041442648 
TM4SF5 XM_001502944 XP_001502994 -0.724263111 0.003839672 
TMEM60 XM_001488320 XP_001488370 0.602420509 0.026684834 
TMEM86A XM_001504973 XP_001505023 0.989725936 0.045763512 
TMPRSS6 XM_001499386 XP_001499436 -0.793618707 0.010138285 
TNFRSF11B XR_036157 NULL -1.003769927 0.045532736 
TRAPPC6A XM_001502472 NULL 0.701696566 0.029711442 
TSPO XM_001503143 XP_001503193 -0.685253525 0.045634441 
U2AF2 XM_001496109 XP_001496159 -1.014113889 0.03850713 
UBC XM_001499082 XP_001499132 -1.029557409 0.004146667 
UBP1 XM_001489950 XP_001490000 0.690667964 0.008448361 
UQCR DN508330 NULL -0.71106548 0.008736253 
UROS XM_001490158 XP_001490208 -1.278854565 0.008720487 
UTP6 XM_001504028 XP_001504078 0.767721739 0.010602056 
VPS33B XM_001498840 XP_001498890 1.016084454 0.006130397 
VTN XM_001504123 XP_001504173 -0.76527476 0.016391353 
VWF NULL NULL -0.736158608 0.015957781 
WDR76 CX602330 NULL -1.190662663 0.035751286 
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WNT11 XM_001495163 XP_001495213 0.908741195 0.002654203 
ZC3H11A XM_001488552 XP_001488602 0.671539747 0.027301477 
ZCCHC10 XM_001504415 NULL -0.669967344 0.027040513 
ZNF2 XM_001493971 XP_001494021 0.805254836 0.022108275 
ZNF266 XM_001491960 XP_001492010 0.853414065 0.001243353 
ZNF295 XM_001492957 XP_001493007 -0.611785979 0.042952336 
ZNF709 XM_001489853 NULL 0.727714625 0.017516736 
ZNF92 XM_001494628 NULL -1.076826878 0.036612228 
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